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Abstract 
Cancer biomarkers provide an opportunity to identify those patients most at risk 
for disease recurrence, predict which tumours will respond to different 
therapeutic approaches and ultimately define candidate biomarkers that may 
serve as targets for personalized therapy. New biomarkers are especially 
needed in the management of lymphoid cancers. At present, these tumours are 
diagnosed using a combination of morphologic, phenotypic and molecular 
features but prognosis and overall survival are mostly dependent on clinical 
characteristics. In most lymphoma types, these imprecisely assess a significant 
proportion of patients, in particular, those with very poor outcomes. Follicular 
lymphoma (FL) is the second most common lymphoma subtype worldwide. It is 
typically an indolent disease with current median survivals in the range of 8-12 
years, but is usually fatal when it transforms into an aggressive high-grade 
lymphoma, characteristically Diffuse Large B Cell Lymphoma (DLBCL). 
Morphologically and functionally it recapitulates the normal cells of the germinal 
center with its survival dependency on non-malignant immune and immune-
related cells. Informative markers of transformation related to the intrinsic 
biology of FL progression are needed. Within this thesis two separate 
approaches to biomarker discovery were employed. The first was to study the 
global expression of genes (‘genomics’) obtained using high-throughput, whole-
genome-wide approaches that offered the possibility for discovery of new 
genetic abnormalities that might represent the important biological mechanisms 
of transformation. Gene signatures associated with early events of 
transformation were found. Another approach relied on hypothesis-driven 
concepts focusing upon the microenvironment, rich in several non-malignant 
cell types. The immunoarchitectural studies of macrophages, regulatory T cells 
and microvessel density on diagnostic biopsies of uniformly treated FL patients 
significantly predicted clinical outcome and, importantly, also informed on the 
risk of transformation. Techniques that enabled the use of routine formalin fixed 
paraffin embedded diagnostic specimens from the pathology department 
archives were preferentially used in this thesis with the goal of fulfilling a rapid 
“bench-to-beside” translation for these new findings. Although FL was the main 
subject of the thesis the new findings and hypotheses allowed easy transition 
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into other lymphoma types. Several promising biomarkers were proposed and 
validated including the implication of several non-neoplastic immune cells as 
important contributors to lymphoma biology, opening new options for better 
treatment planning and eventually new therapeutic targets and candidate 
therapeutics. 
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Resumo 
Os biomarcadores tumorais permitem identificar os doentes com maior risco de 
recorrência da doença, predizer a resposta tumoral à terapêutica e, finalmente, 
definir candidatos a novos alvos terapêuticos. Novos biomarcadores são 
especialmente necessários na abordagem clínica dos linfomas. Actualmente, 
esses tumores são diagnosticados através de uma combinação de 
características morfológicas, fenotípicas e moleculares, mas o prognóstico e o 
planeamento terapêutico estão quase exclusivamente dependentes de 
características clínicas. Estes factores clínicos são, na maioria dos linfomas, 
insuficientes numa proporção significativa dos doentes, em particular, aqueles 
com pior prognóstico. O linfoma folicular (LF) é, globalmente, o segundo 
subtipo mais comum de linfoma. É tipicamente uma doença indolente com uma 
sobrevida média entre os 8 e 12 anos, mas é geralmente fatal quando se 
transforma num linfoma agressivo de alto grau, habitualmente o linfoma difuso 
de grandes células B (LDGCB). Morfologicamente e funcionalmente, as células 
do LF recapitulam as células normais do centro germinativo na sua 
dependência de sobrevivência do microambiente não-tumoral, especialmente 
das células do sistema imunológico. Biomarcadores preditivos de 
transformação não existem pelo que um melhor conhecimento da biologia 
intrínseca de progressão do LF poderá revelar novos candidatos. Nesta tese 
descrevo duas abordagens distintas para a descoberta de novos 
biomarcadores. A primeira, o estudo da expressão global de genes ('genomics') 
obtidos por técnicas de alto rendimento que analisam todo o genoma humano 
sequenciado, permitindo identificar novas anomalias genéticas que possam 
representar mecanismos biológicos importantes de transformação. São 
descritos novos genes e alterações genómicas associados à transformação do 
LF, sendo especialmente relevantes as relacionadas com os eventos iniciais de 
transformação em LDGCB. A segunda, baseou-se em várias hipóteses 
centradas no microambiente do LF, rico em vários tipos de células não-
malignas. Os estudos imunoarquitectural de macrófagos, células T regulatórias 
e densidade de microvasos efectuado em biopsias de diagnóstico de doentes 
com LF tratados uniformemente correlacionaram-se significativamente, e 
independentemente dos critérios clínicos, com a evolução clínica e, mais 
 5 
importante, com o risco de transformação em LDGCB. Nesta tese, foram 
preferencialmente utilizadas (e optimizadas) técnicas que permitam o uso de 
amostras fixadas em parafina e formalina (FFPET). Estas são facilmente 
acessíveis a partir das biopsias de diagnóstico de rotina presentes nos arquivos 
de todos os departamentos de patologia, facilitando uma transição rápida dos 
novos marcadores para a prática clínica. Embora o FL fosse o tema principal 
da tese, os novos achados permitiram estender facilmente hipóteses 
semelhantes a outros subtipos de linfoma. Assim, são propostos e validados 
vários biomarcadores promissores e relacionados com o microambiente não-
tumoral, sobretudo dependentes das células do sistema imunológico, como 
contribuintes importantes para a biologia dos linfomas. Estes sugerem novas 
opções para a abordagem clínica destas doenças e, eventualmente, novos 
alvos terapêuticos. 
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Section 1: Introduction  
 
1.1 LYMPHOMA 
   
1.1.1. Definition 
Lymphoid neoplasms are clonal tumours of mature and immature B, T or 
natural killer (NK) cells at various stages of differentiation. 
Lymphomas represent approximately 4% of new cancers per year worldwide, 
are more common in the Western world and contrary to most other common 
neoplasias, have been increasing in incidence worldwide (1). Mature B cell non-
Hodgkin lymphomas (NHL) comprise over 90% of these (2).  
 For the majority of lymphomas, tumour cells recapitulate the normal stages of 
differentiation so they can be classified according to their normal counterpart. 
However, some neoplasms do not have as yet a well-defined normal 
counterpart and within each lymphoma type there is morphologic, phenotypic 
and molecular heterogeneity.  
B cell development takes place in distinct steps characterized by the structure 
of the B cell Receptor (BCR). Two pairs of identical heavy-chain and light-chain 
immunoglobulin (IG) peptides compose the BCR. After cross-linking, the BCR 
and associated membrane components transmit cytoplasm signals through 
several tyrosine kinases. Proliferation and differentiation of B cells depends on 
the recognition of antigens and on the activation of other modulator B cell 
surface receptors. Early B cell development occurs in the bone marrow where 
precursor cells rearrange IG heavy and light chain genes resulting in the 
expression of a functional surface antigen receptor on naïve B cells as they exit 
the bone marrow. These cells can join the immune response upon antigen 
binding to the BCR resulting in lymphoid follicle formation. They undergo clonal 
expansion in germinal centers (GC), where T cells and other accessory 
lymphoid cells enable naïve B cells to gain antigen specificity by modification of 
IG genes through somatic hypermutation (SHM) and class-switch recombination 
(CSR).  Cells failing to express functional BCR or high affinity antigen specificity 
undergo apoptosis (3). 
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T cells arise from bone marrow precursors and mature in the thymus gland. 
Mature T cells are characterized by a rearranged antigen specific T cell receptor 
(TCR), either αβ or γδ, and associated with a fully expressed CD3 complex. 
They have a wide functional spectrum of both innate and adaptive immune 
responses. Mature T cells are functionally heterogeneous and quite plastic with 
differences difficult to characterize in vivo and in vitro, that are highly dependent 
on the particular techniques used to study them. These include cells of the 
innate immune system (γδ T cells), naïve, effector, regulatory, cytotoxic and 
memory T cells. 
NK cells participate mostly in innate immune response, contain cytoplasmic 
cytotoxic granule proteins and do not have a complete TCR or a CD3 
membrane complex. 
Recently, much has been learned from new techniques of flow cell sorting and 
cell phenotyping as well as gene expression profiling (GEP). New techniques 
such as genome-wide platforms to study GEP, genomic copy number 
alterations (array comparative genomic hybridization or aCGH), genome 
methylation or genome sequencing had  increased our understanding of 
lymphoid neoplasms. 
 
1.1.2. Classification 
The observation of BCR and TCR particular structure, the expression patterns 
of differentiation markers and the specific histological structures where it takes 
place was used to determine the origin of the various lymphomas. The rational 
used in the current classification of lymphoid neoplasms reflects the “frozen” 
state of the malignant cells in a particular differentiation stage, reflecting their 
cell of origin. For B cell tumours, most subtypes are derived from GC or 
immediate post-GC stage of differentiation. Classical Hodgkin lymphoma, 
considered historically as a separate disease, is in almost all cases a B cell 
lymphoma lacking a functional immunoglobulin.  
For most lymphomas, morphology and immunophenotype have been correlated 
with the clinical features and together provide enough detail for an accurate 
diagnosis. Yet, no single antigenic or molecular marker is specific for any 
tumour and the correlation of clinical, morphological and a panel of antigen 
expression (detailed immunophenotype) or genomic mutations are needed for a 
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correct diagnosis. Thus, the current standard classification (2) uses all available 
information to define lymphoma types, including morphology, 
immunophenotype, genetic features and clinical features. The relative 
importance of each of the features varies among diseases, but there is no one 
gold standard for defining any lymphoma type. 
Recent techniques such GEP have further characterized unrecognized 
differences within what were perceived to be specific subtypes. Moreover, while 
cell lineage defines most lymphoid malignancies, lineage plasticity within the 
hematopoietic system is increasingly recognized. 
Finally, we have appreciated the common presence of small clonal populations 
of atypical lymphoid cells in otherwise asymptomatic patients that may or may 
not represent early involvement by a lymphoid neoplasm. 
 
1.1.3. Therapy 
Lymphoma can be treated in many ways from watch and wait to single or 
multiple agent chemotherapy, radiation, surgery, monoclonal antibodies, stem 
cell transplantation or a combination of these. Therapeutic decisions are mostly 
dependent on staging and clinical factors, but a key step in this process is 
dependent on the histopathological subtype of lymphoma. Thus, the most 
important step is determining whether a given patient will be offered treatment 
given with curative intent versus treatment given to relieve symptoms or to offer 
palliation. For most entities there are multiple treatment options for a single 
disease (4). 
 
1.1.4. Prognosis 
There are now more than a hundred well-defined lymphoma types in the WHO 
classification (2). Yet, even within each type, especially the most common 
lymphomas, such as Follicular Lymphoma (FL) or Diffuse Large B cell 
Lymphoma (DLBCL), these tumours are quite heterogeneous and often 
clinically similar diseases show different responses to the same treatment 
regimens. This variability in outcome underscores the need to gain further 
insight into the biology and clinical behavior of the disease to enable more 
precise individualized therapy. On the other hand, different drugs impact 
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differently in the tumoural cells, thus biomarkers need to be re-evaluated 
specifically and uniformly for each new therapeutic modality. 
 
 
1.2 FOLLICULAR LYMPHOMA (FL) 
 
1.2.1. Introduction 
FL is the second most common form of indolent lymphoma in North America, 
comprising about 22% of all new cases of non-Hodgkin lymphomas (NHL), but 
70% of the indolent lymphomas (5, 6). FL is a clinically heterogeneous disease 
with some patients progressing or transforming early and 15% dying within 2 
years from diagnosis, whereas others remain alive without needing treatment 
after more than a decade. The median disease survival from diagnosis is now 
8-12 years. FL may transform over time to a more aggressive lymphoma, 
mostly resembling DLBCL. This is a dominant clinical event that is frequently 
associated with a rapid clinical course, refractoriness to treatment and short 
survival. However, its incidence varies dramatically, with histological 
transformation being reported to affect between 10-70% of FL patients (7).   
Prognosis and therapy of FL are currently based on clinical criteria, the 
International Prognostic Index (IPI) and more recently the Follicular Lymphoma 
Prognostic Index (FLIPI) 1 & 2 (8-10). The IPI, originally developed for 
aggressive lymphomas, identifies four different risk groups based on age, 
tumour stage, serum lactate dehydrogenase (LDH) concentration, performance 
status and number of extranodal sites of disease. The FLIPI published in 2004, 
is made up of five adverse prognostic factors including: age (>60 years vs. ≤ 60 
years), stage (III-IV vs. I-II), anaemia (haemoglobin < 120 g/l vs. ≥120 g/l), 
number of involved nodal areas (>4 vs. ≤4 areas) and serum LDH (elevated vs. 
normal).  
Besides these clinical features, many different biological markers have been 
proposed to impact prognosis in FL. However, most studies are retrospective 
using cohorts of patients treated with various protocols and thus consensus on 
what biomarkers to use in clinical practice and how these might impact 
treatment decisions is still lacking. Most prognostic markers were studied in the 
era of chemotherapy and require validation in the current era of chemo-
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immunotherapy. The impact of host immune-genetics, microenvironment and 
therapy in FL are still not well elucidated (11). 
Because there is no clear standard of care for FL treatment, a multitude of 
treatment options are available, ranging from simple observation in 
asymptomatic disease, single or multi-agent chemotherapy, monoclonal 
antibody therapy, with or without radioimmunoconjugates, to haematopoietic 
stem cell transplantation. There is no consensus approach for initial therapy. FL 
shows high sensitivity to initial therapy but becomes increasingly resistant 
following each successive treatment. The patients will invariably experience 
shorter remission durations and eventual relapses over time, in some cases 
leading to transformation.  An association between increased FLIPI score and 
Risk of Transformation (RT) has been reported but not validated in other studies 
(12).  
Despite the vast amount of biological data published on transformation very few 
biological markers have been shown to impact FL prognosis, most representing 
isolated reports and therefore none are used in routine clinical practice for 
clinical decision making. This is due in part to the low frequency of most of 
these markers as well as to the lack of data from cohorts with uniform 
treatment.  
In BC, the BCCA lymphoma database represents a population-based electronic 
database that includes comprehensive information on diagnosis, treatment and 
outcome for virtually all patients with lymphoma in the province. Centralized 
data on diagnosis and treatment of FL patients is a powerful tool to assess 
incidence and outcome associated with this event (7). 
 
1.2.2. Germinal Centre  
FL is a B cell neoplasm characterized by a nodular histologic pattern and 
germinal centre origin. Its normal counterpart is a mature B cell with two 
important features: 1) it has a unique BCR that results from VDJ recombination 
of the IGH locus within the bone marrow, and 2) it is activated by recognising 
cognate antigen through an interaction with T cells and/or antigen presenting 
dendritic cells (DC), usually in the T cell zone of the lymph node. This activated 
mature B cell migrates into B cell follicles, up-regulates and express the 
hallmark and GC master gene BCL6, proliferates and differentiates into 
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centroblasts; thereby establishing secondary lymphoid follicles characterized by 
germinal centres and a surrounding mantle zone. The proliferating centroblasts 
activate the process of somatic hypermutation that generates mutations at a 
high rate in some genes including V-region genes of the immunoglobulin 
molecule resulting in the generation of antibody diversity (3). The different 
centroblasts are selected by the affinity of their BCR to the antigen that induced 
the formation of the follicle. Only those cells that have acquired high affinity 
mutations escape apoptosis. This process of differentiation terminates with a 
resting centrocyte having high affinity antibody on its surface. Some of these 
cells will then exit the follicle to become either short-lived plasma cells or long-
lived memory B cells. The process requires the interaction of the B cells with the 
follicular T follicular helper cells and follicular dendritic cells (FDC) within the 
germinal centre. These cells provide the survival signals that rescue B cells 
from apoptosis. Furthermore, the FDC meshwork embodies the scaffolding 
structure of the follicle. Thus, FL is characterized by the development of 
neoplastic follicles, often morphological similar to reactive follicles, harbouring 
benign FDC meshwork, small blood vessels, macrophages and a variable 
percentage of non-neoplastic follicular T cells and benign B cells.  
 
1.2.3. t(14,18) & Genomic Mutations  
FLs are composed of neoplastic monoclonal B cells that in the majority of cases 
have a characteristic cytogenetic abnormality, the t(14;18)(q32;q21) or its 
variants t(18;22)(q21;q11) and t(2:18)(p11;q21). The translocation induces 
deregulated expression of the antiapoptotic BCL2 gene, but additional 
cytogenetic alterations are required to establish a fully malignant phenotype 
(13). Although 15% of FLs are t(14;18)-negative, the translocation has been 
used as a genetic marker for FL.  It has been postulated that it occurs as an 
error during VDJ rearrangement at the pre-B cell stage of differentiation in the 
bone marrow, and although necessary, is insufficient on its own to induce 
malignant transformation. The t(14;18) has been found in the blood of healthy 
blood donors as well as in germinal centers (“in situ” localization of FL) of 
patients who may not develop clinical disease or only develop FL several years 
later (14, 15).  The favored hypothesis regarding the pathogenesis of FL 
suggests that B cells harboring a t(14;18) arise in the marrow and eventually 
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enter the circulation, home to the lymph node and seed the follicles. Here they 
undergo several rounds of replication within an environment where SHM and 
CSR are physiological processes that require double-strand DNA breaks. 
Eventually, a second and subsequent additional genetic hit occurs, some of 
which lead to the development of clinically evident FL. Like benign germinal 
centers, malignant follicles are further targeted by hypermutational events 
favoring accumulation of genomic abnormalities. One recently described and 
highly recurrent genetic event is inactivating mutations of MLL2, found in nearly 
90% of FL biopsies (16). It remains possible that MLL2 mutations and the 
subsequent changes in gene expression that follow loss of this H3K4 activating 
chromatin mark may represent the illusive 2nd hit that allows the fully malignant 
phenotype of FL to emerge. 
Numerous structural chromosomal aberrations have been described, including 
gains, deletions, balanced and unbalanced translocations, all of which define 
the clonal evolution and disease progression of FL. Some of the most common 
events follow different pathways, which show clinical impact in the progression 
of FL (13). However, the majority of the breaks including those associated with 
transformation are thought to be stochastic, providing the lymphoma cells with a 
growth advantage and thus accelerate the clinical behaviour.  
The dramatic advances in biology, specially the emergence of new technologies 
to assess gene expression and genomic abnormalities such as GEP array 
platforms, high-resolution comparative genomic hybridization (CGH) and 
multicolour fluorescence in-situ hybridization (M-FISH) have increased the 
number of genomic alterations, such as gene signatures and copy number 
deletions and amplifications characteristically found in FL (17).  
 
1.2.4. Crosstalk Between Malignant & Non-malignant cells 
Though a B cell neoplasm, FL lymphoma retains many of the morphological 
features of the normal follicle. Cellular interactions between tumoral B cells and 
their surrounding follicular T cells (helper, cytotoxic and regulatory), FDC and 
macrophages are maintained in FL. T cell ligands and specific cytokines, (such 
as CD40 ligand and IL4) play a major role in the growth of both non-neoplastic 
B cells and follicular lymphoma cells, indicating that responsiveness to 
paracrine factors is not a characteristic of the malignant phenotype. Important 
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survival and trophic signals from FDCs/macrophages and T cells reach the 
neoplastic B cells which are highly dependent on these, as suggested by the 
difficulty of establishing FL cell-lines in vitro (18). 
The importance of the microenvironment and non-malignant cells within human 
tumours is not a recent finding. Rudolf Virchow first suggested it more than one 
hundred years ago (19, 20). Similarly the concept of tumoural 
immunosurveilance proposed by Paul Ehrlich represents a pivotal observation 
(21). Since then, tumoral immunity has been shown to evolve over time, 
characterized by crosstalk between tumour cells helping to shape their 
microenvironment and in turn being shaped by these surrounding non-
neoplastic immune cells. Along with dampening the anti-tumoral response there 
are several different mechanisms by which the microenvironment promotes 
tumoral growth, so called cancer immunoediting, as the tumour sculpts its own 
immunity in favour of growth and proliferation signals (22). 
Tumour associated macrophages (TAM) have been shown to promote not only 
neoplastic growth but also angiogenesis (23). Angiogenesis plays a vital role in 
growth and progression of both solid and hematological tumours. The 
"angiogenic switch" results from interactions of vessels with cancer cells as well 
as non-neoplastic cells in the microenvironment, including macrophages 
themselves (24). The abundance of macrophages, microvessel density (MVD) 
and recently of a subset of T cells, regulatory T cells (Tregs) associated with 
tumours, has been reported to correlate with poor prognosis in solid tumours. 
These cells are recruited and “educated” by tumours using a range of growth 
factors and chemokines, so that they adopt a “trophic” role that facilitates matrix 
breakdown, tumour-cell motility and angiogenesis (23). In FL, the role of cellular 
components of microenvironment in tumour progression and transformation is 
not well known with few studies published, many with conflicting results. In 
2004, GEP studies highlighted the role of non-neoplastic immune cells in 
influencing overall survival of FL (25, 26). The Leukemia/Lymphoma Molecular 
Profiling Project (LLMPP) consortium study first revealed that non-neoplastic 
immune cells (not the malignant cells) were predominantly responsible for the 
GEP signatures most contributing to the outcome predictor. One signature, 
referred to as immune response-1, appeared to be derived from reactive T cells 
in the lymph node biopsies and conferred a favourable outcome. The other 
 33 
signature, referred to as immune response-2, revealed a gene expression 
pattern most reminiscent of macrophages and/or FDCs and was associated 
with an inferior clinical outcome (25). However, the correlation of the gene 
signatures and the cellular components of the microenvironment and prognosis 
were not clear. These provocative data raised the question of non-neoplastic 
immune cells could be reproducibly identified and shown to be associated with 
survival and risk of transformation in FL. Could these cells be used to risk-
stratify patients with FL and ultimately become the targets of novel future 
therapies?  
The precise biological function of these non-malignant cells in FL remains 
poorly understood. Mouse models have shown great phenotypic heterogeneity 
amongst morphologically similar macrophages, but much less are known about 
human macrophages. The plasticity of macrophages is evident in the diverse 
range of functions of these cells, including inflammatory responses, immune 
reactions, tissue remodelling and morphogenesis. Macrophages can be 
functionally subdivided into two main classes, including “killer” or classically 
activated M1 macrophages or “healer”, alternatively activated M2 macrophages. 
These two types of macrophages differ in their receptor expression, cytokine 
and chemokine profiles as well in their metabolic pathways (27, 28). In vivo and 
within the tumoural microenvironment, macrophages of both kinds coexist with 
some cells showing overlapping or hybrid features. However, if markers 
representing the disparate ends of the macrophage spectrum are defined, these 
could be used as surrogate markers of anti or protumoral macrophages within 
routine FL biopsies.  
Besides TAMs, there are other relevant non-neoplastic cell types with 
interesting features found within the tumour microenvironment in FL. Tregs 
have also been shown to promote tumour growth in mice models as well as to 
correlate with inferior survival in human tumours (29).  In FLs, the role and 
significance of intra-tumoral T cells in the pathogenesis of the disease is still 
unclear. Cytotoxic CD8+ T cells and CD4+ helper T cells are usually present 
and classically have been considered as mediators of anti-tumour immunity 
(30). Tregs, a subset of CD4+ T cells with high expression of the IL2Rα chain 
(CD25), are crucial for the maintenance of self-tolerance (31). These cells 
represent less 1-3% of CD4+ T cells in humans (32). In addition to CD25, they 
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also express cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and 
glucocorticoid-induced TNFR-related protein (GITR), which are associated with 
suppressive features of these cells (33). However, the critical regulator of the 
development and function of Treg cells and the most lineage-defining marker is 
forkhead box P3 (FOXP3) (33-35). Although the mechanisms of suppression by 
Tregs are not completely understood, they seem to require direct cell-to-cell 
contact between Tregs and target T cells (36). Recently, in vitro studies using 
FL samples demonstrated that Tregs are present in significantly increased 
numbers when compared with normal tissues and these cells suppress other 
intra-tumoral CD4+ and CD8+ T cell by inhibiting proliferation and decreasing 
perforin and granzyme B production (37, 38). Tregs are not only attracted to the 
lymphoma microenvironment by their CCR4 receptor ligand CCL22, produced 
by lymphoma cells, but there is also local up-regulation of FOXP3+ cells by 
malignant cells in part by CD27-CD70 signaling (39).  These data suggests a 
suppressive and pro-lymphoma function of Tregs.  
Other T cells resident in the follicle have been recently described and their 
biology studied in great depth, including CD4+ follicular T helper cells. These 
cells are vital to the normal physiology of the germinal center and usually 
express CD57 and/or Programmed Cell Death 1 (PD1). In lymphoma, these 
cells are the benign counterpart of (at least) angioimmunoblastic lymphoma (40) 
and perhaps HTLV-1 induced lymphomas (41). In FL, the role of benign 
follicular T helper cells is poorly understood. 
FDCs are the supportive scaffolding of follicles and are responsible for helping 
to foster B cell maturation within the germinal center. In FL it has been shown 
that progression of disease is associated with less mature phenotype of these 
cells (42). 
Finally, angiogenesis is considered crucial in carcinogenesis (24) and has also 
been studied, although in less depth in lymphoid neoplasms. In FL, data are 
controversial with some studies suggesting a positive correlation between 
vascularization and tumour grade (43), while others have shown increased 
microvessel density to correlate with improved clinical outcome (44). A direct 
link has been shown between angiogenesis and macrophages as monocytes 
may be recruited to sites of tissue injury or tumour microenvironment and 
directly contribute to angiogenesis, reaffirming the close relationships between 
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various cell types within the reticulo-endothelial system and even suggesting 
possible targets for anticancer treatments (45).  
As indicated above, FL is characterized by the t(14;18)(q32;q21). In vitro 
studies have shown that precursor cells of the B cell lineage can differentiate 
into other cell types including tissue-based macrophages (46). Interestingly, in 
FL, a subpopulation of endothelial cells shows the characteristic t(14;18) 
translocation of FL (47), although this finding remains controversial. This finding 
may indicate (among other hypotheses) plasticity of a neoplastic precursor cell 
in the marrow that maintains the ability to differentiate into different mature cell 
types.  Eventually, one can hypothesis that the pro-malignant t(14:18)+ clone 
could seed follicles not only with pre-malignant B cells but also with other types 
of “non-malignant” accessory cells that could provide the malignant cells with 
pro-survival signals.    
Little is known about a possible role of the non-neoplastic cells in the 
microenvironment impacting the risk of FL transformation. Transformation is 
typically associated with the effacement of the follicular architecture, 
accompanied by loss and immaturity of the FDCs and a decrease in the 
admixed T cell content. These changes correlate with the accumulation of 
additional genetic abnormalities. However, in a GEP study cases that 
transformed more rapidly were characterized by an abundance of activated T 
cells (26). 
 
1.2.5. Transformation 
Several genetic alterations have been associated with histologic transformation 
of FL, including aberrations involving dominant oncogenes; loss of tumour 
suppressor genes and many as yet poorly characterized cytogenetic events. 
Well-known examples include rearrangements of the MYC gene, mutations or 
loss of the TP53 or TP16 genes, and rare somatic alterations of the BCL6 and 
BCL2 genes (48-55). However, these alterations are observed in limited 
subsets of transformed FLs, suggesting that the process of histological 
transformation can occur by multiple different mechanisms (56).  
Studying transformation of FL requires the use of paired specimens comparing 
biopsy material from the same individual pre and post transformation, which 
explains the limited number and size of reported studies. Microarray CGH 
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studies have recently shown a heterogeneous pattern of genomic aberrations 
acquired upon transformation. These include gain/amplification of 1q21-q24, 
2p16 (REL/BCL11A), 3q27-q29 (including the BCL6 locus), 7q11.2-q22.1, 
12pter-q12, 18q21 (including the BCL2 locus) and Xq, and deletion of 6q22-
q24, 13q14-q21 and 17p13 (TP53 locus) that had been previously implicated in 
the FL & DLBCL pathogenesis (57). Additional changes include novel 
imbalances such as over-representation of 4p12-pter, 5p12-p15, 6p12.3-p21, 
9p23, 9q13-q31, 16q, 17q21, and loss of the 1p36.3, 4p21-q23, 5q21-q23, 
9q31-qter, 11q24-q25, and 15q23.  None of these recently described changes 
were specific for transformation. More importantly, the specific genes involved 
at these sites are unknown (57). 
These areas of amplification and deletion likely represent strong candidate loci 
to harbour genes important for cancer development and progression. Moreover, 
alterations of these loci likely influence gene expression secondary to copy 
number alterations. Knowledge of the key genes and the resultant aberrant 
expression patterns may also represent potential new targets for future 
therapies.  
Previous GEP studies using cDNA microarray techniques have identified two 
groups of patients with distinct transformation profiles. One pattern 
demonstrated increased expression of MYC and its target genes and a second 
group demonstrated decreases in MYC and its downstream targets (58). 
However, many of the genes that were located in the abnormal chromosomal 
regions (found in some cases studied by low-resolution array-CGH) did not 
show significant alterations in expression. In addition, the majority of the genes 
that showed increased or decreased expression upon transformation were not 
located within these identified regions based on aCGH (e.g. the MYC gene).  
More recently, Davies et al reported data on 20 paired fresh frozen specimens 
using Lymphochip cDNA microarray of transformed FL to have GEP similar to 
germinal centre B cell type (GCB) of DLBCL and none with the activated B cell 
type (ABC) DLBCL profile (56). Furthermore they suggested transformation 
could occur by at least two pathways, distinguished by cellular proliferation. One 
is characterized by increased proliferation, including recurrent higher expression 
of MYC and its targets as well as TP53 mutations, cREL amplification and 
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CDNK2A loss. No characteristic features were recognized in the other subset of 
cases in which proliferation was not a dominant feature (56). 
Despite the small number of studies, these current data suggest that FL 
transformation to DLBCL occurs by diverse genetic alterations. No single 
genetic event is responsible for all cases.  The most common changes appear 
to affect different aspects of cell physiology (apoptosis, cell cycle control and 
specially proliferation) and are not specific for transformation, being present in 
non-transformed FL as well as in other lymphoma subtypes. Yet, early steps of 
the transformation event have proven difficult to study as has the role of FL 
microenvironment in transformation.  
 
1.2.6. Prognostic Markers in FL 
Many biomarkers associated with outcome have been proposed over the years, 
as is shown in Figure 1.1 (Prognostic markers in FL). For complete details see 
review (11). Yet, most studies are single reports, with very few validation 
studies reported and more importantly most studies were done retrospectively 
in cohorts of patients treated with inconsistent treatment protocols, the vast 
majority before the introduction of biological agents such as rituximab. 
Consensus on which biomarkers to use in clinical practice and how they might 
impact treatment decisions are still lacking. Currently, clinical characteristics 
included in robust indices such as FLIPI or FLIPI-2 (9, 10) are still the basis for 
clinical decision making. Inclusion of candidate biomarkers in prospective 
randomized clinical trials is mandatory to validate their future use and possible 
contribution to a combined clinical & biological index. 
Finally, most of the aforementioned biomarkers with prognostic impact in FL 
patients used cohorts of patients administered heterogeneous treatment 
protocols. As there is no accepted standard of care treatment for FL, therapy 
varies from observation to high-dose chemotherapy and a bone marrow 
transplant. This variability undoubtedly impacts on overall survival as well as 
affecting the risk of transformation. Interesting clinical data supporting this were 
recently published by Al-Tourah et al, where a series of indolent B cell 
lymphomas treated with high-dose chemotherapy and involved field radiation 
showed a significant decrease in the risk of transformation when compared with 
lymphomas treated with a less aggressive regimen (7). Thus, it is of vital 
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importance that before comparisons are done of different clinical cohorts of FL 
that attention be paid to those reports that included uniform treatment. As 
therapy itself is an important prognostic variable, studies that include patients 
with vastly different therapy cannot easily be interpreted. As the treatments 
used are differentially visited upon both the malignant B cells and the immune 
cells in the microenvironment, the interpretation of prognostic biomarkers and 
those related to risk of transformation require that the treatment variable be held 
constant (11). 
 
 
1.3 OTHER LYMPHOMAS 
 
1.3.1. Diffuse Large B Cell Lymphoma 
DLBCLs are a heterogeneous group of tumours consisting of large, transformed 
B cells, accounting for more than 30% of adult lymphomas in the western world. 
DLBCL occurs at any age, more commonly in the 6th & 7th decades of life. The 
disease typically presents as a nodal or extranodal mass with rapid tumour 
growth associated with systemic symptoms. Approximately 50 to 60 percent of 
patients will present with advanced stage. DLBCL includes an increasingly 
complex spectrum of lymphoid neoplasms with different morphologic, 
phenotypic, genotypic and clinical characteristics (2). Immunodeficiency is a risk 
factor for DLBCL, and about 5-10% of DLBCLs are EBV+, depending on the 
geographic population studied. 
This disease is potentially curable with combination chemotherapy, such as 
cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). 
Importantly, the addition of immunotherapy using an antibody against CD20, 
rituximab (R) to multi-agent chemotherapy has significantly improved outcome 
(59, 60). High-dose chemotherapy with autologous stem cell transplantation is 
effective in relapsed or refractory DLBCL. Yet, despite the improvements, 30 to 
40% of the patients will not be cured of their DLBCL. 
DLBCL can arise de novo, or as a result of a transformation event in a patient 
with previous low-grade lymphoma, including small lymphocytic lymphoma / 
chronic lymphocytic leukemia (Richter´s syndrome), follicular lymphoma and 
marginal zone lymphomas. These DLBCL represent a common final pathway of 
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histologic transformation of antecedent indolent lymphomas and are likely to be 
biological distinct from DLBCL cases that arise de novo. 
 
1.3.2. Hodgkin Lymphoma 
Hodgkin lymphoma (HL) was the first recognized lymphoma entity originally 
described in 1832 by Thomas Hodgkin (61-63). Called Hodgkin disease for 
more 150 years due to its unknown etiology, only in 1993 molecular studies on 
the microdissected pathognomonic Hodgkin and Reed-Sternberg (HRS) cells 
showed this to be a B cell tumour (64). The malignant HRS cells usually 
account for only 1% of cells in tumour tissue, whereas the majority of the cells in 
the biopsy represent non-neoplastic cells of the immune system. HL accounts 
for approximately 30% of all lymphomas with an incidence in the western world 
of 3 cases per 100.000 people per year. There are two distinct types of HL that 
show biological and clinical differences; classical HL (CHL) representing 95% of 
HL cases and nodular lymphocyte-predominant Hodgkin´s lymphoma 
accounting for the remaining 5%. Within classical HL four subtypes are 
distinguished including nodular sclerosis, mixed cellularity, lymphocyte-rich and 
lymphocyte-depleted with some differences in anatomic sites of involvement, 
clinical features, growth pattern, presence of background fibrosis and 
composition of the cellular infiltrate and frequency of EBV infection. In common 
to all CHL subtypes is the HRS immunophenotype, characterised by strong 
expression of CD30 and CD15 and no or weak expression of CD20, PAX5 and 
CD45. Nodular sclerosis accounts for 60-85% of HL (2).  
Treatment is based on clinical, radiological imaging and pathological staging. A 
modified Ann Arbor staging system is used as follows: limited disease (stages I 
and IIA without constitutional symptoms) or advanced disease (stages IB and 
IIB with bulky disease [largest deposit, ≥10 cm in diameter] and stages III and 
IV either A or B [with or without constitutional symptoms]) (65, 66). 
Dramatic therapeutic benefits where achieved in the last 2-3 decades. 
Currently, most patients receive at least four cycles of polychemotherapy and, if 
indicated, radiotherapy (67). Yet, at least 20% of patients are still not cured and 
a similar or greater proportion of patients maybe overtreated (68) Autologous 
hematopoietic stem-cell transplantation can rescue about 50% of patients in 
whom primary therapy has failed. Initial clinical decisions and risk stratification 
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for patients with Hodgkin’s lymphoma are largely based on clinical variables that 
distinguish those who are at high risk from those at standard risk. The 
International Prognostic Score (IPS) (on a scale of 0 to 7, with higher scores 
indicating increased risk) is the standard that is used for risk stratification of 
advanced stage HL, but it does not apply to limited stages, and none of the 
published prognostic factor systems can reliably identify patients in whom 
treatment is likely to fail (69). Moreover, neither the IPS nor its individual clinical 
components are suitable for accurately predicting the outcome of autologous 
hematopoietic stem-cell transplantation in patients with HL. For these reasons, 
reliable biomarkers for predicting long-term survival at diagnosis are needed for 
such patients.  
In HL, unlike most other cancers, the malignant HRS cells are outnumbered by 
non-neoplastic cells in the microenvironment of the tumour. The frequency and 
distribution of these cellular components and HRS cells vary considerably 
among individual patients and among subtypes of HL (2). Several studies have 
focused on the prediction of outcomes by means of markers expressed 
predominantly by HRS cells or the microenvironment (70-75). However, most of 
these markers require validation in independent cohorts. 
 
1.3.3. Mantle Cell Lymphoma 
Mantle cell lymphoma (MCL) accounts for roughly 6% of NHL and is 
characterized by the presence of the t(11;14) translocation that juxtaposes the 
CYCLIN D1 (CCND1) gene downstream of the immunoglobulin heavy chain 
gene promoter resulting in deregulated G1/S phase transition leading to cellular 
proliferation (2). MCL usually shows widespread disease in most patients at the 
time of diagnosis with lymphadenopathy, hepatosplenomegaly and bone 
marrow involvement (76-78). The behaviour of MCL has largely been attributed 
to the intrinsic features of the tumour cells induced by the CCND1 
overexpression, which is supported by studies relating mitotic rate and Ki67 
expression, a marker of proliferation, with patient outcomes (79, 80). While MCL 
is essentially incurable, the clinical behaviour is heterogeneous with previous 
studies also identifying variations in mode of clinical presentation (76), tumour 
histology (81, 82), cytogenetic alterations (83, 84), immunoglobulin gene status 
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(85, 86), TP53 gene mutations and TP53 protein overexpression (87, 88) and 
proliferation signature (89) as predictors of outcome. 
The disease has a lower rate of complete remission, duration of response, and 
overall survival after conventional chemotherapy when compared with other 
lymphomas, with a rather short median survival of 5-7 years using aggressive, 
multidrug therapy, usually including cytarabine and R (90, 91). Consolidation 
therapy with autologous stem cell transplantation is also used. New 
chemotherapeutic agents and radioimmunotherapy may add further to 
advances in treatment. 
 
1.3.4. Primary Mediastinal Large B Cell Lymphoma 
Primary Mediastinal Large B Cell Lymphoma (PMBCL) is a distinct lymphoma 
entity arising in the mediastinum from putative thymic B cells (2). Biopsies of 
PMBCL are composed of medium to large-sized cells with abundant pale 
cytoplasm, ovoid nuclei and are characteristically associated with background of 
fine sclerosis. PMBCL accounts for 2-4% of NHL and occurs predominantly in 
young adults with a female predominance. It is locally aggressive, but less likely 
to extend beyond the anterior mediastinum. With similar therapy the outcomes 
are typically superior to nodal DLBCL in most series with a survival plateau after 
2.5 years (92, 93). Yet, clinical criteria, such as IPI, imprecisely predict therapy 
response (94).  PMBCL shares histological and gene expression features with 
both GCB subtype of DLBCL and classical Hodgkin lymphoma (95, 96).  
 
 
1.4 GENOTYPE & PHENOTYPE ASSESSMENT IN CANCER 
 
1.4.1. Gene Expression Profiling (GEP) 
Microarray technology relies on the binding of a target molecule, either labeled 
RNA or cDNA fragments to an immobilized detecting reagent (oligonucleotides / 
cDNA) as a means to study the expression of thousands of molecules 
simultaneously (97). Developed since the 1950s, the technology benefited from 
widely disparate advances in a number of unrelated fields, such as the 
quantitative detection of complementary hybridization of nuclei acid; parallel 
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generation of gene fragments through PCR technology; laser and robotic 
application of multiple samples to small arrays; availability of large sets of cDNA 
clones, improvements in computing and software design, mathematics and 
bioinformatics and finally the completion of first reference human genome in 
early 2001.  Both of the most common platforms; spotted arrays, in which 
measured amounts of specific cDNA or oligonucleotides are accurately spotted 
on microscope glass slides, and synthetic arrays, in which short 
oligonucleotides are synthesized in situ on the surface by photolithography 
(developed by Affymetrix®), rely on the hybridization of free, labeled nuclei 
acids derived from sample RNA to known gene sequences immobilized on 
glass (98). Upon hybridization, fluorescent signals are generated, captured and 
a ratio calculated that enables the quantification of the bounded probe. Data 
analysis and interpretation follows through quality assessment, filtering and 
normalization (98). Once these data has been processed, most researchers 
usually employ some form of clustering in order to identify and represent 
different patterns of expression hidden in the data. Differences and similarities 
between patterns (Class Discovery) and whether the distinctions can determine 
functional groups (Class Prediction) can be evaluated (99). Clustering can take 
two main forms, unsupervised and supervised. In unsupervised clustering, no 
previous information is assumed. Data are presented to an algorithm, such as 
the average-linkage hierarchical clustering algorithm (100), which organizes 
data based on similarities between either the levels of GE across samples or 
their expression patterns. It is hierarchical because it starts with one gene and 
progressively scores other genes for identity with the first gene, creating a 
branching tree-like structure in which the length of the branches represents the 
degree of relatedness between genes. This or other methods (101) result in 
grouping the samples with similar patterns of GE, with the assumption that 
similar transcriptional profiles indicate a close relationship between samples. 
In supervised clustering, groups are defined previous based on expression 
profiles, clinical or biological distinctions and profiled. A learning algorithm, such 
as Nearest Neighbor Analysis, is applied to identify the smallest set of genes 
that can reliably distinguish between the predefined categories (99). The 
accuracy of the predictor is then validated on a separate set of data, or using 
different statistically approaches for cross-validation, often using Bayesian 
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mathematics to generate classifiers that include an element of probability in the 
value of each given gene within the classifier. 
Microarray GEP of hematological malignancies has been instrumental in the 
early stages of this field (102). Reported studies have covered several aspects 
of molecular biology. Most have been basic profiling studies, primary 
descriptive, often trying to gain new insights of the origins or etiology of 
tumours. This is achieved by comparing the tumour gene signature with 
signatures of “normal” development counterparts (103). Likewise, divergent 
profiles from the nearest normal cell type may reveal insights into important 
pathways or mechanisms important in tumorigenesis. Other studies aim to 
identify the minimum set of genes required to identify a particular tumour 
subclassification, resulting in minimum diagnostic classifiers. Specific profiles 
can also be correlated with known clinical outcome of patients thereby creating 
prognostic classifiers. 
One of the difficulties in microarray gene array studies is the comparison and 
validation of experiments. Despite the trend to uniformity in data storage and 
increased data availability for comparison, application of results to diagnostic 
and clinical decisions has been very slow to develop. For some diseases and 
often using similar technology, lists of genes for classification or outcome can 
vary widely. Yet, often the different gene sets are accurate in classifying and 
predicting tumours. Individual genes or set of genes may not be the most 
informative data, but the underlying disrupted intracellular pathways, often 
affecting large number of genes, can be of more value for classification 
purposes. Both technical and analytic issues are responsible for this variability. 
A wide range of factors are responsible for the technical discrepancies 
including, sample variability and archive conditions, RNA extraction methods, 
RNA amplification, which platform is used, when it is used and by whom, 
hybridization conditions, uniformity of samples and even the size of the sample 
(104). Analytic factors are the greatest source of variability as different 
algorithms and analysis method can produce different classifiers beginning with 
the same raw input data. The introduction of the minimum information about a 
microarray experiment (MIAME) protocol, which recommends all experiments to 
be similarly stored and make available a minimal set of data about the 
experiments, some of the issues have now been overcome (105). Yet, the issue 
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of lack of comparability is still present as evidenced by the lack of independent 
validation of many studies. The high cost of performing studies with enough 
samples to achieve statistical power, which usually requires series of hundreds, 
makes most of these experiments difficult to repeat or validate. 
 
1.4.2. Genome-wide Scanning for Copy Number Alterations - Bacterial 
Artificial Chromosome (BAC) Array Comparative Genomic Hybridization 
(aCGH) 
Using aCGH, an array of specific chromosome segments, in this study Bacterial 
Artificial Chromosomes (BAC), immobilized on a glass slide is used as the 
target (106). aCGH resolution is only dependent by the size and distance 
between each DNA segments spotted on the glass arrays. Figure 1.2 
summarizes the principle of the method. Firstly, test tumour DNA and control 
normal DNA are differently labeled with fluorescent dyes and hybridized to each 
spot. The resulted ratio of fluorescence intensities is proportional to the copy 
number difference in that DNA segment. The utility of aCGH in detecting 
recurrent sites of DNA gain and loss in cancer is well established on the basis 
of numerous reports (107, 108). As technology has improved, several groups 
applied this method for high-resolution, genome-wide scanning of abnormalities. 
At the British Columbia Cancer Research Centre (BCCRC), an aCGH platform 
was built with a minimal tiling set of 32,433 BAC clones covering >95% of the 
human genome (109). The BAC library was fingerprinted using Hind III. Using a 
linear PCR method, the clones were then converted to Amplified Fragment 
Pools, representing segments of DNA with specific chromosome locations 
(110). These AFP were represented in triplicates in the array. Later the same 
group revised the platform to 27,000 BAC clones, having removed a number of 
redundant clones. The technical details of the array production, hybridization 
and imaging are published (109). To analyze the approximately 100,000 ratio 
signals (32,433 clones spotted in triplicate) and align on the human genome 
map, bioinformatic tools were developed by the same group (SeeCGH 
software) (111).   
 
1.4.3. FICTION Technique 
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Simultaneous fluorescence immunophenotyping and fluorescence in situ 
hybridization (FISH), so called, fluorescence-immunophenotyping and 
interphase cytogenetics as a tool for investigation of neoplasms (FICTION) 
provides the advantage of both techniques and allows a simultaneous analysis 
of the phenotype and genotype of tumour cells at the single-cell level (112, 
113). Using specific cell lineage and differentiation associated monoclonal 
antibodies for immunophenotyping as well as DNA probes specific for known 
chromosome alterations by FISH, this combined technique makes it possible to 
correlate particular gene aberrations directly with the differentiation capacity of 
tumour cells. This is especially important in cases where the cells of interest 
may be in the minority and morphological features are an important and defining 
criterion of the disease (113, 114). In formalin fixed paraffin embedded tissue 
(FFPET) sections, several early reports described difficulties in obtaining an 
efficient hybridization signal while retaining immunofluorescent staining (115). 
However, these problems can be overcome, and recent studies have shown 
simultaneous application of FISH and immunofluorescence on FFPET sections, 
including bone marrow samples (116). 
  
1.4.4. Tissue Quality & Fixatives 
Until recently, both GEP and aCGH studies have been done using frozen 
material because quality of RNA influences the reliability of the output data. 
Snap fresh frozen (FF) tissue from diagnostic biopsies is the preferred source of 
RNA for GE studies in oncology. Yet, often these biopsies are limited in size 
and provide barely enough for morphological procedures done using standard 
FFPET techniques. It is not uncommon that biopsies may be partially involved 
by disease and thus frozen samples may not be representative. Often 
morphologic and cytological features in FF sections are not helpful in distinguish 
different types of cells. Finally, this is not a routine procedure in many centres, 
thus limiting sample size and the number of successful cases with paired 
specimens to study lymphoma histologic transformation. 
Ideally, a clonal relationship should be established between paired biopsies so 
as to exclude the possibility of a 2nd de novo lymphoma. Often this may not be 
demonstrable due to clonal evolution with loss of common abnormalities or 
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emergence of a different subclone from a precursor “FL stem cell”, which 
hampers interpretation of these data. 
These are several different reasons why FFPET represent excellent materials to 
study lymphoma biomarkers, primarily because it is widely available as a 
routine source of biopsy material for more than 100 years. Biopsies kept in 
formalin can be retrospectively retrieved from most Anatomic Pathology 
Department archives; they are mandatory in the diagnosis of transformation in 
most cases and usually they are the most abundant and representative tissue of 
the tumour. 
However, DNA and specially RNA quality extracted from FFPET has been an 
important issue in the past. Its consistent poorer quality is attributed to formalin 
fixation inducing the formation of methylene bridges between amino group in 
the DNA and proteins; cross-linking of RNA and proteins as well as 
monomethylol group addition to bases. These processes are helpful in 
preserving cellular composition and morphology of tissue, but unfortunately 
reduce the penetration of both antibodies, nuclei acid probes and importantly 
are known to interfere with reverse transcription and amplification reactions due 
to cross-linking of nucleic acids. Moreover, deficiencies in several steps of the 
routine acquisition, handling and processing of the samples can contribute to 
irreversible degradation of both DNA and RNA.  
One important factor that determined the success of FISH and 
immunohistochemistry (IHC) in FFPET samples is adequate unmasking of the 
target nuclei acids before staining or hybridization. Thus, pre-treatment methods 
are vital to expose target genes or proteins to allow penetration and reaction of 
the probes with preservation of tissue morphology. 
High-throughput microarray GEP analysis of FFPET samples has been 
infrequently reported. Yet, FFPET isolated RNA has been shown to be suitable 
in viral detection or quantitation of mRNA levels by PCR. Recently, several 
protocols have been reported to improve robust isolation and amplification of 
RNA from FFPET (117). Recent reports have shown successful results of both 
aCGH and GEP using FFPE samples (118-122) 
Finally, reliable amplification has been a challenge not only in FFPET but also in 
FF samples. Due to technical biases of the methods, most GEP reports 
correlating pre and post amplification samples have shown important changes 
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in results precluding accurate and precise conclusions (123). FFPET 
consistently shows poorer profiles than FF. However, if amplification can be 
avoided and degradation measured and quantified, FFPET samples have 
shown consistent GEP results (117). 
 
1.4.5. Tissue Microarray 
As previously mentioned, Anatomic Pathology archives store large numbers of 
specimens of human tumours in various stages of development as well as 
normal tissue counterparts, and have become very precious since the 
completion of the first reference human genome. Thus, FFPET samples have 
gained importance in cancer research in view of the recent developments. The 
arrival of the array technology to morphologic pathology happened in 1998 as a 
high-throughput facility to use several (hundreds) tissue samples on a single 
slide (124).  
The idea of embedding many pieces in a single block existed in the early days 
of anatomical pathology, but several embedding instruments for this purpose 
recently became popular, and technical refinements are under way. One well 
established brand of microarray instruments is Beecher Instruments (Beecher 
Instruments, Inc. Sun Prairie, WI, USA). Their models have 0.6 mm, 1 mm and 
1,5 mm cylinders. There are pros and cons in regard to using the method. Yet, 
several validation studies in regard to possible sampling error when small core 
specimens are collected have been performed confirming its use. Very recently, 
donor blocks with different variations are available, enabling a tissue microarray 
(TMA) platform to be used for genomic, immunohistochemical and proteomics 
using imaging spectroscopy. 
TMA technology rapidly became the preferred technique in the validation and 
clinical correlation of the GEP arrays. It facilitates the simultaneous analysis up 
to 1000 specimens in a single slide of numerous tissue samples based on their 
morphology, protein expression (IHC) and genomic mutations (FISH). It allows 
the multiple use of often limited biopsy material in a cost & time effective 
manner where samples are exposed to the same experimental conditions 
during analysis. Furthermore, arraying of multiple cores ensures the 
consistency of analyzed features diminishing technical errors when analyzing 
hundreds of samples (125). This led to improvements in translational research 
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by correlating proposed biological markers of disease with clinical outcome 
analysis.  
Entire cohorts of patient´s biopsies can be stored in few blocks & slides 
enabling easy querying for phenotypic and genotypic abnormalities using 
immunohistochemistry or in situ hybridization. Using a combination of these 
methods facilitates identification of changes of protein expression or genomic 
locus in several hundreds of tissue samples at once. Libraries of antibodies that 
recognize almost all human proteins (such as the Human Protein Atlas project 
(http://www.proteinatlas.org) or of Bacterial Artificial Chromosomes (BAC)  that 
cover all the genome enabling the construction of FISH probes that recognize 
any specific sequence of human DNA facilitates their use not only in research, 
but can also be used in routine diagnostic laboratories as a means of verifying a 
diagnosis, selecting subjects for particular molecularly targeted therapies, and 
for predicting recurrence. Similarly, FISH techniques can be performed as a 
means of validation, that is, to verify amplification data generated by other 
methodologies, such as by quantitative PCR, array based comparative genomic 
hybridization (aCGH), and single nucleotide polymorphism (SNP) arrays. These 
approaches can be further combined with other techniques such as 
immunofluorescence, including FICTION (Fluorescence Immunophenotyping 
and Interphase Cytogenetics) as a tool for the investigation of neoplasms.  
When BAC clones are used for FISH studies in paraffin-embedded tissue 
sections, several steps must be carefully controlled including labelling and 
hybridizing to DNA. The BAC clone must be confirmed to map to the desired 
location using normal cells, because assignments of BAC clones often change 
to reflect the daily process of refining the human genome database. The 
information on exact location of each BAC probe according to the most recent 
annotation of the human reference genome is necessary (publically available in 
different sites, such as University of California Santa Cruz (UCSC) genome 
browser (http://genome.ucsc.edu/). Thus, all BAC probes must be tested to 
determine whether they are hybridized to the two corresponding sites (or two 
pairs of the signals on the sister chromatids) in the metaphase chromosome 
spread before they are applied to human tissues containing cancer cells.  
In addition to the above-mentioned hurdles to obtaining the right BAC probes, 
there is another stumbling block to completion of a FISH study: the labelling 
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step. Several labelling methods are available, and some are commercially 
available, using protease treatment, microwave treatment, heating, and other 
treatments including various detergents. Since overlapping cells and cells 
whose nuclei are partially cut can cause miscounting of the numbers of signals, 
cut-off values must be set based on preliminary evaluation of the signals in 
several non-neoplastic tissue controls.  
 
1.5 HYPOTHESES & SPECIFIC AIMS  
  
Aim 1- Mechanisms Underlying Transformation of FL into DLBCL 
 The general aim of this study was to investigate how alterations in the genome 
impact transformation of FL into DLBCL. We hypothesized that structural 
genetic abnormalities found during transformation should impact on the 
transcriptome of important candidate genes responsible for transformation. As 
time and burden of disease may influence the spectrum of abnormalities 
detected or not detected, a proper study should focus not only on paired 
specimens of both disease components separated in time, but also in cases 
with both diseases showing early events in transformation. The correlations of 
alterations of GEP with copy number alterations may indicate important 
biological pathways of transformation. Differences of GEP in composite 
lymphomas may show features associated with early events of transformation 
and thus were a focus of our studies. 
 
Aim 2 – Role of the Microenvironment in FL Transformation into DLBCL 
The general aims of this study were to investigate how alterations in the 
microenvironment collaborate in the progression of FL into DLBCL, aiming to 
identify biomarkers heralding transformation and eventual future therapeutic 
targets. We hypothesized that non-neoplastic cells in FL are not just innocent 
bystanders. A symbiotic relationship exists between the neoplastic B cells, 
reactive T cells, FDCs, vessels and macrophages that may have an important 
impact in the clinical outcome of this disease and thus the risk of transformation. 
Tumour immunity may be a driving force in FL progression and transformation. 
The content and distribution of non-malignant cells may correlate with clinical 
outcome and risk of transformation and be used as biomarkers helping current 
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clinical indices in therapeutic decisions or prognostic information. Thus, we 
hypothesized that non-malignant cell content and distribution within FL may be 
a surrogate marker of protumoral immunoedited tumour immunity. 
 
Aim 3 - Monocyte & Macrophage Interactions in Patients with FL 
Harboring a t(14;18): Is There a Clonal Relationship? 
As indicated previously, some follicular lymphomas sculpt their 
microenvironment attracting and/or retaining predominantly M2-type 
macrophages. These reactive “non-malignant” cells may not be just “reactive” 
but eventually derived from FL clonally related precursors cells. A subset of 
these monocytes/macrophages could differentiate from the FL “stem cell pool” 
in the marrow and then be recruited to lymphoma sites. Once in the lymph 
node, these cells may provide the neoplastic B cells with a trophic environment 
in cooperation with regulatory T cells leading to an immunosuppressive intra-
tumoral milieu. Identifying macrophages within the lymphoma microenvironment 
from patients with follicular lymphoma previously shown to have a t(14;18) 
might allow us to determine if a subset of these cells similarly harbour a t(14;18) 
and thus are clonally related. 
 
Aim 4 – Identification of New Biological Predictors of Survival in Different 
Human Lymphomas Subtypes. 
Expanding aim 2, the general aims of this study were to identify biomarkers with 
prognostic impact in different types of biologically and clinical relevant 
lymphomas and eventually inform on a list of future therapeutic targets. Similar 
to FL, we hypothesized that the microenvironment is not just an innocent 
bystander, but an active player in lymphomagenesis. The content and 
distribution of non-malignant cells may correlate with clinical outcome and be 
used as biomarkers helping current clinical indices in therapeutic decisions or 
providing prognostic information. Finally, special importance was given to the 
re-evaluation of previously studied biomarkers in non-Hodgkin lymphomas 
receiving recently introduced immunotherapy (monoclonal antibody anti-CD20, 
R). 
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1.6 FIGURES 
 
 
 
Figure 1.1 - Prognostic markers in FL. For complete details see review (11). 
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Figure 1.2 - Bacterial Artificial Chromosome (BAC) array comparative genomic 
hybridization (aCGH) – The British Columbia Cancer Research Centre built an 
aCGH platform was built with a minimal tiling set of 32,433 BAC clones covering 
>95% of the human genome. Using a linear PCR method, the clones were then 
converted to Amplified Fragment Pools, representing segments of DNA with 
specific chromosome locations.  Test tumour DNA and control normal DNA are 
differently labeled with fluorescent dyes and hybridized to each spot. The 
resulted ratio of fluorescence intensities is proportional to the copy number 
difference in that DNA segment.  
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Section 2: Mechanisms of Follicular Lymphoma 
Transformation into Diffuse Large B Cell Lymphoma 
 
2.1 INTRODUCTION 
This study was undertaken to further elucidate the biological mechanisms 
underlying the transformation of FL. The comparison of biopsy material from the 
same individual pre and post-transformation has been classically defined as the 
prerequisite for a clear understanding the molecular mechanisms driving the 
event. Until recently, most studies have revealed a number of recurring 
cytogenetic abnormalities (see Section 1) each one occurring in a small subset 
of cases, highlighting the molecular diversity of the transformation event. The 
combination of global gene expression analysis supplemented with genomic 
copy-numbered analysis may provide new insights into the mechanisms of FL 
transformation. 
In the current study we performed two experiments using: (1) a series of paired 
fresh snap frozen (FF) lymph node biopsies material retrieved pre and post the 
transformation event and (2) a cohort of FFPET composite lymphomas with FL 
and DLBCL diagnosed in the some lymph node, most likely representing early 
transformation events. We used a combination of genome-wide microarray 
techniques including different commercially available expression array platforms 
(both Affymetrix® & Agilent® arrays) as well as the Vancouver BCCRC 
microarray-based CGH (array-CGH) using the submegabase resolution tiling 
arrays (see Section 1). 
 
 
2.2 EXPERIMENT 1: Comparison of Gene Expression Profiling and 
Genomic Abnormalities Using Paired Fresh Frozen Samples 
 
2.2.1. Material & Methods 
2.2.1.1 Patients & Sample Selection 
Twelve patients with sequential fresh frozen paired biopsies from pre- and post-
transformation FL were identified from the Arhus University Hospital based on 
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histological transformation of FL to DLBCL (1) and fresh frozen tissue 
availability. Cases had a wide range of time to transformation (ranging from 1 to 
10 years post FL diagnosis). In reviewing the available tissue samples at the 
BCCA, it was not possible to show definitive histological transformation into 
DLBCL in the available material in five cases and in two cases there was 
insufficient viable material. We next examined the clonal relation between 
biopsy pairs using extracted DNA and routine standard heteroduplex IGH and 
BCL2 PCR methods based on established techniques at the BCCA pathology 
laboratory (http://www.bccancer.bc.ca/HPI/labservices/). Only four pairs were 
confirmed by PCR to be clonally related, harbouring both IGH & BCL2 clonal 
rearrangements, which were identical size between the original FL and post-
transformation tumors (Figure 2.1). The remaining three pairs failed due to 
either poor quality DNA or different IGH & BCL2 clone rearrangement between 
the pairs, raising concerns about the possibility of completely unrelated 
lymphoid malignancies. 
RNA was isolated from frozen tissue biopsies using standard protocols 
(http://www.bccancer.bc.ca/HPI/labservices/) and gene expression profiling 
(GEP) was performed using Affymetrix® Human Genome U133 Plus 2.0 Array 
(> 54,000 transcripts). All tumor samples were stored as tissue fragments in 
Optimal Cutting Temperature (OCT) medium. Total cellular RNA (Trizol) was 
isolated using standard protocols (http://www.bccrc.ca/). Extracted RNA was 
applied to the Affymetrix® array according to the manufacturer’s instructions 
(http://www.affymetrix.com/). 
 
2.2.1.2. Affymetrix U133 Plus 2.0 Array 
The four samples were applied to the arrays following by reverse transcription 
using the manufacturer’s standard protocol (http://www.affymetrix.com/). For 
each specimen, total RNA was converted into double-stranded cDNA using a 
cDNA Synthesis System kit. The cDNA resulting from this reaction was purified 
using the GeneChip Sample Clean-up Module (Affymetrix®). Labeled cRNA 
was generated using in vitro transcription labeling nucleotide mix (Affymetrix®). 
The resulting cRNA was then purified using the GeneChip Sample Clean-up 
Module (Affymetrix®) and quantified using the Nanodrop ND-1000 
spectrophotometer (NanoDrop technologies®). Hybridization, washing, staining 
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and scanning protocols, respectively, were performed on Affymetrix GeneChip 
instruments as recommended.  
The image files (DAT.) and cell intensity files (CEL files) were analyzed using 
Genespring 6.01 software package. Both supervised and unsupervised 
analyses were performed to determine differentially expressed genes using 
different cutpoints: 2x, 3x, 5x fold-change at a False Discovery Rate (FDR) 
<0.05.  In the unsupervised analysis using 595 differentially expressed genes, 
the eight samples cluster by patient origin (Figure 2.2). In the supervised 
analysis of gene expression that compared directly between pairs of pre and 
post-transformation, we used p<0.05 and different multiple testing correction 
strategies, generating two gene lists with 273 (110 false-positive) and 18 (1 
false-positive) genes, respectively (Figure 2.3). All GEP protocol and data 
analysis was done in collaboration with specifically trained staff from Genome 
Sciences Centre, Vancouver (http://www.bcgsc.bc.ca/), in particular Tarun 
Nayar and Alan Delaney. 
 
2.2.1.3. CGH: BCCA Array  
ArrayCGH was performed using formalin-fixed paraffin-embedded tissue 
(FFPET) and the same control of pooled male genomic DNA. In order to enrich 
the purity of malignant B cells, the FL samples were laser microdissected 
(Leica®) so that only malignant follicles were used in the comparison. In the 
setting of FL and its transformation to DLBCL histology, pure target material is 
particularly critical for follicular histology, where great care must be given to the 
retrieval of the tumor cell population devoid, as much as possible, of tumor-
infiltrating non-neoplastic cells. A T cell marker (CD3) and/or follicular dendritic 
cell stain (CD21) were used to highlight the follicles (Figure 2.4). Standard 
protocols were used and an average of 106 malignant cells was used for each 
case.  
Routine DNA extraction methods were used. 100-200ng of purified DNA from 
each sample was required per slide. Hybridization was successful in the 4 pairs 
and results are summarized in Table1. Total cellular DNA (using a proteinase K 
protocol) was isolated using standard protocols (http://www.bccrc.ca/). 
Extracted DNA was applied to BCCA aCGH tiling arrays according to the 
manufacturer’s instruction. The sub-mega base resolution tiling array contains 
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26,819 BAC clones spotted in duplicate and covers >95% of the human 
genome (2). Array CGH was performed as previously described (3). The array 
slide was scanned using a charged-couple device (CCD) camera system to 
capture the cyanine-3 and cyanine-5 channels (Applied Precision®, Issiquah, 
WA). The images were then analyzed by SoftWoRx microarray analysis 
software (Applied Precision®), followed by a stepwise normalization procedure 
(4). Data were filtered based on both replicate standard deviation (data points 
with >0.1 standard deviation removed) and signal-to-noise ratio (data points 
with a signal to noise ratio <3 removed). Copy number alterations were 
visualized using the “SeeGH” software available at 
http://www.flintbox.ca/technology.asp?tech=FB312FB (5) – Figure 2.5. All 
aCGH protocol and data analysis were done in collaboration with W. Lam 
research group, in particular Brian Chi and Ronald deLeeuw, from BC Cancer 
Research Centre, Vancouver, who are responsible for this platform. 
 
2.2.2. Results & Discussion  
2.2.2.1. GEP 
By hierarchical clustering using the 595 most differentially expressed genes, the 
4 pairs clustered by patient and showed similar gene expression profiles upon 
transformation to DLBCL (Figure 2.2). When the gene expression changes of all 
FL cases transforming to DLBCL were analyzed, 18 genes showed a change in 
expression level that was highly significant (at least 5-fold change with standard 
deviation < 0.5 and multiple testing correction - Benjamin and Hochberg False 
Discovery Rate). These 18 genes were either up- (7genes) or down-regulated 
(11genes) upon transformation (Figure 2.3). These are poorly annotated genes 
have not been previously associated with transformation events in lymphoma 
(6-8).  
Yet, some of the genes have potential associations of interest and might be 
relevant for the transformation event, including one up-regulated gene, ADP-
ribosylation factor-like 4D (ARF4L), and four down-regulated ones, sirtuin 2 
(SIRT2), chromodomain helicase DNA binding protein 6 (CHD6), cytochrome c 
oxidase subunit VIIa polypeptide 2-like (COX7A2L) or EB1(estrogen receptor 
binding CpG Island) and nucleosome assembly protein 1-like 4 (NAP1L4). 
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ARFL4 expression is controlled by the activated Akt/mTOR pathway, which is a 
downstream effect of the loss of PTEN function. Its increased expression 
follows the loss of the tumor suppressor PTEN (9). In gliomas, it is a Tumor 
Associated Antigen (TAA) that is regulated post-transcriptionally, at the level of 
translation, by the Akt/mTOR pathway. Although the exact function of ARF4L is 
unknown, evidence suggests that it participates in vesicle transport between the 
endoplasmic reticulum and Golgi complex. Peptide motifs from ARF4L were 
recently identified to induce HLA-A2–restricted and tumor-reactive cytotoxic T 
lymphocytes in peripheral blood mononuclear cells from patients with brain 
tumors (9). This may suggest ARFL4L as a candidate antigen to be used in 
cancer immunotherapy.  
SIRT2 is a NAD+-dependent deacetylase gene and is involved in the direct 
deacetylation of α-tubulin and histone H4. It has been reported that SIRT2 
down-regulation caused centrosome fragmentation in response to nocodazole, 
a microtubule inhibitor, prior to the alteration in spindle checkpoint function, 
implying not only a novel function of SIRT2 for centrosome maintenance upon 
exposure to mitotic stress caused by microtubule inhibitors, but also its role in 
centrosome-mediated signaling pathway to sustain the spindle checkpoint (10). 
Moreover, SIRT2 interacts with p65 in the cytoplasm and deacetylates p65 in 
vitro and in vivo at Lys310. In Sirt2-/- cells, p65 is hyperacetylated at Lys310 
after TNFα stimulation, which results in an increase in expression of a subset of 
p65 acetylation-dependent target genes. This provides evidence that p65 is 
deacetylated by SIRT2 in the cytoplasm to regulate the expression of specific 
nuclear factor kappa B  (NFκB) dependent genes, an important pathway for 
lymphomagenesis (11). 
CHD6 is thought to be a core member of one or more of the multisubunit protein 
complexes that remodel chromatin to allow patterns of cell type-specific gene 
expression. It colocalizes with both hypo- and hyper-phosphorlylated forms of 
RNA polymerase II (12). In human lymphoblastoid AHH-1 cells, silencing of 
CHD6 mediated by siRNA increased the growth rate and led to an increased 
radioesistance to radiation, highlighting a role of CHD6 in cell proliferation and 
radiosensitivity (13).  
Finally, cytochrome c oxidase subunit VIIa polypeptide 2 like cytochrome c 
oxidase, COX7A2L or EB-1, the terminal component of the mitochondrial 
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respiratory chain, catalyzes the electron transfer from reduced cytochrome c to 
oxygen. This component is a heteromeric complex consisting of 3 catalytic 
subunits encoded by mitochondrial genes and multiple structural subunits 
encoded by nuclear genes. This gene is expressed in all tissues, and is up-
regulated in a breast cancer cell line after estrogen treatment and is also a 
target gene of TP53 under stress conditions (14).  
 
2.2.2.2. aCGH 
Two sets of paired specimens submitted to GEP, were analysed using aCGH 
(Table 2.1). Common genomic alterations were present in both cases (80% in 
case 2 and 40% in case 4), which favors and confirms a clonal relationship. 
Examining global differences upon transformation, case 2 had more gains (4) 
than losses (1) while in case 4 the FL had many more gains (11) than the 
DLBCL (1) - Table 2.1. This latter finding suggests outgrowth of a less evolved 
subclone, as previously reported (15, 16). Classical karyotyping and recent 
CGH studies of paired specimens have shown that the transformed biopsy 
shares some, but not all, of the changes seen at FL diagnosis (8, 17). This 
suggests subclone selection and evolution from a common malignant initial 
clone in contrast to clonal evolution only resulting from stochastic genetic hits 
accumulated over time. It has been reported in several studies, as previously 
mentioned in chapter 1, that transformation of FL can occur over approximately 
0-17 years after initial FL diagnosis with a constant rate of 3% per year (18, 19). 
One of these studies suggests that most FL patients may not be at risk to 
transform beyond 15 years. If clonal selection and evolution were the main and 
only drivers of the process, the transformation rate would likely have to change 
over time. The observed constant rate might be better explained if an ancestral 
pool of clonal lymphoma-originating-cells with limited proliferation capacity 
existed and is at risk for stochastic genetic events that may provide a growth 
advantage (15). Case 4 in this study supports this hypothesis as the 
transformed lymphoma cells had less overall genomic abnormalities than the 
initial FL suggesting outgrowth of a subclone closely related to the putative 
resting lymphoma-originating-cells. 
 
2.2.2.3. Correlation GEP vs. aCGH 
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In the two pairs with available data, we looked for those genes differentially 
expressed that mapped to regions of genomic imbalance between the FL and 
subsequent transformed histology (19 gains and 4 losses) (Table 2.2). Five of 
the seven genomic imbalances acquired upon transformation have been 
described previously, including the common 2p15-q16 and 7q gains (8, 20-23). 
The “new” small deletion on 8q24.13-q24.21 followed by a gain 8q24.1-qter in 
case 2 suggests a MYC translocation with subsequent amplification (70x). This 
was confirmed by FISH analysis performed in the FFPET sample using a 
Vysis® breakapart probe (Figure 2.6). 
Importantly, none of the 18 genes reveled by GEP were present in the genomic 
imbalances of cases 2 & 4. Moreover, the correlation between GEP and aCGH 
is complex, highlighted by the complete lack of correlation between gene 
expression and copy numbers alterations (Table 2.2). This is exemplified by the 
examples of the “top” three over expressed genes (>10 fold change) mapping to 
chromosome13 in case 2 (Figure 2.7). Two hypotheses can be put forward to 
explain these results. One is technical, as individual correlation of two whole 
genome platforms measuring different features of one case is challenging 
because significant biological characteristics cannot be clearly determined due 
to the complex bioinformatic analysis imposed by hundreds of thousands of 
variables in one sample. Despite the use of statistical tools most results called 
significant can simply be random changes reflecting the analysis method. 
Biological relevant variations will be more significant as we increase our sample 
size, but then many changes of individual samples will probably be non-
significant. An alternative hypothesis is biological and relates to the many 
mechanisms that can explain the lack of correlation between gene expression 
changes and corresponding gene copy number alterations. These include 
epigenetic changes, RNA editing and microRNA modifications, all of which 
could preclude a direct correlation of copy number alterations and gene 
expression variations. 
 
2.2.3. Conclusion 
This pilot study, in agreement with the previous reports, suggested that 
mechanisms other than copy number alterations are responsible for 
deregulated gene expression during FL transformation. Furthermore, given this 
 75 
heterogeneity and the complex relationship between genomic aberrations and 
GEP, a much large number of cases will need to be studied to fully appreciate 
the specific genetic events responsible for transformation, especially if using 
whole-genome analysis. 
 
 
2.3 EXPERIMENT 2: Gene Expression Profiling of Composite Follicular 
and Diffuse Large B cell Lymphoma Using Formalin Fixed Paraffin 
Embedded Tissue Samples 
 
2.3.1. Introduction 
As previously discussed and shown in experiment 1 of the current study, 
suitable paired fresh frozen (FF) samples pre and post transformation from the 
same patient, a mandatory requisite for GEP transformation studies, are not 
easily available. Due to the wide range of time to transformation, the quality and 
quantity of the paired biopsies are often not ideal for study. And as shown in 
experiment 1, some of the pairs were not clonally related. Moreover, and as 
discussed previously, the interpretation of data obtained with whole-genome 
platforms needs a significant number of samples. The need for such a large 
amount of specimens makes it logistically impossible outside the scope of a 
multi-institutional consortium, as reported by Davies (24). Thus, due to the rarity 
of paired FF samples in a single institution we decided to focus on diagnostic 
biopsies of composite lymphomas showing in the same lymph node biopsy 
concurrent FL (grade 1 to 3a) and DLBCL (Figure 2.8).  
All reported studies on FL transformation have used clinically and pathologically 
confirmed transformed disease, i.e. transformed lymphomas separated in time. 
What constitutes the early driving mutations in FL transformation remains 
mostly unknown.  Although uncommon, composite FL and DLBCL are archived 
in routine FFPET blocks present in most departments of pathology. Thus, we 
chose to focus a study of composite histology FL cases in order to study early 
events in FL transformation. Moreover, GEP variability relates not only to the 
disease type under study, but also can be related to other variables such as 
tissue type, user variability, contamination of non-neoplastic cell types, the time 
from acquisition to sample preparation and tissue processing, etc. These biases 
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can be avoided using our study strategy and thus represents a significant 
advantage over the FF paired specimen experiments. Moreover, centralized 
hematopathology departments like BCCA do have FF samples of composite 
lymphomas but often the stored material is composed of just one (the 
predominant) of the components of the composite histology. Thus, composite 
lymphoma samples with enough tissue to be properly diagnosed and dissected 
are typically only available in the form of FFPET. Until recently, these tissues 
have been automatically excluded from RNA analyses, due to poor quality RNA. 
However, recently described new methods of nucleic acid extraction have 
improved and are reported to be suitable for low-density GEP (25).  
Our next aim was to assess biological mechanisms underlying early events of 
FL transformation into DLBCL using GEP of routinely diagnosed lymph node 
biopsies with composite lymphomas comprising FL and areas of transformation 
to DLBCL.  
 
2.3.2. Material & Methods 
2.3.2.1. Patients & Sample Selection 
We started this study by verifying the quality of RNA extracted from routine 
diagnostic lymph node samples, comparing the GEP of FF and FFPET from five 
reactive LN biopsies (cases recently diagnosed within less than one year old at 
the BCCA) using the 44K Whole-Genome Agilent 60mer oligo microarray – 
Figure 2.9. In each experiment sample RNA was extracted using standard 
methodology Ambion® Optimum™ FFPET RNA Isolation Kit and was DNase-
treated, precipitated and ran against a universal reference (UR) RNA derived 
from pool of cell lines (Stratagene). Hybridization conditions were established 
using the universal reference RNA pool for optimal dynamic range, sensitivity 
and linearity in self-self hybridization: more than 99% of the data points fall in 
less than 2x ratio. For the 5 cases the log comparison of expression for all 
transcripts showed moderate correlations between FF and FFPET samples with 
ratio ranging from 0.46 to 0.65 (average 0.57). If we selected only the 
differentially expressed genes, the ratio of correlation increased to an average 
of 0.8 with expected less detection or more “loss” of gene expression in FFPET 
samples compared to FF. As an example, in Figure 2.10 are plotted some 
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lymphoid markers showing good correlation between samples. Finally, if we 
limit the analysis of the differentially expressed genes to a 2-fold change cut-off, 
the correlation is generally good, as the majority of the differentially expressed 
genes are still detected in both samples with more genes detected in FF 
samples and a smaller proportion detected in FFPET (in red). 
 In conclusion, in this pilot study of 5 recently diagnosed reactive LN biopsies 
we were able to successfully isolate RNA and generate array data from both FF 
and paired FFPET using standard extraction protocols and Agilent Whole 
Genome microarrays. Despite some loss of signal in FFPET vs. FF, the majority 
of relevant gene expression changes were nonetheless detected in FFPET, 
including appropriate detection of pan-lymphocyte markers. 
 
2.3.2.2. Composite FL and DLBCL 
The study sample consisted of 14 lymph node biopsies with composite FL & 
DLBCL diagnosed at the BCCA. There were six females and eight males with a 
median age of 71 years (range 45-79). Histology was reviewed using the 2008 
WHO Classification scheme (26). Both components were characterized 
morphologically, phenotypically and lymphoma cell purity (LCP) was separately 
determined for both diseases. By standard immunohistochemistry (Ventana), 
immunostains for B (CD20 [clone L26]), T cells (CD3 [clone CD3 - Cell 
Marques/Novomix]), BCL2 (clone 124), CD10 (clone 56C6), BCL6 (clone PG-
B6p) and IRF4 (clone MUM1)  were performed to better characterize both 
components of the disease, determine DLBCL IHC subtype using the Hans 
algorithm (27) and help assessing LCP – Figure 2.11.  
Distinct components were dissected separately and RNA extracted using the 
previously mentioned protocol Optimum™ FFPET RNA Isolation Kit. For each 
case RNA from each disease component was arrayed together in the same 
array slide - Figure 2.12. 
 
2.3.2.3. Agilent 44K Whole Human Genome-60mer Oligo Microarray 
This microarray is comprised of approximately 41,000 (60-mer) oligonucleotide 
probes, which span conserved exons across the transcripts of the targeted full-
length genes. The probes represent the whole human genome as known at the 
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time of its building using well-characterized full-length and partial genes from a 
number of major public data sources. The sequence and annotation information 
used in this microarray product is available through Agilent and publicly-
available databases such as RefSeq, GoldenPath, Ensembl and more. Virtually 
all of the genes were mapped to the human reference genome and 
experimentally validated at Agilent´s laboratories (http://www.genomics. 
agilent.com ). 
 
2.3.2.4. Oligo Microarray Data Analysis  
Microarray image files (DAT.) and cell intensity files (CEL files) were generated 
using default Agilent software (http://www.genomics.agilent.com). Data 
preprocessing is described in the manufactures protocols. Data visualization 
and exploratory analysis, such as principal component analysis (PCA) and 
hierarchical clustering were performed with Genespring software (6.01). 
Network analysis was done using Ingenuity Knowledge Database software 
(www.ingenuity.com).  
We performed paired Student t-test analysis of all patients including all probes 
and 2-fold change in at least 5 samples as well as global expression profiles 
obtained for both FL and DLBCL separately as well as combined FL & DLBCL 
and log-ratio (DLBCL vs. FL). Differential expression of DLBCL vs. FL in each 
sub-group and differential expression among sub-groups were done. 
Publicly available GEP data from two previously reported studies of FL 
transformation (24) and DLBCL GEP classification (28) were used to query and 
cluster our data. This included predictor profiles of FL transformation as well as 
genes differentially expressed between DLBCL vs. FL used in Davies et al. and 
the different DLBCL gene signatures reported by Rosenwald et al: lymph node, 
MHCII, Germinal Center B Cell (GCB) and proliferation (28). 
 
2.3.3. Results 
Eleven cases were successfully arrayed for both components (Figure 2.12). 
Three cases were excluded due to poor RNA quality and/or insufficient RNA 
quantity to be arrayed. There were five females and six males, median age at 
diagnosis 69 years old. All specimens were nodal composite lymphomas; 
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including five FL grade one, three FL grade two and three FL grade 3A. As 
expected, the  DLBCL component were all of the Germinal Center B Cell-like 
type (27) and  had a higher concentration of malignant cells – Lymphoma Cell 
Purity - (median 93%, range 90-95%) than FL (median 76%, range 65-85%). 
Paired Student  t-test of all cases including all probe profiles with a 2-fold 
change in at least 5 samples showed a small subset of 328 genes to be 
significantly differentially expressed between both components (FDR<0.1) – 
Figure 2.13. The vast majority of the transcripts are poorly annotated genes. 
Yet, like Davies et al report (24), among the up-regulated probes were genes 
involved in cell cycle and proliferation, growth factors and DNA binding and 
repair. The down-regulated genes included tumor suppressor genes, immune 
defense, T cells and macrophage associated genes – Figure 2.14. 
Clustering the patients using global expression profiles of isolated DLBCL and 
FL components, combined FL & DLBCL and log-ratio (DLBCL vs. FL) showed 
three distinct clusters with two, four and five cases each (Figure 2.15). 6275 
probes were differentially expressed between sub-groups (Standardized with 
mean 0, SD1, IQR>1.5, FDR<0.05). Cluster #1 included two high-grade FL3A, 
and both cluster #2 and #3 had cases with low-grade FLs (grades 1 and 2). The 
third FL3A was included in cluster #2. Neither grade nor LCP correlated 
significantly with GEP clustering, except for #1 including two FL grade 3A 
lymphomas [(#1 LCP: FL(80%) & DLBCL (95%); #2 LCP: FL(76%) & DLBCL 
(93%) and #3 LCP: FL(70%) & DLBCL (93%)] – Figure 2.16.  
Not surprisingly, cluster 1, showed a predominance of up-regulated genes 
(1256) in comparison to down regulated genes (307) – Figure 2.17. Many of 
these genes mapped to network containing cell cycle, cell growth and 
proliferation MYC and 38pMAPK pathways (despite both genes, individually, 
were not differentially expressed) – Figure 2.18.  
Profiles #2 and #3 were characterized by a lower number of significant genes 
and did not highlighted distinct pathways. In cluster 2 there were 34 up-
regulated genes and 18 down-regulated ones (Figures 2.19 & 2.20). These 
mapped to different cell functions including up-regulation of cell transduction, 
cell cycle, apoptosis and DNA repair genes and down-regulation of genes 
related to transcription, protein-tyrosine kinases and macrophages genes. 
Within cluster 3 there were 20 up-regulated genes related to cell survival, 
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transcription and MAPkinase activity and 28 down-regulated genes related to 
protein transport, RNA binding, apoptosis and transcription (Figures 2.21 & 
2.22). 
Using the various signature gene profiles from the two published reports to 
query our data a similar three cluster structure is observed (Figures 2.23 & 
2.24). 
  
2.3.4. Discussion 
This is the first study focusing in the early events of transformation using GEP 
composite FL and transformed disease present in the same FFPET diagnostic 
biopsy.  In a pilot study using five FF vs. FFPE lymph node tissue, we 
demonstrate a reasonable correlation of GEP using the 44K Agilent® array 
between FF vs. FFPET. However, the results improved with a good correlation 
obtained in the differentially expressed genes instead of the whole genome.  
In the study set of 14 composite lymphomas, eleven were successfully arrayed 
after dissection of disease components. Small subsets of genes were 
significantly differentially expressed between FL vs. DLBCL. As expected, 
among the up-regulated probe sets upon transformation were genes involved in 
cell cycle and proliferation, growth factors and DNA binding and repair. Among 
the down regulated genes, tumor suppressor genes, immune defense, T cells 
and macrophages-associated genes were enriched. 
Three different clusters were observed with no correlation to either FL grade or 
non-malignant cell content evaluated by immunohistochemistry. Interestingly, a 
similar cluster structure was observed using various gene profiles characterized 
in reported studies of transformation or classification of DLBCL. Of note, is the 
identical three clustering obtained with the genes significantly differentially 
expressed in Davies et al (24), where the three clusters are separated by 
disease type (FLs and DLBCLs separated) and not by patient.  
Cluster #1 showed relatively more consistent expression profile with a 
predominance of over-expression including genes involved in cell cycle, cell 
growth and proliferation, including several oncogenes and target genes mapped 
to MYC and MAPK pathway networks. This cluster is more distinguishable 
using the proliferation signature profile from Rosenwald et. al. and is in keeping 
with the results by Davies et. al., where 10 of the 20 paired specimens were 
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characterized by an increase of proliferation gene signature. Like Davies et. al., 
proliferation signature clearly identified a distinct cluster of 2 out of 11 
transformed FL. 
In our study, profiles #2 and #3 were characterized by a lower number of 
significantly differentially expressed genes with a predominance of poorly 
annotated genes covering diverse cell functions. No significant network was 
highlighted in these two clusters. Yet, lowering the FDR to 0.1, we could map 
385 significant probes for cluster #2 and 849 probes for cluster #3. As seen in 
Figures 2.20 & 2.22, different networks were obtained. 
 For cluster #2, three up-regulated cell transduction genes are highlighted: 
GRB2, PTK2 and RALA.  
Growth factor receptor-bound protein 2 (GRB2) is a ubiquitously expressed 
adaptor protein, which activates RAS and MAPkinases in growth factor receptor 
signaling that mediates B cell receptor (BCR) signaling pathways. B cell-specific 
Grb2-deficient mice showed impaired IgG and B cell memory responses, and 
impaired germinal center formation (29). It is associated with GCET2 adaptor 
protein in GC B cells in transducing signals from GC B cell membrane to the 
cytosol (30). Strong, cytoplasmic GRB2 expression has been reported in most 
NHLs including neoplastic cells of FL and DLBCL, while it is lost in Hodgkin 
lymphoma cells (31). Interestingly`, in T cells it is involved in TCR & CD28 
signaling regulation including the transcription factor NFκB pathway in naïve 
and memory T cell responses (32).  
PTK2, protein tyrosine kinase 2 or Focal Adhesion Kinase (FAK) is a protein 
tyrosine kinase essential for intracellular regulatory events, such as cell growth, 
differentiation, migration and tumor metastasis. Analysis of FAK promoter 
sequences revealed that FAK promoter harbors the NFκB and TP53 binding 
domains. It has been shown that bortezomib transcriptionally suppresses FAK 
expression by interrupting the NFκB pathway, which suggests that FAK could 
be a potential molecular target for bortezomib, a selective potent proteasome 
inhibitor that has been approved for treatment of non-Hodgkin lymphomas such 
as DLBCL (33). Studies of FAK promoter activity, real-time PCR, electrophoretic 
mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay 
revealed that bortezomib inhibits NFκB binding on the FAK promoter, thereby 
reducing FAK expression (34). 
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RALA, v-ral simian leukemia viral oncogene homolog A (ras related) belongs to 
the small GTPase superfamily, Ras family of proteins. RALA is a downstream 
effector of Ras function and are critical for both tumor growth and survival. The 
RAS/RAF1/RALA pathways converge to modulate NFκB activation and SF-
mediated survival signaling (35).  
In cluster #3, cell survival genes PPARG and PPARGC1A are key network 
genes. Peroxisome proliferator-activated receptor gamma (PPARG) and 
peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-
1alpha) are multifunctional transcription factor that regulates adipogenesis, 
immunity and inflammation. It has been shown that silencing PPARG 
expression in human lymphoma B cells increased basal and mitogen-induced 
proliferation and survival, which was accompanied by enhanced NFκB activity 
and increased expression of BCL2. These cells also had increased survival 
upon exposure to PPARG ligands and exhibited a less differentiated phenotype. 
In contrast, PPARG overexpression in lymphoma B cells inhibited cell growth 
and decreased their proliferative response to mitogenic stimuli. These cells 
were also more sensitive to PPARG-ligand induced growth arrest and displayed 
a more differentiated phenotype. Collectively, these findings support a 
regulatory role for PPARG in the proliferation, survival and differentiation of 
malignant B cells (36). 
2.3.5. Conclusions 
This is an exploratory study of a small clinical cohort in which we show that 
RNA can be extracted from FFPET diagnostic samples in reasonable quantity 
and quality for GEP studies. Based on our findings using composite 
lymphomas, we propose that there might be three potential different 
mechanisms responsible for early events in FL transformation. One distinct 
pattern is associated with proliferation as previously reported. Despite the small 
number of genes, distinctive gene sets characterizes the other two clusters with 
several good candidate genes for diagnostic and eventual therapeutic use. 
Further cases are needed to validate these results. 
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2.4 TABLES 
 
 
 
Table 2.1 - ArrayCGH genomic copy number gains (red) & losses (green) 
alterations in pairs 2 & 4. 
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Table 2.2 - Correlation aCGH & GEP (cases 2 & 4). Regions of loss and gains 
are correlated with up and down regulated genes present in those areas with 
fold changes of 10x & 3x.  
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2.5 FIGURES 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 - Agarose PCR of four paired samples showing clonal relation. 
Case 2 
A   B 
Case 3 
A   B 
Case 4 
A   B 
Case 1 
A   B 
Control 
100bp 
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Figure 2.2 - Gene Expression Profile (cases 1 to 4). Unsupervised analysis 
using 595 differently expressed genes cluster the eight samples by patient 
origin. 
 
Case #              1A       1B      2A     2B       3A     3B       4A     4B 
 87 
 
 
 
Figure 2.3 - Sequential sections of a microdissected FL case (Olympus BX40 / 
Nikon Elipse®; Digital Camera Dxm1200; 40x). 
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Figure 2.4 - The 18 genes (down regulated in blue & up-regulated in red) 
differently expressed upon transformation not previously reported in GEP 
studies. Small tables show the best characterized ones. 
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Figure 2.5 - ArrayCGH profile of case 2. Highlighted in the red box is a small 
region of amplification of chromosome 13q. 
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Figure 2.6 - Case 2 aCGH & FISH. A deletion on 8q24.13-q24.21 followed by a 
gain 8q24.1-qter is gained in case 2 upon transformation suggestive of MYC 
translocation. This was confirmed by FISH analysis performed in the FFPET 
sample using a Vysis® split apart probe. Zeiss & MetaSystems software; 
1000x. 
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Figure 2.7 - ArrayCGH of chromosome 13 (case 2). Enlarged are the “top” three 
over expressed genes (>10 fold change) in case 2 showing lack of correlation 
between gene expression profiling and copy numbers alterations. 
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Figure 2.8 - Composite lymphoma with distinct follicular and diffuse large B cell 
components (H&E; Olympus BX40 / Nikon Elipse®; Digital Camera Dxm1200; 
40x). 
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Figure 2.9 - Comparison GEP of FF and FFPET from the same reactive LN 
biopsies using the 44K Whole-Genome Agilent 60mer oligo microarray. 
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Figure 2.10 - Gene expression Log comparison of all Agilent® microarray 
transcripts between FF and FFPET samples from the same LN.  If only the 
differentially expressed genes (not blue) are considered, the ratio correlation is 
approximately 0.8 with expected less detection or more “loss” of gene 
expression in FFPET. If the analysis of the differentially expressed genes is 
limited to a 2-fold change cut-off (highlighted in the red box), the correlation is 
improved, to around 0.9. 
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Figure 2.11 - Histology and immunohistochemistry of a composite lymphoma 
case - H&E (upper images) & IHC stains (lower images) (Olympus BX40 / Nikon 
Elipse®; Digital Camera Dxm1200; 40x; 100x & 400x). 
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Figure 2.12 - Distinct components were dissected separately and arrayed 
together in the same slide. 
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Figure 2.13 - GEP of 11 composite lymphomas. Paired Student  t-test of all 
cases including all probes profiles with a 2-fold change in at least 5 samples 
showed a small subset of 328 genes to be significantly differentially expressed 
between both components (FDR<0.1). 
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Figure 2.14 - Significant differently expressed genes & annotated gene 
functions. Among the up-regulated annotated probes predominated genes 
involved in cell cycle and proliferation, growth factors and DNA binding and 
repair. Among the down-regulated ones, predominated tumor suppressor genes 
and immune defense, T cells and macrophages-associated genes. 
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Figure 2.15 - Clustering the patients using global expression profiles of log-ratio 
(DLBCL vs. FL) showed three distinct clusters with two, four and five cases 
each. Cluster #1 included two high-grade FL3A, and both cluster #2 and #3 had 
cases with low-grade FLs (grades 1 and 2). The third FL3A was included in 
cluster #2. Neither grade nor LCP correlated significantly with GEP clustering, 
except for #1 including two FL grade 3A lymphomas. 
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Figure 2.16 - Correlation of clusters with FL grade & Lymphoma-Cell-Purity 
(LCP). Neither grade nor LCP correlated significantly with GEP clustering, 
except for cluster #1 including two FL grade 3A lymphomas. 
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Figure 2.17 - GEP of Cluster #1.  
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Figure 2.18 - Cluster #1 profiling network analysis was done using Ingenuity 
Knowledge Database software. It shows relatively more consistent expression 
profile with a predominance of gene over-expression with up-regulation 
enriched with genes involved in cell cycle, cell growth and proliferation, 
including several oncogenes and target genes mapped to MYC and MAPK 
pathway networks. 
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Figure 2.19 - GEP of Cluster #2. 
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Figure 2.20 - Cluster #2 profiling network analysis was done using Ingenuity 
Knowledge Database software. It is characterized by a lower number of 
significantly differently expressed genes with predominance of poorly annotated 
ones with diverse cell functions. No significant network was highlighted. Yet, 
several interesting genes are referenced, such as GRB2, PTK2 and RALA. 
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Figure 2.21 - GEP of Cluster #3. 
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Figure 2.22 - Cluster #3 profiling network analysis was done using Ingenuity 
Knowledge Database software. It is characterized by a lower number of 
significantly differently expressed genes with predominance of poorly annotated 
ones with diverse cell functions. No significant network was highlighted. Yet, 
several interesting genes are referenced, such as PPARG and PPARGC1A. 
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Figure 2.23 - Using the signature gene profiles from Davies et al, a similar three 
cluster structure is observed. 
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Figure 2.24 - Using the four gene signatures profiles from Rosenwald et al, a 
similar three cluster structure is observed, except for the MHCII one. 
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Section 3: New Biological Predictors of Survival and 
Transformation in Follicular Lymphoma: The 
Microenvironment  
 
3.1 INTRODUCTION 
FL retains many of the morphological features of the normal follicle suggesting 
functional crosstalk between malignant B cells and non-malignant cells, 
including T cells, follicular dendritic cells (FDCs), macrophages, mast cells and 
endothelial cells. T cell ligands and derived cytokines, (such as CD40 ligand 
and IL4) play a major role in the growth of both non-neoplastic B cells and 
follicular lymphoma B cells, indicating that responsiveness to paracrine factors 
is not a preserved characteristic of the malignant phenotype (1). Important 
trophic signals from FDCs/macrophages and T cells are essential for the 
neoplastic B cells which are highly dependent on these for survival and 
proliferation, as evidenced by the difficulty of establishing FL cell-lines without 
cytokine support or feeder layers (2).  
In solid tumours, it has been shown that tumour-associated macrophages 
(TAMs) can promote not only neoplastic growth but also angiogenesis (3). 
Angiogenesis plays a vital role in growth and progression of tumours. The 
"angiogenic switch" results from interactions of vessels with cancer cells but 
also with non-neoplastic cells in the microenvironment, including macrophages 
(4). The abundance of macrophages, microvessel density (MVD) and recently 
of a subset of T cells, regulatory T cells (Tregs) associated with tumours has 
been reported to correlate with poor prognosis in solid tumours (5). These cells 
can be recruited and “educated” by tumours using a range of growth factors and 
chemokines, so that they modulate tumour microenvironment characterized by 
“trophic” protumoural signalling, immunosuppression, matrix breakdown, 
tumour-cell motility and angiogenesis.   
In FL, the role of cellular components of the microenvironment in tumour 
progression and transformation is not as well studied. Recent GEP studies have 
shown that the immune response plays a role in predicting the outcome and 
clinical aggressiveness of FL (6, 7). The LLMPP consortium study revealed that 
gene expression derived from non-neoplastic immune cells were the primary 
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contributors to the outcome predictor. One signature appeared to be derived 
from reactive T cells in the lymph node biopsies and conferred a favourable 
outcome (so-called IR-1, immune response-1). The other signature revealed a 
gene expression pattern most reminiscent of macrophages and/or FDCs and 
was associated with inferior survival (IR-2, immune response-2) (6). However, 
the determination of the cellular components within the tumoural 
microenvironment responsible for the gene signatures and the linkage to 
prognosis was less clear. Moreover, the two studies referenced produced 
conflicting results that may be dependent on methodology as well as the 
heterogeneity of therapeutic regimens given to the patients in both study 
populations (8). Importantly, these conflicting data raise the important question 
of whether specific cell populations of non-neoplastic cells can directly impact 
both survival and transformation risk in FL and might be targeted by novel, 
future therapies.  
 
 
3.2 AIM 
We planned to survey both malignant and non-malignant cells of FL 
microenvironment as relevant and promising biomarkers that might have 
translation into clinical practice using a uniformly treated cohort of patients. 
 
 
3.3 MATERIAL & METHODS 
3.3.1. Patients & Samples Selection  
The BCCA is the primary referral center for patients diagnosed with lymphoid 
malignancies in the province of British Columbia, Canada. The BCCA 
coordinates cancer care for the entire province of BC with most patients 
receiving treatment directly under the guidance of a province-wide medical 
oncology network 
(http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Lymphoma/). In 
addition, most of the diagnostic materials both FF and FFPET are centrally 
reviewed and processed at the Vancouver Cancer Centre of the BCCA. In this 
study, we used BCCA´s clinical and pathological electronic database. FL 
transformation was defined as histologically proven biopsy demonstrating 
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diffuse large B cell lymphoma (DLBCL), or alternatively those patients with 
clinical evidence of transformation as defined by one or more of the following 
criteria: 1)  a sudden rise in serum lactate dehydrogenase (LDH)  to more than 
twice the normal level, 2)  a rapid, discordant localized nodal enlargement, and 
3) a new or unusual extranodal involvement of organs such as brain, lung and 
bone (9). All samples were reviewed by two hematopathologists (PF and RDG) 
based on the criteria defined by the 2008 World Health Organization 
classification of tumours of hematopoietic and lymphoid tissue (10). This study 
was performed in accordance with the Declaration of Helsinki after receiving 
ethical approval from the University of British Columbia and the BCCA 
Research Ethics Board. 
In this study, consecutive patients seen at the BCCA between July 1987 and 
May 1993 were offered enrolment in a phase II trial consisting of multi-agent 
chemotherapy (bleomycin, cisplatin, etoposide, doxorubicin, cyclophosphamide, 
vincristine and prednisone) followed by involved field irradiation to sites of 
original nodal involvement (hereafter referred to as BP-VACOP).  Patients were 
eligible for enrolment if they were aged 16 to 61 years, with newly diagnosed, 
treatment-naïve, HIV-negative and had advanced-stage indolent non-Hodgkin’s 
lymphoma.  Advanced-stage disease was defined as Ann Arbor stage III or IV, 
or stage II with B symptoms, non-radioencompassable disease, or bulk10 cm 
in maximum diameter at any individual tumour site. The source of pathology 
specimens for diagnosis included only lymph node biopsies. One-hundred and 
twenty six patients with FL were included in the study. Clinical files were 
reviewed and the clinical data collected included the following information: age, 
sex, stage (Ann Arbor), performance status (Eastern Cooperative Oncology 
Group – ECOG), LDH levels, presence of bulky disease and B symptoms 
(fever, night sweats, weight loss). Date of death or last clinical follow-up visit as 
well as date of progression of FL or transformation to aggressive disease was 
annotated. The International Prognosis Index (IPI) factors were determined. 
Due to the era of the study, the FLIPI index was unavailable. 
 
3.3.2. Tissue Microarray & Immunohistochemistry  
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Only those FL cases with adequate biopsy material and available blocks were 
included. Of the126 cases of FL, paraffin blocks were available for 110 patients. 
Of these, 105 had adequate material remaining in the block to be used for the 
TMA including 75 cases in FFPET and 78 in with B5-fixed material. Duplicate 
1.0mm cores were used to construct the TMA. Slides from the TMA block were 
cut at 4 microns. Hematoxylin & Eosin (H&E) sections and representative 
regions were selected and duplicate cores were done and used to build one 
FFPET TMA and one B5-fixed TMA (Beecher Instruments, Inc. Sun Prairie, WI, 
USA).  43 patients were represented in both fixatives which resulted in 40% of 
the cohort having quadruplicate cores of disease (Figure 3.1). Slides from the 
TMA block were cut at 4 microns and an H&E stain of the TMA was prepared 
using routine methods. All cores contained neoplastic follicles (average of 3 
follicles per core) and no major discrepant results were seen between duplicate 
cores. A battery of immunohistochemical stains were performed including CD20 
(clone L26), CD3 (clone Cell Marque/Novo Mix), CD4 (clone 4B12), CD7 (clone 
CD7-272), CD8 (clone C8/144B), CD10 (clone 56C6), CD21 (clone 1F8), CD25 
(clone IL2-R), CD34 (clone QBEnd-10), CD57 (clone NK-1), CD68 (clones Kp1 
and PGM1), CD163 (clone 10D6), S100A8 (clone CF-145), KI67 (clone MIB-1), 
TIA1 ( clone 2G9A10F5), FOXP3 (collaboration Roncador, G et al, CNIO), PD1 
(clone NAT150), BCL2 (clone 124), BCL6 (clone GI191E/A8), BCLxL (clone 
2H12)  and NOXA (114C307) (Table 3.1) using a Dako® autostainer and the 
EnVision polymer detection system. Pressure cooking antigen retrieval was 
used for all antibodies. A variety of buffers were used depending on the specific 
antibody to allow optimal detection of the antigens. The chromogen in all cases 
was diaminobenzidine. The immunostained TMA slides were first screened with 
CD20 to ensure tumour cell content.  
The different immunostained TMA slides were scored both for architectural 
pattern and the number of positively stained cells. Prior to counting the 
morphological patterns and cell content were first evaluated for their 
consistency between duplicate cores and between TMAs (B5 vs. formalin for 
the 43 overlap cases). Several biomarkers of different cell types were analyzed 
in this study.  
 
3.3.2.1. Malignant B Cells 
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Malignant cells were studied using antibodies against CD10, CD20, BCL6, 
BCL2 and two BCL2-family proteins, one anti-apoptotic with reported impact in 
FL prognosis, BCLxL (11) and a BCL2 homology 3-only member that promotes 
apoptosis, NOXA. This latter gene/protein has been reported in DLBCL and FL 
transformation GEP studies (12, 13). We included NOXA in the study after 
querying the publicly available GEP database of the Lymphoma/Leukemia 
Molecular Profiling Project (LLMPP) consortium on FL (http://llmpp.nih.gov) 
which showed NOXA to correlate with better OS (P=0.049) (Figure 3.2). All 
these immunohistochemical markers were scored qualitatively, as duplicate 
cores were either completely positive or negative. In addition to the qualitative 
CD10 scoring, the presence or absence of interfollicular CD10+ neoplastic cells 
was noted. NOXA protein expression has not been previously reported in FL, 
thus we sored it using a histoscore, NOXA Protein Expression (NPE) by 
combining the intensity (1-3) and percentage of positive cells (400Xfield) with 
scores ranging between 0 and 300. Cases were dichotomized in high vs. low 
NPE (Figure 3.3). The proliferation rate of the neoplastic cells was scored 
based on the percentage of MIB1-positive cells within neoplastic follicles (MIB1 
<10% = 1, MIB1 >10 and <50% = 2, MIB1 > 50% = 3). 
 
3.3.2.2. Follicular Dendritic Cell (FDC)  
FDC meshworks (CD21+) were morphologically classified either as follicular 
pattern (tight concentric FDC cytoplasmic processes) or expanded when there 
was dissolution of the normal pattern and coalescence of FDC processes in a 
loose arrangement between follicles (Figure 3.4).  
 
3.3.2.3. Macrophages 
Three macrophages markers were used: CD68 and two markers referenced in 
some reports as M2-like macrophages, CD163 and a less studied marker 
S100A8.  The initial analysis using CD68 revealed that macrophage content 
could be divided into two groups, cases with either none or few cells positive vs. 
many positive cells. To make the determination of macrophage numbers more 
objective, we counted CD68+ cells using high power magnification (Olympus 
BX40; 1,000X oil lense). This high magnification was used so as to avoid 
counting neutrophils, mast cells and intercellular debris occasionally stained 
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with this antibody. Five representative fields per case were counted. We chose 
to count in areas where the staining was the strongest and most uniform. In 
virtually all of the cases scoring was made easier by the fact that cases were 
either clearly positive or negative (Figure 3.5). FDCs did not stain with any 
macrophage marker nor did the neoplastic B cells in any case. 
S100A8+, also known as MRP8 or Calgranulin A, is a member of the calcium-
binding-S100 protein family and is expressed by monocytes and macrophages. 
Recently, it has been shown to be characteristic of late-stage inflammatory 
macrophages, with anti-inflammatory homeostatic functions and is up-regulated 
by glucocorticoids and IL10 (14). These are features suggestive of a M2 
phenotype. In a MALT lymphoma mouse model, S100A8 up-regulation was the 
single gene associated with the lymphoma stage when compared with gastric 
chronic inflammation (15). Interestingly, we queried the reported data by Dave 
et al and S100A8 was predictive of survival in both univariate and multivariate 
analysis in the 191 FLs (6) [IPI: RR =4.6, 95% CI =1.8-11.5, P=0.001; S100A8: 
RR =1.7, 95% CI =1.1-2.7, P=0.012]. S100A8 positive cells stain cells mostly in 
the interfollicular areas (Figure 3.6). 
 
3.3.2.4. T Cells 
T cells markers (CD3, CD4, CD7, CD8, CD25, CD57, TIA1, FOXP3 and PD1) 
were evaluated both for their content and distribution in relation to the 
neoplastic follicles (intrafollicular or perifollicular/interfollicular compartments).   
The total number of positive cells (FOXP3, CD57, PD1 and CD25) was counted 
per core (X100 lenses). Immunoarchitectural patterns of distribution of the 
different T cell markers were determined in relation to the neoplastic follicles 
(Figure 7, 8 & 9). A FDC meshwork stain (CD21) was also used to better 
classify the several T cell patterns. Whenever the majority of positive cells were 
within the follicles in each core, cases were labelled as having a follicular 
pattern. From the remaining cases with predominance of positive cells outside 
the follicles, those with a predominant perifollicular rim of positive cells were 
labelled perifollicular. For purposes of analysis both groups, those with a 
follicular distribution of positive cells and those with a perifollicular distribution, 
were grouped together as having a “follicular” pattern (Figure 3.10). 
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Assignment of the CD4 pattern and the combined CD4 vs. CD8 were scored 
semi-quantitatively and in the CD4 vs. CD8 pattern determination, both stains 
were evaluated using sequential sections by overlaying both slides on the 
microscope. Cases with a follicular predominance of CD4 vs. CD8 cells were 
identified as having a “follicular” pattern, whereas cases with a similar 
distribution of CD4 vs. CD8 cells were defined as “diffuse” (Figure 3.9).   
Cytotoxic granule TIA1+ cells were scored qualitatively, with cases called 
positive in the presence of more than 10% of positive T cells.  
 
3.3.2.5. Microvessel Density & Follicle Size 
For microvessel density (MVD), 84 cases had formalin-fixed paraffin blocks with 
adequate material remaining in the block to be used for whole sections. 
Immunohistochemistry was performed routinely for CD20 and CD34 using a 
Dako® autostainer and the EnVision polymer detection system.  
Images of whole sections were stained for CD34 and captured using a cooled 
charge-coupled device (CCD) camera, a motorized stage and customized NIH 
software (16). Thresholding was applied to identify CD34+ objects. The 
motorized stage allowed for tiling of adjacent microscopic fields, thereby 
allowing reassembly of the entire tumour section at high resolution (Figure 
3.11). High-resolution images of tumour vasculature over the entire whole 
sections of each case, defined “distance maps”. The distance from each tumour 
cell in the tissue to the nearest CD34+ pixel was measured automatically and 
the mean of distances of all cells to the nearest vessel in the whole section was 
used to calculate the tumour to vessel distance that encompassed 90% of the 
tumour (TVD90).  
Average follicle size per case was visually ranked according to the following 
groups: 0 - loss of follicular pattern; 1 - small follicles (dense staining), and 2 -
large follicles (sparse staining) – (Figure 3.12). 
 
3.3.3. Data analysis Statistics and Survival Analysis 
Progression-free survival (PFS) was defined as the interval between diagnosis 
and progression of lymphoma or death due to lymphoma or toxicity of 
treatment. Overall survival (OS) was defined as the interval from date of 
diagnosis until death from any cause and Risk of Transformation (RT) was 
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defined as the interval from diagnosis until clinical or biopsy-confirmed 
transformation into aggressive disease. The following variables: IPI score, 
histologic grade, age, gender and each of the biomarkers (see Table 3.2) were 
evaluated for prognostic significance. Survival estimates were calculated using 
the Kaplan-Meier method (17). Significance levels, estimates of hazard ratios 
(HR), and their 95 percent confidence intervals (CI), were calculated using the 
proportional-hazards regression model (18). Data were analyzed using the 
Statistical Software Package for the Social Sciences (SPSS version 10.1 for 
Windows; SPSS Inc®, Chicago, IL). 
 
 
3.4 RESULTS 
3.4.1. Clinical Characteristics & Outcome (Table 3.1) 
105 patients were included in this study, representing the FL patients from the 
original clinical cohort (n = 126) with available blocks, sufficient tissue remaining 
in the blocks and successful TMA construction and interpretation.  
The median age of the evaluable patients was 45 years (range 19-61 years). 
There were 51 women and 54 men. The distribution of IPI scores included 65 
patients with IPI scores of 0/1 (group 1), 41 with IPI score of 2/3 (group 2) and 
only a single patient with an IPI score of 4/5 (group 3). For analysis purposes, 
the single patient in IPI group 3 was included with IPI group 2 in order to 
eliminate a clinical group with only one patient. The median follow-up of living 
patients (n = 51) was 17.1 years and 20 patients underwent transformation. The 
median OS was 15.5 years. The IPI was highly significant as a predictor of OS 
(HR=2.4, 95% CI=1.4-4.2, P=0.001) and PFS (HR=2.0, 95% CI=1.2-3.3, 
P=0.006), but not RT. Estimated 10-year OS and RT for all patients was 65% 
and 20%, respectively. Importantly, this cohort was treated uniformly with 
aggressive therapy and thus the “treatment variable” was held constant. 
 
3.4.2. Pathology Variables 
A small subset of cores was lost during the preparation of the sections or was 
uninterpretable due to poor fixation and/or inadequate staining (varies with 
biomarker). The percentage of informative individual cores was 96%, which 
varied with the different biomarkers (1-18%) (see Table 3.2).   
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Histologic grading of FL subtypes according to the WHO - 2008 classification 
(10) included 80 with grade 1, 17 grade 2 and 7 cases with grade 3A. A total of 
15 patients were determined to have marginal zone differentiation, as defined 
by a zone of pale cells at least three cells in thickness, expressing CD20 and 
surrounding neoplastic follicles. Neither histologic grade nor the presence of 
marginal zone differentiation had an effect on OS, PFS or RT (data not shown). 
 
3.4.2.1. Malignant B Cells Markers 
The percentage of the positive cases for BCL2, BCL6 and CD10 were in line 
with previous reports. In total, 16% of the CD10+ FL had no or minimal 
interfollicular involvement by CD10+ neoplastic cells. Only a small number of 
cases (14%) had more than 10% BCLxL+ cells. None of these markers had 
impact on survival. Of the 100 evaluable FLs with NPE, 50 had a high NPE ≥ 20 
and median OS of 16.3 years while 50 had low NPE<20 and median OS of 10.7 
years (P=0.057) – (Figure 3.13). Increased NPE correlated with both higher 
grade (X2, P=0.04) and increased proliferation index (X2, P=0.02) It did not 
correlated with any clinical features. 
There was a correlation between the proliferative rate (MIB1) and the histologic 
grade, at least for the small number of grade 3a cases. The majority (83%) of 
grade 3a FL cases had a proliferative rate > 50%. Grade 2 FL cases showed 
more heterogeneity, with 62% having a proliferative rate between 10 and 50%, 
while the bulk of the remaining cases had >50% MIB1+ cells. Only 50% of the 
grade 1 FL cases revealed < 10% MIB1+ cells, with the majority of the 
remaining cases demonstrating proliferative rates between 10 and 50%. These 
data indicate the imperfect relationship between histological grade and 
proliferative rate. Importantly, neither grade nor MIB1 score were predictive of 
outcome in the setting of uniform therapy.  
 
3.4.2.2. Follicular Dendritic Cell marker 
The follicular FDC pattern (CD21) was disrupted with expansion of the 
meshwork and fusion of the follicles in 27% of the cases. This pattern had no 
impact on prognosis. 
 
3.4.2.3. Macrophages Markers 
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The numbers of CD68+ macrophages or lymphoma-associated-macrophages 
(LAM) were initially determined using low power magnification. None of the 
cases showed staining of neoplastic B cells with anti-CD68 antibody. It was 
clear that most cases had few or no macrophages, while a small number had 
many (Figure 3.5). The distribution of these CD68+ cells was uneven 
throughout cores with both intrafollicular and perifollicular macrophages 
observed. We then used high power magnification (1,000X oil lense) to count 
the CD68+ macrophages, which ranged between 1 and 25 cells per high power 
field (hpf). Because many of the cases had no or few macrophages, we 
established a cut-off of 15 cells/hpf for analysis purposes. 
Importantly, the majority of the negative cases had less than 10 cells (82%) and 
positive cases more than 20 cells (58%) per hpf, respectively. Table 3 shows 
the distribution of clinical and pathologic variables for the FL cases with high 
LAM 
(n=12) versus those with low LAM content (n= 87).  
Cases with less and more than 15 CD68+ macrophages/hpf had median OS of 
16.3 and 5.0 years, respectively (P=0.0003)( Figure 3.14). Cases with less and 
more than 15 CD68+ macrophages/hpf had a median PFS of 7.05 and 1.69 
years, respectively (P=0.001). The inferior PFS and OS of the patients with a 
high LAM score cannot be explained by a lower response rate to treatment 
(Table 3.3), nor an increased risk of histologic transformation nor lack of 
appropriate treatment for relapse (all patients with relapse were treated with 
systemic chemotherapy, three with high dose chemotherapy and hematopoietic 
stem cell transplant). All but one of the ten deaths among the patients with high 
LAM scores resulted from progressive lymphoma. 
As expected, cases with increased S100A8+ cells (14 cases) correlated 
significantly with LAM cases ((n=12) - X2, P<0.001)). S100A8+ stained cells 
located in the interfollicular areas (Figure 3.6). A subset of 14 cases showed 
high density of S100A8+ cells defined by > 5 per high power field (100x lense). 
Like LAM, cases with increased S100A8+ cells had inferior OS (P=0.04), but 
S100A8+ cells did not predict RT (P=0.4) (Figure 3.15). 
 
3.4.2.4. T Cell Markers 
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The reactive T cells showed a predominantly perifollicular distribution (CD3) in 
the majority of the cases (70%) as well as a CD4 phenotype (76%). In 71% of 
the cases there was a clear follicular pattern with CD4 cells inside the follicles 
surrounded by CD8+ cells outside the follicles, whereas in other cases the 
distribution was diffuse for both subsets. CD57+ cells represented more than 
10% of the T cells in the majority of the cases (64%) and they had a clear 
follicular pattern in 68%, with most of the positive cells localized inside the 
follicles. In 82% of these cases the CD57 follicular pattern correlated with the 
CD4/CD8 follicular pattern and both CD57+ and CD4+ cells had an equal 
distribution within the follicles. Cases with more than 10% cytotoxic TIA1-
granule+ cells were found in 45 % of the cases.  
Follicular vs. diffuse pattern of distribution of CD4 vs. CD8+ cells was 
associated with PFS only (HR=0.54, 95% CI=0.29-1.0, P=0.05) (Figure 3.9), 
CD25 pattern was significant for both PFS (HR=2.4, 95% CI=1.4-3.9, P=0.001), 
and OS (HR=1.8, 95% CI=1.1-3.1, P=0.024) but not risk of transformation. Only 
the FOXP3 score had a significant impact in PFS, OS and risk of transformation 
(Table 3.2).  Cases with a follicular vs. diffuse FOXP3+ pattern of distribution 
had a median OS of 7.13 years and not reached, respectively (HR=3.1, 95% 
CI=1.8-5.4, P<0.0001) (Figure 3.16) and median PFS of 2.2 and 8.8 years, 
respectively (HR=2.7, 95% CI=1.6-4.6, P=0.0003). Finally, cases with follicular 
vs. diffuse patterns had median risks of transformation of 13.3 years and not 
reached, respectively (HR=3.7, 95% CI=1.5-8.9, P=0.004) (Figure 3.16). 
Histological grade, IPI, and bone marrow involvement were evenly distributed 
between these two groups (Table 4). Interestingly, all but one case with a high 
content of LAM had a FOXP3+ follicular pattern and a follicular pattern of 
CD25+ cells. The pattern of CD25+ and FOXP3+ cells were also significantly 
correlated (Table 3.4).   
Cases revealed zero to 731 FOXP3+ cells per core (median of 242 cells per 
core) and zero to 654 PD1+ cells per core (median of 102 cells per core).  There 
was a predominantly intrafollicular or perifollicular localization of positive cells (
follicular pattern ) in 38 and 43 patients for FOXP3 and PD1, respectively. 
There was no significant correlation between cell density (χ2=0.1) or pattern 
(χ2=0.8) between markers.  Separately, cell density of both FOXP3 (P=0.7) and 
PD1 (P=0.16) did not impact prognosis. Yet, when quartiles were combined and 
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dichotomized, cases with high cell content of FOXP3+/PD1+ cells correlated 
with inferior OS & increased RT in univariate (P=0.002 & P=0.01) (Figures 3.8 & 
3.17) and multivariate Cox models (RR=2.18, 95% CI=1.2-3.9, P=0.01 & 
RR=3.4, 95% CI=1.3-8.8, P=0.015).  
In univariate analysis, a PD1 follicular pattern correlated with inferior OS 
(P=0.027) but did not impact on RT. When combined with follicular FOXP3 
cases, a subset of 15 “double follicular” FOXP3+&PD1+ cases correlated with 
inferior OS in univariate (P=0.0016) and multivariate Cox models (RR=2.1, 95% 
CI=1-4.3, P=0.04).  They also showed a trend for increased RT (P=0.09) 
(Figure 3.9). 
 
3.4.2.5. Microvessel Density 
There were 84 suitable cases for analysis. TVD90 ranged from 50.3 to 144 
microns (median 78.4) and these data were divided into quartiles. In univariate 
analysis the quartile (21 cases) with low TVD90 (i.e. high MVD) showed inferior 
OS (P=0.0001) and an increased RT (P=0.01) (Figure 3.18). Clinical 
characteristics are summarized in Table 3.5. As most cases showed a distinct 
perifollicular pattern, we correlated TVD90 with follicle size in each case. There 
was a significant association between low TVD90 and small follicle size (x
2, 
P=0.01). Low TVD90 also correlated with younger age (x
2, P=0.034), increased 
IPI (x2, P=0.01) and increased CD68+ macrophages (x2, P=0.025). In univariate 
analysis, TVD90 and IPI are significant for both OS and RT, but not age or 
follicle size. In this cohort, CD68+ macrophages predicted OS (P=0.0004), but 
not RT (P=0.38).  
 
3.4.3. Multivariate Analysis  
A multivariate proportional hazards model (Cox model) was constructed for all 
of the variables significant by univariate analysis including the NPE, FOXP3+ 
immunoarchitectural pattern, LAM content, TVD90  and IPI and all were shown 
to be independent predictors of OS; NPE (RR=1.89, 95%CI=1.1-3.3, P=0.03), 
FOXP3 (HR=2.9, 95% CI=1.7-5.1, P=0.001), LAM content (HR= 2.4, 
95%CI=1.3-4.5, P=0.004); TVD90 (RR=2.5, 95% CI=1.1-5.0, p=0.01) and IPI 
(HR=2.1, 95% CI=1.1-3.7, P=0.008). Interestingly, in the multivariate Cox model 
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for Risk of Transformation only FOXP3 positivity showed significance (HR = 3.9, 
95% CI =1.5-9.9, P=0.004) and TVD90 showed borderline significance (P=0.08).  
 
 
3.5 DISCUSSION 
FL represents a lymphoma subtype characterized by a significant degree of 
clinical heterogeneity (19). New clinical prognostic models, namely FLIPI 1 & 2, 
may help to define those patients at risk of failing current therapies, but the 
degree to which these clinical variables will be helpful in planning initial therapy 
for newly diagnosed patients remains undefined (20, 21). Importantly, both 
models include clinical surrogates for the underlying molecular genetic 
alterations and thus, will not further our understanding of the biology of FL and 
clearly do not help to identify novel targets for therapy. An improved 
understanding of the molecular abnormalities that underlie the survival 
differences among patients with FL may lead to improvements in risk-
stratification, but more importantly would offer the possibility of identifying new 
targets for rationale design of future treatments. To a large extent, the future of 
tailored or personalized therapies in cancer will depend on this very hypothesis. 
Most published data for FL suggest that the molecular alterations that 
characterize this lymphoma result from a combination of abnormalities present 
at the time of diagnosis and ongoing stochastic events that occur in association 
with clonal evolution & selection (6, 12, 22-25). Because FL is a germinal center 
derived neoplasm and frequently reveals intra-clonal heterogeneity at the level 
of the immunoglobulin heavy chain, there is a belief that additional molecular 
alterations are occurring over time and contribute to disease progression. 
However, a number of other possibilities exist to explain disease progression in 
FL, including the outgrowth of subclones that may have been present as minor 
populations at diagnosis, as resting lymphoma-originating-cells (22, 26). 
Whatever the relative contribution of these two processes, there is little doubt 
that the molecular signature present in initial diagnostic biopsies plays a 
prominent role in predicting outcome in FL. GEP studies of the LLMPP have 
clearly shown that the signatures from co-ordinately expressed genes play a 
dominant role in affecting survival, as evidenced by widely divergent survivals 
(6). The most important gene expression signatures in the recently developed 
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molecular predictor were not derived from neoplastic B cells but instead were 
expressed by non-neoplastic immune response cells. One of these signatures, 
IR-2, included a number of genes that appeared to correspond to the repertoire 
expressed by macrophages and was associated with inferior survival. Thus, our 
finding of high LAM associated with inferior survival is consistent with the GEP 
data identifying increased IR-2 as a poor prognostic finding. Data supporting 
such a role for reactive macrophages as biomarkers in cancer have been 
described in a number of different solid tumours (3). A suspected role in 
lymphoma was untested until the aforementioned recent studies by the LLMPP 
consortium (6). 
 
3.5.1. Neoplastic FL B Cells 
Of the biomarkers studied and expressed by the neoplastic cells only NOXA 
protein expression significantly correlated with a favourable OS in FL. In this 
uniformly & aggressively treated cohort from the BCCA, NPE was an 
independent predictor of outcome. This is an interesting result as in the 
literature (see Section 1) only anti-apoptotic genes & proteins members of the 
BCL2-family have been reported as relevant and with clinical impact in FL 
outcome, such as MCL1 and BCLxL (11, 27). None of the pro-apoptotic 
members of the family, specially the apoptosis regulators or 
“sensitizers/derepressors” class BH3–only, such as NOXA, have been 
correlated with FL prognosis. NOXA is a TP53 target gene, which is 
physiologically up-regulated in cell stress and damage (28, 29). Not surprisingly, 
it is over-expressed by hypoxia (HIF1α) (30). In accordance with our study NPE 
correlated with increasing grade and proliferation index, features that did not 
impact survival. The significant impact in survival, independent of both clinical 
and microenvironment, is quite interesting as it has been shown that 
intracellular levels of NOXA in human tumours like melanoma, myeloma or 
mantle cell lymphoma can be increased by therapeutic agents such as 
proteasome inhibitors into levels that trigger NOXA-mediated apoptosis (31, 32) 
(Figure 3.19).   
 
3.5.2. Macrophages 
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The current study clearly shows that LAM content is an independent predictor of 
survival in uniformly treated FL. The content of LAM was predictive of survival, 
including OS (P=0.003) and PFS (P=0.001) and remained an independent 
variable distinct from the IPI in a Cox multivariate model (P=0.004). These data 
agree with similar observations made in epithelial cancers that increased 
numbers of macrophages portend a worse outcome (3, 33). Moreover, these 
results also validate the recent GEP studies and provide indirect validation at 
the protein level for the role of IR-2. The precise biological function of tissue-
based macrophages in this setting remains largely undefined, but suggests that 
these cells may be providing important growth signals to the FL cells in the form 
of cytokine stimulation or specific chemokine production. Macrophage 
heterogeneity is well studied in the mouse but less is known about human 
macrophages (34-36). The plasticity of macrophage function is evident in the 
diverse range of functions of these cells, including inflammatory responses, 
immune reactions, tissue remodelling and morphogenesis. Depending on the 
microenvironment, macrophages appear to be either “classic” M1 (inflammatory 
responses induced by IL12 and TNFα) or “alternative” M2 (tissue remodelling 
and morphogenesis induced by IL4, IL13 and IL10) subtypes, referred to as 
polarized macrophages. These two types differ in their receptor expression and 
cytokine/chemokine profiles (37). In advance of this study we studied 
macrophage content and distribution in a series of reactive lymph nodes (n=10, 
data not shown). Virtually all cases showed large numbers of tissue-based 
macrophages both within and between reactive lymphoid follicles. Thus, we 
were surprised to find that most cases of FL in this study had no or very few 
macrophages. We hypothesize that in the minority of cases of FL with large 
numbers of macrophages the neoplastic B cells display signals that attract 
and/or retain predominantly M2-type macrophages. Alternatively, an 
inflammatory microenvironment might be created by the anti-tumour responsive 
T cells that attract or retain the macrophages. Once in the lymph node, these 
cells might provide the neoplastic B cells with trophic/survival signals, facilitate 
tumoural invasion by disrupting basement membranes, promote angiogenesis 
by secreting angiogenic factors, alter the phenotype and/or function of antigen-
presenting dendritic cells or amplify Tregs leading to an immunosuppressive 
intra-tumoural environment (38).  
 129 
 
3.5.3. Regulatory T Cells 
It has been almost a century since immunosurveillance was proposed as a 
mechanism responsible for the repression of cancer growth (39). Since then, 
our understanding of tumour immunobiology has increased indicating that 
immunosurveillance represents one dimension of the complex relationship 
between the immune system and cancer (38). It is now a widely held belief that 
the growth of tumours is influenced by non-neoplastic cells of the immune 
system. These cells are thought to exert selective pressure on the malignant 
cells. Ultimately, the malignant cells escape immune recognition and destruction 
and much like tolerance to self-antigens, tolerance to tumour-associated 
antigens may arise and permit or even promote disease progression (38).   
Tregs were initially defined as a subset of suppressor T cells that mediate 
immune tolerance by inhibiting autoreactive T cells (40).  Naturally occurring 
Tregs play a vital role in maintenance of tolerance to self-antigens and 
immunologic homeostasis through the antigen specific suppression of effector 
CD4+ and CD8+ T cells (41).  Yet, mechanisms whereby Tregs, including 
peripherally induced cells, bring about the inhibition of other T cell subtypes are 
still not well understood (42). They include direct suppression by cell contact 
and/or cytokine production, as well as inhibition of antigen-presenting cell 
function. The T cell receptor repertoire of Treg cells is as broad and diverse as 
that of other CD4+ T cells, but it is skewed towards recognizing complexes of 
self-peptides and MHC.   
Many of the tumour-associated antigens recognized by autologous T cells in 
cancer are antigenically normal self-constituents. This suggests that Tregs 
normally engaged in the maintenance of self-tolerance may also suppress 
immunosurveillance against autologous tumour cells. Depletion of these Treg 
cells before a tumour challenge encourages effective immune responses to 
tumours in mouse models (43). In mice with advanced tumours, including 
lymphoma, the administration of anti-CD25 or intratumoural agonistic anti-GITR 
antibodies reduces tumour-infiltrating Foxp3+CD25+CD4+ Tregs and results in 
enhanced anti-tumour immunity with a significant decrease of the tumour 
burden without causing autoimmune disease (44, 45). In humans, T cells 
reactive to tumour-associated-antigens can expand and become detectable in 
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the peripheral blood when Tregs are first depleted (46, 47). Tregs accumulate 
within different types of tumours draining lymph nodes and the peripheral blood 
(5, 48-51). FOXP3+ T cells present in the tumour microenvironment contribute 
to the growth of the tumour and their presence is associated with unfavorable 
prognosis in patients with ovarian carcinoma (5). This study by Curiel et al. 
highlights the importance of the chemokine network in the recruitment and 
function of these cells. Decreased CCL22 produced by the tumour cells and/or 
TAM reduced the recruitment of the Tregs that characteristically express the 
CCL22 cognate receptor CCR4.  
In reactive lymphoid tissues, FOXP3+ Tregs are found mostly at the borders 
between T and B cells and within germinal centers where they suppress T cells 
as well as B cell responses through both inhibition of immunoglobulin class 
switch recombination (52) or generation of “Treg-epitopes” identified in the Fc 
region of the immunoglobulin molecule itself (53).  
Intratumoural CD4+ T cells (CD25+ or CD25-) expressing FOXP3 are increased 
in FL compared to reactive lymph nodes (54). These FOXP3+ cells are either 
attracted (CCL22) or induced locally by lymphoma cells through cell contact 
without stimulation of TCR but by expressing CD70 (54-56). These FOXP3+ 
cells suppress intra-tumoral CD4+ or CD8+ T-cells either through TCR 
activation, cell contact or by producing TGFβ (54, 56, 57). In a small series of 
FL cases purified using fluorescence activated cell sorting; we found that 
CCL22 was one of the chemokine genes most highly expressed by the 
malignant B cells (unpublished observation 2008, RDG). Moreover, Tregs have 
also been shown to induce alternatively-activated macrophages, the so-called 
M2-type (58), which are also associated with pro-tumoural immunity.  Finally, in 
combination with CpG vaccination, antibody-mediated T cell modulation, mostly 
by depletion of Tregs through anti-folate receptor 4 (FR4) antibodies or 
functionally blocking them using anti-GITR, anti-CTLA4 or anti-PDL1 antibodies, 
correlates with a significant reduction of tumour burden both in mouse models 
and a phase II clinical trial in patients with recurrent FL (59, 60).  
In concordance with most published data, including mouse models and a 
number of different primary human tumours as well as in vitro and functional 
data in FL, where Tregs are associated with a pro-tumoral immunity, we found a 
follicular pattern of FOXP3+ Tregs to be associated with inferior survival in FL. 
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Importantly, this follicular pattern also predicted an increased risk of 
transformation. Superficially, this finding appears to contradict previous 
retrospective studies of the survival impact of Tregs in FL using TMAs and 
immunohistochemistry (61, 62). However, in contrast to those studies, our 
analysis found the distribution of Tregs to be more important than their 
numbers. In addition, our patients received uniform therapy, thus holding this 
important variable constant. Recent data convincingly demonstrate the 
dramatically variable impacts that different therapies have on the non-neoplastic 
immune cells in the microenvironment (8, 63-65). Indeed, studies of the 
microenvironment in FL become nearly impossible to interpret when patients 
receive very heterogeneous treatments, because the specific chemotherapeutic 
agents, radiation and biological agents differentially impact benign immune 
cells. As was shown in several recent series studying the impact of LAM in FL, 
the specific therapeutic regimens used decisively influenced the prognostic 
impact of non-neoplastic cells in the microenvironment (8, 63-66).  
In FL, where the content and distribution of various immune-related cells is 
markedly heterogeneous, we reasoned that the topographic distribution of 
Tregs relative to the neoplastic follicle might reflect their function and thus their 
clinical impact. Qualitative (architectural patterns) or semi-quantitative 
biomarkers (cell counts) such as those measured in this study may be difficult to 
reproduce (67). However, the use of TMAs and immunohistochemistry at least 
partially overcomes this difficulty and has been shown to provide a reliable 
strategy to assess large numbers of clinical samples and validate novel 
biomarkers discovered by GEP (25, 63).  
In this study, we analyzed Tregs within FL biopsies using three markers known 
to be characteristically expressed by Tregs: CD4, CD25 and FOXP3. As 
previously described, Tregs belong to the CD4+CD25+ T cell subset. However, 
Tregs can be CD25- and CD8+CD25+ T cells can exhibit regulatory activity 
(68). FOXP3 is the single best marker of activation of Tregs (69). Simple 
enumeration of cells identified using these markers showed no impact on 
survival or risk of transformation. However, we found a follicular distribution of 
these CD25+ or/and FOXP3+ cells strongly correlates with outcome (Table 3). 
Interestingly, the survival associations in our cohort followed a pattern linked to 
specificity for the regulatory phenotype: CD4/8 pattern had an impact just on 
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PFS, CD25 showed significance for PFS and OS and FOXP3 had an impact on 
PFS, OS and, importantly, RT. 
Programmed death-1 (PD1) belongs to the immunoglobulin CD28 receptor 
family and is characteristically expressed by germinal center-associated T cells. 
These cells have immunoregulatory activity and are FOXP3 negative (70). In 
the current study, we showed that combined cell density and distribution within 
FL of differently expressed immunoregulatory cell markers are important 
predictors of OS & RT in advanced-stage FL patients treated uniformly with an 
aggressive treatment regimen.  
This impact of either follicular or perifollicular FOXP3+ cells suggests a 
functional suppression of immunosurveillance within the tumour 
microenvironment that is present at the time of diagnosis. The malignant cells 
may have the capacity to “recruit” or “skew” Treg activity towards the 
suppression of anti-tumoral T-cells, thus allowing the malignant cells to 
“escape” from the regulatory activity (38). Interestingly, eleven of 12 cases with 
a high content of LAMs in this series had a follicular FOXP3 pattern. Both Tregs 
and macrophages may cooperate, in a subset of cases, providing the neoplastic 
B cells with trophic and survival signals that promote tumour progression, the 
accumulation of further genetic damage and transformation. 
 
3.5.4. Vessels 
Angiogenesis plays a crucial role in the growth and progression of human solid 
tumours (4). In most tumour types, increased MVD correlates with increased 
disease progression and decreased survival. Similar results have been reported 
in hematopoietic tumours, including multiple myeloma and lymphoma (71-74). 
In murine lymphoma models and in lymphoma patients, circulating endothelial 
cells and serum vascular endothelial growth factor (VEGF) levels appear to 
correlate with lymphoma volume and increased angiogenesis (75, 76). In 
contrast, previous studies of MVD in FL have resulted in conflicting results. 
Koster et al showed increased MVD to be associated with a more favourable 
OS in a series of 36 uniformly treated patients given CVP and interferon (IFN) 
α2b followed by IFN maintenance (77). In a later report, Jorgensen et al. 
analyzed 107 FL cases with heterogeneous treatments and found increased 
interfollicular MVD predicted inferior OS and increased transformation to 
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DLBCL(78). In both studies, MVD was calculated using quantification of focal 
“vessel hot spots” within the tumour. In FL however, the vessels show a 
heterogeneous distribution. Therefore, in order to avoid a scoring bias, we 
studied whole sections of FL biopsies and quantified automatically the average 
distance from CD34 stained vessel that included 90% of tumour cells – TVD90. 
We believe this is a more accurate measurement of vessel density within the 
lymph node.  
Because of vessel predominance within the interfollicular and perifollicular 
areas, TVD90 was correlated with the average size of the follicles in each case. 
Interestingly, cases with low TVD90 correlated with small sized follicles although 
follicle size itself did not affect survival or risk of transformation.  
In the current study, all 84 patients were treated uniformly with multi-agent 
chemotherapy and radiation, while in the series by Koster et al, all 36 patients 
were treated with CVP chemotherapy and IFN followed by IFN maintenance. In 
addition to the difference in cohort size, different therapeutic regimens may 
explain the contradictory results. IFN has both immunomodulatory and anti-
angiogenic effects and thus may have been more effective in tumours with 
increased MVD (79). Radiation has been shown to induce tumour cells to 
secrete cytokines capable of inhibiting apoptosis in endothelial cells, thereby 
diminishing treatment response (80, 81). It remains possible that this treatment 
modality influenced survival and transformation risk in our study.  
It is well known that angiogenesis in cancer is critically influenced by the local 
tumour microenvironment (82). In this study using the same uniformly treated 
cohort, increased numbers of LAM is associated with adverse outcome (63). 
Similar to solid tumour-associated macrophages, these LAM, possibly 
originating from bone marrow derived myeloid cells, may be attracted by 
hypoxia and tumour-derived chemotactic factors and show a distinct phenotype 
that promotes angiogenesis (83-85). Consistent with this hypothesis, we show a 
significant association between TVD90 and LAM. In previous published NHL 
studies that included FL cases, increased angiogenesis and macrophage 
density simultaneously correlated with pathological progression in lymphoma 
(86, 87).  Given the inferior outcome associated with increased LAM in FL, 
macrophages are a good candidate to be supportive of angiogenesis in FL. 
S100A8+ is characteristic of late-stage inflammatory macrophages with anti-
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inflammatory homeostatic functions and is up-regulated by glucocorticoids and 
IL10 (14). These are features suggestive of a M2 phenotype. We show in the 
current study a significant association between S100A8 and TVD90, consistent 
with this hypothesis (Figure 3.20 & 3.21). 
 
 
3.6 CONCLUSION 
This study provides compelling data that support a role for benign 
macrophages, vessels and Tregs in predicting outcome in aggressively treated 
FL patients and further substantiate the gene expression profiling data 
highlighting the importance of non-neoplastic cells in determining prognosis in 
FL (Figure 3.22). These biomarkers may become useful in initial therapeutic 
decisions of patients with FL, and may even provide a rationale for trials of new 
therapies, such as anti-angiogenic therapy in FL patients with increased MVD. 
This cohort has the important and rare advantage of its patients being treated 
uniformly. Heterogeneous treatment modalities within and between different 
series of FL has been considered responsible for the controversy in the 
published literature (Figure 3.23). Yet, at present, these significant biomarkers 
related to the non-malignant microenvironment remain interesting clinic-
pathological findings, but they represent functionally untested hypotheses. An 
improved understanding of the interactions between non-neoplastic 
macrophages, T cells and vessels with neoplastic B cells in FL should provide 
important insights into the biology of this common tumour. Assessment of these 
markers in prospective clinical trials will expedite their validation.  
Ultimately, it may be possible to manipulate the microenvironment of the lymph 
node in favour of the host and turn off tumoural immunosuppression or trophic 
survival signals derived from non-neoplastic tissue cells (Figure 3.24).  
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3.7 TABLES 
 
 
 
Table 3.1 - Antibodies used in the study.
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Table 3.2 - Biomarkers related to FL microenvironment.  
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Table 3.3 - Distribution of clinical and pathology variables between high and low 
Lymphoma-Associated-Macrophages (LAM); IPI = International Prognostic Index 
score, BM = bone marrow, CR = complete remission, PR = partial remission, NR = no 
response; *IPI group 1 vs. 2/3; **CR vs. PR/NR; ***Grade 1 vs. 2/3A. 
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Table 3.4 - Distribution of clinical and pathology variables between Follicular 
and Diffuse pattern of FOXP3+ cells; IPI = International Prognostic Index score, 
BM = bone marrow, CR = complete remission, PR = partial remission, NR = no 
response; *IPI group 1 vs. 2/3; **CR vs. PR/NR; ***Grade 1 vs. 2/3A. 
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Table 3.5 - Distribution of clinical and pathology variables between high TVD90 
and low TVD90 cases. IPI = International Prognostic Index score, BM = bone 
marrow, CR = complete remission, PR = partial remission, NR = no response; 
*IPI group 1 vs. 2/3; **CR vs. PR/NR; ***Grade 1 vs. 2/3A. 
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3.8 FIGURES 
 
 
 
 
Figure 3.1 - Representative tissue microarray cores of follicular lymphoma 
patients (H&E) (Microscope NIKON Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.2 - Overall survival curve based on NOXA gene expression from 
diagnostic biopsies on 191 cases of FL from the freezers of LLMPP institutions 
detected by gene expression profiling using Affymetrix® U133A/B arrays. The 
upper curve represents cases with increased NOXA and the lower curve those 
cases with decreased NOXA.  
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Figure 3.3 - Representative tissue microarray cores of follicular lymphoma 
patients showing NOXA Protein Expression by both malignant and histiocytic-
like cells (Microscope NIKON Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.4 - Representative tissue microarray cores of follicular lymphoma 
patients showing different staining intensity & architectural patterns of CD21+ 
Follicular Dendritic Cells meshwork (Microscope NIKON Eclipse E600; Digital 
Camera Dxm1200). 
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Figure 3.5 - Representative tissue microarray cores of follicular lymphoma 
patients. The image on the left shows the uncommon finding of large numbers 
of macrophages both within and surrounding neoplastic follicles (n=12). The 
image on the right shows the more common finding of very macrophages 
(n=87). The insert shows the typical strong cytoplasmic staining of reactive 
macrophages with anti-CD68 antibodies (Microscope NIKON Eclipse E600; 
Digital Camera Dxm1200). 
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Figure 3.6 - Representative tissue microarray core of a follicular lymphoma 
patient. The image shows a case with increased S100A8+ / Calgranulin A+ 
cells. They have a preferential interfollicular distribution (Microscope NIKON 
Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.7 - Representative tissue microarray cores of follicular lymphoma 
patients showing three distinct FOXP3+ T cells architectural patterns 
(Microscope NIKON Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.8 - Representative tissue microarray cores of follicular lymphoma 
patients showing one case with high and low PD1 cell content (Microscope 
NIKON Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.9 - Representative tissue microarray cores of follicular lymphoma 
patients showing two distinct PD1+ T cells architectural patterns, follicular and 
diffuse (Microscope NIKON Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.10 - Representative tissue microarray cores of follicular lymphoma 
patients showing two major patterns of CD4 & CD8 T cells (Microscope NIKON 
Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.11 - TVD90. Whole sections were used and edges and staining 
artifacts were cropped prior to analysis (Microscope NIKON Eclipse E600; 
Digital Camera Dxm1200). 
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Figure 3.12 - Representative sections of follicular lymphoma cases with low and 
high TVD90 (Microscope NIKON Eclipse E600; Digital Camera Dxm1200). 
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Figure 3.13 - Overall survival curve based on NOXA Protein Expression (NPE). 
The upper curve represents cases with increased NPE and the lower curve 
those cases with low NPE.  
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Figure 3.14 - Progression-free survival curve based on lymphoma-associated-
macrophage (LAM) content. The upper curve represents cases with <15 CD68+ 
macrophages/hpf and the lower curve those cases with >15 CD68+ 
macrophages/hpf. The median PFS were 7.05 and 1.69 years, respectively 
(P=0.001). 
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Figure 3.5 - Overall survival curve based on S100A8+ or Calgranulin A+ cells 
content. The upper curve represents cases with low number of cells and the 
lower curve those cases with increased cell content (n=14).  
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Figure 3.16 - Overall survival & Risk of Transformation curves based on 
architectural patterns of FOXP3+ T cells. 
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Figure 3.17 - Overall survival & Risk of Transformation curves based on 
combined cell content of FOXP3+ & PD1+ cells. 
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Figure 3.18 - Overall survival & Risk of Transformation curves based on 
Microvessel density using TVD90 – Tumor to Vessel density including 90% of 
the malignant cells. 
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Figure 3.19 - NOXA is a pro-apoptotic member of the BCL2 protein family, 
belonging to the BH3-only sub-family. BCL2 family members can form hetero- 
or homodimers, and they act as anti-or pro-apoptotic regulators that are 
involved in a wide variety of cellular activities. The expression of NOXA is 
regulated by the tumor suppressor TP53, is involved in TP53-mediated 
apoptosis and is one of the major “sensitizers / derepressors” favoring 
apoptosis. 
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Figure 3.20 - Increased microvessel density correlated with increased LAM and 
S100A8 positive cells promoting a local pro-tumoral immunity within the 
microenvironment…
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Figure 3. 21 
… this is significantly correlated with increased risk of transformation.
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Figure 3.22 - A model of protumoral immunity within follicular lymphoma. The 
malignant cells have the capacity to “recruit” or “skew” both monocytes and 
Treg activity towards the suppression of anti-tumoral T cells, thus allowing the 
malignant cells to “escape” from the regulatory activity within the tumor 
microenvironment that is present at the time of diagnosis. Both Tregs and 
macrophages cooperate, in a subset of cases, providing the neoplastic B cells 
not only with trophic and survival signals but also promoting tumor progression 
through the accumulation of further genetic damage that will eventual lead to 
transformation into high grade disease, most commonly a Diffuse Large B cell 
lymphoma. 
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Figure 3.23 - Impact of microenvironment in FL prognosis: distinct differences in 
most non-malignant cell content and patterns of distribution within FL are 
present in diagnostic biopsies. Some have been reported to impact survival 
often with contradictory results among studies.  The unique difference 
characterizing these series is different therapeutic regimens used within the 
same cohort and among different series. Limited knowledge on how 
chemotherapy impact on microenvironment limits any interpretation of series 
treated with different protocols. Uniformity of treatment is mandatory. Rx- 
therapeutic regimens 
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Figure 3.24 - Dual model for the role of tumor immunity in FL and its impact on 
survival and/or transformation. A follicular polarization of CD4+ cells, especially 
FOXP3 Tregs (  ), increased numbers of vessels (  ), mast cells ( ) or 
macrophages ( ) represent cases where malignant cells edited local immunity 
to support tumor growth. Alternatively, lack of follicular localization of those T 
cells, low numbers of mast cells, macrophages and vessels may be 
characteristic of an anti-lymphoma immunity. The survival outcome or 
transformation risk is heavily dependent on the type of therapy used and 
baseline immune-response characteristics. These latter factors are poorly 
studied and indeed are major challenges for the future of FL treatment. 
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Section 4: Microenvironment in Follicular Lymphoma: 
Monocyte & Macrophage Interactions in Patients with 
Follicular Lymphoma Harboring a t(14;18): Is There a 
Clonal Relationship? 
 
4.1 INTRODUCTION 
FL is somewhat unique amongst B cell neoplasms as it retains many of the 
morphological features of the normal follicle. Cellular interactions between 
tumoural B cells and their surrounding T cells, follicular dendritic cells (FDC) 
and macrophages are maintained in FL. Survival signals from these non-
neoplastic cells appear to be important for the neoplastic B cells (1). In the 
NOD/SCID mice transplanted with human FL samples, contrary to other 
lymphoma types, these cells fail to maintain their histology for more than one 
graft generation. The malignant cells either die or transform into higher grade 
disease through an apparent EBV-driven mechanism (unpublished observation, 
PF).  
As discussed in the previous chapter, the Leukemia/Lymphoma Molecular 
Profiling Project (LLMPP) using gene expression profiling (GEP) revealed that 
non-neoplastic immune cells were predominantly responsible for the gene 
expression signatures contributing most to an outcome predictor (2). Immune 
response-1 (IR-1) appeared to be derived from reactive T cells in the lymph 
node biopsies and conferred a favorable outcome; while immune response-2 
(IR-2) revealed a gene expression pattern most reminiscent of macrophages 
and conferred an inferior survival on FL patients. Hypotheses raised by these 
observations led us to demonstrate that Lymphoma-Associated Macrophage 
(LAM) content is an independent adverse prognostic factor in advanced-stage 
FL patients treated uniformly (see Section 3), further validating the impact of IR-
2 on FL survival (3). 
These cells may be recruited and “educated” by tumours using a range of 
growth factors and chemokines, so that they adopt a “trophic” role that 
facilitates matrix breakdown, tumour-cell motility and angiogenesis (4).  
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However, the precise biological function of tissue-based macrophages in this 
setting remains largely undefined. Macrophage heterogeneity is better studied 
in the mouse but less is known about human macrophages despite the 
increasingly number of reports on these cells (5-7). The plasticity of 
macrophage function is evident in the diverse range of functions of these cells, 
including inflammatory responses, immune reactions, tissue remodeling and 
morphogenesis. One of the many markers differentially expressed in the 
different types of macrophages is CD163, a receptor that scavenges 
hemoglobin by mediating endocytosis of haptoglobin-hemoglobin complexes. It 
is member of the scavenger receptor cysteine-rich family and exclusively 
expressed on cells of the monocyte lineage. CD163 expression is suppressed 
by pro-inflammatory mediators like lipopolysaccharide (LPS), interferon-gamma 
(IFN), and tumour necrosis factor alpha (TNFα), whereas IL6 and the anti-
inflammatory cytokine IL10 strongly up-regulate CD163 mRNA in monocytes 
and macrophages. This expression pattern implies a functional role of CD163 in 
the anti-inflammatory response of monocytes, characteristic of M2 cells 
reported to be pro-tumoural (8) – see Sections 1 & 3. 
FL is characterized by the t(14;18)(q32;q21), which juxta-poses the BCL2 gene 
on chromosome 18 with the immunoglobulin heavy chain locus on chromosome 
14, resulting in the constitutive expression of BCL2 protein, which is not 
significantly expressed by normal follicular center B cells. Although 15% of FLs 
are t(14;18)-negative, the translocation has been used as a genetic marker for 
FL.  It has been postulated that it occurs as an error during VDJ rearrangement 
at the pre-B cell stage of differentiation in the bone marrow and is insufficient 
but necessary for the malignant transformation (1). Although t(14;18) 
translocation and ectopic BCL2 expression are critical early events in the 
natural history of lymphoma pathogenesis, further B cell differentiation and 
additional oncogenic events are required for full malignant transformation. The 
t(14;18) has been found frequently in the blood of healthy blood donors as well 
as in germinal centers of patients in the absence of manifest clinical lymphoma, 
and who only develop FL several years later (9, 10). The favored hypothesis 
regarding the pathogenesis of FL suggests that B cells harboring a t(14;18) 
arise at the pre-B stage in the marrow.  These cells eventually enter the 
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circulation, home to the lymph node and upon antigenic challenge enter the 
germinal center where they expand and are submitted to the processes of 
somatic hypermutation (SHM), class-switch recombination(CSR) mediated by 
activation-induced cytidine deaminase (AID). Thus, the bulk of circulating 
t(14;18)+ cells detected in healthy individuals and in FLIS lesions is not formed 
by naïve B cells but with already GC-experienced and expanded t(14;18) B cell 
clones. They can seed the follicles and reside, ”inoffensively”, in a resting state 
with a low risk of proliferation, genomic instability or malignant progression.  
Only upon accumulation of additional genetic hits in cells “blocked” as GC like B 
cells, a process rich in double-strand DNA breaks. In such cells the “ectopic” 
expression of BCL2 will allow the hazardous rescue from physiological 
apoptosis, resulting in their accumulation, sustained proliferation, in and off 
target SHM and CSR, favouring second and subsequent additional genetic hits, 
some of which lead to the development of FL (11, 12).  
In vitro studies have shown that precursor cells of the B cell lineage can 
differentiate into other cell types including tissue-based macrophages (13-15). 
Interestingly, it has been shown that in FL, a subpopulation of endothelial cells 
show the characteristic t(14;18) translocation of FL (16).  
These findings may indicate, among other hypotheses, plasticity of a neoplastic 
precursor cell in the marrow that maintains the ability to differentiate into 
different mature cell types, including macrophages. In the lymph node, these 
cells would provide the neoplastic B cells with a trophic environment in 
cooperation with Tregs cells leading to a sculpted immunosuppressive intra-
tumoural milieu. A subset of these monocytes/macrophages might be 
genetically related to lymphoma-originating cells and be recruited to lymphoma 
sites. 
 
 
4.2 AIM  
Our aim is to study intratumoural monocytes & macrophages in FL patients and 
verify the clonal relationship of these “non-neoplastic” cells with the malignant B 
cell clone.  
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4.3 MATERIALS & METHODS 
4.3.1. Patients & Sample Selection  
In this study we used BCCA´s Centre for Lymphoma Cancer clinical and 
pathological electronic database. All samples were reviewed by two 
hematopathologists (PF and RDG) based on the criteria defined by the 2008 
World Health Organization classification of tumours of hematopoietic and 
lymphoid tissue (17). The study was performed in accordance with the 
Declaration of Helsinki. 
The study started with a pilot study using 7 FFPET samples including cases 
from a cohort of patients uniformly treated with a BP-VACOP regimen described 
in the previous section (see Section 3). A FICTION technique was optimized 
using these samples. Then the study was expanded using fresh FL samples. 
These were sorted from consecutive fresh lymph biopsies submitted to BCCA´s 
Immunology laboratory during an 8-month period between October 2005 and 
May 2006. After all routine diagnostic proceedings were preformed following 
BCCA´s Lab Med protocols (http://www.bccancer.bc.ca/HPI/labservices/), touch 
imprints of the lymph nodes were taken. The slides were stained with Giemsa 
and those cases suggestive of reactive lymph nodes or low-grade follicular 
lymphoma were archived and correlated with the final diagnosis often involving 
flow cytometry, histology and cytogenetics or molecular biological ancillary 
studies. A proportion of the samples were submitted for FICTION (see Section 
1). 
 
4.3.2. FICTION Technique 
As previously described this technique preserves cell morphology and 
combines immunofluorescence to detect cellular antigen and fluorescence in-
situ hybridization (FISH) to detect chromosomal abnormalities.  This technique 
has already been successfully applied on FFPET but with a certain level of 
inconsistency due to technical problems, such as poor target signal intensities 
and nonspecific background. These problems have been attributed to the intra- 
and extracellular protein cross-linkages caused by the fixation process, which 
result in a reduction in the accessibility of the target DNA to the specific FISH 
probes. Recently, a pressure-cooking method in combination with Tris-EDTA or 
EDTA buffer as antigen retrieval has been applied in some FISH studies on 
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paraffin tissue resulting in good signal intensity (18). On the other hand, heat 
retrieval and calcium-chelating agents such as EDTA have been shown to 
improve the quality of immunostaining when used on paraffin sections (19). 
Previous studies have identified optimal conditions of antigen retrieval in order 
to obtain consistently good results with the FICTION method on routinely 
processed tissue samples, obtaining a critical duration of antigen retrieval 
essential for a good equilibrium between FISH and immunofluorescence. Long 
periods of pressure cooking could increase FISH signal, but at the expense of 
also damaging the cell membrane, resulting in a decrease of the fluorescence 
signal (20).  We used this approach as a template to optimize the FICTION 
protocol first in FFPET samples of the pilot study and later for touch imprints 
samples. The final protocol used in the study is summarized in Figure 4.1. 
 
4.3.2.1. Paraffin Samples 
Biopsy samples from FL and reactive lymph nodes were obtained from the 
BCCA Pathology Department archive after having been fixed in buffered 
formalin and paraffin embedded by conventional techniques. Six samples were 
FL included in the BP-VACOP study (described in Section 3) and were selected 
based on: 1) the presence of BCL2 rearrangement  in four of 6 cases and; 2) 
LAM cell content including three cases LAM-rich and three LAM-poor (3). One 
reactive lymph node with follicular hyperplasia was added.   
Tissue sections (3 to 4um) were cut and placed on salinized slides (Dako, 
Glostrup, Denmark) and incubated at 56ºC overnight. The slides were then 
deparaffinised twice using xylene (10 min, room temperature in a hood). The 
slides were hydrated in a series of ethanol solutions (100%, 95% and 75% for 
5min each) and then washed with PBS.  
 
4.3.2.2. Touch Imprint Samples 
In an eight month period, 388 fresh lymph node samples were screened. Eighty 
one FLs and 38 reactive nodes (RN) confirmed by both histology and 
phenotypic and/or genotypic studies were selected. Based on the quality of the 
touch preps and tumour cell content fifty four samples (42FLs & 12 RNs) were 
selected for FICTION. Touch preparations obtained from the imprints of fresh 
nodes were air dried for 30 to 60 minutes at room temperature. They were 
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archived in a freezer at -20ºC. Just before FICTION the slides were fixed in 
either buffered formalin or acetone for more than one hour at room temperature. 
 
4.3.2.3. Paraffin & Touches Antigen Retrieval 
Slides were first washed slowly in tap water and placed in a jar with the retrieval 
solution, 50mM Tris/EDTA (pH9) - Dako Target Retrieval Solution ( pH 9)®., in 
a stainless-steel 5l pressure cooker with an operating pressure of 120 PSI at 
120ºC for 2 minutes followed by 30 minutes of cooling time. Thereafter, slides 
were washed slowly in tap water and placed in PBS. 
 
4.3.2.4. Immunofluorescence Staining 
After checking the tissues/cells using the microscope the first antibody, CD163 
(clone 10D6), monoclonal mouse antibody Novocastra (NCL-CD163), dilution 
1:50, was applied (50μl/slide) with plastic lids for 30min to one hour. Slides 
were then washed in PBS 0,1%Tween 20 three times for 5 minutes each and 
the second antibody applied (50 μl /slide)  for one hour in the dark, Alexa Fluor 
594 (excitation/emission maxima ~590/617 nm) Goat anti-Mouse in 1:200 
dilution  - Invitrogen®. Subsequently, they were washed in PBS 0,1%Tween 20 
three times for 5 minutes each. 
Before FISH was done, slides were covered and DAPI II and coverslip and 
checked for positive fluorescence.  Up to 50 CD163 positive cells were mapped 
per case using MetaSystems® platform and image analysis software. 
 
4.3.2.5. Fluorescence In-Situ Hybridization (FISH) 
Slides were placed in 1xPBS till the coverslip felt (5 minutes on average) and 
then dehydrated through a series of ethanol washes (70%, 80% and 100% for 2 
min each). A BCL2 probe from Vysis®, Vysis LSI BCL2 Dual Color, Break Apart 
Rearrangement Probe was denatured separately at 72ºC for 3 minutes and 
then applied to the slide and co-denatured at 65ºC for 90 seconds. It was left 
overnight in a humid chamber at 37ºC in the dark. A rapid first wash was done 
with 2xSSC/0.3% NP40 at 70ºC for 2 minutes and repeated at room 
temperature for 5 minutes and finally with 1xPBS for 5 minutes. The slides were 
dried in the dark for at least 30 minutes and covered with DAPI II (5 to10 μl) and 
cover-slipped and stored at 4ºC.  
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The breakapart probe is easier to score in tissues and smears but only 
documents a break and/or rearrangement within the BCL2 locus with no 
information on the translocation partner. A BCL2 fusion probe (Vysis® LSI 
BCL2 Dual Color, Break Apart Rearrangement Probe) was used in selected 
cases to confirm the BCL2 rearrangement and translocation to the IGH locus.  
 
4.3.3. Image Capturing and Analysis 
Tissues and smears images were captured using the MetaSystems® platform. 
The whole slides were screened for both CD163 positive and negative cells and 
nuclei counted for FISH probe signals. Up to two hundred CD163 negative cells 
and 50 CD163+ cells were counted. Data were analyzed using the Statistical 
Software Package for the Social Sciences (SPSS version 10.1 for Windows; 
SPSS Inc®, Chicago, IL). 
 
4.4 RESULTS 
4.4.1. Paraffin Samples – Pilot Study 
In six out of seven samples, FICTION was successful with good fluorescence 
and FISH signals. Bearing in mind that these are samples from early 90s this 
was a very promising result. Four of the six FL showed a BCL2 translocation. In 
all cases with confirmed translocation we were able to confirm the 
rearrangement in the CD163-negative cells (Table 4.1). CD163+ cells were 
captured in all cases varying between 8 and 80 cells with a median of 44 cells 
(representing the reactive case with the highest number of cells). Most cells had 
normal FISH signals (two red & green signals with no split signals), with roughly 
6 to 75 cells counted (median 36). Abnormal FISH signals including split probe 
signals or extra signals were also present in the CD163 positive cells (Figures 
4.2 & 4.3) but this was not found in all CD163 expressing cells. In order to 
confirm that these few cells with abnormal signals were not just a technical 
artifact of the technique, we used in two cases a fusion probe from Vysis®, 
which confirmed the translocation in some cells. The abnormal FISH signals 
were present in very low numbers in all samples including BCL2-negative FL 
and in the reactive case (Figure 4.4), with 2 to 8 cells identified (median 7). The 
percentage of CD163+ cells with abnormal FISH signals ranged from 6% to 
33% (median 18%). Despite the low number of samples and cells there was no 
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significant difference in the percentage of the CD163+ cells with abnormal FISH 
signals between FL with (median 15%, ranging 10% to 33%) or without BCL2 
rearrangement (23%) or the reactive sample (6%). Similarly, FL rich in LAM 
(median of 11% with abnormal FISH) were not significantly different than cases 
with low numbers of LAMs (median of 18% with abnormal FISH).  
In conclusion, in the pilot study we have found CD163+ cells with abnormal 
signals (Figures 4.2 to 4.4) but the overall results showed no clear evidence that 
macrophages could harbour the same translocation characteristic of the 
malignant cells.   
There are several reasons that might explain these results. First, there were 
limited or only very rare cells that could be clearly evaluated by FICTION, as 
many of the cells showed partial or completely overlapping nuclei making it 
impossible to evaluate the FISH signals. Secondly, a loss in intensity of the 
fluorescence signal which also reduced the number of evaluable cells and lastly 
overlap of nuclei in most of the tissue sections. The number of cells with 
abnormal signals was very limited in all cases (although considerable in relation 
to the total number of cells assessed) and not significant in terms of the FISH 
analysis in FFPET. In most studies using commercially available probes like the 
ones used in this study of whole tissue sections, the threshold value to consider 
a positive result above background is about 20% for breakapart probe signals. 
Thus, we expanded our study changing the type of samples, trying to avoid the 
problem with overlapping nuclei present in FFPET sections.  
 
4.4.2. Touch Imprints Samples 
FICTION was performed using 54 samples including 42 FLs and 12 RNs. After 
optimization of the technique in both reactive and FL samples, we achieved 
successful results in 29 samples and the technique failed in 25. The vast 
majority of the latter were due to poor fixation of the cells resulting in deficient 
antigen retrieval and very limited sample to be analyzed with rare CD163+ cells 
to be evaluated. 
Interestingly, some of the features were related to the sample type as only 2 
(17%) out of 12 RN failed while 23 (55%) out of 42 FL failed. Of the 19 FLs with 
results 14 had a BCL2 translocation and 5 were negative for this 
rearrangement. In all cases with confirmed BCL2 translocation we were able to 
 183 
confirm the rearrangement in the CD163 negative cells (Table 4.2). CD163+ 
cells were captured in all cases varying between 5 to 148 cells with a median of 
21 cells. Most cells had normal FISH signals (two red & green signals with no 
split signals), varying between 4 to 100 cells (median 21). Abnormal FISH 
signals including split probe signals or extra signals also present in the positive 
CD163 cells but not found in all CD163+ cells. CD163+ cells with abnormal 
signals were present in very low numbers in all FL samples with or without 
BCL2 rearrangement, varying from 1 to 48 cells (median 4). No abnormal 
signals, suggestive of split signals were observed in the RNs. The percentage 
of CD163+ cells with abnormal FISH signals ranged from 2% to 33% (median 
21%).  
In the 10 RNs the total cells assessed was between 5 to 50 cells with no cells 
showing documented abnormal signal constellations (Figures 4.5 & 4.6). 
In the five FL cases negative for BCL2 rearrangement total, CD163+ cells 
ranged from 5 to 51 cells and from these only 1 to 3 cells had abnormal FISH 
signals. The percentage of these cells ranged from 2 to 20% (Figure 4.7). 
In the fourteen FL with BCL2 rearrangement, total CD163+ cells ranged from 6 
to 148 cells and from these between 2 to 48 cells had abnormal FISH signals. 
The percentage of these cells ranged from 16 to 33% (Figures 4.8 to 4.15). 
The differences in the cell content of CD163+ cells with abnormal FISH 
between the three groups, reactive LNs, FL with or without BCL2 
rearrangement were significant for the number of cells with FISH abnormal 
signals (χ2, P<0.001) as well as the percentage of these cells (χ2, P=0.001) but 
not for the total number of cells assessed (χ2, P=0.74). BCL2+ FL had 
significant more cells and higher percentage of CD163+ with abnormal FISH 
has both BCL2-negative lymphomas and reactive lymph nodes. 
 
 
4.5 DISCUSSION 
In this study we describe convincing preliminary evidence suggesting that a 
minority of LAMs appear to harbour the BCL2 translocation characteristic of the 
FL B cells. This is not a new finding as Streubel et al. previously reported that 
microvascular endothelial cells within FL samples shared the BCL2 
rearrangement (16). Using various markers, they found that cells lining the 
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microvasculature and expressing an endothelial phenotype, in most cases using 
CD31 but also CD34, von Willebrand factor or Ulex europaeus lectin, also 
shared the genetic hallmark of FL B cells. Interestingly, CD31 is also expressed 
by a subset of circulating monocytes with angiogenic functions that are recruited 
into hypoxic tissues including tumours (21). 
Four mechanisms can be considered to explain our findings: 
First, the reported findings of macrophages with abnormal FISH signals 
indicating BCL2 translocation could represent a technical artifact resulting from 
nuclei of lymphoma cells phagocytized by macrophages, thus explaining why 
only a minority of cells show the abnormal signals. Furthermore, the pattern of 
signals observed in CD163+ and CD163 – are identical for each case (Figures 
4.9 & 4.10). This is a very strong argument favouring FL nuclei within LAM 
cytoplasm, which makes mandatory the validation of these results using other 
techniques such as cell sorting followed by cell culture and repeat FISH studies. 
Yet, the significant differences found in the abnormal signals between cases 
positive and negative for BCL2 rearrangement, independent of the number of 
cells assessed, favours that these abnormal signals reside within macrophages.  
Second, cell fusion could explain the results (22, 23). If true then it should result 
in tetraploid karyotype, an event easily detected using a technique such as 
FICTION. However, some reports have shown that tetraploid hybrids undergo 
reduction divisions resulting in diploid daughter cells (23). 
Third, eventual gene transfer could result from uptake of apoptotic bodies from 
lymphoma cells (24). 
Finally, both FL cells and macrophages derive from a common precursor cell in 
the bone marrow. Cells of the hematopoietic system are derived from common 
precursors that differentiate into lineages with distinct morphologic, 
immunophenotypic, and functional characteristics (25). Most theories of 
hematopoietic cell differentiation have proposed that as cells differentiate fully, 
they become “lineage committed.” Recent data suggests there is more plasticity 
between the B cell and myeloid lineages than previously thought (26). This 
plasticity is associated with changes in transcription factor expression and/or 
activity. Within the lymphoid system, C/EBPα was shown not only to divert 
uncommitted progenitors to the myeloid lineages but also to induce the 
transdifferentiation of committed B lymphocytes into functional macrophages 
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that still retain immunoglobulin gene rearrangements as evidence of their B cell 
origin (15). This transdifferentiation of mature B cells into macrophages is 
associated with inhibition of the B cell commitment transcription factor PAX5 
(27). Conditional deletion of PAX5 causes mature B cells to dedifferentiate into 
uncommitted precursors in the bone marrow (28). PAX5-deficient progenitors 
carrying rearranged IG genes could differentiate into myeloid cells and T cells, 
but not into B cells. Moreover, bipotential B-macrophage progenitors have been 
demonstrated in adult bone marrow from mice (29). Hou et al. reported the 
identification in healthy human bone marrow specimens of a small fraction of 
primitive CD34+/CD19+/CXCL4− cells termed B cell/myeloid progenitors (BMPs) 
(30). When placed in B-lymphoid culture conditions, BMPs acquired 
characteristics of mature B cells, including surface light chain expression. In 
myeloid culture conditions, however, the BMPs formed myeloid colonies. This 
plasticity of hematopoietic cells observed in experimental models in which 
modulation of specific transcription factors can reprogram cells to enter different 
differentiation pathways have been shown to recapitulate in the clinical setting. 
It has been reported previously that two different hematopoietic populations in 
the same patient may share identical genetic changes or abnormalities, raising 
the possibility that tumours expressing the phenotype of one hematopoietic 
lineage might “transdifferentiate” into a genetically similar but phenotypically 
distinct tumour of a different lineage. Recently, the occurrence of histiocytic and 
dendritic cell (H/DC) sarcomas has been described in patients with FL in which 
the sarcomas shared both the IGH and BCL2 rearrangements with the FL. This 
may represent a de-differentiation event of the B cell due to loss of PAX5 
activity (31).  All evaluable H/DC tumours were negative for PAX5, despite 
genotypic evidence of a B cell derivation. In contrast, CEBPβ and PU.1 were 
highly expressed in the same tumours and both of these transcription factors 
play a major role in mediating macrophage and myeloid differentiation (27). 
Interestingly, sporadic H/DC tumours as well as Langerhans cell histiocytosis 
(LCH) have also shown IGH gene rearrangements at a higher frequency than 
expected:  30% (14/46) of LCHs cases had clonal IGH@ (4 cases), IGK@ (5 
cases) or TRG@ (9 cases) gene rearrangements, respectively, but failed to 
express T cell or B cell lineage-specific or associated markers (32). 39% (9/23) 
of cases of H/DC sarcomas showed clonal IGH (+/-IGK) gene rearrangements, 
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whereas 2 (9%) cases showed only clonal IGK gene rearrangements, which 
were further validated and confirmed by direct DNA sequencing. One histiocytic 
sarcoma also showed t(14;18). Notably, all H/DC sarcomas were negative for 
PAX5 (33). The results provide genotypic evidence supporting the notion of 
lineage plasticity of hematopoietic cells and their associated neoplasms. H/DC 
tumours contained both clonal IGH gene rearrangements and t(14;18), both 
which are believed to occur as recombinase-mediated events in the bone 
marrow in the pre-B stage of differentiation by normal or illegitimate VDJ 
rearrangement, respectively (34). Thus, a postulated common precursor would 
be differentiated at least to the point of recombination activating gene (RAG) 
complex activity. It is well established that clonal expansion of B cells carrying 
the t(14;18) translocation are commonly detected in healthy persons, termed 
FL-like B cells (9, 35) . These circulating clonal cells which are much more 
common than FL, appear to lack additional oncogenic events to develop into 
clinical FL. Yet, they represent the pool of cells expressing high levels of BCL2 
and having already passed through the germinal center from which secondary 
hits in germinal centers reactions can drive these cells toward FL as well as 
eventually modifying transcription factors may induce reprograming into 
macrophage phenotype with pro-lymphoma features. Cobaleda et al. showed 
that Bcl2-mediated survival cooperated with pax5 loss in a murine model, 
leading to pax5-deficient progenitors carrying rearranged IG genes that could 
differentiate into myeloid cells (28).  
Thus, macrophages with BCL2 translocation may have resulted from a cell 
already committed to the lymphoid B cell lineage. These cells have been shown 
to have enormous plasticity when PAX5 is deleted or down regulated and can 
give rise to other cell lineages including macrophages (13). We may even 
speculate that this transdifferentiation could eventually happen in the FL 
microenvironment as most CD163+ cells with an abnormal FISH signal showed 
an identical pattern present in the malignant cells, favouring a close clonal 
relation. 
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4.6 CONCLUSION 
Despite the limitations of the study our findings are still provocative and may 
indicate lymphoma precursor cell plasticity and ability to differentiate into 
mature-like monocytes & macrophages providing the neoplastic B cells with a 
trophic / pro-survival microenvironment. Further validation is mandatory to 
convincingly demonstrate these findings. 
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4.7 TABLES 
 
 
Table 4.1 – FICTION results of formalin fixed paraffin embedded samples.  
CASE GRADE 
LAM 
content 
BCL2 
Rear 
CD163 NEG cells CD163 POS cells 
FISH NEG FISH POS 
% FISH 
POS 
FISH NEG FISH POS 
% FISH 
POS 
FL FL1 High POS 20 80 80 68 8 10 
FL FL2 High POS 65 43 40 47 7 12 
FL FL1 Low POS 25 75 75 6 8 25 
FL FL1 Low POS 43 36 46 14 7 33 
FL FL1 Low NEG 89 2 2 26 8 23 
RFH RFH RFH NEG 100 1 1 75 5 6 
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CASE GRADE 
BCL2 
Rearrangement 
CD163 NEG cells CD163 POS cells 
FISH 
NEG 
FISH 
POS 
% FISH 
POS 
FISH 
NEG 
FISH 
POS 
% FISH 
POS 
FL FL1 NEG 34 2 5 48 2 4 
FL FL2 NEG 65 3 4 48 3 5 
FL FL2 NEG 23 1 4 4 1 20 
FL FL3a NEG 15 0 0 49 1 2 
FL FL1 NEG 10 0 0 18 1 5 
FL FL1 POS 21 65 75 18 6 25 
FL FL2 POS 45 54 54 4 2 33 
FL FL1 POS 65 45 40 15 6 28 
FL FL2 POS 87 35 28 6 2 25 
FL FL1 POS 56 90 61 42 9 17 
FL FL2 POS 45 76 62 20 5 20 
FL FL1 POS 78 60 43 16 4 20 
FL FL2 POS 23 45 66 94 32 25 
FL FL1 POS 98 78 44 5 2 28 
FL FL1 POS 67 56 45 100 48 32 
FL FL1 POS 87 32 26 25 8 24 
FL FL2 POS 78 34 30 13 5 27 
FL FL2 POS 98 56 36 10 2 16 
FL FL1 POS 30 111 78 48 24 33 
RFH RFH NEG 98 2 2 21 0 0 
RFH RFH NEG 155 3 1 5 0 0 
RFH RFH NEG 123 0 0 19 0 0 
RFH RFH NEG 98 1 1 8 0 0 
RFH RFH NEG 148 0 0 30 0 0 
RFH RFH NEG 121 0 0 32 0 0 
RFH RFH NEG 89 0 0 50 0 0 
RFH RFH NEG 165 3 1 15 0 0 
RFH RFH NEG 198 2 1 20 0 0 
RFH RFH NEG 134 1 0 15 0 0 
 
Table 4.2 - FICTION results of touch imprints from fresh samples 
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4.8 FIGURES. 
 
Figure 4.1 – Optimized FICTION protocol for detection of CD163 positive cells 
in FFPET and touch imprints. 
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Figure 4.2 - FICTION analysis of one BCL2+ FFPE FL. A CD163 positive cell 
(purple) with one fused signal and one split apart signal (Vysis® LSI BCL2 Dual 
Color, Break Apart Rearrangement Probe).  
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Figure 4.3 - FICTION analysis of one BCL2+ FFPE FL. A CD163 positive cell 
(purple) with two fusion signals using a Vysis® LSI IGH/BCL2 Dual Color, Dual 
Fusion Translocation Probe. This probe was used in selected cases to confirm 
the presence of fused signals IGH & BCL2.  
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Figure 4.4 - FICTION analysis of one reactive FFPE LN. A CD163 positive cell 
(red) with two fused signals (Vysis® LSI BCL2 Dual Color, Break Apart 
Rearrangement Probe).  
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Figure 4.5 - FICTION analysis of one Reactive Fresh LN. Two CD163 positive 
cells (red) with two fused signals (Vysis® LSI BCL2 Dual Color, Break Apart 
Rearrangement Probe).  
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Figure 4.6 - FICTION analysis of one Reactive Fresh LN. Two CD163 positive 
cells (red) with two fused signals (Vysis® LSI BCL2 Dual Color, Break Apart 
Rearrangement Probe).  
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Figure 4.7 - FICTION analysis of one BCL2 negative Fresh FL. One CD163 
positive cell (red) with two fused signals (Vysis® LSI BCL2 Dual Color, Break 
Apart Rearrangement Probe). 
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Figure 4.8 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive cell 
(red) with one fused and one split signals (Vysis® LSI BCL2 Dual Color, Break 
Apart Rearrangement Probe).  
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Figure 4.9 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive cell 
(red) with two fused and one extra green signal (Vysis® LSI BCL2 Dual Color, 
Break Apart Rearrangement Probe).  
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Figure 4.10 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive 
cell (red) with two fused and one extra green signal (Vysis® LSI BCL2 Dual 
Color, Break Apart Rearrangement Probe).  
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Figure 4.11 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive 
cell (red) with one fused and one split signals (Vysis® LSI BCL2 Dual Color, 
Break Apart Rearrangement Probe).  
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Figure 4.12 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive 
cell (red) with one fused and one split signals (Vysis® LSI BCL2 Dual Color, 
Break Apart Rearrangement Probe).  
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Figure 4.13 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive 
cell (red) with one fused and one split signals (Vysis® LSI BCL2 Dual Color, 
Break Apart Rearrangement Probe).  
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Figure 4.14 - FICTION analysis of one BCL2+ Fresh FL. Two CD163 positive 
cells (red) with one fused and one split signal (Vysis® LSI BCL2 Dual Color, 
Break Apart Rearrangement Probe).  
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Figure 4.15 - FICTION analysis of one BCL2+ Fresh FL. One CD163 positive 
cell (red) with two fused signals in a background of CD163 negative cells with 
one fused and one split signal. (Vysis® LSI BCL2 Dual Color, Break Apart 
Rearrangement Probe).  
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Section 5: New Biological Predictors of Survival in 
Diffuse Large B Cell Lymphoma 
    
5.1 INTRODUCTION 
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-
Hodgkin lymphoma, accounting for 30-40% of newly-diagnosed cases (1). 
Although curable in the majority of cases with anthracycline-based combination 
chemotherapy and the monoclonal antibody rituximab (R), approximately 30-
40% of patients with DLBCL will relapse after standard first-line therapy (2, 3). 
This variability in clinical outcome likely relates to genetic heterogeneity within 
DLBCL, reflected in a wide array of cytogenetic and molecular abnormalities. 
Recently, microarray gene expression profiling studies have identified multiple 
genes of potential prognostic significance in DLBCL, and have led to the 
subdivision of DLBCL into two major biological categories based on presumed 
cell of origin: germinal centre B cell (GCB), and activated B cell (ABC) (4, 5). 
The cell-of-origin (COO) distinction provides a prognostic and biologically 
relevant sub-classification of DLBCL and was subsequently validated at the 
protein level as germinal center B cell-like (GCB) and non-GCB-like DLBCL 
subtypes (6). However, the prognostic value of biological markers in DLBCL 
remains controversial, and these have not yet been incorporated into routine 
clinical practice (7).  
Previous to the introduction of R as standard of care (R-CHOP), several biologic 
factors have been studied as prognostic factors in DLBCL, including TP53 
mutations or TP53 overexpression, BCL2 rearrangement or BCL2 expression, 
BCL6 expression and BCL6 rearrangement, CD10 and COO in an effort to 
better understand lymphomagenesis and to potentially identify patients who 
may benefit from specific treatment approaches (6, 8-13). 
Since the introduction of R-CHOP as the current standard of care for the 
treatment of DLBCL, two established biomarkers, BCL2 and BCL6 expression, 
appear to have lost their prognostic significance (14, 15). The specific 
mechanism(s) responsible for this effect is/are largely unknown. Rituximab may 
preferentially prevent chemotherapy failure in DLBCLs that express BCL2 
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protein or fail to express BCL6. It is known that BCL2 over-expression and 
absence of BCL6 protein are more common in the non-GCB subtype. Thus, R 
may benefit mostly non-GCB cases, which were associated with an inferior 
outcome in the pre-R era. 
As therapy changes, all previously identified biomarkers need to be re-
evaluated. Moreover, new candidate prognostic markers need to be identified in 
order to make improvements in risk-stratification and better define the biology of 
treatment failure.  
In this chapter I will focus on previously identified and new candidate 
biomarkers in DLBCL treated with R-CHOP: 
TP53 mutation and expression (Section 5.1) 
Cell-Of-Origin distinctions (Section 5.2) 
BCL6 rearrangements (Section 5.3) 
MYC rearrangements (Section 5.4) 
 
 
Section 5.1: Strong TP53 expression is an independent 
predictor of outcome in de novo diffuse large B cell lymphoma 
treated with either CHOP or R-CHOP 
 
S5.1.1 INTRODUCTION 
TP53 is the most extensively studied tumor suppressor gene and a key 
regulator of cellular homeostasis. It can be activated by different stimuli 
associated with tumorigenesis, resulting in the inhibition of the tumour cell 
growth. This inhibition can involve a number of different cellular pathways, 
including cell-cycle arrest, senescence, differentiation and apoptosis (16) 
(http://p53.free.fr/). And not surprisingly, it is lost or mutated in a sizable 
proportion of cases of almost all cancer types, including lymphoma.  
TP53 has 11 exons, 10 of them coding. It is a transcription factor with an 
important central DNA binding domain that is the target of approximately 95% of 
TP53 mutations found in human cancers (Figure 5.1.1). These are mostly point 
mutations, of which 80% are missense. In cancer, TP53 function is lost due to 
mutation of the gene in about half of all human tumours and there are many 
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reports correlating the presence of mutant TP53 with more advanced cancer 
and worse prognosis (16, 17). 95% of the mutations target in the central DNA 
binding domain of the protein (amino acids 100–300) (16). In most of the cases, 
these mutations are single amino acid substitutions in the form of point 
missense mutations, leading to the synthesis of a stable but functionally inactive 
protein that tetramerizes with wild-type protein, inducing its accumulation in the 
nucleus via a so-called “dominant negative effect” (18, 19). These mutated 
TP53 (missense) proteins have a prolonged half-life compared with wild-type 
(wt) protein as a result of protein stabilization. Thus, in many studies TP53 
protein over-expression has been used as a surrogate marker of mutated TP53. 
Almost every residue of the DNA binding domain has been found mutated, but 
the end result of different mutations in the function of the protein is variable. Six 
well-studied hot spots for mutation comprise 30% of the mutations 
(http://p53.free.fr/). Thus, this selection bias for certain mutations in cancer 
suggests inactivation of the protein and that the dominant-negative effect does 
not represent the whole story. Reports have documented mutant proteins that 
regulate gene expression and induce cell growth, cell death or apoptosis, 
independently of wt TP53 (20, 21). Studies using mice generated to express 
well-known mutated TP53 displayed a considerable different spectrum of 
tumour types and frequencies than simple double TP53 knockout mice, 
suggesting the presence of a mutated protein influences tumorigenesis in a 
manner distinct and more proactive than simply deleting wt TP53 (20, 22). 
Importantly, in common to the vast majority of these engineered TP53 in mice, 
there are very high levels of mutant protein expressed in the tumour cells. 
Different mechanisms have been proposed for this oncogenic gain-of-function 
effect of TP53, such as specific activation of certain promoters by the mutant 
proteins, or the ability of some of these mutants to block TP53 homologues, 
such as TP63 and TP73 (21, 23). Thus, the presence of TP53 overexpression 
in cancer cells may represent both classic dominant-negative loss-of-function 
and oncogenic gain-of-function, suggesting that assessing protein 
overexpression maybe the best single method to study TP53 and its overall 
impact on tumours such as lymphoma. Several translational studies have 
shown correlation of TP53 protein expression detected by 
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immunohistochemistry with the prognosis of human tumours, including 
lymphoma (24-27). 
Despite this level of understanding, the relationship between TP53 mutations 
and their impact on the protein function is not always straightforward and is 
likely dependent of several parameters, including the mutation site, the resulting 
amino acid substitution and even functional alterations associated with some 
single nucleotide polymorphisms (21). The correlation between TP53 
accumulation and TP53 mutation is about 80% as frameshift and nonsense 
mutations do not usually lead to protein accumulation. Moreover, in some 
extreme benign conditions, such as major hypoxia, there is transient 
accumulation of the protein. To distinguish between mutated or wt 
accumulations it is useful to correlate TP53 expression with TP53-regulator 
proteins, like HMD2 or TP21. Most TP53 mutations cannot induce these 
molecules resulting in overexpression of TP53 in the absence HMD2 and TP21. 
Despite the use of different detection methods, including both mutational 
analysis and immunohistochemistry, in the CHOP era TP53 mutations in 
DLBCL were reported in18 to 30% of the cases and were associated in most 
but not all studies with an adverse prognosis (24-30). Correlation of TP53 
expression with COO DLBCL subtypes have also been reported (31). 
 
 
S5.1.2 AIM 
Assess the prognostic value of TP53 overexpression and its correlation with 
TP53 mutational status in routine clinical diagnostic formalin-fixed paraffin-
embedded tissue (FFPET) biopsies using a population-based cohort of DLBCL 
patients treated with either CHOP or CHOP-R. We combined TP53 protein 
expression detected by immunohistochemistry (IHC) with TP53 mutational 
status using an array platform (AmpliChip p53 Test®) of DLBCL also 
distinguished by COO subtypes. 
 
 
S5.1.3 MATERIAL & METHODS 
S5.1.3.1. Patients & Samples Selection 
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The patients included in this study were a subset of the 292 patients and 
published previously by Sehn et al (32). This is a population-based 
retrospective analysis examining outcomes for all patients with advanced-stage 
DLBCL in a single Canadian province during a 3-year interval, September 1, 
1999, through August 31, 2002, including the 18 months before and the 18 
months after the introduction of rituximab plus CHOP into clinical practice in 
British Columbia. All patients were older than 15 years of age and had biopsy 
proven, newly diagnosed DLBCL within the study interval. In addition, all 
patients had advanced stage disease: stage III or IV; stage I or II with “B” 
symptoms or bulky disease (10cm), or a contraindication to radiation; or 
testicular DLBCL of any stage. All patients received a CHOP-like chemotherapy 
regimen with curative intent, whereas R-CHOP was used after March 01, 2001. 
Patients were excluded if they were HIV-positive, had CNS involvement at 
presentation, or had evidence of transformation from an antecedent indolent 
lymphoma. 
Approval was obtained from the University of British Columbia institutional 
review board. Informed consent was provided according to the Declaration of 
Helsinki. 
 
S5.1.3.2. Tumour Specimens - Formalin-Fixed Paraffin-Embedded Tissue 
Samples 
A total of 155 patients were analyzed based on available formalin-fixed paraffin-
embedded tissue (FFPET) blocks with sufficient tissue of the appropriate 
fixative and that had interpretable immunohistochemistry for all antigens. All 
samples were diagnostic biopsies of de novo DLBCL expressing CD20 (clone 
L26). Tissue microarrays (TMA) were built using duplicate 0.6mm cores 
(Beecher® WI, USA) (Figure S5.1.2) and stained with commercially available 
antibodies against CD3, CD10, BCL6, MUM1, BCL2, TP53 (clone DO7) and 
TP21. DLBCL cases were assigned to GCB or non-GCB subgroups based on 
the method of Hans et al (6). Nuclear expression of the TP53 antibody was 
assessed using a TP53 histoscore combining TP53 intensity (ranging 1 - 3) 
multiplied by % of positive malignant cells per TMA core. Strong expression was 
defined as high intensity (3/3) expression in 50% of the malignant cells (Figure 
S5.1.3). TP21 expression was considered positive when expressed in >10% of 
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the malignant cells. The TP53 gene mutational analysis was performed on this 
subset of cases with strong TP53 nuclear expression with DNA extracted from 
FFPET samples using Amplichip p53® (Roche Molecular Systems®).  In these 
samples tumour cell purity was estimated in %, combining CD20 staining 
malignant cells and a CD3 stain for non-malignant T cells. 
 
S5.1.3.3. DNA Extraction 
DNA was extracted from FFPET sections using the AmpliChip p53 Lysis 
Reagent®. Lysis reagent was added to each 1.5mL sterile tube containing a 
tissue section. Samples mixed with 200 uL of lysis reagent were incubated at 
98°C for 30 minutes.  Samples were then cooled for 5 minutes prior to the 
addition of Proteinase K where samples were then incubated for one hour at 
65°C.  Proteinase K (2 mg/mL) was inactivated after lysis by heating at 98°C for 
15 minutes.  Centrifugation of samples was done to remove debris from the 
microcentrifuge tube.  The lysate was carefully removed after centrifugation to 
another sterile tube.   
 
S5.1.3.4. Roche’s AmpliChip p53 Assay(Figure S5.1.4 & S5.1.5) 
The AmpliChip p53 Test is a product which is currently under development at 
Roche Molecular Systems, Inc. The AmpliChip p53 Test reagents were used to 
amplify products encompassing the coding regions of the TP53 gene in two 
reactions (A and B) for all samples including a reference wt DNA.  Exons 2, 5, 
8, 10, exon 4 upstream sequences, and internal control were in the Primer Mix 
A.  Primer Mix B was designed and contained primers for exons 3, 6, 7, 9, 11, 
exon 4 downstream sequences, and an internal control.  After thermalcycling, 
the products from Primer Mixes A and B were combined.  The products 
generated from the A and B reactions were cleaved by a mix containing DNase 
I.  Fragmentation is performed by recombinant DNase I to generate small DNA 
fragments of an average size of 50-100 nucleotides. The Alkaline Phosphatase 
in the Working Fragmentation Mix destroys the residual dNTPs from the 
amplification reactions.  The fragmented DNA amplicons are subsequently 
labeled with biotin at their 3' termini by the action of Terminal Transferase using 
AmpliChip TdT Labeling Reagent as substrate. The biotin-labeled TP53 target 
DNA fragments are added to the hybridization buffer containing the AmpliChip 
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B1 Oligonucleotide Solution which functions as a hybridization control.  The 
mixture is hybridized to the oligonucleotides located on the AmpliChip p53 
Microarray using the Affymetrix GeneChip Fluidics Station 450Dx and an 
AmpliChip p53 specific protocol. The hybridized AmpliChip p53 Microarray is 
washed and stained with a streptavidin-conjugated fluorescent dye 
(phycoerythrin).  
 
S5.1.3.5. Chip Design 
The AmpliChip p53 microarray is designed by RMS® and manufactured by 
Affymetrix using technology that combines photolithographic methods and 
combinatorial chemistry. The microarray consists of a square grid of 228,484 
spotted probes, with each spot being 11 microns in diameter.  Each probe type 
is located in a specific area called a probe cell, which contains approximately 
106 copies of a specific oligonucleotide sequence. Probe microarrays are 
manufactured by light-directed combinatorial chemistry in a series of cycles.  
The glass substrates are coated with linkers containing photolabile protecting 
groups.  A mask is then applied that exposes selected portions of the probe 
microarray.  Illumination removes the photolabile protecting groups enabling 
selective nucleoside phosphoramidite addition only at the previously exposed 
sites. Next, a different mask is applied and the cycle of illumination and 
chemical coupling is repeated. By repeating this cycle, a specific set of 
oligonucleotide probes is synthesized, with each probe type in a known location. 
A single probe set for an interrogating base position includes five probes, one 
probe to hybridize to the wt, three probes to detect three possible single base 
pair mutations, and one probe to detect single deletions (Figure S5.1.6).  There 
are at least 24 probe sets for each nucleotide position, including both sense and 
antisense probe sequences.  A total of 1300 nucleotide positions of coding 
regions of exons 2 – 11 are tiled on AmpliChip p53. After staining, the 
AmpliChip p53 Microarray is scanned by an Affymetrix GeneChip Scanner 
3000Dx using a laser that excites the fluorescent label bound to the hybridized 
p53 target DNA fragments. The amount of emitted light is proportional to bound 
target DNA at each location on the probe microarray. 
 
 216 
S5.1.3.6. Data Analysis of Microarray Signals 
The TP53 mutation status was determined by a TP53 Re-sequencing Algorithm 
developed by RMS®, which is designed to detect single base pair substitutions 
and single base pair deletions of a sample in a background of wt p53 DNA 
probe intensities. 
The Re-sequencing Algorithm first reads the probe intensities generated by the 
GeneChip Operating Software (GCOS) Ver 1.1 provided by Affymetrix. Based 
on these raw data, the algorithm performs an initial exon quality test to detect 
the presence of distinct problems in each PCR product. If an exon fails the initial 
quality test, the exon failure is reported and no further analysis is made. If an 
exon passes the test, the probe intensities are normalized using quartile 
normalization in order to correct array-to-array variability.  The quality of each 
probe set is then examined to eliminate unreliable probe set data for further 
computation. Using only probe sets that have passed the quality tests, the 
algorithm makes a tentative call for each base position.  Possible base calls for 
each nucleotide position are wt, single base substitution, single base deletion, 
or no call (unable to make a call).  In the case of a single base substitution, the 
algorithm identifies the mutated base (e.g., G to A).  After the tentative calls are 
made, the reliability of each base call is re-examined by the algorithm to fine 
tune the calls using various parameters calculated from the neighbouring base 
positions. Each exon quality is also re-examined based on the final base calls.  
If there are too many no calls and/or mutation calls in one exon, these data are 
considered as ‘noisy’ and the exon fails the quality test.  If an exon fails, the 
exon failure is reported and no calls are reported for that exon. 
 
S5.1.3.7. Statistical Analysis 
Prognostic variables were compared between the groups, using the 
independent samples t test for continuous variables and the Χ2 test for 
categorical variables (Table S5.1.1). Overall Survival (OS) was calculated as 
the time from date of diagnosis until death as a result of any cause or date of 
last follow-up. OS was assessed using the Kaplan-Meier method and compared 
between groups using the log-rank test (33). A multivariate analysis was 
performed using a Cox proportional hazards model to assess the independent 
effect of TP53 protein expression in the two treatment era OS, after controlling 
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for relevant clinical prognostic factors (34). Data were analyzed using the 
Statistical Software Package for the Social Sciences (SPSS version 10.1 for 
Windows; SPSS Inc®, Chicago, IL). 
 
 
S5.1.4 RESULTS 
Clinical data was available in all 155 patients, including 77 patients treated with 
CHOP and 78 treated with R-CHOP. Their clinical characteristics, including the 
IPI factors, were evenly matched between CHOP and R-CHOP groups (Table 
S5.1.1). The two treatment regimens represent two consecutive eras of therapy 
and thus the median follow-up of living patients was 5.1 and 4.0 years for 
CHOP vs. R-CHOP, respectively. The 5-year survival estimate for all patients 
was 61% and survival outcomes were significantly better, as expected, for the 
patients treated with R-CHOP. For all 155 patients, the effect of adding 
rituximab to CHOP therapy had a significant impact on OS (P=0.0035). 
Of the 155 cases, 75 had a GCB phenotype and 80 were non-GCB. There were 
19 lymphomas showing strong TP53 nuclear expression (19/155 or 12%). All 
these cases had striking differences of TP53 histoscore between positive cases 
and those called negative, as seen by the values of the median and standard 
deviation of the histoscore (Figure S5.1.7). Of the 19 TP53-positive cases, 10 
had a GCB phenotype and 80 were non-GCB (Figure S5.1.8). All the 19 strong 
TP53 cases were negative for TP21 expression, this combination typically 
associated with TP53 mutations. 
Seventeen samples were successfully arrayed in the AmpliChip p53 microarray. 
In all these cases the tumour cell content was higher than 65% (ranging from 
65% to 90%). Eighteen mutations and four polymorphic mutations were found in 
the 17 samples (Table S5.1.2). Table S5.1.2 summarizes all the detected 
mutations, as well as the common SNP involving codon 72, whose effect in 
carcinogenesis is unclear and controversial. There was only one case with no 
mutation but harbouring a polymorphic SNP. All of the mutations were missense 
mutations (including the SNP) and with the exception of one, all have been 
previously described in the lymphoma literature. The distribution of these 
mutations in the protein follows the reported literature in lymphoma, as shown in 
the frequency plot of the reports of TP53 mutations in lymphoma along with our 
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results (Figure S5.1.9). The vast majority are, as expected, within the DNA 
binding domain. The only outlier belongs to a case with two mutations. 
In univariate analysis, both IPI and strong nuclear TP53 expression had 
significant prognostic impact (P<0.0001) (Figure S5.1.10). A Cox model 
revealed both variables to be independent variables of OS (P=0.005 & 
P<0.0001, respectively).  
As previously reported, the addition of rituximab to the treatment regimen 
resulted in a dramatic improvement in survival (Figure S5.1.11). Importantly, 
when analyzed by treatment era, the IPI was significant in the pre-R era 
(P<0.0001) but not for the post-R era (P=0.2). While strong TP53 was 
significant in both groups (P=0.015 for CHOP and P=0.012 for R-CHOP) 
(Figure S5.1.12). 
When we separate the patients by COO subtype, where strong TP53 
expression resulted in inferior survival only in the GCB group (P<0.0001) vs. 
(P=0.34) for the non-GCB group (Figure S5.1.13). 
 
 
S5.1.5 DISCUSSION 
In this study, we describe for the first time a previously identified prognostic 
marker in DLBCL that did not lose its impact in the new R-CHOP therapy era. 
Using an easily assessable biomarker, we identify cases that over-expressed 
the protein due to missense mutations with resistance to both CHOP and R-
CHOP therapy. Despite the small number of cases with adverse prognosis 
(12%) these patients could be reasonably seen as candidate for new alternative 
therapies. 
Experimental data on the different functional effects of individual TP53 
mutations is increasing and is a crucial goal for the design of future anti-cancer 
targeted therapies (21, 30). However, many factors such as epigenetic 
changes, RNA editing, post-transcriptional protein modifications underlie the 
complex relationships between genotypic and phenotypic abnormalities. As 
mentioned previously, in human cancer there is a bias for certain “malignant” 
mutations but there are also many “benign” mutations with minimal effects on 
the TP53 pathway. Different and divergent functional results of different TP53 
mutations studied either in vitro or in vivo are well known (21). Thus, isolated 
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mutational analysis per se might not be the best approach to determine the 
clinical impact of TP53 gene abnormalities including mutations. The 
assessment of a common final end-result such as TP53 protein expression 
abnormalities seems to be the better strategy to recognize abnormalities with 
functional impact that might influence clinical outcome. In this study we show 
that increased expression of the TP53 protein is associated in all except one 
case to missense, previously reported, “pathologic” mutations. Thus, 
immunohistochemical assessment of routine diagnostic FFPET is an easy and 
efficient technique to evaluate TP53 status. 
Semi-quantitative determination of protein expression of biomarkers using 
FFPET samples has been controversial in many different settings due to 
variability related to fixation time and tissue quality, antigen retrieval techniques, 
antibody clone and dilution, and finally scoring variability that is heavily 
dependent on observer subjectivity (35). Like many other genes with impact in 
human cancer, the correlation between protein and gene mutations is not linear 
(16). But, in contrast to other tumour suppressor genes where large delections 
or frameshift mutations resulting in loss of the protein are common, single 
amino acid substitution missense mutations in TP53 result in strong expression 
of the protein. Only rarely, absence of TP53 protein expression may be 
associated with nonsense or frameshift mutations. On the other hand, cells 
exposed to a stressful microenvironment, such as occurs with hypoxia may 
physiologically increase TP53 overexpression. However, the normal feedback 
loop of the TP53 pathway keeps the level of expression under tight control. This 
mechanism is lost in cases with missense mutations of the core binding domain 
of TP53 as was seen in this study, resulting in striking protein accumulation.  
Importantly, in the human cancer literature there is a significant correlation 
between mutations, increased protein expression and adverse prognosis (16). 
In experimental studies, normal cells have less than 500 TP53 molecules per 
cell. Physiological induction such as occurs with hypoxia can lead to ~ 5,000 
molecules per cell, while in cases of DNA binding domain missense mutations 
the total number rises to 50,000. Thus, there is a log2 difference in TP53 protein 
quantities between reactive and neoplastic mutated TP53 settings (36-39). This 
log difference is in the range of differential assessment by 
immunohistochemistry, using an optimal protocol. We established our protocol 
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by defining as a positive control – the homogeneous nuclear expression of 
TP53 by the lower basal epithelial cells in tonsil squamous epithelium. Next, we 
chose a TP53 antibody with its epitope located outside the DNA binding domain 
and thus infrequently mutated. The DO7 antibody recognizes the epitope 
defined by amino acids 21 to 25 of the amino terminus of the protein. Finally, we 
defined a cut-off value for positivity in maximum protein expression (3/3) in the 
majority of the neoplastic cells (>50%).  
In order to confirm the mutated form of TP53 protein, we evaluated the 
expression of TP21. This is a downstream effector of TP53 activation resulting 
in cell cycle arrest and is physiologically increased in cases of increased TP53 
expression. The accumulation of mutated TP53 is unable to induce TP21 
expression. Consequently, a strong TP53/negative TP21 phenotype is highly 
correlated with mutated TP53 (27, 40). None of the 19 cases with strong 
nuclear TP53 showed expression of TP21. To confirm this hypothesis we 
arrayed the 19 strong-positive TP53 cases and all but one case showed 
missense mutations. Five SNPs were also found. All cases had mutations 
localized to the DNA binding domain and this location overlaps with the known 
mutational data in human cancer and lymphoma in particular (Figure S5.1.9 & 
Table S5.1.2). Curiously, the only case not showing a "pathological” mutation 
had a well-described polymorphic alteration whose role in cancerigenesis is 
controversial, though reported to have a pro-tumoral effect through the TP53 
related transcriptional factor TP73 (23).  
The 19 cases with strong TP53 expression distributed equally between COO 
subtypes (Figure S5.1.8). As recently described by Visco et al, strong TP53 
expression significantly correlated with an adverse outcome in the GCB-like 
lymphomas (Figure S5.1.13) (31). The mechanism remains elusive, but we 
suggest aberrant signalling whereby a mutated TP53, in contrast to normal 
TP53, is not down-regulated by BCL6 protein that characterizes GCB-like 
DLBCLs (41). 
 
 
S5.1.6 CONCLUSIONS 
Strong TP53 protein expression is an easy biomarker to assess in routine 
FFPET diagnostic biopsies of DLBCL patients and correlates almost universally 
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with TP53 missense mutations. Importantly, strong TP53 protein expression is 
an independent prognostic factor for patients with DLBCL even when treated 
with R-CHOP. TP53 mutations were found in both GCB and non-GCB 
subtypes, but of prognostic importance only in the GCB subgroup. Finally, the 
prognostic impact of TP53 is not diminished in the era of CHOP-R, identifying a 
subgroup of patients with inferior survival deserving alternative therapies. 
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S5.1.7 TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S5.1.1 - Clinical & pathological characteristics, including the IPI factors, 
were evenly matched between CHOP and R-CHOP groups. 
 
 CHOP (77) CHOP-R (78) p (
2
) 
High IPI (%) 73 70 0.8 
Female (%) 40 42 0.8 
Median Age 66 (22-85) 58 (20-84) 0.1 
Median follow-up time 
living patients 
5.1 years 4 years nd 
Strong p53 (%) 12 13 0.8 
p53 mutations 9/9 9/10 0.9 
p53 histoscore 38 (0-300) 45 (0-300) 0.8 
GCB (%) 49 47 0.7 
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Table S5.1.2 - TP53 mutations found in the cohort. All but one missense 
mutation have been previously reported in lymphoma. 
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 S5.1.8 FIGURES 
 
Figure S5.1.1 - TP53 gene structure with 11 exons, 10 of them coding (yellow 
box). It is a transcription factor with an important central DNA binding domain 
that is the target of approximately 95% of TP53 mutations found in human 
cancers.
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Figure S5.1.2 -Tissue microarrays (TMA) were built using duplicate 0.6mm 
cores. 
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Figure S5.1.3 - TP53 protein expression. Nuclear expression of the TP53 
antibody was assessed using a TP53 Histoscore combining TP53 intensity 
(ranging 1 to 3) multiplied by % malignant cells per TMA core. Strong 
expression was defined as high intensity (3/3) expression in >50% of the 
malignant cells (one pair shown in the lower row). 
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Figure S5.1.4 - Roche’s AmpliChip p53 Assay 
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Figure S5.1.5 - AmpliChip p53 Microarrays are manufactured using technology 
that combines photolithographic methods and combinatorial chemistry. Over 
220,000 different oligonucleotide probes are synthesized on a glass surface to 
analyze both sense and antisense strands of an amplified target DNA 
specimen. Each probe type contains approximately 106 copies of a given probe. 
After staining, the AmpliChip p53 Microarray is scanned using a laser that 
excites the fluorescent label bound to the hybridized p53 target DNA fragments. 
The amount of emitted light is proportional to bound target DNA at each location 
on the probe microarray. 
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Figure S5.1.6 - Each sequence from a known reference is present in different 
probes, differing only by one base. Thus, this allows all different point mutations 
to be detected, like in this example with one substitution of Guanine to Adenine. 
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Figure S5.1.7 - TP53 Histoscore. The differences in staining were striking 
between strong nuclear staining and negative cases. 
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Figure S5.1.8 - Distribution of the cases with strong nuclear TP53 expression. 
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Figure S5.1.9 - The distribution of TP53 mutations found in the current study 
(red) follows the reported literature in lymphoma, as shown in the frequency plot 
of the reports of TP53 mutations in lymphoma (blue). 
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Figure S5.1.10 - In univariate analysis the IPI had prognostic impact on OS 
(P<0.0001).
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Figure S5.1.11 - Impact of R therapy addition in DLBCL overall survival. As 
previously reported, the addition of R in the whole group resulted in a dramatic 
improvement in survival. 
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Figure S5.1.12 - Strong TP53 was significant in both treatment era groups.
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Figure S5.1.13 - Separated by COO subtype, strong TP53 expression resulted 
in inferior survival only in the GCB group (P<0.0001) vs. (P=0.34) for the non-
GCB group. 
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Section 5.2: Addition of Rituximab (R) to CHOP 
Improves survival in non-GCB subtype of DLBCL 
 
S5.2.1 INTRODUCTION 
The Cell-of-Origin (COO) distinction in DLBCL is well established, since the 
initial studies using gene expression profiling identifying two distinct subgroups 
of DLBCL: germinal center B cell–like (GCB) activated B cell–like (ABC) (1). 
The GCB subgroup is characterized by expression of a germinal center B cell 
molecular signature, can be associated with the BCL2 translocation,  
t(14;18)(q32;q21) (2, 3) and carries a better prognosis than the ABC subgroup 
(4). The molecular signature of the ABC subgroup is distinctly different and is 
characterized by overexpression of a group of genes that are up-regulated in 
peripheral-blood B cells activated by mitogenic stimulation in vitro, many of the 
genes included in the nuclear factor-kappa B (NFB) pathway. (1, 4) (Figure 
S5.2.1). Tissue microarrays (TMA) and immunohistochemical staining can be 
used to provide biomarker data that correlates closely with the results of gene 
expression profiling in predicting outcome (5) (Figure S5.2.2). 
BCL2 is an anti-apoptotic factor that is important in normal B cell development 
and differentiation (6, 7). The t(14;18)(q32;q21) brings the BCL2 gene under the 
control of immunoglobulin heavy-chain gene (IGH) enhancer and leads to 
overexpression of BCL2 protein. However, BCL2 expression can also be up-
regulated by alternate mechanisms, including copy number increases in the 
gene and downstream of NFB signalling, as is often observed in the ABC 
subgroup of DLBCL, which lacks this translocation. BCL2 overexpression 
provides a survival advantage for malignant B cells and is thought to play a 
critical role in resistance to chemotherapy. As a result of these biologic 
functions, BCL2 overexpression should be of prognostic importance in DLBCL. 
However, correlation of BCL2 expression with survival in patients with DLBCL is 
controversial, with studies showing no difference in overall survival (OS) (8, 9) 
or decreased OS (10-12). BCL2 expression is highly correlated with the 
t(14;18)(q32;q21) in the GCB subgroup, but the translocation had no impact on 
survival (3). However, the influence of BCL2 expression on survival within the 
ABC subgroup of DLBCL is not clear. The existing controversy regarding BCL2 
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expression and survival may be related to studying DLBCL as a single entity. In 
contrast, analyzing BCL2 expression in the context of DLBCL subgroups might 
indeed clarify its clinical relevance.  
At BCCA, we previously studied a group consisting of 94 patients with de novo 
DLBCL, all with a clonal karyotype at diagnosis and treated with curative intent 
in the pre-R era. A TMA was constructed with duplicate 0.6mm cores and 
stained for BCL2, CD10, BCL6, MUM1 and FOXP1. Cases were called positive 
if more than 30% of the tumor cells expressed a given protein. Cases were 
defined as GCB if they were CD10+. Non-GCB was defined as CD10-, MUM1+ 
and/or FOXP1+. Cytogenetic studies were performed routinely and locus-
specific FISH was performed using commercially available Vysis probes (dual-
color LSI IGH/BCL2) to detect the t(14;18). Unbalanced increases in BCL2 gene 
copy number were determined by comparison of BCL2 and IGH signals. The IPI 
was highly predictive of OS (P<0.00001). The t(14;18) was detected by both 
routine cytogenetics and FISH in 24 (25%) cases, but did not predict survival 
(P=0.78). None of the non-GCB cases harbored a t(14;18) and importantly, the 
presence of t(14;18) and isolated BCL2 copy number gain were mutually 
exclusive (Figure S5.2.3). Expression of BCL2 protein and non-GCB-type 
immunostaining profile both predicted a poor OS (P=0.008 and P=0.03, 
respectively). Expression of BCL2 was imperfectly correlated with either 
t(14;18) or a non-GCB immunostaining profile, but was highly correlated with 
cases harboring an increased gene copy number for BCL2 (see Figure S5.2.4, 
2 P=0.005). Increased BCL2 gene copy number did not predict OS (P=0.43), a 
not unexpected finding as it accounts for only a proportion of BCL2 protein-
positive cases. Cases lacking both the t(14;18) and increased BCL2 copy 
number were deemed cytogenetically “normal”, accounting for 47 cases. These 
cases were distributed between the GCB (42%) and non-GCB subtypes (62%). 
Of the cytogenetically “normal” cases, 33% of the GCB and 75% of the non-
GCB expressed BCL2 protein. In this study, we concluded that multiple 
mechanisms are responsible for BCL2 expression in DLBCL. DLBCL cases with 
a t(14;18) are always GCB and never show BCL2 gene copy number gains in 
addition to the BCL2 translocation, suggesting that these two events are 
mutually exclusive. Non-GCB cases do not harbour the t(14;18), more 
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commonly have isolated BCL2 gene copy number gain and have a higher 
percentage of cytogenetically “normal” BCL2 protein-positive cases. The latter 
finding suggests a prominent role for transcriptional up-regulation resulting from 
constitutive activation of NFB. Other mechanisms, such as epigenetic changes 
or promoter hypomethylation that might be deregulating BCL2 expression 
requires further study. Importantly, in this small cohort treated with CHOP & 
CHOP-like protocols, BCL2 protein expression and COO (GCB vs. non-GCB) 
were predictive biomarkers in DLBCL (13). 
The addition of R to CHOP chemotherapy has shown a significant improvement 
in the outcome of patients with DLBCL (14, 15). The underlying mechanism(s) 
responsible for this effect in vivo is still largely unknown. When classical DLBCL 
biomarkers were studied in the new R-CHOP era, R was show to preferentially 
prevent chemotherapy failures in DLBCLs that express BCL2 protein and in 
those patients whose biopsies failed to show expression of BCL6 protein (16, 
17) (Figure S5.2.5). These two proteins are well known to be differentially 
expressed between the two COO DLBCL subtypes, as the non-GCB phenotype 
is usually more often associated with both over-expression of BCL2 and down 
regulation of BCL6. Thus, it is expected that the effect of the introduction of R is 
greater in this group, the non-GCB lymphomas.  
 
 
S5.2.2 AIM 
The aim of our study was to examine the clinical impact of R added to in DLBCL 
distinguished by COO subtype. 
 
 
S5.2.3 MATERIAL & METHODS 
S5.2.3.1. Patient & Sample Selection 
The patients included in this study were a subset of the 292 studied published 
previously by Sehn et al (15). This is a population-based retrospective analysis 
cohort examining outcomes for all patients with DLBCL in a single Canadian 
province during a 3-year interval, September 1, 1999, through August 31, 2002. 
Rituximab was added to CHOP as the standard of care for DLBCL on March 01, 
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2001. All patients were older than 15 years of age and had biopsy proven, 
newly diagnosed DLBCL within the study interval. In addition, all patients had 
advanced-stage disease: stage III or IV; stage I or II with “B” symptoms or bulky 
disease (10cm), or a contraindication to radiation; or testicular DLBCL of any 
stage. All patients received a CHOP-like chemotherapy regimen with curative 
intent. Patients were excluded if they were HIV-positive, had CNS involvement 
at presentation, or had evidence of transformation from an antecedent indolent 
lymphoma. 
Approval was obtained from the University of British Columbia institutional 
review board. Informed consent was provided according to the Declaration of 
Helsinki. 
 
S5.2.3.2. Tumor Specimens Formalin-Fixed Paraffin-Embedded Tissue 
(FFPET) Samples 
We identified 163 patients with DLBCL treated with either CHOP or R-CHOP 
with available paraffin blocks and interpretable immunostaining. A total of 155 
patients were analyzed based on available FFPET blocks with sufficient tissue 
of the appropriate fixative that had interpretable immunohistochemistry for all 
antigens. All were diagnostic biopsies of de novo DLBCL expressing CD20 
(clone L26). TMA were built using duplicate 0.6mm cores (Beecher® WI, USA) 
and stained with antibodies against CD3, CD10, BCL6, MUM1 and BCL2 
(Figure S5.2.6 & Table S5.2.1). DLBCL cases were assigned to GCB or non-
GCB subgroups based on the method of Hans et al (5). BCL2 positivity was 
defined as ≥ 30% malignant cells positive.  
 
S5.2.3.3. Statistical Analysis 
Prognostic variables were compared between the groups, using the 
independent samples t test for continuous variables and the Χ2 test for 
categorical variables (Table S5.2.1). OS was calculated as the time from date of 
diagnosis until death as a result of any cause or date of last follow-up. OS was 
assessed using the Kaplan-Meier method and compared between groups using 
the log-rank test (18). A multivariate analysis was performed using a Cox 
proportional hazards model to assess the independent effect of BCL2 and COO 
protein expression in the two treatment eras after controlling for relevant clinical 
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prognostic factors (19). Data were analyzed using the Statistical Software 
Package for the Social Sciences (SPSS version 10.1 for Windows; SPSS Inc®, 
Chicago, IL). 
 
 
S5.2.4 RESULTS 
Clinical data were available in all 163 patients including 81 patients treated with 
CHOP and 82 treated with R-CHOP. Their clinical characteristics, including the 
IPI, were evenly distributed between the two treatment cohorts (Table S5.2.2). 
The median follow-up of living patients was 4.6 years. The IPI was predictive of 
OS (P<0.0001) for the entire study population (Figure S5.2.7). Six cases had 
uninterpretable immunostains resulting in 74 cases with a GCB phenotype and 
83 with a non-GCB phenotype (n=157) (Figure S5.2.8). Overall, 71% and 75% 
of the cases over-expressed BCL2 and BCL6, respectively (Figure S5.2.9). 
When comparing GCB vs. non-GCB groups there was no statistical difference 
in the number of cases expressing BCL2; as BCL2 protein was expressed in 
70% of the GCB cases and 73% of the non-GCB (P= 0.72), while, as expected, 
BCL6-positive cases were over-represented in the GCB group as BCL6 was 
expressed in 96% GCB cases and 63% non-GCB cases (P<0.0001) (Figure 
S5.2.10). The COO phenotype and both BCL2 and BCL6 expression profiles 
were evenly distributed between the two treatment groups (Table S5.2.2). As 
previously reported, the addition of R in the whole group resulted in a dramatic 
improvement in survival (Figure S5.2.11). In univariate analysis, the addition of 
R was associated with a better prognosis in the non-GCB cases (P=0.02), but 
not in the GCB cases (P=0.3) (Figure S5.2.12). The addition of R to CHOP 
chemotherapy and IPI were independent predictors of OS in non-GCB DLBCL 
(P=0.02; P=0.016, respectively). 
Next, we evaluated the effect of R on survival in relation to both BCL2 and 
BCL6 expression profiles. As described, lymphomas over-expressing BCL2 
benefit significantly with immunochemotherapy. The addition of R was also of 
prognostic importance in the lymphomas over-expressing BCL2 (P=0.0081).The 
effect on BCL6-negative cases was of borderline significance. However, the 
number of cases was small, precluding any definitive conclusions (Table 
S5.2.3). Bearing in mind the significant effect of R in the BCL2-positive cases, 
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and that BCL2 expression was evenly distributed between both COO subtypes, 
we analysed the survival of BCL2-positive and negative cases within each COO 
subtype. This analysis revealed that only the non-GCB cases expressing BCL2, 
but not the GCB cases, benefitted from the addition of R to the treatment 
regimen (Table S5.2.4). Thus, this survival difference was not solely explained 
by either BCL2 or BCL6 expression, suggesting an important role of the 
biological mechanism responsible for the expression of these proteins within 
COO subtypes. 
 
 
S5.2.5 DISCUSSION 
The addition of R to standard chemotherapy, as we show in the current study 
and in agreement with several previous studies, overcomes BCL2 over-
expression associated resistance to chemotherapy in patients with DLBCL (16). 
BCL2 is a member of the family of proteins that regulate programmed cell 
death. Its overexpression in B cell NHL is thought to result in chemotherapy 
resistance of the lymphoma cells both in vitro and in vivo (20, 21). As a 
consequence, BCL2 protein overexpression is generally associated with poor 
survival in patients with DLBCL who are treated with standard chemotherapy 
(10, 11, 20, 21). R has eliminated the negative effect of BCL2 protein 
overexpression in patients with DLBCL, and more specifically, we showed R to 
overcome this adverse influence on survival mostly due to its impact on non-
GCB DLBCL. 
Despite the widespread use of R in the treatment of B cell NHL, the 
mechanisms by which R exerts its anti-lymphoma effect are still not fully 
understood. Evidence from in vitro studies that have used lymphoma cell lines 
or fresh tumor cells, and from in vivo animal studies, suggest that R acts 
through three different mechanisms including, 1) complement-dependent 
cytotoxicity (22-24) , 2) antibody-dependent cell-mediated cytotoxicity (25); and 
3) induction of apoptosis (26, 27). Among these, induction of apoptosis may be 
particularly important for a chemotherapy-sensitization effect of R. It appears to 
induce apoptosis through multiple signalling pathways that inhibit at least two 
anti-apoptotic proteins, namely BCL2 and BCLxL (28, 29). Studies of two 
Epstein-Barr virus–positive Burkitt lymphoma cell lines (Ramos and Daudi) have 
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shown that the binding of R to CD20 inhibits both the NFκB and the ERK1/2 
pathways via an increase in Raf-1 kinase inhibitor, which results in decreased 
expression of BCLxL and BCL2 (30-32).  
When the COO subgroups were analyzed separately, BCL2 expression level 
was associated with inferior survival only in the non-GCB subgroup, suggesting 
that the addition of rituximab to chemotherapy for DLBCL may be of benefit 
mainly in the subgroup with BCL2 expression. Thus, BCL2 expression could be 
a biomarker of more aggressive disease in the non-GCB but not the GCB type. 
Alternate mechanisms promoting BCL2 expression unrelated to the t(14;18) 
must be occurring in ABC DLBCL. As previously reported NFκB is constitutively 
expressed in ABC DLBCL and has a critical role in its pathogenesis (33). BCL2 
is a target gene for NFκB (34) and in many ABC DLBCL patients, BCL2 up-
regulation may be mediated through the NFκB pathway. Another possible 
mechanism is the amplification of the chromosomal locus 18q21 where the 
BCL2 gene resides. Studies using comparative genomic hybridization have 
shown that approximately 20% of DLBCL patients have 18q gains (35). As 
mentioned, we previously investigated the incidence of 18q21 using the FISH 
technique, finding gain or amplification of 18q21 more frequently in the non-
GCB DLBCL subgroup compared with the GCB DLBCL subgroup (13). As 
BCL2 is up-regulated by different mechanisms in the GCB vs. non-GCB 
DLBCLs,  BCL2 overexpression is a biomarker for events that are responsible 
not only for poor prognosis (e.g., NFκB activation or 18q21 amplification) but 
also for being a good target for R therapy. In vitro, R negatively regulates NF-κB 
and down regulates BCL2.  Thus, R lowers the apoptotic threshold of the 
lymphoma cells, facilitating cell death induced by the accompanying cytotoxic 
agents. In the GCB subgroup, BCL2 expression is mainly a result of the 
t(14;18), thus representing a completely different mechanism of expression, 
appearing to be less affected by R.  
In summary, our study has demonstrated immunochemotherapy using R-CHOP 
is associated with better OS for patients with DLBCL due largely to its effect on 
the non-GCB subgroup. As previously reported, BCL2-positive lymphomas 
benefited significantly from the addition of R to CHOP chemotherapy. Although 
the frequency of BCL2 expression was not statistically different between COO 
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subtypes, only non-GCB BCL2-positive lymphomas showed an improved 
outcome.  
The suggestive inhibition of the NFκB pathway by R is a possible candidate 
mechanism to explain the differences in OS between GCB-type and non-GCB 
type DLBCL (Figure S5.2.13). Finally, assessing the prognostic impact of the 
expression of BCL2 and eventually other biomarkers on survival without taking 
subgroup distinction into consideration may result in erroneous conclusions.  
 
 
S5.2.6 CONCLUSIONS 
Immunochemotherapy using R-CHOP is associated with better OS in DLBCL, 
due largely to its effect on the non-GCB subgroup. Although BCL2 expression 
does not contribute to the determination of COO distinctions, the OS of BCL2-
positive DLBCL patients is significantly improved by the addition of R. These 
results provide insight into the possible mechanisms by which R exerts its 
beneficial therapeutic effect. 
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S5.2.7 TABLES 
 
 
Table S5.2.1 – Antibodies used in the study. 
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Table S5.2.2 - Clinical and pathological characteristics of the entire cohort. 
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Table S5.2.3 - Effect of R on DLBCL survival in relation to both BCL2 and BCL6 
expression profiles. DLBCLs over-expressing BCL2 benefit significantly with 
immunochemotherapy. The effect on BCL6 negative cases was of borderline 
significance, precluding any conclusions. 
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Table S5.2.4 - Effect of R on DLBCL survival in relation to COO phenotype and 
both BCL2 and BCL6 expression profiles. Only the non-GCB cases expressing 
BCL2, benefited from the addition of R to the treatment regimen. 
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S5.2.8 FIGURES 
 
 
Figure S5.2.1 - Cell-of-Origin distinction in DLBCL. 
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Figure S5.2.2 - Cell-of-Origin distinction using tissue microarrays (TMA) and 
immunohistochemical staining algorithm. 
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Figure S5.2.3 - FISH BCL2 results in 100 DLBCL patients diagnosed at BCCA. 
Increased gene copy number and t(14;18) were mutually exclusive. 
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Figure S5.4 - Correlation between BCL2 FISH results, BCL2 expression and 
COO phenotype. Cases lacking both the t(14;18) and increased BCL2 copy 
number (47 cases) were distributed between the GCB (42%) and non-GCB 
cases (62%). Of these, only 33% of the GCB compared with 75% of the non-
GCB expressed BCL2 protein.  
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Figure S5.2.5 - In the new R-CHOP era, rituximab shows to preferentially 
prevent chemotherapy failures in DLBCLs that express BCL2 protein and failed 
to express BCL6 protein. 
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Figure S5.2.6 - Tissue microarray (TMA) built using duplicate 0.6mm cores from 
diagnostic DLBCL FFPET samples. 
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Figure S5.2.7 - The IPI was predictive of overall survival (OS) (P<0.0001) for 
the entire study population. 
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Figure S5.2.8 - Cell-of-Origin phenotype sub-types.  
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Figure S5.2.9 - BCL2 & BCL6 expression: Overall, 71% and 79% of the cases 
over-expressed BCL2 and BCL6, respectively. 
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Figure S5.2.10 - Correlation of BCL2 & BCL6 with COO phenotype. When 
comparing GCB vs. non-GCB groups there was no statistical difference in the 
number of cases expressing BCL2, while, as expected, BCL6-positive cases 
were over-represented in the GCB group. 
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Figure S5.2.11 - Impact of R therapy addition in DLBCL overall survival. As 
previously reported, the addition of R in the whole group resulted in a dramatic 
improvement in survival. 
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Figure S5.2.12 -  Impact of R therapy addition in DLBCL COO subgroups 
overall survival. The addition of R was associated with a better prognosis in the 
non-GCB cases, but not in the GCB cases. The significant result in the non-
GCB was independent of IPI group in a Cox multivariate analysis. 
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Figure S5.2.13 - NFκB pathway. The candidate mechanism responsible for 
differences in BCL2 expression, response to Rituximab therapy and OS 
between GCB-type and non-GCB type DLBCL. 
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Section 5.3: Prognostic Significance of BCL6 
Rearrangements Detected by Fluorescence in situ 
Hybridization (FISH) in Diffuse Large B Cell Lymphoma 
 
S5.3.1 INTRODUCTION 
As a master regulator of germinal center (GC) formation, the BCL6 protein plays 
a critical role in promoting rapid proliferation, survival, attenuating sensing and 
response to DNA damage, and blockade of terminal differentiation. Given the 
unusual tolerance of germinal centre B cells to simultaneous proliferation and 
somatic hypermutation, it is perhaps not surprising that a majority of B cell 
lymphomas arise from GC B cells, among which the DLBCL is the most 
common subtype.  Constitutive expression of BCL6 is often observed in DLBCL, 
frequently in association with promoter translocations or point mutations (1). 
Indeed, rearrangement of the BCL6 proto-oncogene located at chromosome 
band 3q27 is one of the most frequent cytogenetic abnormalities in DLBCL, 
occurring in up to 35% of cases (2-4). The BCL6 gene, a zinc-finger 
transcription factor, may be translocated with diverse partners in DLBCL, 
including both immunoglobulin heavy-chain (IGH) and non-IGH loci (5, 6). 
Clinical studies investigating the prognostic impact of BCL6 rearrangement in 
DLBCL have yielded contradictory results, variably demonstrating favourable 
(2), intermediate (3, 4, 7), or adverse outcome (8, 9). However, an association 
has recently been reported between BCL6 rearrangement and ABC phenotype 
(10). This Cell-Of-Origin (COO) profile was initially demonstrated as an adverse 
biological marker in DLBCL patients treated with CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisone), and has been shown to retain its 
predictive impact in patients treated with CHOP plus rituximab (R-CHOP) (11). 
The introduction of R to standard first-line therapy has significantly improved 
clinical outcome in DLBCL, and may alter the prognostic impact of both clinical 
and biological factors in this disease (12, 13). The prognostic significance of 
BCL6 rearrangement has not yet been reevaluated since the introduction of R 
to DLBCL therapy. We have used a tissue microarray (TMA)-based 
fluorescence in-situ hybridization (FISH) strategy to analyze BCL6 
rearrangement status in a retrospective cohort of patients with DLBCL.  
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S5.3.2 AIM  
The objectives of this study were to compare the effect of BCL6 rearrangement 
on survival in DLBCL patients treated with CHOP and R-CHOP, and to evaluate 
the relationship between BCL6 rearrangement and other clinical and biological 
prognostic variables in this disease, including COO phenotype.   
 
 
S5.3.3 MATERIAL & METHODS 
S5.3.3.1. Patients & Sample Selection 
We included all patients identified through the Centre for Lymphoid Cancer 
database of the BCCA who met the following criteria: 1) confirmed diagnosis of 
DLBCL (excluding primary mediastinal B cell lymphoma) by pathology review, 
2) treatment with either cyclophosphamide, doxorubicin, vincristine and 
prednisolone (CHOP) alone or in combination with rituximab immunotherapy (R-
CHOP), 3) available diagnostic paraffin material on a TMA, 4) negative HIV 
status 5) treated at the BCCA between the years 1999-2007. Ethical approval 
for this study was obtained from the University of British Columbia – British 
Columbia Cancer Agency Research Ethics Board (UBC BCCA REB).   
 
 
S5.3.3.2. Fluorescence in-situ Hybridization and Immunohistochemistry 
Using Tissue Microarrays 
For TMA construction archival, formalin-fixed, paraffin-embedded tissue 
(FFPET) diagnostic biopsy specimens were selected and 0.6mm duplicate 
cores were obtained from representative areas containing large B cells with 
typical morphology. FISH was performed according to a standard protocol for 
paraffin material as described elsewhere (10, 14) using commercially available 
Vysis LSI BCL6 Dual Color, Break Apart Rearrangement Probes (Abbott 
Molecular, IL, USA). Cases were recorded as rearranged for the BCL6 locus 
(BCL6+) if break apart occurred at least in one signal of more than 5% of nuclei. 
All other signal constellations were regarded as negative (BCL6-). 
Immunohistochemical analysis was performed using monoclonal antibodies for 
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BCL2 (Dako, clone 124, Denmark), BCL6 (Ventana Medical Systems, Tucson, 
Arizona), CD10 (Ventana Medical Systems, Tucson, Arizona), and MUM1 
(Dako, Denmark), following routine protocols for automated 
immunohistochemistry on the Ventana Benchmark XT (Ventana Medical 
Systems, Tucson, Arizona). Cases were then categorized as germinal centre B 
cell-like (GCB) or non-GCB using a standard algorithm (15). Accordingly, for 
each case, the core with the highest percentage of tumor cells stained was used 
for analysis. Cases were considered positive if 30% or more of the tumor cells 
were stained with an antibody.  
 
S5.3.3.3. Statistical Analysis 
Group comparisons were performed by means of Χ2 and student t tests. For 
time to event analyses we used SPSS Software Version 11.0.0 applying Kaplan 
Meier survival estimates (16), univariate and multivariate Cox proportional 
hazard models with the endpoint of overall survival (OS) (17), defined as the 
time from initial diagnosis to death from any cause.  P-values < 0.05 were 
reported as significant.   
 
 
S5.3.4 RESULTS 
A total of 174 patients with DLBCL who met all inclusion criteria were identified.  
FISH was successfully performed in 164 out of 174 cases (94.3%), of whom 65 
received CHOP and 99 received R-CHOP. BCL6 rearrangement was detected 
in 32 out of 164 cases (19.5%), including 17 CHOP-treated patients and 15 R-
CHOP-treated patients. Representative BCL6+ FISH images of the TMA 
sections are shown (Figure S5.3.1).  
Baseline clinical characteristics according to BCL6 rearrangement status are 
listed in Table S5.3.1. There were no significant differences in initial treatment 
regimen between the two subgroups, with similar proportions of BCL6+ (15/32) 
and BCL6- (84/132) patients receiving R as part of initial therapy. A higher 
proportion of patients in the BCL6+ subgroup had a high-intermediate or high-
risk International Prognostic Index (IPI) score (IPI 3-5) (62.5% vs. 40.2%, 
P=0.02). Analyzing the individual IPI parameters, the proportion of patients with 
elevated serum lactate dehydrogenase (LDH) was higher in the BCL6+ group 
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(P=0.007). No significant difference in age, performance status, Ann Arbor 
stage or number of extranodal sites was found between subgroups. 
Immunohistochemical characteristics according to BCL6 rearrangement status 
are listed in Table S5.3.2. BCL6 staining and COO classification (15) was 
successfully performed in 162 of 164 patients, respectively. Representative 
BCL6 staining results are shown in Figure 1B. BCL2 staining was available in 
115 of 164 (70%) patients. The presence of a BCL6 rearrangement was 
significantly correlated with COO; 68% of BCL6+ patients were of non-GCB 
subtype, as compared with 48% of BCL6- patients (P=0.006). No association 
was found between BCL6 rearrangement and either BCL6 (P=0.78) or BCL2 
(P=0.95) protein expression.   
The median follow-up duration was 2.9 years (range, 0.33-8.68). Kaplan-Meier 
analysis of the entire cohort revealed an OS benefit for patients treated with R-
CHOP compared to CHOP alone (5-year OS, 66.6% vs. 44.1%, P=0.007), as 
previously reported (18), and a trend toward decreased OS in patients with a 
BCL6 rearrangement (5-year OS, 59.4% vs. 43.4%,P=0.07). Within treatment 
groups, BCL6 rearrangement was associated with a trend toward inferior OS (5-
year OS, 45.3% vs. 70.1%; P=0.08) among patients treated with R-CHOP, but 
not among patients treated with CHOP (5-year OS, 41.2% vs. 45%; P=0.64) 
(Figure S5.2.2). Conversely, R use was significantly associated with an OS 
benefit in BCL6- patients (5-year OS, 70.1% vs. 45.0%, P=0.009), but not in 
BCL6+ patients (5-year OS, 45.3% vs. 41.2%, P=0.70). In agreement with 
previously published data, BCL6 protein expression was associated with a trend 
toward prolonged OS, but only in CHOP-treated patients (5-year OS, BCL6+ vs. 
BCL6-, 52.2% vs. 31.8%, P=0.11)(19). 
In R-CHOP treated patients, high IPI score (IPI 3-5) predicted significantly 
worse OS (5-year. OS, 46.1% vs. 77.8%, P=0.002), while non-GCB 
immunohistochemical profile was associated with a trend toward inferior 
outcome (50.8% vs. 76.8%, P= 0.07). A Cox regression analysis was performed 
for the R-CHOP-treated cohort using the following four variables: IPI score, 
COO immunophenotype, BCL2 protein expression, and BCL6 gene 
rearrangement status. In multivariate analysis, only high IPI score was found to 
be an independent adverse prognostic factor for overall survival (P=0.002). 
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S5.3.5 DISCUSSION 
The BCL6 proto-oncogene encodes a transcriptional repressor essential for 
normal germinal center formation, whose deregulated expression has been 
implicated as an important pathway in lymphomagenesis (20). Recently, in 
collaboration with others, we have shown that BCL6 binds to the promoters of 
approximately 3000 genes, representing more than 10% of the genes in the 
whole genome microarrays used for these assays. This number of target genes 
is consistent or even slightly less in number than those identified for other 
transcription factors, such as MYC, HES, NOTCH1, and several of the E2F 
isoforms (21). This indicated that BCL6 regulates a biologically coherent set of 
pathways such as DNA repair, cell cycle, chromatin formation, and regulation, 
protein stability and transcriptional regulation that showed  represented in both 
normal and malignant B cells (21).  
This study analyzed the clinical impact of BCL6 gene rearrangement in a 
retrospective cohort of DLBCL patients, treated in both the pre- and post-R 
eras. Our data suggest an association between BCL6 rearrangement and 
inferior outcome in patients treated with R-CHOP, but not in patients treated 
with CHOP. However, BCL6 rearrangement also correlated with the presence of 
high-risk clinical features and did not demonstrate prognostic significance 
independent of the IPI.   
The effect of BCL6 rearrangement on outcome in DLBCL has remained 
uncertain despite previously published work. In a seminal study by Offit et al., 
BCL6 rearrangement was found to be a favorable prognostic marker in DLBCL, 
possibly due to an association with less extranodal disease (2). Most 
subsequent investigators failed to demonstrate any influence of BCL6 
rearrangement on prognosis in DLBCL, and similarly our analysis showed this 
marker to have no predictive value in patients treated with CHOP alone (3, 4, 7, 
10). A more recent analysis, restricted to DLBCL patients with primary nodal 
disease, reported inferior survival in patients with BCL6 rearrangement, as well 
as a correlation between this marker and non-GCB immunophenotype (8). In 
agreement with our results, several prior investigators have reported a 
correlation between BCL6 rearrangement and adverse clinical features (6), but 
this has not been a uniform finding. These discrepancies may be explained in 
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part by heterogeneity between study populations due to selection biases and to 
differences in molecular diagnostic techniques and their interpretation. 
The addition of R to first-line combination therapy has led to a significant 
survival improvement in patients with DLBCL, requiring a re-evaluation of 
established prognostic markers (13). Biological prognostic markers in particular 
may be influenced by changes in standard therapy, due to the differential 
effects of new agents within previously defined biological subgroups. It has 
recently been reported that BCL2 protein expression, an adverse prognostic 
marker in CHOP-treated patients, loses its prognostic effect in the R-CHOP era, 
due to a disproportionate benefit from R in BCL2+ cases (22). In our analysis, 
the addition of R appeared primarily to benefit patients without BCL6 
rearrangement, and was associated with significantly prolonged OS in this 
subgroup. In contrast, little improvement in outcome was observed with the 
addition of R among BCL6+ patients, in whom long-term survival remained less 
than 50% even with R-CHOP. BCL6 rearrangement was associated with a trend 
toward poorer outcome in R-CHOP-treated patients, suggesting that it may 
have value as a predictive biomarker in DLBCL in the R era. 
The IPI remains the most successful clinical prognostic instrument in DLBCL (5, 
23). However, the IPI appears to lose discriminatory power in R-CHOP-treated 
patients, and in a recent analysis was unable to identify a subgroup with less 
than a 50% chance of long-term survival (13). Biologic markers may help to 
refine risk-stratification in DLBCL, and to identify high-risk subgroups which 
might benefit from intensified or novel therapies. However, to be clinically useful 
these markers must provide prognostic information complementary to the IPI. In 
our study, the presence of BCL6 gene rearrangement correlated with high IPI 
score, and in multivariate analysis this biomarker did not show independent 
prognostic significance. BCL6 rearrangement also showed an association with 
non-GCB immunophenotype, previously demonstrated to be an unfavorable 
prognostic marker in CHOP-treated patients with DLBCL (15). However, in our 
cohort of R-CHOP-treated patients, COO phenotype did not emerge as an 
independent prognostic variable by multivariate analysis. BCL6 protein 
expression has been identified as a hallmark of GCB derivation in DLBCL, and 
has been associated with favorable clinical outcome (15, 24). However, in 
keeping with prior studies, we did not find a correlation between BCL6 
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rearrangement and BCL6 protein expression, but demonstrated a relationship 
between BCL6 rearrangement and non-GCB phenotype (8, 10). This seemingly 
paradoxical finding may relate to several factors. First, mechanisms other than 
gene rearrangement have been shown to deregulate BCL6 expression in 
DLBCL, including targeted mutations that may interrupt negative gene auto-
regulation (20). Second, the functional effect of BCL6 rearrangement may vary 
depending on other biological factors, including the chromosomal translocation 
partner and cellular context. One group of investigators has demonstrated 
significantly lower BCL6 expression with non-IGH/BCL6 than with IGH/BCL6 
rearrangements, and has also reported inferior survival in DLBCL patients with 
non-IGH/BCL6 translocations (9, 25). A more recent study by the 
Leukemia/Lymphoma Molecular Profiling Project (LLMPP) examined the effect 
of BCL6 rearrangement on gene expression, in patients with both GCB- and 
ABC-subtype DLBCL (10). In this analysis, BCL6 rearrangement was 
associated with increased BCL6 mRNA levels in patients with ABC-subtype 
DLBCL, but not in patients with GCB-subtype DLBCL. The clinical significance 
of these biological subdivisions remains to be clarified. 
 
 
S5.3.6 CONCLUSION 
In summary, the introduction of R may have altered the prognostic impact of 
BCL6 rearrangement in patients with DLBCL. However, to be incorporated into 
clinical practice as a useful prognostic biomarker, BCL6 rearrangement must be 
shown to provide prognostic information additional to the IPI. BCL6 
rearrangement also correlates strongly with non-GCB immunophenotype, and 
the interdependence of these two prognostic variables requires further study. 
Correlative biomarker analysis within prospective randomized clinical trials will 
be needed to determine the prognostic value of this marker in the R era. 
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S5.3.7 TABLES 
 
Table S5.3.1. Clinical characteristics of 164 DLBCL patients subject to 
successful FISH for the BCL6 locus 
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Table S5.3.2 - Immunophenotypic characteristics of 164 DLBCL patients 
subject to successful FISH for the BCL6 locus. 
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S5.3.8 FIGURES 
 
Figure S5.3.1 - (A) FISH on FFPET sections on a TMA. Left panel: Interphase 
nuclei with BCL6 break apart (BCL6+). The most common signal pattern is 1 
fusion signal (yellow) and 2 split signals (1 red, 1 green) visualized at 200x 
magnification. Right panel: BCL6+ interphase nuclei with break apart (split 
signals) and polyploidy (multiple fused signals) of the BCL6 locus (high power 
field). (B) Immunohistochemistry for BCL6 on TMA cores. Left panel: Positive 
staining in virtually all large B cells Right panel: Negative staining.    
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Figure S5.3.2 - Overall survival in BCL6+ vs. BCL6- disease. A. OS, CHOP-
treated patients (n=65). B. OS, R-CHOP-treated patients (n=99). 
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Section 5.4: MYC Aberrations are Associated with a 
Poor Prognosis in DLBCL Patients Treated with R-
CHOP Immunochemotherapy 
 
 
S5.4.1 INTRODUCTION 
Diffuse large B cell lymphoma (DLBCL) is recognized to be a heterogeneous 
group of diseases with clinical, morphological, immunohistochemical and 
molecular subtypes defined in the new World Health Organization (WHO) 
classification (1). Further, a new category has been created defined as 
‘borderline cases’ which are considered B cell lymphomas, unclassifiable, with 
features intermediate between DLBCL and Burkitt lymphoma (2).   
Morphologically, these tumors typically have a mixture of medium to large sized 
cells, a high proliferation rate and 35-50% of cases have an 8q24/MYC 
translocation (2). However, approximately 5-10% of DLBCLs with typical 
morphology also harbour a MYC rearrangement and these cases are 
considered in the category of DLBCL, not otherwise specified (NOS) in the 
updated WHO classification (3). Although approximately 20% of these cases 
may also harbor a concurrent IGH-BCL2 translocation i.e. t(14;18)(q32;q21), the 
so-called ‘double-hit’ or dual translocation lymphomas (4), which is known to be 
associated with a poor outcome, there is very little information of the prognostic 
importance of MYC aberrations in isolation in DLBCL.   
Gene expression profiling studies suggest that some MYC+ DLBCL have a 
molecular signature that is distinct from Burkitt lymphoma (5, 6).  MYC+ cases 
of aggressive B cell lymphoma lacking a molecular Burkitt’s lymphoma 
signature had an inferior prognosis, however, this analysis was not confined to 
DLBCL and almost half had a concurrent t(14;18) (6). A recent study suggests 
that MYC aberrations identified by fluorescence in situ hybridization (FISH) in 
pathologically defined DLBCL patients treated with CHOP-like chemotherapy is 
associated with an inferior prognosis (7). However, the presence of concurrent 
IGH-BCL2 translocation was not assessed and none of the patients in this 
analysis had received rituximab (R) containing treatment regimens. With the 
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established superiority of R-CHOP compared to CHOP (8-10), the importance 
of MYC rearrangements in this population must be re-established. 
 
 
S5.4.2 AIM 
The purpose of this study was to screen an unselected series of patients with 
DLBCL for MYC aberrations to determine the frequency of this occurrence and 
whether if there were any pathologic or clinical defining features as well as to 
assess the prognostic impact of MYC aberrations in DLBCL patients treated 
with R-CHOP immunochemotherapy. 
 
 
S5.4.3 MATERIAL & METHODS 
S5.4.3.1. Patients & Samples Selection 
The BCCA Centre for Lymphoid Cancer Database was screened to identify 
adult patients (> 15 years of age) with newly diagnosed DLBCL treated with 
CHOP in combination with R (R-CHOP) with curative intent. Patients that were 
HIV-positive were excluded.  Those cases with paraffin blocks available were 
utilized to construct a tissue microarray (TMA). For this analysis, only those 
cases that are considered to be DLBCL not otherwise specified (DLBCL-NOS) 
by the updated WHO classification of lymphomas recently published were 
included (3). Clinical information including for the calculation of the International 
Prognostic Index (IPI) was determined (11). This study was approved by the 
BCCA Research Ethics Board.    
 
S5.4.3.2. Tissue Microarray & Immunohistochemistry 
The TMA was constructed using duplicate 0.6mm cores from formalin-fixed 
paraffin-embedded tissue (FFPET) derived from newly diagnosed cases of 
DLBCL. Immunohistochemistry (IHC) was performed on archived FFPET using 
CD20 (L26, Dako, CA), CD3 (Dako, CA), CD10 (Clone 56C6, Vector, CA), Ki-67 
(Dako, CA) and BCL2 (clone 124, Dako, CA). The TMAs were stained using 
automated immunohistochemistry on a Ventana Benchmark using standard 
protocols. Cases were considered positive for CD10 or BCL2 if > 30% of the B 
cells were positive. The Ki-67 antibody MIB1 was used to determine the 
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proliferation rate and >80% was defined as ‘high proliferation’ as previously 
described (12).   
 
S5.4.3.3. Cytogenetic Analysis  
All cases were screened for a MYC rearrangement using a Vysis dual color 
FISH break-apart probe (Abbott Molecular, Abbott Park, IL). Cases harbouring a 
MYC rearrangement were also screened for the presence of a t(14;18) 
rearrangement using the LSI IGH/BCL2 dual color, dual fusion translocation 
probe (Abbott Molecular Abbott Park, IL). Partner chromosomes were 
determined using additional BAC probes. 
 
S5.4.3.4. Determination of DLBCL Cell of Origin Subtypes 
For 62 patients, frozen tissue was available for gene expression profiling 
analysis. RNA was extracted using the ALL PREP kit (Qiagen) and following 
reverse transcription it was hybridized to the U133-2 Plus arrays (Affymetrix) 
according to the manufacturer’s protocol. CEL files were normalized using 
robust multi-chip analysis (RMA). The cell of origin (COO) phenotype was 
determined using model scores for the activated B-cell type (ABC) and germinal 
centre type (GCB) using the Bayesian formula previously described (13). For 
the remaining patients, the COO was determined to be GCB or non-GCB using 
immunohistochemistry according to the Hans criteria (14).   
 
S5.4.3.5. Statistical Analysis 
Progression-free survival (PFS) was determined from the date of the 
pathological diagnosis to the date of relapse, progression or death due to 
lymphoma or treatment toxicity. Overall survival (OS) was determined from the 
date of diagnosis to the date of death of any cause. The time to central nervous 
system (CNS) relapse was defined from the date of diagnosis to the date of 
documented relapse in the CNS. The Χ2 test was used to compare baseline 
characteristics between MYC+ and MYC- – cases. Survival curves were plotted 
using the Kaplan Meier method and compared using the log-rank test (15). The 
Cox Proportional Hazards model was used to determine the impact of multiple 
factors on PFS, OS and time to CNS relapse (16). All statistical analyses were 
 290 
performed using SPSS software (SPSS version 11.5 for Windows; SPSS Inc®, 
Chicago, IL). 
 
 
S5.4.4 RESULTS 
A total of 137 newly diagnosed cases of DLBCL treated with R-CHOP 
chemotherapy and with paraffin blocks available for the construction of the TMA 
were included in this analysis.  FISH was successful in 135 cases at defining 
the presence or absence of a MYC rearrangement and 2 cases were 
considered technical failures. In total, 12/135 (8.8%) cases of DLBCL were 
positive for MYC in this series. Patients that were DLBCL MYC+ were 
predominantly male (75%) with a median age of 69 (22-85) with no particular 
high risk defining clinical features at disease presentation compared to MYC- 
cases (Table S5.4.1). Half were early stage and were in a good risk group by 
the IPI (Table S5.4.1). Only 33% had >1 extranodal site of involvement and 
testicular involvement was more common than in MYC negative patients. 
      
S5.4.4.1. Cytogenetics, Immunohistochemistry and Cell of Origin 
The partner chromosome information for the MYC rearrangement was available 
in 6/12 cases and 3 involved the IG loci t(8;14) and 3 involved a variant partner 
chromosome (non-IG). Three of the MYC positive cases (25%) had a 
concurrent BCL2 t(14;18) so-called dual translocations or ‘double-hit’. In total 
8/12 cases were BCL2+ (67%) using the Dako antibody with no difference in 
frequency observed compared to the MYC- cases (Table S5.4.1). Of interest, 
2/3 of the MYC+ cases that were also t(14;18)+ were BCL2- by IHC using the 
DAKO antibody. MYC+ cases were more likely to have a high proliferation rate 
(Table S5.4.1).       
In the updated WHO classification of lymphomas, the COO phenotype 
distinguishes two molecular subtypes of DLBCL-NOS, germinal centre-like 
(GCB) and activated B cell-like (ABC) (3, 13). This was further validated at the 
immunohistochemical level into GCB and non-GCB subgroups based on the 
presence or absence of CD10, BCL6 or MUM1 (14). The COO phenotype was 
available for 131 cases (97%) (4 missing in the MYC- group); 62 were assigned 
by gene expression profiling (GEP) (13) and 69 by the Hans algorithm (14). For 
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the purpose of the COO assignment two groups were considered: GCB and 
non-GCB (the latter including those assigned ABC by GEP). There was no 
difference in frequency of GCB vs. non-GCB between the MYC+ and MYC- 
cases (Table S5.4.1). Not surprisingly, the 3 cases with dual translocations had 
a GCB phenotype.  
 
S5.4.4.2. Impact on Survival of MYC Rearrangements in R-CHOP Treated 
Patients 
The 5-year PFS (65% vs. 31%, P=0.006) and OS (72% vs. 33%, P=0.016) was 
inferior in cases of DLBCL treated with R-CHOP that harboured a MYC 
rearrangement (Figure S5.4.1a and 1b). Within the favourable GCB COO 
(n=68), cases that harboured a MYC translocation had an inferior PFS 
(P=0.049) and OS (P=0.014). However within the non-GCB subgroup (n=63), 
there was an inferior PFS (P=0.033) but not OS (P=0.303). In univariate 
analysis, in addition to the presence of a positive MYC break-apart assay, the 
IPI, a non-GCB phenotype, extranodal involvement and bone marrow 
involvement with DLBCL were all associated with an inferior PFS (Table 
S5.4.2). Similar results were observed for OS, although only a trend for an 
inferior outcome was observed with a non-GCB phenotype. Of note, BCL2 
expression and a high proliferation rate, including variable cutoffs for Ki-67 (> 
80%, >90% or >95%) were not prognostic for PFS or OS (Table S5.4.2). 
Multivariate analysis using a Cox proportional hazard model was performed on 
the R-CHOP cohort including factors that had a P-value of < 0.1 in univariate 
analysis. The presence of a MYC rearrangement remained a significant factor 
for both PFS (HR 3.28 (1.49, 7.21), P=0.003) and OS (HR 2.98 (1.28, 6.95), 
P=0.011) (Table S5.4.3). Of note, if the MYC+ cases with a dual translocation 
(n=3) are removed and the analysis is repeated, MYC retains prognostic 
significance for both PFS (P=0.009) and OS (P=0.05).  
 
S5.4.4.3. Risk of CNS Relapse in R-CHOP Treated Patients with a MYC 
Rearrangement 
Given that CNS relapse is a known consequence in Burkitt lymphoma, we 
evaluated whether there was an increased risk of CNS relapse in cases of 
DLBCL that harbour a MYC translocation. Only one patient with testicular 
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involvement received intrathecal prophylaxis at the time of primary therapy, 
otherwise CNS prophylaxis was not utilized as part of the primary therapy.    
Using the time to CNS relapse as the endpoint, the presence of a MYC break-
apart (P=0.018) was predictive of a CNS relapse in R-CHOP treated patients 
(Figure S5.4.2). In multivariate analysis, the presence of a MYC break-apart 
(HR 8.0 (1.33, 48.03) P=0.023) and kidney involvement (HR 25.28 (2.60, 
245.86) P=0.005) remained significant in the Cox proportional hazards model 
after adjusting for the IPI, extranodal sites>1 or other high-risk extranodal sites 
(bone marrow, testicular involvement and sinus involvement). Of interest, a high 
proliferation rate was not predictive of an increased risk of CNS relapse. 
 
 
S5.4.5 DISCUSSION 
The recently published updated WHO defines three subgroups of aggressive 
lymphomas that may harbor a MYC gene rearrangement:  Burkitt lymphoma; a 
new category defined as B cell lymphoma, unclassifiable with features 
intermediate between DLBCL and Burkitt lymphoma (BCLU) as well as DLBCL-
NOS (1). Overall, the frequency of MYC aberrations in DLBCL ranges from 
approximately 5-15%, however, in many studies it is often unclear how the 
patients are selected for cytogenetic analysis and some older studies may have 
included so-called ‘Burkitt-like’ cases.  
 A limited number of studies have evaluated the prognostic importance of MYC 
in patients treated with CHOP-like regimens (7). The German High-Grade Non-
Hodgkin’s Lymphoma Study Group (DSHNHL) recently evaluated 177 patients 
who were treated in the BH1 and BH2 clinical trials which compared CHOP-like 
regimens (7). Patients were included if they had tumor tissue available for the 
construction of a TMA to assess for the presence of a MYC gene 
rearrangement.   In this comprehensive analysis, the presence of a MYC 
aberration was associated with an inferior OS (P=0.047) and there was a trend 
to a reduction in EFS (P=0.062). It is unclear from this analysis what proportion 
of cases had a concurrent t(14;18) translocation. In a Japanese study, 11% of 
cases of DLBCL were found to harbor a MYC translocation however, the cases 
evaluated were those that had abnormal karyotypes that may have been 
selected based on high risk features, which is also reflected by the high 
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proportion of cases with a concurrent BCL2 translocation (17). Nevertheless, 
the presence of a MYC translocation was associated with an inferior prognosis, 
particularly if in concert with a t(14;18). In contrast, one study found that the 
presence of a MYC rearrangement did not predict for a worse outcome, 
however, the treatment received is not detailed and it is possible patients may 
have received more dose-intensive regimens (18).    
The present study is the first published to evaluate whether the presence of 
MYC gene rearrangements is still of clinical relevance in patients treated in the 
R-CHOP, which is now the accepted standard of care in the treatment of 
DLBCL given confirmed superiority in a number of randomized clinical trials. In 
this ‘unselected’ population-based registry cohort of DLBCL, the frequency of 
MYC aberrations was 8.8%, which is comparable to the German study (7.9%). 
Similar to the German study, we did not identify any high-risk clinical features at 
presentation in the MYC positive group. Although there was a tendency for the 
tumours in our study to have a high Ki-67 score, a wide range was seen and 
this feature cannot be relied upon to identify patients at higher risk to harbor a 
MYC rearrangement. Further, our results contrast the DSHNHL study in which 
no correlation between a high proliferation rate and the presence of a MYC 
rearrangement was found which may reflect the high variability and poor 
reproducibility of this immunohistochemical marker (19). Regardless, a high 
proliferation rate was not associated with outcome in this analysis. In contrast, 
the presence of a MYC rearrangement retained prognostic significance in R-
CHOP treated patients in multivariate analysis for both PFS and OS and thus it 
is independent of clinical risk factors and COO. Further, we were able to define 
a poor risk group of patients with DLBCL with MYC rearrangements within the 
favorable GCB subgroup.  
In our series, 72% of cases were BCL2+ using the commercially available Dako 
antibody. In the R-CHOP treated subgroup 4/12 cases were BCL2- (including 2 
t(14;18)+) and interestingly, 3 of 4 are long-term survivors compared to 2 of 8 
who were BCL2+. Although it is possible that false-negative results may occur 
based on the sensitivity of the Dako BCL2 antibody, it would appear that the 
combination of MYC driving proliferation and the anti-apoptotic effect of BCL2 
are critical in determining outcome. However, given the small number of 
patients in this study, this requires further validation. In a recently described 
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large series of dual MYC/BCL2 translocations (double-hit cases) from the 
BCCA, it was shown that overall survival of patients with these concurrent 
translocations was extremely poor (20). Cases with of DLBCL with dual 
translocations had an improved but still unsatisfactory outcome compared to 
those that were aggressive B cell lymphoma unclassifiable and were more likely 
to be BCL2- (20). Thus, cytogenetic studies and BCL2 status should be tested 
in all DLBCL MYC+ cases to determine the critical factors impacting prognosis 
in this population.    
Central nervous system relapse is a known risk in patients with Burkitt 
lymphoma and as a result, chemoprophylaxis is incorporated into treatment 
regimens for this disease. Similarly, we found an increased risk of CNS relapse 
in cases of DLBCL treated with R-CHOP that harbored a MYC aberration.  
Given the overall poor outcome, of patients with secondary CNS disease, these 
results raise the question as to whether this population should be treated with 
Burkitt lymphoma type regimens which include intensive CNS prophylaxis. 
 
 
S5.4.6 CONCLUSION 
In summary, MYC rearrangements define a small group of patients with DLBCL, 
independent of COO, who are less likely to be cured with R-CHOP and may 
have an increased risk of CNS relapse. There are no identifiable clinical, 
histological, or immunophenotypic features that signal that a case of DLBCL 
may harbor a MYC aberration. Thus, all patients with DLBCL should undergo 
FISH analysis for assessment of the MYC rearrangement in addition to analysis 
for the t(14;18) and BCL2 expression. MYC+ DLBCL likely represent a distinct 
DLBCL subtype and regimens more in line with those used in Burkitt lymphoma 
may be more appropriate in this patient population.    
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S5.4.7   TABLES 
Feature MYC
+
 (n = 12) MYC
− 
(n = 123) P 
Median age, y 68 61 — 
Age > 60 y 8 (67) 68 (55) .448 
Male sex 9 (75) 73 (59) .289 
Stage 3 or 4 6 (50) 75 (61) .459 
B symptoms    
    Extranodal any site 8 (67) 72 (58) .584 
    Extranodal > 1 4 (33) 25 (20) .295 
        Bone marrow 0 11 (9) .280 
        Testicular 2 (17) 3 (2) .013 
        Sinus 0 2 (1.6) .280 
        Gastrointestinal 2 (17) 19 (15) .911 
        Kidney 0 2 (1.6) .656 
        Liver 0 7 (6) .396 
Bulky disease
*
 4 (33) 31 (26) .575 
PS > 2
*
 5 (42) 42 (36) .677 
LDH abnormal
*
 9 (75) 54 (50) .100 
LDH > 2× ULN 3 (25) 28 (26) .930 
IPI 0-2 vs 3-5 6 (50) 48 (39) .459 
Ki-67
†
    
    More than 80% 7 (58) 27 (22.5) .007 
    More than 90% 6 (50) 9 (7.5) < .001 
    More than 95% 4 (12) 8 (6.7) .002 
BCL2 protein
+‡
 8 (67) 86 (70) .782 
GCB phenotype
§
 7 (58) 61 (51) .640 
PS indicates Performance Status; LDH, lactic dehydrogenase; and ULN, upper 
limit of normal.* Missing data: LDH, n = 15; bulky disease, n = 3; PS, n = 5. † 
Failed in 3 MYC− cases. ‡ Results using the Dako antibody; not available in 1 
MYC− case. § Not available in 4 MYC− cases.  
Table S5.4.1 - Characteristics of MYC+ and MYC- DLBCL patients.  
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Risk factor PFS P OS P 
MYC+ .006 .016 
IPI ≥ 3 < .001 < .001 
Non-GCB phenotype .041 .058 
BCL2 protein* .313 .492 
Ki-67   
More than 80% .582 .418 
More than 90% .759 .751 
More than 95% .351 .642 
Extranodal sites, any .014 .034 
Extranodal sites > 1 .013 .040 
Bone marrow DLBCL+ < .001 < .001 
Testicular .124 .263 
Bulky disease .334 .841 
 
Table S5.4.2 - Univariate analysis of risk factors for PFS and OS for DLBCL 
patients treated with R-CHOP  
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Risk factor 
PFS OS 
Hazard ratio (CI) P 
Hazard ratio 
(CI) 
P 
MYC+ 3.28 (1.49-7.21) .003 2.98 (1.28-6.95) .011 
IPI ≥ 3 2.69 (1.48-4.86) .001 3.29 (1.68-6.46) .001 
Non-GCB phenotype* 1.86 (1.04-3.34) .038 — NS 
Bone marrow DLBCL+ 3.74 (1.67-8.36) .001 4.06 (1.72-9.58) .001 
NS indicates not significant; and —, not applicable. * Not available in 4 MYC− 
cases.  
Table S5.4.3 - Multivariate analysis of risk factors of PFS and OS of DLBCL 
patients treated with R-CHOP. 
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S5.4.8 FIGURES 
 
 
Figure S5.4.1 - Outcomes of patients with MYC+ DLBCL treated with R-CHOP, 
Progression free survival (A) and overall survival (B). 
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Figure S5.4.2 - Time to central nervous system relapse of MYC+ and MYC− 
DLBCL. 
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Section 6: New Biological Predictors of Survival in 
Hodgkin Lymphoma: The Microenvironment 
 
 
6.1 INTRODUCTION 
Classical Hodgkin lymphoma (CHL) is one of the successes of recent treatment 
strategies in oncology. Despite great progress, about 20% of patients with 
advanced-stage disease still die of relapse or progressive disease while a 
similar proportion of patients are over-treated (1, 2), many of whom suffer from 
treatment-related late sequelae, such as solid tumours and end-stage organ 
dysfunction (3-5). 
None of the clinical variables, namely the International Prognostic Score (IPS) 
(6), used to help guide treatment decisions can predict the majority of patients 
in whom standard treatment will fail to eradicate disease. New biological 
markers that can improve on outcome prediction will be important to advancing 
the field.  
CHL most characteristic and defining features is the predominance of reactive 
cells in the tumour microenvironment, which largely outnumber the malignant 
cells (7). Thus, many studies have focused on the features of this prominent 
and abnormal immune microenvironment, exploring whether immune related 
cells can contribute to outcome prediction (8-11). Although some biomarkers 
have proven to be predictive in more than one study, most of these markers 
require validation in independent cohorts. Importantly, these studies must 
include patients treated uniformly, as heterogeneity of treatments has been 
recently implicated as an important factor contributing to the marked variability 
in published studies that have examined the role of various immune cells in the 
tumour microenvironment of lymphoid cancers (12).      
 
 
6.2 AIM 
The aim of our study was to determine cellular signatures that correlate with 
treatment outcome in CHL, using gene-expressing profiling (GEP) and 
immunohistochemical (IHC) analysis of diagnostic lymph node biopsies in CHL.  
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We further sought to validate any significant findings using a cohort of CHL 
patients uniformly treated in a single institution.  
 
 
6.3 MATERIAL AND METHODS 
6.3.1. Patients & Samples Selection 
For GEP, we selected fresh frozen lymph node specimens, which had been 
obtained at the time of diagnosis from 130 patients with CHL, from the tissue 
archives at the BCCA and the University of Nebraska Medical Center. The 
criteria that we used included a primary diagnosis of CHL after central review, 
representative lymph node tissue (at least 1 cm2 in tissue sections), negative 
status for HIV infection, and first-line treatment with ABVD chemotherapy 
(doxorubicin, bleomycin, vinblastine, and dacarbazine) or an ABVD-like regimen 
and, if indicated, radiation therapy (including wide-field radiation for patients 
with limited-stage disease). Primary treatment was defined as a failure if the 
lymphoma had progressed at any time after the initiation of therapy; treatment 
success was defined as the absence of progression or relapse. The median 
follow-up time for living patients in the treatment-success group was 3.9 years 
(range, 0.5 to 21.0). The GEP cohort was stratified according to treatment 
outcome (failure vs. success) in order to analyze differences between the two 
outcomes (Figure 6.1). Advanced-stage disease was defined with the use of 
Ann Arbor staging criteria (13). On the basis of the availability of formalin-fixed, 
paraffin-embedded tissue (FFPET) biopsies of diagnostic lymph node 
specimens, we also selected samples from 166 independent cases of CHL for 
IHC testing on a tissue microarray (TMA). To increase the statistical power for 
observations linked to progression-free survival (PFS) and disease-specific 
survival (DSS), this cohort was enriched for all available cases of treatment 
failure that were identified through the Centre for Lymphoid Cancer database at 
the BCCA. The number of cases of treatment failure was roughly matched to 
the number of cases of treatment success and both groups were roughly 
matched for clinical characteristics at diagnosis. For the independent validation 
cohort, we also recorded the outcome of salvage therapy delivered with curative 
intent in 61 patients; these secondary therapies included autologous stem-cell 
transplantation in 55 patients, CVPP chemotherapy (cyclophosphamide, 
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vinblastine, procarbazine, and prednisone) plus involved-field radiation in 5 
patients, and GDP chemotherapy (gemcitabine, dexamethasone, and cisplatin) 
plus extended-field radiation in one patient. In this cohort, the median follow-up 
time was 4.0 years (range, 0.5 to 20.8). The study was approved by the 
institutional review boards at the University of British Columbia-BCCA & 
University of Nebraska Medical Center. Written consent was obtained from all 
patients in accordance with the principle of the Declaration of Helsinki. 
 
6.3.2. Gene Expression Analysis 
Total RNA was extracted from multiple (10 to 20) 20-μm freshly cut tissue 
sections after mechanical homogenization. Expression profiles were obtained 
with the use of GeneChip Human Genome U133 Plus 2.0 arrays containing 
54,120 probe sets for genome-wide analysis of the human transcriptome 
(Affymetrix Inc., U.S.A). (Data are available at 
www.ncbi.nlm.nih.gov/geo/query/acc.cgi [accession number, GSE17920].  
RNA preparation, array hybridization, and washing were performed according to 
routine protocol with modifications. All 130 microarray experiments met 
homogeneous criteria for quality control. Total RNA was extracted using Allprep 
RNA extraction kits (Qiagen Inc., ON, Canada). 1-8 μg of extracted RNA were 
subsequently used to prepare biotinylated cRNA in a one-cycle reaction 
following routine protocols including reverse transcription and labelling in-vitro 
transcription reactions. 11μg of labelled cRNA were then hybridized on the 
array overnight and the arrays were washed, stained and scanned using 
Affymetrix Fluidics Station 450 and Affymetrix GeneChip Scanner. All 130 
reported microarrays passed homogeneous criteria for testing quality control 
including present call rates >20% and normalized unscaled standard errors 
<1.05 (NUSE). Thirteen microarrays were excluded from the analysis.  
 
6.3.3. Immunohistochemical Analyses 
To confirm the findings of the gene expression analysis, we performed IHC 
analysis using TMAs that was constructed from duplicate 1.5mm cores of 166 
independent samples enriched for cases of treatment failure (Beecher 
Instruments, Silver Springs, MD). Antibodies used for IHC included CD3, CD20, 
CD30, CD68, and MMP11. IHC scoring ranged from 1 to 3 for CD68, from 1 to 
 306 
4 for CD20, and from 0 to 3 for MMP11, with higher scores indicating a greater 
proportion of positive cells. TMA sections were evaluated by both morphology 
and IHC stains performed for routine diagnostic purposes. TMA sections were 
stained for CD68 (Dako, KP1), MMP11 (Abcam, ab52904), CD20 (Dako, L26), 
CD3 (polyclonal, Cell Marque) and CD30 (Dako, Ber-H2) following routine 
protocols for automated immunohistochemistry on the Ventana Benchmark XT 
(Ventana Medical Systems, Tucson, Arizona). The slides were independently 
scored by RDG, GH and PF. For CD68 staining, cells were scored in three 
representative high-power fields (tumour cell regions) and the relative 
percentage of CD68+ cells in relation to overall cellularity was reported as an 
average of both duplicate cores according to four groups: <5% IHC score 1, 5-
25% IHC score 2, >25-50% IHC score 3 and > 50% IHC score 4. However, 
there were only eight cases with > 50% CD68+ macrophages and thus this 
latter group was merged with cases showing 25-50% (IHC score 3). Elevated 
numbers of CD68+ cells were defined as IHC scores 2 and 3 according to a 
threshold of 5% established on 5 benign tonsil controls and previous studies 
(14). Subgroup analysis of limited-stage CHL patients included a total of 41 
cases. Due to the small sample size in IHC scoring groups 3 & 4 (n = 5 and n = 
1, respectively), these groups were merged with IHC score group 2 (n = 17) for 
the purposes of DSS analysis. Discrepant cases between observers were 
centrally reviewed to reach consensus.  
To control for case to case histologic variability, areas of sclerosis, necrosis and 
presence of primary or secondary lymphoid follicles, we recorded: 1) HRS cell 
CD20 positivity, 2) positivity of the surrounding reactive small B cells only 
(excluding sclerotic areas and follicles) and, 3) presence of B cell follicles. 
MMP11 staining was recorded as the overall cellularity of MMP11+ cells: IHC 
score 0 (no positivity), IHC score 1 (<1% of cells), IHC score 2 (1-10% of cells) 
and IHC score 3 (>10% of cells). Positive cells included HRS cells, 
macrophages and microvessels. Scores were stratified as high (3 or 4) or low (1 
or 2) for CD20 staining.  
 
6.3.4. Data Analysis  
6.3.4.1. Predictive Models 
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In brief, we used the gene expression data from the 130 patients for whom all 
prognostic factors of the IPS were recorded and constructed a multidimensional 
classifier on the basis of feature selection, using sparse multinomial logistic 
regression (SMLR) and leave one-out cross-validation (15). Our aim was to 
build a robust discriminative model that was predictive of treatment failure in 
addition to identifying a small set of features (genes) that could be used as the 
basis for separating these data into the respective outcome groups (treatment 
success vs. failure). SMLR imposes a sparsity promoting prior distribution that 
models whether a gene should be considered in the construction of the 
classifier. As such, the model heavily penalizes a gene for being included in the 
feature set, resulting in a small set of discriminative features that are strongly 
supported by these data. SMLR performs feature selection and classification 
simultaneously (15). We trained an SMLR classifier using leave-one-out cross 
validation (LOOCV) analyzing pre-treatment data of the 130 patients with 
diagnostic lymph node biopsies. For feature selection in the training sets we 
also included the 7 clinical variables as defined in the IPS (age, Ann Arbor 
stage, sex, albumin, absolute lymphocyte count, lymphocyte percentage and 
hemoglobin) in addition to the 25,388 gene expression probe sets.  
We measured classification accuracy using a Receiver Operator Characteristic 
(ROC) curve, the Area under Curve (AUC), the confusion matrix and class-
specific error rates (15). Treatment failure was assigned as the positive class, 
and treatment success as the negative class. Thus, an accurate prediction of 
failure was a true-positive result, and an inaccurate prediction of failure was a 
false-positive result; an accurate prediction of success was a true-negative 
result, and an inaccurate prediction of success was a false-negative result. We 
compared three types of input data with respect to predictor performance: gene 
expression data only, clinical variables only, combination of the two. For 
determining relative variable importance we created Random Forests (RF) 
using the SMLR selected features (16). Following settings were used: 1) 
number of predictors considered for each node, 2) square root (number of input 
variables), 3) number of trees to build 10,000, class weights and 4) balanced. A 
ranked list of these variables (relative variable importance) was plotted using 
the standard method, which is based on randomizing of the variable values and 
measuring the resultant decline in model accuracy. 
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6.3.4.2. Statistical Analysis 
Group comparisons were performed by means of the Χ2 test and Student’s t-
test. For time-to-event analyses, we used two primary end points: progression-
free survival (PFS - based on the time from initial diagnosis to progression at 
any time, relapse from complete response, or initiation of new, previously 
unplanned treatment) and disease specific survival (DSS - based on the time 
from initial diagnosis to death from lymphoma or its treatment, with data for 
patients who died of unrelated causes censored at the time of death). Cox-
proportional-hazards models and time-to-event analyses with the use of the 
Kaplan–Meier method were performed with SPSS software, version 11.0 (17, 
18).Two-sided P values of less than 0.05 were considered to indicate statistical 
significance. 
 
 
6.4 RESULTS 
6.4.1. Gene Expression Analysis 
Unsupervised hierarchical clustering of the gene expression results did not 
identify clusters that were significantly associated with the outcome of treatment 
or any other reported clinical variable. However, using Global Test, with which 
we tested all pre-filtered genes, we found a significant correlation between the 
gene expression profile and the outcome of first-line treatment (P=0.02) (Table 
6.1). Table 6.2 shows the clinical characteristics of the gene expression cohort. 
On the basis of supervised analyses with the data set stratified according to the 
failure or success of primary treatment, we identified 271 differentially 
expressed genes in the two outcome groups. Unsupervised hierarchical 
clustering of all 130 expression profiles with the use of these differentially 
expressed genes identified two clusters, one of which was associated with 
treatment success (cluster A) and the other with both success and failure 
(cluster B) (Figure 6.2). In the treatment-failure group, pathway analyses 
identified the following functions, 1) cell-mediated immune response, 2) cell-to-
cell signalling and interaction, and 3) up-regulation of pathway genes involved in 
interleukin-12 signalling, 4) macrophages and 5) apoptosis (Table 6.3 & 6.4). 
Down-regulated pathways in the treatment-failure group included genes 
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involved in CTLA4 signalling in cytotoxic T lymphocytes and G-protein–coupled 
signalling (Table 6.5 & 6.6).  
These results prompted an investigation of the association between 
microenvironment gene signatures and outcome. Using Global test, we 
performed associative testing to identify previously described cellular and 
pathway gene signatures that were differentially expressed in the two outcome 
groups – Figure 6.3 to 6.6 (19). In the treatment-failure group, there was over 
expression of gene signatures of tumour-associated macrophages (P=0.02) and 
monocytes (P=0.01), findings that are in agreement with the reported over 
expression of macrophage-signalling–associated genes according to pathway 
analysis (20, 21) – Table 6.1 & Figure 6.5. There was also over expression of 
gene signatures for angiogenic cells (P=0.04), adipocytes (P=0.01), and HRS 
cells (P=0.047) and under expression of a signature for germinal center B cells 
(P=0.01) in the treatment-failure group (22-25). Furthermore, previously 
described genes that are associated with an unfavorable outcome in CHL, such 
as lysozyme (LYZ) and cathepsin L1 (CTSL1), were over expressed in the 
treatment failure group (P=0.04) (26).  
To test the overall power of expression profiles for outcome prediction, we 
constructed a classifier by means of SMLR (15). This algorithm identified 86 
non-redundant annotated genes, age, and Ann Arbor stage by a cross-
validation approach (Table 6.7). Figure 6.7 shows the 30 features with the 
highest discriminative power, as determined by a random-forest algorithm (16). 
Among the 27 individual genes with discriminative power exceeding that of the 
best clinical variable (age) was MMP11 (probe set235908_at), which was over 
expressed in the treatment-failure group (P=0.03 after adjustment for the false 
discovery rate). We selected this gene for further immunohistochemical testing, 
since previous studies have shown that the gene family of matrix 
metallopeptidases is over-expressed in patients in whom treatment has failed 
and that MMP11 in particular is expressed by tumour-associated macrophages 
(27, 28). 
We compared the three data sources for feature selection and settled on a gene 
expression profiling model for gene expression probe sets only, a clinical model 
based on the International Prognostic Score only, and a combination model 
including both features. This comparison showed that the AUC value was 
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highest for the gene expression model, as compared with the clinical and 
combination models (0.837 vs. 0.625 and 0.821, respectively) (Figure 6.8). The 
differences in accuracy among the models were most prominent at low false-
negative rates, with the gene expression model and the combination model 
yielding higher true-negative rates than the clinical model.  
 
6.4.2 Immunohistochemical Analysis 
Our gene expression study and previous studies by other investigators 
suggested that a predominance of tumour-infiltrating macrophages, a lack of 
small B cells, and over expression of matrix metallopeptidases were correlated 
with the failure of primary treatment. For these reasons, we selected the 
markers CD68 (macrophages), CD20 (B cells), and MMP11 for 
immunohistochemical analysis of a tissue microarray containing lymph node 
biopsies of 166 patients with CHL (who were unrelated to the patients in the 
gene expression analysis), including 79 patients in whom treatment had failed 
(Table 6.2). Of these markers, CD68 and CD20 antibodies are routinely used in 
the diagnosis of lymphoma. The TMA was also stained for CD30 (a sensitive 
marker for HRS cells) and CD3 , but neither the number of CD30+ cells nor the 
number of CD3+ cells was correlated with outcome. Of these IHC markers, 
CD68 stood out because of its significant correlation with primary and 
secondary treatment outcomes (Figure 6.9). Using univariate analysis, we found 
a significant correlation between the number of CD68+ lymphoma-associated 
macrophages (LAM) and shortened PFS (P=0.03) (Table 6.8). Patients with a 
high number of CD68+ cells (an IHC score of 3) had a median PFS of 2.7 
years, whereas during an observation period of 16.4 years, the median survival 
was not reached in patients with a score of 1 (Figure 6.10). In a multivariate Cox 
regression model that included all 7 clinical factors of the International 
Prognostic Score and immunohistochemical scores for CD68, CD20, and 
MMP11, CD68 was not an independent factor for an association with PFS. In 
contrast, an increased number of CD68+ macrophages correlated with DSS in 
both univariate and multivariate analysis (P=0.003 for both comparisons) and 
outperformed the International Prognostic Score (P=0.03) (Table 6.8). The 10-
year disease-specific survival rate was significantly lower among patients with a 
CD68 immunohistochemical score of 3 (59.6%) than among those with a score 
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of 2 (67.4%) or 1 (88.6%) (P=0.003 for all comparisons) (Figure 6.11). The 
number of LAM was also correlated with the outcome after secondary 
treatment. Secondary treatment that was administered with curative intent failed 
in only 12.5% of patients with a CD68 immunohistochemical score of 1, as 
compared with failure in 51.7% of those with a score of 2 and in 62.5% of those 
with a score of 3 (P=0.009 for all comparisons). In particular, there was a 
significant correlation between the failure of autologous hematopoietic stem-cell 
transplantation and a CD68 score of more than 1 (P=0.008). A high-risk 
International Prognostic Score (>3) was not significantly associated with the 
number of CD68+ macrophages in diagnostic biopsy samples (8.7% for a score 
of 1, as compared with 18.1% for a score of 2 and 22.9% for a score of 3; 
P=0.17 for all comparisons). When the analysis was restricted to limited stage 
disease, a CD68 score of 1 was associated with a long-term DSS rate of 100% 
(P=0.04) (Figure 6.12). In agreement with the findings of the gene expression 
study, MMP11 immunohistochemical staining showed a significant correlation 
with progression-free survival in both univariate analysis (P=0.008) and 
multivariate analysis (P=0.009), although not with DSS (Table 6.8). Among the 
cells with positive staining were HRS cells, macrophages, and endothelial cells. 
Using univariate analysis, we also found that an increased number of CD20+ 
small B cells (IHC score, >2) was significantly associated with prolonged PFS 
(P=0.02) and DSS (P=0.02) (Table 6.8). However, the number of CD20+ small 
B cells was not an independent predictor of survival and was strongly correlated 
with advanced stage disease (P=0.002). Neither the number of CD20+ HRS 
cells nor the presence or absence of primary or secondary lymphoid follicles 
was associated with the outcome. 
 
 
6.5 VALIDATION STUDY  
In a retrospective analysis of 167 adult patients with CHL, prospectively treated 
in a single institution, Centro Hospitalar Lisboa Central (CHLC) with Stanford V 
regimen, the impact of CD68+ IHC score prognostic factor was evaluated. 
 
6.5.1. Material & Methods 
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From November 1996 to December 2009, 218 consecutive patients with newly 
diagnosed CHL at CHLC were included in a prospective study using the 
Stanford V regimen. The study included patients between the ages of 15 and 60 
years with untreated locally extensive or advanced stage, biopsy-proven CHL, 
stage I to IV disease.  Exclusion criteria included a positive HIV test, pregnancy, 
significant malignant disease other than CHL and a serum bilirubin greater than 
5 mg/dL. This is a brief chemotherapy regimen given weekly for 12 weeks as 
follows: vinblastine 6 mg/m2 and doxorubicin 25 mg/m2 on weeks 1, 3, 5, 7, 9, 
and 11; vincristine 1.4 mg/m2 (maximum dose, 2 mg) and bleomycin 5 units/m2 
on weeks 2, 4, 6, 8, 10, and 12; mustard 6 mg/m2 on weeks 1, 5, and 9; and 
etoposide 60 mg/m2 daily times two on weeks 3, 7, and 11. Prednisone 40 
mg/m2 was administered orally every other day on weeks 1 through 10 and 
tapered during weeks 11 and 12. Doses of doxorubicin, vinblastine, mustard, 
and etoposide were reduced to 65% if the absolute neutrophil count was less 
than 1,000/µL, and treatment was delayed if the absolute neutrophil count was 
less than 500/µL. When it became commercially available, granulocyte colony-
stimulating factor (G-CSF) was incorporated after the initial dose reduction or 
delay. G-CSF was administered thereafter for 5 days on the odd weeks after 
myelosuppressive chemotherapy. Prophylactic ancillary medication included 
trimethoprim-sulfamethoxazole, ranitidine, and acyclovir, which were given 
throughout the treatment period. Initially, 36 to 44 Gy RT was delivered 2 to 4 
weeks after chemotherapy to initial bulky disease sites and to residual 
radiographic disease. Most patients with bulky mediastinal disease received a 
modified mantle field that included mediastinal, bilateral hilar and bilateral lower 
neck irradiation but excluded axillary, occipital, and cervical irradiation.  
Response and follow-up evaluation included a complete blood cell count, 
chemistry panel, erythrocyte sedimentation rate, chest x-ray, and plain film of 
the abdomen every month during treatment, at the completion of RT, and every 
2 months during year 1, every 3 months during year 2, every 4 months during 
year 3, and every 6 months during years 4 and 5. All computed tomography 
scans that were abnormal at diagnosis were repeated at the conclusion of 
chemotherapy and RT and scans of the chest, abdomen, and pelvis were done 
at the end of years 1, 2, and 5 (29, 30).  
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Five patients were not evaluable for response and the remaining 213 were the 
source cohort for this study. The end date for follow-up was June 2010. 
We received diagnostic lymph node FFPET biopsies of 191 patients for central 
review using 2008 WHO criteria (31). Standard IHC analysis for CD68 (KP1, 
Dako®, Glostrup, Denmark) were done on a representative whole section for 
each case. A total of 167 cases had the diagnosis confirmed and representative 
whole sections as well as interpretable IHC results were analyzed. Tumour cell 
regions were assessed for CD68+ cell content at low power (Olympus BX40, 
40x). At least three areas representative of CD68+ cell content variability were 
scored at high power (400x) as the relative percentage of positive cells in 
relation to overall cellularity, according to similar 3 groups stratification: <5% - 
IHC score 1; 5 – 25% - IHC score 2 and > 25%  IHC score 3. The predominant 
IHC score determined the final IHC score – Figure 6.13.  
Data regarding patient demographics and patient outcome were obtained from 
the existing registry (Table 6.9). Treatment failure was defined as progression at 
any time after the initiation of therapy. Advanced-stage disease was defined 
using Ann Arbor staging criteria. 
Comparisons between groups were performed by means of the Χ2 test for 
categorical data. For time-to-event analyses, we used two primary endpoints: 
overall survival (OS), calculated from the date of diagnosis to the date of death 
or last follow-up) and disease free survival (DFS), measured from achievement 
of complete remission until the date of relapse, last follow-up or death). 
Probabilities of OS and DFS were calculated using the Kaplan-Meier method 
(17). Univariate comparisons were made using the log-rank test for OS and 
DFS. Multivariate analysis was carried out using the Cox proportional hazards 
model (18). Two-sided P values of less than 0.05 were considered to indicate 
statistical significance. Statistical analysis was performed with SPSS software, 
version 17.0®.  
 
6.5.2. Results 
The baseline characteristics of the 167 treated patients are listed in Table 6.6. 
The median age at diagnosis was 29 years (range, 15-69 years), with half of 
patients (51%) presented with advanced stage disease. The median follow-up 
 314 
duration was 75 months (range 7 months to 14 years). All patients received at 
least 2 cycles of chemotherapy and no major protocol violations were observed.    
Complete response rate was 91% (152/167). Fifteen patients were primary 
refractory and the relapse rate was 22% (33/152). Treatment failure was 
significantly associated with male gender (P=0.017), advanced stage (P<0.001), 
presence of B symptoms (P=0.002), IPS>3 (P<0.001) and 
immunohistochemical CD68 score>1 (P<0.001). A high-risk IPS (>3) was also 
significantly associated with high LAM score (>1) (P=0.037).  
At 10 years, OS and DFS in this cohort were respectively 86% and 74%, 
respectively. The 10-year OS was significantly lower among patients with an 
IHC score of 2 or 3 (82% and 79%) than among those with a score of 1 (100%) 
(P=0.001 for high score vs. low score comparison) (Figure 6.14). Using 
univariate analysis (Table 6.9), we found a significant correlation between a 
high CD68+ LAM IHC score (>1) and a shortened overall survival (P=0.001). 
Importantly, cases with limited stage disease (IA/IIA) and low LAM content (IHC 
score 1) had 100% OS and 97% DFS, respectively. However, in a multivariate 
Cox regression model, IHC LAM score was not an independent factor of OS.  
The 10-year DFS was also significantly lower among patients with an IHC LAM 
score of 2 or 3 (68% and 69%) in comparison to those with a low score (96%) 
(P<0.001 for high score vs. low score comparison) - Figure 6.15. Both 
univariate and multivariate analysis (Table 6.9), demonstrated a significant 
correlation between high CD68+ LAM score and shortened DFS. In multivariate 
analysis, this factor out-performed the IPS for DFS (P=0.003 vs. not significant).  
A total of 33 patients, 8 with primary refractory disease and 25 in relapse, 
received high-dose chemotherapy and autologous stem cell transplantation. 
The median age at diagnosis was 28 (range, 15-61 years), with 64% of patients 
presenting with advanced stage disease. The median follow-up for living 
patients was 53 months after transplantation (range, 7 months to 13 years). The 
response rate was 73% (24/33) and 4 patients relapsed (17%). In this 
subgroup, OS and DFS at 5 years were 67% and 87%, respectively. We found 
a trend for better OS and DFS among patients with low LAM IHC score in 
comparison to high LAM IHC score (80% vs. 64% for OS and 100% vs. 84% for 
DFS), but this did not reach statistical significance. Univariate and multivariate 
analysis did not allow us to identify independent risk factors for outcome after 
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autologous stem cell transplantation. It is likely that statistical significance could 
be achieved with a larger cohort of patients. 
 
 
6.6 DISCUSSION 
We found that the overexpression of a macrophage signature based on gene 
expression profiling studies of diagnostic lymph node specimens obtained from 
patients with CHL was associated with the failure of primary treatment. Using 
immunohistochemical analysis, we also found that an increased number of 
CD68+ cells in the diagnostic sample was associated with an inferior outcome 
in an independent set of samples from 166 patients. Multivariate analysis 
revealed that the number of CD68+ cells was also associated with the outcome 
of secondary treatment, independently of the IPS. We further validated the LAM 
IHC results using a different validation cohort of uniformly treated patients 
(Stanford V) in a single institution and using routine whole section diagnostic 
biopsies.  
Three previous studies that have used expression profiles of the 
microenvironment in CHL have been reported (26, 27, 32). Of these, one 
identified a gene signature of macrophages but did not show the clinical value 
of LAM assessed by means of a common immunohistochemical marker (26). 
The association between the number of macrophages and treatment outcome 
has also been studied in other B cell lymphoid malignancies (14, 25, 33). 
Differences in survival among patients with various lymphoma subtypes, which 
are linked to macrophage content, might be explained by the variable presence 
of macrophages with M1 or M2 differentiation in biopsy samples, indicating 
distinct biologic features of the tumours (34). However, in these lymphoma 
subtypes, including Hodgkin’s lymphoma, the functional link between 
macrophage numbers and the contribution of these cells to the treatment 
outcome remains unclear (7). Our gene expression classifier for the outcome of 
primary treatment outcome revealed MMP11, a gene that has been found by 
other investigators to be expressed in tumour-associated macrophages involved 
in remodelling of apoptotic lymphatic tissue (28). Using IHC analysis, we were 
able to confirm the correlation between the number of MMP11+ cells and PFS 
in an independent cohort of patients. However, MMP11 stained many different 
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cell types, including macrophages, and thus did not allow us to identify the 
particular cells that were responsible for the production of the protein.  
Our findings also validate the recent report of a correlation between an 
increased number of small B cells and a favorable outcome (32). The recently 
described correlation between the number of CD20-positive B cells and survival 
in patients with CHL needs to be reassessed in the context of clinical studies 
showing successful treatment with the addition of rituximab to standard 
chemotherapy (35, 36).  
We report and validate the clinical value of a single marker, CD68, in the 
identification of LAM by IHC analysis, an analytic method that can be easily 
incorporated into a routine diagnostic approach.  
The use of such markers in combination with well-established clinical risk 
factors could improve on the predictive value of a single biomarker. We focused 
on LAM because of the strong signal from the gene expression data and the 
recently renewed interest in these non-neoplastic cells as major contributors to 
the biologic features of lymphoma and outcome prediction. The value of 
assessing the number of LAM as a biomarker is highlighted by the association 
between these cells and the outcome after secondary therapy with autologous 
stem-cell transplantation, a widely used salvage treatment option. Accurate 
prediction of the outcome after secondary treatments delivered with curative 
intent would provide better risk stratification for these expensive therapeutic 
options. Clinical predictors of the outcome after autologous stem-cell 
transplantation have been of limited value (37). In addition, our findings based 
on the TMA cohort are not restricted to advanced-stage disease alone. Thus, 
the IHC CD68+ macrophage content represents a biomarker with clinical 
applicability in all stages of CHL, both at the time of diagnosis and at the time of 
relapse.  
In summary, our study showed the value of enumerating CD68+ macrophages 
in diagnostic lymph node samples for prediction of the outcome after both 
primary and secondary treatments (in particular, autologous stem-cell 
transplantation). The absence of an increased number of CD68+ cells in 
patients with limited stage disease defines a subgroup of patients for whom the 
rate of long-term disease-specific survival is 100% (and 97% in the validation 
set) with the use of available treatments. 
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Moreover, the LAM IHC score was applied and validated using routine 
diagnostic whole section biopsies, which not only validates the aforementioned 
results obtained using TMAs, but also underscores its use in daily practice. 
Given these results, we posit that the amount of CD68+ LAM in lymph node 
specimens, a routine pathology test easily applied to routine biopsy samples, is 
a solid predictive factor for outcome in CHL. At this time, a relevant question is 
whether these results will have impact in the management of HL patients. A 
personalized treatment strategy may be developed, identifying at diagnosis 
those patients with increased resistance to current therapeutic options. 
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6.7 TABLES 
 
 
Table 6.1 - Association of previously described gene signatures with treatment 
outcome: Results of Global Test. Signatures with P < 0.05 are shown. 
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Table 6.2 - Demographic and clinical characteristics of the two cohorts of 
patients. 
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Table 6.3 - Ingenuity Pathway Analysis: genes high in primary treatment 
failures, top 10 Functions. 
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Table 6.4 - Ingenuity Pathway Analysis: genes high in primary treatment 
failures, top 10 Canonical Pathways. 
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Table 6.5 - Ingenuity Pathway Analysis: genes low in primary treatment failures, 
top 10 Functions. 
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Table 6.6 - Ingenuity Pathway Analysis: genes low in primary treatment failures, 
top 10 Canonical Pathways. 
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Table 6.7 - SMLR combination model features and their relative importance 
rankings according to Random Forests (RF) (16) – 86 annotated genes and 2 
clinical variables. 
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Table 6.8 - Progression-free and Disease-Specific Survival in a Validation 
Cohort of 166 Patients. 
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Clinical & Pathological 
characteristics 
Overall Survival Disease Free Survival 
N=167 # (%) Univariate Multivariate Univariate Multivariate 
Male gender 83 (50) 0.155 ns 0.553 ns 
Age > 44 y 32 (19) 0.541 ns 0.058 ns 
Histologic subtype 
Nodular sclerosis 
Mixed cellularity 
Lymph.-rich 
Lymph.-depleted 
Not classifiable 
 
135 (82) 
22 (13) 
3 (2) 
1 (0.6) 
4 (2) 
? ns ? ns 
Stage 
IA/IIA 
IB/IIB 
III/IV 
 
82 (49) 
28 (17) 
57 (34) 
0.010* ns 0.031* ns 
B symptoms 56 (34) 0.088 ns 0.215 ns 
Bulky disease 90 (54) 0.821 ns 0.025  
IPS 
≤ 3 
> 3 
Missing 
125 (75) 
25 (15) 
17 (10) 
<0.001** 0.037 0.018** ns 
IHC  score 
1 
2 
3 
 
58 (35) 
90 (54) 
19 (11) 
0.001*** ns <0.001*** 0.003 
 
Legend: ns – non significant, *- early stage vs. advanced stage; ** IPS 1 & 2 vs. 
IPS>3; *** - IHC score 1 vs. IHC score 2 & 3 
 
Table 6.9 – Clinical and pathological characteristics of the uniformly treated 
validation cohort of 167 cHL patients. 
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6.8 FIGURES 
 
 
Figure 6.1 - Gene expression study cohort of 130 patients with classical 
Hodgkin lymphoma. Dichotomy of comparison groups according to clinical 
extremes: primary treatment success vs. failure. 
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Figure 6.2 - Hierarchical clustering of 130 gene-expression profiles for patients 
with cHL. Cluster A has been enriched with primary treatment successes and 
Cluster B with both primary treatment successes and failures. Immediately 
below 
the cluster bars, the first multicolored bar indicates sex (red for male and black 
for female), the second bar indicates stage (yellow for limited disease and gray 
for advanced disease), the third bar indicates the type of treatment failure 
(green for no treatment failure, purple for refractory, dark blue for early relapse, 
and light blue for late relapse), and the fourth bar indicates the primary 
treatment outcome (black for failure and red for success). (For details, see 
Tables 6.2 & 6.3) 
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Figure 6.3 - Global test diagrams (probe set influence): Angiogenesis signature 
(25). 
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Figure 6.4 - Global test diagrams (probe set influence): Adipocyte signature 
(22). 
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Figure 6.5 - Global test diagrams (probe set influence): Tumor-associated 
macrophage signature (21). 
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Figure 6.6 - Global test diagrams (probe set influence): Resting monocyte 
signature (20). 
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Figure 6.7 - Importance of Individual Genes for Outcome Prediction. Relative 
importance is shown for 30 annotated probe sets (selected with the use of 
sparse multinomial logistic regression) that were more influential than Ann Arbor 
staging. Among the 27 individual genes exceeding the importance of the best 
clinical variable, age (shown in red), was MMP11. 
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Figure 6.8 – It shows plots of true positive and false positive rates and true 
negative and false negative rates (receiver-operating-characteristic curves) for 
three models that were used for feature selection: gene-expression profiling 
(GEP), a model based on the International Prognostic Score (IPS) for clinical 
variables, and a model combining these two features. This comparison showed 
that the value for the area under the curve (AUC) was highest for the GEP 
model, as compared with the clinical and combined models (0.837 vs. 0.625 
and 0.821, respectively). For comparison with the established IPS, red asterisks 
indicate an IPS of more than 3, as calculated with the use of IPS thresholds (6). 
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Figure 6.9 - Representative Immunohistochemical Analyses for CD68 in Lymph-
Node Biopsy Samples from Two Patients. Upper image shows a sample 
obtained from a patient in the treatment-success group, with few CD68+ 
macrophages, and lower image shows a sample from a patient in the treatment-
failure group, with many CD68+ macrophages. Both patients had the nodular 
sclerosis subtype of CHL. 
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Figure 6.10 - Progression-Free Survival in a validation cohort of 166 patients, 
according to the number of infiltrating CD68+ macrophages in pre-treatment 
lymph-node biopsy specimens. According to the immunohistochemical scoring 
system that was used, a score of 1 indicates less than 5% CD68+ cells, a score 
of 2 indicates 5 to 25%, and a score of 3 indicates more than 25%.  
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Figure 6.11 - Disease-Specific Survival in a validation cohort of 166 patients, 
according to the number of infiltrating CD68+ macrophages in pre-treatment 
lymph-node biopsy specimens. According to the immunohistochemical scoring 
system that was used, a score of 1 indicates less than 5% CD68+ cells, a score 
of 2 indicates 5 to 25%, and a score of 3 indicates more than 25%. 
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Figure 6.12 - Limited-stage disease Specific Survival in a validation cohort of 
166 patients, according to the number of infiltrating CD68+ macrophages in pre-
treatment lymph-node biopsy specimens. According to the 
immunohistochemical scoring system that was used, a score of 1 indicates less 
than 5% CD68+ cells, a score of 2 indicates 5 to 25%, and a score of 3 
indicates more than 25%. 
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Figure 6.13 - Representative Immunohistochemical Analyses for CD68 in 
Lymph-Node Biopsy Samples from three Patients from CHLC. The left image 
shows a sample obtained from a patient in the treatment-success group, with 
few CD68+ macrophages, while the central and right ones show samples from 
patients in the treatment-failure group, with many CD68+ macrophages. All 
patients had the nodular sclerosis subtype of classical Hodgkin´s lymphoma. 
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Figure 6.14 - Overall survival in a validation cohort of 167 patients, according to 
the number of infiltrating CD68+ macrophages in pre-treatment lymph-node 
biopsy specimens.  
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Figure 6.15 - Disease-Free Survival in a validation cohort of 167 patients, 
according to the number of infiltrating CD68+ macrophages in pre-treatment 
lymph-node biopsy specimens.  
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Section 7 : New Biological Predictors of Survival in 
Mantle Cell Lymphoma: The Microenvironment 
 
 
7.1 INTRODUCTION 
Mantle cell lymphoma (MCL) is a clinically aggressive small B cell lymphoma 
characterized by frequent relapses and short survival. Clinical behavior and 
response to therapy vary considerably and are often unpredictable based on 
clinical factors. Prior gene and protein expression studies have demonstrated 
proliferation and TP53 expression as biological mechanisms that strongly 
influence survival (1-3). Recent studies have highlighted the role of the 
microenvironment in follicular lymphoma (FL) demonstrating both T cell and 
macrophage numbers and immuno-architectural patterns that correlate with 
patient survival (4-6). Within most tumors, different T cell subsets co-exist, 
including cells with cytotoxic or regulatory functions and macrophages may 
display marked plasticity including an M2 phenotype promoting tumor growth 
and angiogenesis (7). The significance of the non-malignant cellular 
compartment in the prognosis of patients with MCL is unknown. 
 
 
7.2 AIM 
Assess the prognostic impact of different non-malignant cells in MCL patients 
from a single institution experience using flow cytometry (FCM), gene 
expression profiling (GEP), tissue microarrays (TMA) and 
immunohistochemistry (IHC) of diagnostic lymph node biopsies in combination 
with clinical correlates.  
 
 
7.3 MATERIAL & METHODS 
7.3.1. Patients & Samples Selection 
The study includes two cohorts of patients diagnosed and treated at BCCA. The 
first cohort was studied based on available FCM data from the initial biopsy, 
while the second was organized based on diagnostic biopsies of formalin-fixed 
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paraffin-embedded tissue (FFPET) samples. For both series, the baseline 
clinical characteristics, including the international prognostic index (IPI) 
variables, pathology of their staging bone marrow, and clinical outcomes were 
recorded. 
The Ethical approval to conduct this retrospective review was granted by the 
University of British Columbia–BCCA Research Ethics Board, and informed 
consent was obtained in accordance with the Declaration of Helsinki. 
 
7.3.1.1. Cohort 1 
7.3.1.1.1. Patients & Samples Selection 
Firstly, patients with de novo MCL (122 patients), diagnosed and reviewed by 
BCCA hematopathologists according to the 2008 WHO criteria (8) who had 
FCM analysis performed using their diagnostic biopsies between 1992 and 
2007.  Patients were excluded if they were too frail to receive chemotherapy or 
if FCM was only performed on peripheral blood or bone marrow. For a subset of 
these patients with available diagnostic frozen tissue (28 patients) and 
diagnostic FFPET (53 patients), Affymetrix GEP and IHC & TMA correlative 
studies were performed. 
 
7.3.1.1.2. Monoclonal Antibodies 
Cell suspensions from freshly disaggregated lymph node biopsies were stained 
according to the manufacturer's recommendations with monoclonal antibodies 
conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), or PE-Cy5. 
The routine diagnostic panel comprised the following 7 tubes. Tube 1 contained 
anti-CD45–FITC, anti-CD14–PE, and anti-CD19–PE-Cy5. Tube 2 contained 
isotype controls IgG1-FITC, IgG1/IgG2a-PE, and IgG1–PE-Cy5. Tube 3 
contained anti-CD10–FITC, anti-CD11c–PE, and anti-CD20–PE-Cy5. Tube 4 
contained anti-CD5–FITC, anti-CD19–PE, and anti-CD3 PE-Cy5. Tube 5 
contained anti-CD7–FITC, anti-CD4–PE, and anti-CD8–PE-Cy5. Tube 6 
contained anti-FMC7–FITC, anti-CD23–PE, and anti-CD19–PE-Cy5. Tube 7 
contained anti–kappa-FITC, anti-lambda–PE, and anti-CD19–PE-Cy5. All 
antibodies were obtained from Beckman Coulter (Fullerton, CA) except CD23 
and CD19–PE-Cy 5 which were obtained from Dako North America 
(Carpinteria, CA).  
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7.3.1.1.3. Cell Preparation 
The cell suspensions were generated by disaggregating cells from fresh tissue 
and suspending them in phosphate-buffered solution (Dulbecco PBS; StemCell 
Technologies®, Vancouver, BC) to a lymphocyte concentration approximating 
107/mL. Cell concentration and viability was assessed using Trypan blue 
exclusion dye (Invitrogen®, Carlsbad, CA). A total of 500 000 live cells were 
stained with the appropriate antibody combinations (see above) and incubated 
at 4°C for 30 minutes. Cells were treated with 250 µL Opti-Lyse C containing 
1.5% formaldehyde (Beckman Coulter®) to deplete red cells and fix the 
lymphocytes. The remaining cells were then washed once with IsoFlow sheath 
fluid (Beckman Coulter) before FCM analysis.  
 
7.3.1.1.4. FCM Analysis 
Quantitative fluorescence analysis was performed using a Beckman Coulter 
Cytomics FC500 equipped with a single 488-nm argon laser source. 
FITC/PE/PE-Cy5 emission was collected in FL1/2/4 channels using 
525/575/675 nm bandpass filters, respectively. Daily instrument calibration was 
performed using Flow-Set/Flow-Check beads (Beckman Coulter). List mode 
files were analyzed using FlowJo software, version 8.7.1 (TreeStar, Ashland, 
OR). A minimum of 5000 events was analyzed for all gated populations 
presented. Live cells were gated using forward and side scatter criteria. FCM 
data was analyzed for expression of CD3, CD4, CD8, CD19, CD20, and kappa 
and lambda light chains on cells gating on lymphoid populations. Estimates of 
the non-neoplastic B cells were derived from total CD19/CD20 positive B cells 
excluding the light chain restricted population. 
 
7.3.1.1.5. Gene Expression Analysis 
RNA was extracted from frozen lymph node tissue taken at diagnosis (28 
samples) using  Qiagen Allprep extraction kits (Qiagen Inc., ON, Canada) and 
hybridized to Human Genome U133A Plus 2.0 arrays (Affymetrix®, Santa 
Clara, USA) according to the manufacturer`s protocol with modifications. The 
raw expression data were background corrected, normalized and summarized 
using RMA procedure (9). Gene expression analysis was performed using the 
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statistical computing environment R (10) and Bioconductor packages (11) 
(http://www.bioconductor.org). 
Differentially expressed genes were analyzed by Ingenuity® Pathway Analysis 
(IPA) (Ingenuity® Systems, www.ingenuity.com, Mountain View, CA). Fisher’s 
exact P-values are reported for groups of overexpressed genes in the CD8-high 
group that could be mapped to annotated biological functions. 
 
7.3.1.2. Cohort 2 
7.3.1.2.1. Patients & Samples Selection  
Patients diagnosed and treated at BCCA were included in the study if they had 
MCL with available diagnostic FFPET biopsy and had adequate clinical 
information. 185 patients treated at the BCCA between 1983 and 2004 were 
included. All cases were confirmed to have MCL based on FISH for the t(11;14) 
and/or Cyclin D1 (CCND1) IHC staining. 
 
7.3.1.2.2. Tissue Microarray & Immunohistochemistry 
A TMA was built with duplicate 0.6mm cores from each case using a tissue 
arrayer device (Beecher Instruments®, Silver Spring, MD). Slides from the TMA 
were cut at 4 μm. A haematoxylin and eosin (H&E) stain of the TMA was 
prepared using routine methods. The immunohistochemical stains performed, 
included CD20, CCND1, CD3, CD8, CD4, CD68, CD34, TIA1 (a cytotoxic 
marker), CD163 (monocyte & macrophage marker with M2 phenotype), FOXP3 
(regulatory T cell), PD1 (immune-modulatory T cell), CD57, CD21, TP53 and 
KI67. Standard IHC was performed using a Dako autostainer and the EnVision 
polymer detection system. Antigen retrieval was used for all antibodies and 
included enzyme pre-digestion for CD21 and pressure cooking (5 minutes) for 
the remainder. A variety of buffers were used depending on the specific 
antibody to allow optimal detection of the antigens. The chromogen in all cases 
was diaminobenzidine. TP53 and Ki67 IHC were scored using image analysis 
(VIAS). 
The immuno-stained TMA slides were scored into three expression groups for 
each marker in duplicate according to the percentage of positive cells: (CD3, 
CD4, CD8, CD57, TIA1, CD68, CD163, FOXP3, PD1, Ki67) or as either positive 
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or negative: (CCND1, CD21, TP53). Microvessel density as assessed by CD34 
was scored similarly.  
 
7.3.2. Statistical Analysis 
Univariate survival analysis was performed using the log-rank test and Kaplan-
Meier method using SPSS software, version 17 (12). The primary endpoint 
used was overall survival (OS) defined as the time from diagnosis to death of 
any cause. As initial management included observation only for several 
patients, event-free survival was not assessable. The Cox proportional hazard 
model was used to determine the relationship between survival and the known 
covariates in this study (13). The χ2 test was used to compare patient and 
pathological characteristics. Non-parametric correlations were assessed by the 
Spearman Rank method. Two-sided P values less than 0.05 were considered 
significant.  
 
 
7.4 RESULTS  
 
7.4.1. Cohort 1 
Patients & Samples Selection  
The 122 patients with newly diagnosed MCL had FCM performed on their 
primary biopsy, of which 53 were also part of cohort 2 and were included in the 
tissue microarray. The median age was 67 years (range 22-94) with 69% male. 
91% had advanced-stage disease with 16% having a high IPI (4/5) and 34% a 
high MIPI. Fifty (41%) patients received rituximab (R) as part of initial or 
subsequent therapy. Primary and secondary treatment regimens were markedly 
heterogeneous and included: observation (17 pts); single agent alkylators (48 
pts); CHOP-like with R (39 pts); CHOP-like without R (42 pts); CVP-like (8); 
fludarabine-based (18); gemcitabine-based (9); biological agents (17 pts); 
autologous stem cell transplant (12 pts); allogeneic stem cell transplant (2 pts); 
radiation (33 pts); and therapeutic splenectomy (6 pts) (Tables 7.1 & 7.2). 
The median follow up of the living patients was 30 months. The five-year OS for 
the group was 21%. Use of R was associated with superior survival with a 
median survival of 4.0 years in recipients and 1.6 years in non-recipients. 
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(P=0.001). The median survival by IPI group was as follows: low (39 pts) 3.9 
years, intermediate (62 pts) 2.5 years and high (20 pts) 0.7 years. Median 
survival for 83 patients with data available for calculation of MIPI was as follows: 
low (31 pts) 5.9 years, intermediate (24 pts) 2.3 years and high (28 pts) 0.7 
years (P<0.001). 
 
Non-neoplastic Lymphoid Population 
FCM analysis revealed considerable variation in the composition of the non-
neoplastic lymphoid populations with median CD3 of 12%, (range: 0.6-69%), 
CD4 of 7%, (range: 0-39%), CD8 of 4% (range: 0-28%) and non-tumour B cells 
of 2%, (range: 0-18%) (Figure 7.1). There was no significant difference in the 
composition of the non-neoplastic population according to age, gender, stage, 
IPI, MIPI, LDH, and site of biopsy.  
 
Increased CD8 expression by FCM is associated with inferior survival 
Comparison of OS according to FCM marker expression, dichotomized using 
the median values, revealed an inferior outcome for patients whose biopsies 
contained more than 4% of CD8+ cells (Table 7.3). Further analysis revealed 
optimal separation of survival curves at a cut-point of 8%.  Patients with ≥8% 
CD8+ T cells in their biopsies had a median survival of 1.4 years compared with 
2.8 years for those with <8% CD8 T cells. (P=0.009) (Figure 7.2). The number 
of CD3, CD4 and non-clonal B cells did not correlate with survival.  
 
MIPI, CD8 and Rituximab therapy are independent predictors of outcome 
Multivariate analysis was performed to examine the relationship of tumor CD8+ 
T cell content with covariates known to predict outcome in MCL including IPI 
and prior R therapy. The association was also examined on a subset of patients 
(83 pts) where the MIPI could be ascertained (Table 7.4). This analysis 
confirmed tumor CD8+ T cell content to be a predictor of overall survival, 
independent of MIPI score and prior R therapy. Stratifying cases by R usage, 
revealed a survival benefit for the patients with low CD8+ T cells in their 
biopsies that received R (Figure 7.3).  
The median survival of patients receiving R with low biopsy CD8+ was 4.9 
years compared with a median survival between 1.3-1.8 years for those who did 
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not receive R or with high CD8+ T cell content (P<0.001). Correlation of tumour 
CD8+ T cell content with other clinical and pathological parameters did not 
identify any significant differences between CD8 expression groups in relation 
to age, gender, extent of disease, IPI and MIPI, MCL subtype, blastoid features, 
therapy received and best treatment response (Table 7.5). We can therefore 
surmise that in this cohort, CD8+ cell content is not a surrogate for other clinical 
or biological factors that may influence outcome. 
 
IHC analysis confirmed CD8 outcome correlation and identified the 
number of TIA1+ T cells and CD163+ macrophages to be associated with 
inferior survival 
53 of the 122 cases also belonged to cohort 2 and thus were included in the 
TMA and were analyzed for expression of a wider range of markers (see below) 
including: CD20, CCND1, CD3, CD8, CD4, CD68, CD34, TIA1, CD163, FOXP3, 
PD1, CD57, CD21, TP53 and KI67. Findings for CD8 by IHC were similar to 
those observed using FCM, including the favorable response to R in patients 
with few CD8 positive cells. However, CD8 expression by FCM and IHC were 
only moderately correlated (r=0.497, P=0.01). In addition, an increase in TIA1 
positive cells was also adversely prognostic (median survival 3.7 years for 
lowest expressers versus 1.4 years for highest expressers, P=0.004), and 
correlated with expression of CD8 (r=0.523, P<0.001) suggesting that many of 
CD8 T cells were cytotoxic T cells. Immunohistochemical analysis also 
identified a poor outcome for patients with more than 5% of CD163 positive 
macrophages in their biopsies (P=0.008) with a median survival of less than 
one year. The same tendency was also noted for CD68+ cells (P=0.057). While 
CD68 and CD163 expression were weakly correlated (r=0.35, P=0.01) there 
was no significant association between macrophage markers and CD8 (r=0.23, 
p=0.09 for both) (Figure 7.4 & Table 7.6). 
Ki-67 expression (>35%) was also adversely associated with survival (P=0.028) 
as described previously (14-16). However, there was no correlation between 
Ki67 expression and CD8 expression (P=0.565). CCND1, CD3, CD4, CD34, 
FOXP3, PD1, CD57, CD21 and TP53 expression did not correlate with survival. 
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Cases with high CD8+ T cell content exhibit increased expression of Th1 T 
cell and M1 macrophage genes 
Differences in gene expression between cases with high and low CD8 T cell 
content were surveyed using cases at the extremes: low CD8 group was 
composed of samples with CD8 2% (12 cases) and the high CD8 group was 
composed of samples with CD89% (7 cases). Differential expression was 
measured by a modified t-test and genes were ranked by their P-values 
adjusted using Benjamini-Hochberg multiple test correction (17). Although there 
were no significantly differentially expressed probe sets after the adjustment, 
gene enrichment analysis of the top 200 overexpressed genes using Ingenuity® 
Pathway Analysis (IPA) (Ingenuity® Systems, www.ingenuity.com, Mountain 
View, CA) identified significant overrepresentation of genes involved with an 
inflammatory Th1 response (P=5.7 x 10-7), chemotaxis of T cells (P=2.0 x 10-5) 
and macrophages (P=3.3 x 10-4) (table 7). Moreover, global associative testing 
found significant association between an M1 macrophage gene signature 
(CXCL9, CXCL10, CXCL11, CCL5, CCL19, CTSC, FAS, IL15RA) (18) and 
increased CD8 content of the samples (P=0.023). The Th1 immune response 
genes (19) (IFNG, IRF1, MT1H, GBP1, TNFSF10) similarly showed increased 
expression in the CD8 high cases in comparison to the CD8 low group 
(P=0.006). Using the top 200 differentially expressed genes, the heatmap in 
Figure 7.5, shows unsupervised clustering of samples resulting in complete 
separation of gene expression profiles with high and low CD8 cellular content. 
 
7.4.2. Cohort 2 
Patients & Samples Selection  
The median age was 68 years (range 22-91) with 67% males. 89% had 
advanced-stage disease with 13% having a high IPI (4/5). The IPI predicted OS 
(P=0.0013). 
Twenty seven (15%) patients received R as part of initial or subsequent 
therapy. 
Primary and subsequent therapy included multiple regimens including 
observation (22 pts); single agent alkylators (50 pts); CHOP-like with R (25 pts); 
CHOP-like without R (61 pts); CVP-like (11 pts); fludarabine-based (14 pts); 
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gemcitabine-based (6 pts); biological agents (15 pts); autologous stem cell 
transplant (9 pts); allogeneic stem cell transplant (1 pts); radiation (33 pts); and 
therapeutic splenectomy (6 pts) (Table 7.3).  
The median follow-up of living patients was 5.75 years. The IPI was predictive 
of OS (RR=2.5, 95% CI =1.5-4.4, P=0.002). 
 
Besides KI67 and TP53, IHC analysis showed increased density of CD68+ 
cells and microvessels CD34+ to be significantly associated with inferior 
survival  
All 185 cases were either CCND1and/or t(11;14) FISH-positive. The numbers of 
evaluable cases varied for the different biomarkers (range 157 to 167).  
Both proliferation (quartiles of Ki67+ cells) and TP53 (dichotomized based on 
cut-off >40%) were significant predictors of OS independent of IPI (OS, 
P=0.0002). Cases showing more than 5% infiltrating CD68+ cells (18/185) had 
a 4 years OS of 5% vs. 35% (P=0.0081). These CD68+ cases significantly 
correlated with 12 cases showing more than 5% infiltrating CD163+ cells (x2, 
P=0.001), which by itself also significantly influenced OS (P=0.008) (Figure 7.6 
& Table 7.8).  
Seventeen cases had increased microvessel density (MVD), defined by CD34+ 
cells, which correlated with inferior OS (P=0.02). The cases with increased 
MVD typically had >5% CD163+ cells (a M2 marker) (x2, P=0.05), but not 
increased CD68+ cells.  
Two T cell biomarkers, CD3 and CD8, showed significant correlation with 
survival limited to patients who did not received R. In line with the results 
presented in cohort 1, cases showing more than 5% infiltrating CD8+ cells 
(7/122) had an inferior outcome (P=0.006) and this finding significantly 
correlated with cases showing increased CD68+ and CD163+ (x2=0.01). Cases 
with more than 5% infiltrating CD3+ cells (31/122) had a superior outcome 
(P=0.06) and significantly correlated with CD8+ infiltrating cells (P<0.0001), but 
not with macrophage markers. Multivariate analysis of the entire cohort 2 
including IPI, TP53, Ki67, CD68, CD163, CD34, CD8 and CD3 showed IPI 
(RR=1.8, 95%CI=0.98-3.2, P=0.024), TP53 (RR=2.3, 95%CI=1.3-4.2, P=0.007), 
Ki67 (RR=2.2, 95%CI=1.4-4.1, P=0.018), CD34 MVD (RR=1.8, 95%CI=1.0-3.2, 
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P=0.039) and CD68 (RR=2.2, 95%CI=1.6-4.1, P=0.016) to be independent 
predictors of OS (Table 7.9).  
In 27 patients who received R at some time during their disease course, 
increased CD68+ cells did not significantly affect OS (P=0.1), suggesting that, 
similar to FL, the prognostic effect of LAM may be abolished by R. 
 
 
7.5 DISCUSSION 
While the influence of the tumor microenvironment has been described in other 
lymphoid neoplasms, there is a paucity of information in MCL, perhaps due both 
to the strong correlation of survival with the proliferation rate of the malignant 
cells and to the relative paucity of non-neoplastic immune cells observed during 
routine microscopic analysis of tumor biopsies. However, it is increasingly 
apparent that MCL are not just large collections of autonomously proliferating 
cells occurring in isolation, but interact with a complex microenvironment 
composed of immune cells, microvasculature, mesenchymal cells and other 
stromal elements.  
The difficulty in propagation of MCL cells ex vivo (20), highlights the necessary 
requirement for interaction between tumor cells and non-neoplastic cells, all of 
which comprise the normal lymph node microenvironment. In this study we 
analysed the microenvironmental impact on MCL prognosis using two different 
cohorts (except for 53 patients (17%) in common to both arms of the study) 
ranging across different time & treatment periods; 1993 to 2007 (cohort 1) and 
1983 to 2004 (cohort 2), and using different methodologies. Importantly, in both 
cohorts we found that patients whose tumours exhibited an inflammatory 
reaction characterised by increased cytotoxic T cells and macrophages had 
significantly shortened overall survival independent of the IPI. This represents 
the first study showing a significant impact of non-malignant cells present in 
microenvironment of MCL. The subset of patients with an adverse outcome is 
small, but may represent a group of patients with such a grim outcome that new 
therapeutic regimens are urgently needed.  
A similar finding has been noted in DLBCL, with tumours exhibiting a “host 
response” (HR) signature characterized by increased expression of T cell and 
natural killer cell receptor and activation pathway components, complement 
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cascade members, macrophage/dendritic cell markers, and inflammatory 
mediators experiencing inferior outcome following CHOP chemotherapy (21).  
Importantly, there were interesting differences in the study of both cohorts, with 
apparently conflicting results. In the FCM data, gene expression data on 
selected samples (19 cases) representative of cases with increased vs. 
decreased CD8+ cells shows an association between a M1 macrophage gene 
signature and increased CD8+ cell content suggesting that a cytotoxic and pro-
inflammatory milieu would be advantageous to the MCL cells. In contrast, in the 
TMA & IHC study the adverse prognosis is significantly associated with 
increased CD68+ and CD163+ macrophage cell content, with CD163 a 
previously reported marker of M2 macrophages (22). Notably, the higher CD163 
cell content correlates significantly with increased MVD measured by CD34, 
which is also associated with adverse prognosis. Functionally, M2 macrophages 
are known to be pro-angiogenic. Finally, in the same cohort these markers are 
correlated with increased CD8 cell content. Despite being unable to validate 
CD8 cell content as an independent marker of prognosis, these results are 
consistent with findings from cohort one.  
The impact of tumour cytotoxic T lymphocyte (CTL) content on outcome has 
been previously examined in several other lymphoid neoplasms. While results 
vary between studies, elevated levels of CTLs have been found to be 
unfavorable in Hodgkin lymphoma (HL) (23-26), DLBCL (27, 28), anaplastic 
large cell lymphoma (24), but favorable in FL (29) and DLBCL (30, 31). 
M1-type macrophages or “classically-activated” macrophages support a Th1 
response while “alternatively-activated” macrophages (M2-type) support a Th2 
response and/or regulatory T cell expansions. M1 macrophages are involved in 
inflammatory reactions whereas M2 are involved with tissue remodelling and 
angiogenesis (7). Macrophages in solid tumours have previously been reported 
to show an M2 phenotype, which supports tumour progression and metastasis 
(32). Yet, macrophage polarization in lymphoma is less well defined (33). In the 
current study, there are apparently conflicting results related to the macrophage 
phenotype associated with inferior prognosis between the two cohorts. Similar 
findings have been reported in other lymphomas subtypes, including some 
original work in FL. There are a few hypotheses that may explain these findings. 
Firstly, the methodologies used for analysis of the macrophage phenotypes are 
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not directly comparable, as the IHC markers used in the TMA studies may be 
imperfectly correlated with live gated cells obtained by FC. Moreover, the GEP 
study focussed on the extremes of CD8 counts and may not be representative 
of the entire cohort. Secondly, it has been shown that in-situ macrophages 
cannot be rigidly categorised as distinct M1 vs. M2 phenotypes, which are 
mostly derived based on data from in vitro studies. Often, these cells are neither 
classically nor alternatively activated, but possess aspects of both phenotypes 
consistent with an immune regulatory phenotype determined by tissue stimulus 
and phase-of-inflammation (33). Thirdly, the impact of heterogeneous treatment 
protocols used in these cohorts maybe an important factor explaining the 
divergent results. The two cohorts, organized by the availability of diagnostic 
tissue biopsy blocks and/or FC covers a number of different treatment eras 
including an increased number (34%) of patients receiving rituximab in cohort-1 
in contrast to 15% in cohort-2. In FL, the favourable immune response-1 
signature included genes mainly expressed by T cells and the unfavourable 
immune response-2 signature, mainly expressed by macrophages or follicular 
dendritic cells (4). Validation studies using TMA and IHC have shown increased 
macrophage number in FL biopsies to correlate with both favorable (29, 34), 
unfavorable (5, 35-37) or to have no effect on FL outcomes (38, 39). While 
some of this variability is due to the heterogeneity of treatment protocols 
included in most studies, in the few series with uniformly treated patients the 
use of R abrogated the negative impact of high content of LAM in FL. Indeed, 
studies performed in the R era suggested that biologic prognostic factors may 
be treatment dependent (34, 37, 40). In support of this concept, in vitro studies 
have shown that M2 macrophages phagocytize R-opsonized cells more 
efficiently than M1 cells (41). Thus, in the current MCL study the cases 
analyzed by GEP were enriched for cases treated with R, which might have 
modulated the macrophage phenotype differently than cases studied in cohort 2 
that included fewer cases exposed to R. Furthermore, the high IFN 
microenvironment present in tumors with increased CD8 content may prevent 
significant Th2 T cell or M2 macrophage recruitment within the tumour (41). 
Therefore, the most probable cause of the suboptimal response to R in patients 
with elevated tumour CD8 content could be related to the association of 
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elevated tumor CD8 content and an M1 macrophage gene signature. Similar to 
what has been described in solid tumors and FL treated before the introduction 
of R, the study arm including mostly cases not treated with R showed the worse 
prognosis associated with increased M2 macrophages. 
 
 
7.6 CONCLUSION 
This study provides data that inform for the first time on the prognostic impact of 
the non-neoplastic immune cells in the microenvironment of MCL, independent 
of clinical parameters, proliferation and TP53 While the non-neoplastic cellular 
infiltrate often constitutes only a minor fraction of the tumour mass in MCL, it 
appears similar to other lymphoma subtypes suggesting that the 
microenvironment is important in MCL biology, prognosis and response to 
therapy. We suggest that MCL shows two distinct microenvironments 
depending on the therapeutic regimen used; the first characterized by the 
production of IFN, a Th1 cellular response and M1 macrophages heralds a 
diminished response to R; the second being a more permissive or 
immunosuppressive microenvironment that permits recruitment of M2 
macrophages within the tumor eventually promoting tumour growth and 
inducing angiogenesis. Yet, it portends a more favorable response to R (Figure 
7.8). Expression of CD163, described as a marker of M2 polarized 
macrophages, also predicts survival and correlates with increased 
angiogenesis.  
Further studies are required to prospectively validate these observations and 
define the mechanism by which the immune response negatively influences 
outcome. With time and improvements in our understanding of MCL biology, it 
is possible that treatments targeting the microenvironment may become a 
treatment option in MCL. Inclusion of these biomarkers (and others) into the 
design of prospective clinical trials in MCL would seem prudent. 
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7.7 TABLES 
Clinical features Cases 
Age 67(22-94) 
Male 84(69) 
Stage 
Advanced 99(91) 
Limited 10(9) 
Bulk (≥10cm) 21(20) 
LD>ULN 35(37) 
IPI Group 
Low 39(32) 
Intermediate 63(52) 
High 20(16) 
MIPI 
Low 31(37) 
Intermediate 24(29) 
High 28(34) 
Extranodal sites 
0 29(24) 
1 59(48) 
2 27(22) 
3 or more 7(6) 
Location 
Bone Marrow 80(82) 
Peripheral blood* 22(18) 
Oro/Nasopharynx 14(11) 
Lung/Pleural 7(6) 
Gastrointestinal 7(6) 
Liver 2(2) 
CNS/Ocular 3(2) 
Cutaneous 2(2) 
Other 8(7) 
 
Table 7.1 - Clinical features of Cohort 1 MCL patients. 
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Therapy Initial Subsequent 
Radiotherapy 12 21 
CHOP-like 27 15 
R-CHOP-like 23 4 
R-CHOP then ASCT 11 1 
Allogeneic SCT  2 
CVP-like 3 5 
R-CVP-like  2 
Alkylator 22 26 
Fludarabine based 4 14 
Gemcitabine based  9 
Biological agents  17 
Splenectomy 3 3 
Observation 15 2 
Other 1 10 
No of Therapies 
1 59 (55) 
2 21 (19) 
3 12 (11) 
4 7 (6) 
5 3 (3) 
6 3 (3) 
7 3 (3) 
Best treatment reponse 
CR 36 (30) 
PR 38 (31) 
SD 3 (2) 
PD 19 (16) 
NA 26 (21) 
 
Table 7.2 - Therapy regimens used in Cohort 1 MCL patients. 
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  Cut-point (percent) P 
CD19 84 0.516 
CD20 86 0.435 
CD3 12 0.256 
CD4 8 0.778 
CD8 4 0.015 
Non-clonal B cells 2 0.662 
 
Table 7.3 - Univariate analysis comparing survival outcomes for the highest and 
lowest expression groups by marker. The cut-point is the median percentage 
expression for each marker. Statistical analysis was performed using the log 
rank test. 
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 Univariate Hazard Ratio (95% CI) Multivariate 
IPI group P<0.001 1.147 (0.776-1.698) P=0.491 
MIPI group P<0.001  P<0.001 
Rituximab P<0.001 2.860 (1.701-4.807) P<0.001 
CD8 <8% P=0.009 0.578 (0.339-0.986) P=0.044 
 
Table 7.4 - Multivariate analysis by Cox Regression examining the impact of IPI 
score, MIPI score, rituximab therapy and CD8 content on overall survival of 
patients with mantle Cell Lymphoma. 
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Clinical features CD8 <8 % CD8 ≥ 8% P 
Total 95 27  
Age median (range) 66 (22-94) 66(31-89) 0.819 
Male gender 69 (73) 15 (56) 0.091 
IPI 
Low (0/1) 33 (34) 7 (26) 
0.543 Intermediate (2/3) 50 (52) 14 (52) 
High (4/5) 14 (14) 6 (22) 
MIPI 
Low 27 (41) 4 (22) 
0.347 Intermediate 16 (25) 8 (44) 
High 22 (34) 6 (33) 
Advanced stage 90 (95) 24 (89) 0.279 
Mass > 10cm 16 (17) 5 (19) 0.933 
Increased Lactate Dehydrogenase 26(31) 8(35) 0.818 
Extranodal disease 70 (74) 20 (74) 0.964 
BM involvement 63 (66) 17 (63) 0.746 
PB involvement 24 (25) 7 (26) 0.943 
Pathology features 
Nodular 35 (36) 5 (19) 
0.224 Diffuse 54 (57) 19 (70) 
Mantle Zone 8 (8) 3 (11) 
Blastoid Features 18 (19) 6 (22) 0.670 
Best treatment 
response 
CR 27 (28) 9 (33) 
0.910 
PR 31 (32) 7 (26) 
SD 3 (3) 0 (0) 
PD 14 (15) 5 (19) 
NA 20 (21) 6 (22) 
Table 7.5 - Clinical and pathologic characteristics of patients with MCL biopsies 
according to tumor CD8 T cell content.  Parentheses contain percentages 
except for age as indicated. Statistical analysis was performed using Pearson 
Chi-test, except for age which was assessed by T-test. IPI indicates 
International Prognostic Index; MIPI, Mantle Cell Lymphoma International 
Prognostic Index. BM, Bone Marrow; PB, Peripheral Blood; CR, Complete 
Response; PR, Partial Response; PD, Progressive Disease; SD, Stable 
Disease; NA, Not Available 
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Marker Cut-points (%) P 
CD3 <1, 1-5, >5 0.837 
CD8 <1, 1-5, >5 0.006 
CD4 <1, 1-5, >5 0.774 
CD68 <5, >5 0.057 
CD163 <5, >5 0.008 
CD34 Vessel density/core 0.669 
TIA1 <5, >5 0.004 
FOXP3 <5, >5 0.79 
CD57 <5, >5 0.245 
P53 Image analysis 0.42 
Ki67 Image analysis 0.177 
 
Table 7.6 - Univariate analysis comparing survival outcomes for the highest and 
lowest expression groups by biomarker. Cut-points for each marker were set 
based on the expression patterns observed following an initial inspection of all 
cases. Statistical analysis was performed using the log rank test. 
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Function Annotation P-value Molecules 
Inflammatory 
response 
5.7 x 10-7 AIF1, ANXA1, AOAH, C3, CASP1, CCL5, CCR5, 
CD28, CSF2RA, CXCL9, CXCL10, CXCL11, 
GNLY, IFNG, IGHG1, PLA2G7, SBNO2 
Th1 immune response 
of organism 
4.7 x 10-6  
CCR5, CLEC7A, CXCL10, IFNG, TBX21 
 
Chemotaxis of T 
lymphocytes 
2.0 x 10-5  
CCL5, CCR5, CXCL9, CXCL10, CXCL11, GNLY 
 
Trafficking of 
macrophages 
6.1 x 10-5  
CCL5, CCR5 
 
Chemotaxis of 
mononuclear 
leukocytes 
1.4 x 10-4  
ANXA1, CCL5, CCR5, CXCL9, CXCL10, CXCL11, 
GNLY 
 
Invasion of 
macrophages 
1.8 x 10-4  
CXCL10, IFNG 
 
Chemotaxis of 
phagocytes 
3.3 x 10-4  
CCL5, CD28, CSF2RA, CXCL9, CXCL10, IFNG 
 
 
Table 7.7 - Gene enrichment analysis of the top 200 overexpressed genes 
using Ingenuity® Pathway Analysis (IPA) (Ingenuity® Systems) identified 
significant overrepresentation of genes involved with an inflammatory Th1 and 
macrophages responses. 
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Biomarker # Failed # Positive (%) Comments 
TP53 18 17 (10) >40% of positive cells per core 
Ki67 18 Quartiles % of positive cells per core 
CD68 28 18 (12) >5% CD68
+
 cells per core 
CD163 22 12 (8) >5% CD163
+
 cells per core 
CD34 20 17 (10) >30 luminal CD34
+
 structures per core 
 
Table 7.8 - Significant biomarkers in IHC cohort 2 studied by IHC & TMA, Cut-
points for each marker were set based on the expression patterns observed 
following an initial inspection of all cases. 
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Biomarker 
> 5% CD163
+
 cells 
(12) 
< 5% CD163
+
 cells 
(151) 

2
 (P) 
OS 
0.008 
IPI (2-5) 66% (8) 67% (101) 0.14 0.0013 
Ki67 
(>50%) 
66% (8) 34% (45) 0.06 0.0002 
TP53 (POS) 17% (2) 10% (14) 0.34 0.0002 
CD68 
(>5%) 
42% (5) 9% (13) 0.006 0.008 
CD34 
(POS) 
33% (4) 8% (12) 0.02 0.02 
 
Table 7.9. Clinical and pathologic characteristics of patients with MCL biopsies 
according to tumor CD163 macrophage content.  Parentheses contain number 
of positive cases). Statistical analysis was performed using Pearson Chi-test 
and survival analysis was performed using the log rank test. IPI indicates 
International Prognostic Index 
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7.8 FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 - Composition of the non-neoplastic lymphoid populations within MCL 
microenvironment studied by FCM analysis.  
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Figure 7.2 - Optimal separation of survival curves of CD8+ cells at a cut-point of 
8%  Patients with ≥8% CD8+ T cells in their biopsies had a median survival of 
1.4 years compared with 2.8 years for those with <8% CD8 T cells.  
Years 
CD8<8 (95 pts) 
CD8≥8 (27 pts) 
Median Survival  
CD8 < 8% 2.8 y 
CD8 ≥ 8% 1.4 y 
P=0.009 
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Figure 7.3 -  CD8+ T cell content by FCM stratified by R usage is a predictor of 
OS. It shows a survival benefit for the patients with low CD8+ T cells in their 
biopsies that received R. 
 
 
 
Years 
R+ CD8<8 (38) R+ CD8≥8 (12) 
R- CD8<8 (58) 
 
Median Survival 
R+ CD8 < 8  4.9 y 
R+ CD8 ≥ 8  1.7 y 
R- CD8 < 8  1.8 y 
R- CD8 ≥ 8     1.3 y 
P<0.001  
R- CD8≥8 (15) 
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Figure 7.4 - CD8+ T cell content alone and stratified by R usage,TIA1+ T cell 
content analyzed by IHC & TMA are predictors of OS. There was a significant 
correlation between FCM and IHC & TMA assessment of CD8+ cell content 
(r=0.497, P=0.01for both) 
Correlation 
r=0.497  
P=0.01 
Perce
nt 
CD8 
by 
IHC 
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Figure 7.5 - GEP of MCL cases with high and low CD8 cellular content.  
Unsupervised clustering of samples using the top 200 differentially expressed 
genes shows resulting in complete separation of GEPs. 
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Figure 7.6 --Lymphoma-associated-macrophages infiltrating MCL (cohort 2). 
Most cases had very few LAMs (left image). A subset of cases showed 
increased LAM within the tumour (right image). (Microscope NIKON Eclipse 
E600; Digital Camera Dxm1200). 
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Figure 7.7 - Impact of LAM on MCL prognosis (cohort 2).  Patients with >5% 
CD163+ cells in their biopsies had a median survival of 1.1 years compared 
with 4.0 years for those with <5% CD163+ cells. 
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Figure 7.8 - Dual model for the role of tumor immunity in MCL and its impact on 
survival of patients treated with or without R. In the pre-R era increased 
numbers of vessels (  ) and macrophages M2 type  (   ) represent cases 
where malignant cells edited local immunity to support tumor growth. Yet, when 
R is added to therapy these effects are minored and alternatively, increased 
cytotoxic CD8+ cells (      ) and macrophages M1-type (         ) are characteristic 
of cases resistant to therapy including R. 
     
 
 379 
 
7.9 REFERENCES 
 
1. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VV, Schluger A, et al. p53 
overexpression as a marker of poor prognosis in mantle cell lymphomas with 
t(11;14)(q13;q32). Blood. 1995 Oct 15;86(8):2892-9. 
2. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, 
et al. The proliferation gene expression signature is a quantitative integrator of 
oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 
2003 Feb;3(2):185-97. 
3. Katzenberger T, Petzoldt C, Holler S, Mader U, Kalla J, Adam P, et al. 
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle 
cell lymphoma. Blood. 2006 Apr 15;107(8):3407. 
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et 
al. Prediction of survival in follicular lymphoma based on molecular features of 
tumor-infiltrating immune cells. N Engl J Med. 2004 Nov 18;351(21):2159-69. 
5. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et 
al. Analysis of multiple biomarkers shows that lymphoma-associated 
macrophage (LAM) content is an independent predictor of survival in follicular 
lymphoma (FL). Blood. 2005 Sep 15;106(6):2169-74. 
6. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The 
architectural pattern of FOXP3-positive T cells in follicular lymphoma is an 
independent predictor of survival and histologic transformation. Blood. 2010 Jan 
14;115(2):289-95. 
7. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-
associated macrophages and the related myeloid-derived suppressor cells as a 
paradigm of the diversity of macrophage activation. Hum Immunol. 2009 
May;70(5):325-30. 
 380 
8. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. 
World Health Organization Classification of Tumours of Haematopoietic and 
lymphoid Tissues. Lyon: IARC press; 2008. 
9. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003 
Feb 15;31(4):e15. 
10. RDevelopment C. R: A language and environment for statistical 
computing. Vienna, Austria: R Foundation for Statistical Computing.; 2007. 
11. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et 
al. Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biol. 2004;5(10):R80. 
12. Kaplan E, Meier P. Nonparametric estimation from incomplete 
observations. J Am Stat Assoc. 1958;53:457-81. 
13. Cox D. Regression models and life tables (with discussion). J R Stat Soc, 
B. 1972;34:187-220. 
14. Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 
expression level, histological subtype, and the International Prognostic Index as 
outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002 
Jul;69(1):11-20. 
15. Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, et al. Ki67 and 
PIM1 expression predict outcome in mantle cell lymphoma treated with high 
dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia 
Group B 59909 correlative science study. Leuk Lymphoma. 2008 
Nov;49(11):2081-90. 
16. Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger 
F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus 
guidelines of the pathology panel of the European MCL Network. J Hematop. 
2009 Jun 16. 
 381 
17. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A 
Practical and Powerful Approach to Multiple Testing. Journal of the Royal 
Statistical Society Series B (Methodological). 1995;57(1):289-300. 
18. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling 
of the human monocyte-to-macrophage differentiation and polarization: new 
molecules and patterns of gene expression. J Immunol. 2006 Nov 
15;177(10):7303-11. 
19. Rogge L, Bianchi E, Biffi M, Bono E, Chang SY, Alexander H, et al. 
Transcript imaging of the development of human T helper cells using 
oligonucleotide arrays. Nat Genet. 2000 May;25(1):96-101. 
20. Lai R, McDonnell TJ, O'Connor SL, Medeiros LJ, Oudat R, Keating M, et 
al. Establishment and characterization of a new mantle cell lymphoma cell line, 
Mino. Leuk Res. 2002 Sep;26(9):849-55. 
21. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. 
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes 
including one characterized by host inflammatory response. Blood. 2005 Mar 
1;105(5):1851-61. 
22. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. 
Regulation of scavenger receptor CD163 expression in human monocytes and 
macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000 
Jan;67(1):97-103. 
23. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, 
Baars JW, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's 
disease. Blood. 1997 Feb 15;89(4):1376-82. 
24. ten Berge RL, Oudejans JJ, Dukers DF, Meijer JW, Ossenkoppele GJ, 
Meijer CJ. Percentage of activated cytotoxic T-lymphocytes in anaplastic large 
cell lymphoma and Hodgkin's disease: an independent biological prognostic 
marker. Leukemia. 2001 Mar;15(3):458-64. 
 382 
25. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory 
T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical 
Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin 
Pathol. 2007 Dec;128(6):958-65. 
26. Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, et al. 
Prognostic significance of new immunohistochemical markers in refractory 
classical Hodgkin lymphoma: a study of 59 cases. PLoS One. 2009;4(7):e6341. 
27. Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, 
et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary 
nodal diffuse large B-cell lymphomas. Leukemia. 2004 Mar;18(3):589-96. 
28. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, 
Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but 
not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell 
lymphoma. Br J Haematol. 2007 May;137(4):364-73. 
29. Alvaro T, Lejeune M, Salvado MT, Lopez C, Jaen J, Bosch R, et al. 
Immunohistochemical patterns of reactive microenvironment are associated 
with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006 
Dec 1;24(34):5350-7. 
30. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic 
cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. 
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6666-72. 
31. Linderoth J, Eden P, Ehinger M, Valcich J, Jerkeman M, Bendahl PO, et 
al. Genes associated with the tumour microenvironment are differentially 
expressed in cured versus primary chemotherapy-refractory diffuse large B-cell 
lymphoma. Br J Haematol. 2008 May;141(4):423-32. 
32. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. 
Macrophage polarization in tumour progression. Semin Cancer Biol. 2008 
Oct;18(5):349-55. 
 383 
33. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, et 
al. Transcriptomic analyses of murine resolution-phase macrophages. Blood.  
Dec 22;118(26):e192-208. 
34. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. 
A high tumor-associated macrophage content predicts favorable outcome in 
follicular lymphoma patients treated with rituximab and cyclophosphamide-
doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007 Oct 1;13(19):5784-9. 
35. Alvaro T, Lejeune M, Camacho FI, Salvado MT, Sanchez L, Garcia JF, et 
al. The presence of STAT1-positive tumor-associated macrophages and their 
relation to outcome in patients with follicular lymphoma. Haematologica. 2006 
Dec;91(12):1605-12. 
36. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in 
follicular lymphoma: importance of markers of immune response. Leuk 
Lymphoma. 2007 Dec;48(12):2403-11. 
37. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser 
F, et al. High numbers of tumor-associated macrophages have an adverse 
prognostic value that can be circumvented by rituximab in patients with follicular 
lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008 
Jan 20;26(3):440-6. 
38. Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press 
OW, et al. Prognostic value of regulatory T cells, lymphoma-associated 
macrophages, and MUM-1 expression in follicular lymphoma treated before and 
after the introduction of monoclonal antibody therapy: a Southwest Oncology 
Group Study. Ann Oncol.  Jun;21(6):1196-202. 
39. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, 
et al. Gene-expression and immunohistochemical study of specific T-cell 
subsets and accessory cell types in the transformation and prognosis of 
follicular lymphoma. J Clin Oncol. 2007 Feb 1;25(4):390-8. 
 384 
40. de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, 
Heisterkamp S, et al. Impact of the tumor microenvironment on prognosis in 
follicular lymphoma is dependent on specific treatment protocols. 
Haematologica. 2009 Jan;94(1):70-7. 
41. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 
macrophages phagocytose rituximab-opsonized leukemic targets more 
efficiently than m1 cells in vitro. J Immunol. 2009 Apr 1;182(7):4415-22.~ 
 
 385 
Section 8: New Biological Predictors of Survival in 
Primary Mediastinal Large B Cell Lymphoma: The 
Microenvironment 
 
 
8.1 INTRODUCTION 
Primary Mediastinal large B Cell Lymphoma (PMBCL) is a distinct lymphoma 
entity arising in the mediastinum from putative thymic B cells (1). It is composed 
of medium to large-sized B cells with abundant cytoplasm, ovoid nuclei and is 
characteristically associated with fine, background fibrosis (Figure 8.1). It 
accounts for 2-4% of all non-Hodgkin-lymphoma and occurs predominantly in 
young adults with a female predominance. It is locally aggressive, but less likely 
to extend beyond the mediastinum. The therapy is similar and outcome superior 
to nodal DLBCL in most series with a survival plateau after 2.5 years (2, 3). Yet, 
clinical criteria, such as the IPI, imprecisely predict the response to therapy (4).  
PMBCL shares histological and gene expression features with both DLBCL and 
Classic Hodgkin Lymphoma (CHL) (5, 6). Like DLBCL, PMBCL may show loss 
of expression of Major Histocompatibility Class II (MHC II) antigens (7). The 
MHC II genes (HLA-DR, HLA-DQ, HLA-DP, HLA-DM and HLA-DO) are located 
in a single locus on chromosome 6p. Expression of all MHCII genes is regulated 
by the MHCII master transactivator, MHCIITA, and its expression is usually 
highly correlated with MHCII expression. Class II MHC antigens are 
constitutively and concurrently expressed in antigen-presenting cells, including 
monocytes, macrophages, dendritic cells and B cells responsible for presenting 
antigens and stimulation of T cells invoking an immune response against 
peptides (8). 
In PMBCL and most DLBCLs, mechanisms of MHCII loss of expression are 
largely unknown, but loss of HLA-DR and related antigens may constitute a 
mechanism by which tumour cells escape immunosurveillance. Indeed, the 
association of loss of MHCII molecules on high-grade lymphoma cells has been 
described since the 1980s (9, 10) including an impact on patient prognosis (11). 
Recently, MHC class II genes enrich in one of the 4 gene expression signatures 
associated with clinical outcome in a large study of 240 DLBCLs as reported by 
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the Leukemia and Lymphoma Molecular Profiling (LLMPP) consortium in 2002 
(12). In subsequent studies, these same authors also showed a significant 
reduction in the number of tumour infiltrating CD8+ lymphocytes to be 
associated with the lack of MHCII proteins in a small subset of DLBCLs (7). 
Similarly, a minority (12%) of a series of 42 PMBCLs reported by the LMMPP 
showing loss of MHCII gene expression had a worse survival(13). 
 
 
8.2 AIM 
The aim of our study was to validate HLA-DR protein expression as a 
prognostic biomarker in a larger cohort of PMBCLs and correlate it with the 
immune response using immunohistochemistry (IHC). New, easily measured 
biomarkers are needed to better stratify patients and to evaluate relevant 
candidate pathways for therapy. 
 
 
8.3 MATERIALS & METHODS 
8.3.1. Patient Characteristics 
The BCCA is the primary referral center for patients diagnosed with lymphoid 
malignancies in the province of British Columbia, Canada. 103 patients 
diagnosed with PMBCL at the BCCA between 1980 and 2005 had available 
formalin-fixed paraffin-embedded tissue (FFPET) diagnostic biopsies were 
included. All patients were treatment-naive and therapy included multi-agent 
chemotherapy CHOP (cyclophosphamide, doxorubicin, vincristine and 
prednisone) in 38 patients, or CHOP-like regimens (ACOP, CEOP, CVPP, ECV 
and VACOPB) in 65 patients. Rituximab (R) and radiation were added in 18 
patients and 25 patients, respectively. 12 patients received bone marrow 
transplant at relapse. Patients were aged 16 to 61 years and were HIV-
negative. Approval to this study was given by the University of British Columbia 
– BCCA Research Ethics Board. All biopsies were reviewed and classified 
according to the 2008 WHO Lymphoma Classification (1). 
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8.3.2. Tissue Microarray Construction (TMA) 
Duplicate 0.6mm cores were used to construct a TMA using a tissue arrayer 
device (Beecher Instruments®, Silver Spring, MD) (Figure 8.2). Slides from the 
TMA block were cut at 3-4 microns. 
 
8.3.3. Immunohistochemistry 
An H&E stain of the TMA was prepared using routine methods. 
Immunohistochemistry (IHC) was performed routinely for CD20 (clone L26), 
HLA-DR (IgG2b), CD3 (polyclonal Cell Marque/Novo Mix), CD4 (clone 4B12), 
CD8 (clone C8/144B), CD57 (clone NK-1), CD68 (clone KP1), TIA1 (clone 
2G9A10F5) and Granzyme B (clone GrB-7) using a Dako® autostainer and the 
EnVision polymer detection system. Antigen retrieval was used for all antibodies 
using pressure cooking (5 minutes). A variety of buffers were used depending 
on the specific antibody to allow optimal detection of the antigens. The 
chromogen in all cases was diaminobenzidine. 
 
8.3.4. Scoring 
HLA-DR expression was assessed combining both intensity (1 to 3) and 
percentage of positive cells (0 to 100%), using a Histoscore – (HScore) (14). All 
the other markers were quantified counting the number of positively-stained 
cells compared to the number of malignant cells per core. For each marker 
results were dichotomized about the median and correlated with overall 
survival.  Further analysis revealed optimal separation of survival curves at the 
following cut-off points:  5% for CD4, CD57 and Granzyme B; 10% for TIA1; 
25% for CD3, CD8 and CD68. 
 
 
8.3.5. Statistics & Survival Analysis 
 Analysis was performed using Pearson Chi-test. Overall survival (OS) was 
defined as the interval from date of diagnosis until death from any cause. 
Progression free survival (PFS) was defined as the interval from date of 
diagnosis until death from disease Survival estimates were calculated using the 
Kaplan-Meier method (15) and multivariate analysis using the proportional-
hazards regression  Model (16) 
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8.4 RESULTS 
There were 92 suitable cases for analysis. The median follow-up of the living 
patients was 10 years. Estimated 5-year OS and PFS was 85% and 73%, 
respectively. The IPI was significant for OS (P=0.042), but not PFS (P=0.17) 
(Figure 8.3). In total, 32 cases showed strong cytoplasm membrane HLA-DR 
staining (mean HScore of 253; range 100-300; standard deviation 80) while 60 
cases showed decreased expression of the protein (mean HScore 5.5; range 0-
80; standard deviation 17) (Figures 8.4 & 8.5). Patients with strong cytoplasm 
membrane HLA-DR staining and patients with decreased expression of HLA-
DR- had 10-year OS of 86% vs. 61% (P=0.006) and 2-year PFS of 78% vs. 
53% (P=0.018), respectively (Figure 8.5). The distribution of clinical and 
pathology variables between cases with strong HLA-DR+ and cases with 
decreased HLA-DR expression were evenly matched (Table 8.1). A Cox 
multivariate model established both HLA-DR status and IPI as independent 
predictors of OS (RR=0.3, 95%CI=0.12-0.75, P=0.01; RR=2.9, 95%CI=1.2-6.9, 
P=0.06, respectively). HLA-DR expression correlated significantly with 
increased content of all analyzed T cell markers, especially CD3, CD8 and TIA1 
(x2, P<0.001), but not with macrophage content (CD68) (Table 8.2). Clinical and 
pathological characteristics are summarized in Table 8.1 & 8.2.  
Of all non-malignant markers, only TIA1+ cell content significantly correlated 
with survival. Of the 83 cases with interpretable staining, 43 had more than 10% 
of infiltrating TIA1+ cells and 40 had less, with 10-year OS of 83% vs. 57% 
(P=0.0014) and 2-year PFS of 76% vs. 50% (P=0.014) (Figures 8.6 & 8.7), 
respectively. In multivariate analysis, including IPI and HLA-DR and cytotoxic 
markers, only TIA1 status was an independent predictor of OS (RR=0.3, 
95%CI=0.11-0.63, P=0.003). 
 
 
8.5 DISCUSSION 
The impact of tumour immunity in both low and high-grade B cell lymphomas 
and the relationship to prognosis has been recently highlighted with an ever 
increasing number of reports using both gene and protein expression profiling 
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(17-19). MHCII loci are one of the key elements defining immune reactions 
including immunosurveillance and anti-tumoral immune responses. Thus, the 
association with prognosis has been recognized early on in cancer research (9, 
10). HLA-DR is the member of the MHCII family whose protein expression has 
been used in most studies (11). It is one of the mostly highly expressed MHCII 
proteins and IHC antibodies have been widely used for years in routine practice 
in different areas of Haematopathology. Easily measured and robust biomarkers 
are essential so that their use can be incorporated into routine practice. 
Moreover, tumour immunity pathways are increasingly relevant not only in 
lymphoma, but also in solid tumors (20) as this may become an important 
pathway to target by therapy.  
In this study we validated the impact of HLA-DR expression in PMBCL using 
FFPET diagnostic biopsies of patients treated in a single institution. HLA-DR 
loss is a common event in DLBCL involving immune-privileged sites such as 
testis and the central nervous system (21).  In these anatomic sites, MHCII loss 
has been reported in more than a half of the cases and it is frequently 
associated with deletions in the MHCII loci involving chromosome 6p. In non-
immune-privileged DLBCL, loss of MHCII has been variably reported, ranging, 
from 10% to more than 50% of cases, depending on the techniques used (7, 11, 
13, 22, 23) Most recent gene and protein expression studies report the loss of 
HLA-DR to occur in approximately 10% of the cases. Yet, in both non-immune-
privileged DLBCL and PMBCL, the mechanism of reduced MHCII expression 
remains unclear. Genetic deletions in the MHCII locus or of its transactivator, 
MHCIITA, as well epigenetic alterations, such as hypermethylation of its 
regulators, do not seem to account for the loss of expression (7, 24). In PMBCL, 
one interesting candidate mechanism relates to the common high expression of 
PDL1 and PDL2 (programmed cell death 1 & 2 ligands) by the tumour cells (6). 
Both genes are located at 9p24 in a region often amplified in PMBCL. These 
genes encode members of the B7 family, ligands to PD1 receptor on T cells. 
They have been reported to have regulatory effects on T cell responses, 
including inhibition of tumour immunity (25). Recently, our group has 
demonstrated one prominent mechanism responsible for this finding as 
genomic CIITA breaks are highly recurrent in PMBCL (38%), and although the 
fusion partners are promiscuous, 50% involve in-frame gene fusions with PDL1 
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and PDL2.(26). Functionally CIITA gene fusions promote HLAII down-regulation 
and over-expression of PDL1 and PDL2 and were shown to be associated with 
inferior prognosis. 
Loss of HLA-DR expression has been associated with decreased survival in 
cohorts of treated patients pre and post addition of R to chemotherapy (11, 13, 
27). Although in the most recent reports the complete loss of expression defined 
cases with markedly inferior prognosis, even when the whole cohort was 
divided in quartiles, the impact on survival was still significant (7). This suggests 
that  a decrease in HLA-DR expression is associated with survival as a 
continuous variable. Similarly, in PMBCL, only a minority of the cases showed 
complete loss of MHCII expression and the overall survival of this subset of 
patients was poor. In agreement with our findings, poor patient survival 
correlated with incremental decreases in MHCII expression in a series of 40 
patients (13).  
Thus in the current study we used a method of protein expression assessment 
that combines both intensity and percentage of positive cells, such as the 
Histoscore (HScore) (14). Applied on a TMA section it allows the comparison of 
a large series of cases to be assessed using a consistent 
immunohistochemistry technique. The HScore enabled us to distinguish cases 
with HLA-DR bright cytoplasm membrane expression in the majority of cells 
from those cases with only a minor subset of HLA-DR+ tumor cells as well as 
cases with diminished expression of the marker. These latter cases were not 
only significantly associated with worse survival (independent of the IPI), but 
also significantly correlated with decreased T cells assessed using different 
markers. Moreover, CTL content, measured by the expression of TIA1 antibody 
was also significantly and independently associated with prognosis in this 
series. These results strongly suggest in PMBCL that decreased expression of 
HLA-DR is an immune editing mechanism allowing tumor cells to escape T cell 
surveillance and concurs with novel mechanisms recently described (26). 
The analysis of prognosis using patients with heterogeneous treatments has 
been suggested to be responsible for the controversy in studies that address 
the role of the microenvironment impact on prognosis (28). In this series, 
spanning almost two decades, several chemotherapy protocols were used. 
Given that PMBCL is a rare disease, it would be difficult to achieve statistical 
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significance using uniformly treated patients. In addition to chemotherapy, 
radiation was included in the treatment package in 27 cases and 18 patients 
also received R. Interestingly, for those patients receiving radiation (despite the 
low number) both HLA-DR and TIA1 markers did not impact significantly on 
survival (P=0.28 & P=0.19, respectively) when compared with the patients that 
did not receive radiation (P=0.0074 for both). Radiation affects not only tumoral 
cells, but also impacts the microenvironment. In murine models, radiation 
decreases the numbers of all lymphocyte subsets, but differentially affects  
some T cell subsets, as immunosuppressive regulatory T cells (Tregs) have 
been shown to be more resistant to radiation than other T cell subtypes (29). In 
human lymphoma, Tregs are increased in number and associated with 
suppression of anti-tumoral immunity promoting tumoral growth (30, 31). Yet, in 
PMBCL Treg cell content assessed by the expression of its master transcription 
factor, FOXP3, did not have an impact on prognosis (unpublished observation, 
data not shown). 
 
 
8.6 CONCLUSION 
In this study, we validated the negative prognostic impact of loss of HLA-DR 
expression by neoplastic B cells in PMBCL patients treated with multi-agent 
chemotherapy in a single institution experience. Loss of HLA-DR expression 
correlated with decreased numbers of infiltrating benign T cell populations, 
especially CD8+ and TIA1+ cells. Significantly, decreased CTL content 
correlated independently with inferior survival (Figure 8.8). This study shows 
loss of immunogenicity and cultivating immune privilege are key oncogenic 
mechanisms in PMBCL and suggests that specific therapies focused on this 
pathway may benefit patients. Yet, validation of both markers in a large cohort 
of patients receiving uniform, standard of care therapy is needed. 
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8.7 TABLES 
Feature 
Strong 
HLA-DR # (%) 
Decreased 
HLA-DR # (%) 
Total  
(%) 
p-value 
(χ2) 
Number 32 (35) 60 (65) 92 (100) - 
Clinical Features     
Median age (y) 34 36 - 0.2 
Female (%) 56 48 - 0.5 
Median follow-up (y) 12.5 9.2 - 0.5 
IPI Group 1 (0/1) 15 (47) 25 (42) 40 (44) 
0.6 Group 2 (2/3) 15 (47) 27 (45) 42 (46) 
Group 3 (4/5) 2 ( 6) 8 (13) 10 (11) 
Treatment regimen     
CHOP 7 (22) 21 (35) 28 (30) 
0.5 
CHOP-like 25 (78) 39 (65) 64 (70) 
With rituximab® 4 (13) 13 (28) 17 (19) 0.4 
With Radiation 10 (31) 15 (25) 25 (27) 0.6 
Treatment Response     
CR 30 (94) 45 (75) 75 (82) 
0.09 PR 1(3) 8 (13) 9 (10) 
NR 1 (3) 7 (12) 8 (9) 
Pathology Features     
Non-malignant  
cell content 
    
↑CD3(%) 19 (59) 14 (24) 33 (36) 0.001 
↑CD4(%) 14 (45) 10 (17) 24 (27) 0.006 
↑CD8(%) 15 (48) 4 (7) 19 (21) <0.001 
↑CD57(%) 17 (55) 11 (19) 28 (32) 0.001 
↑TIA1(%) 23 (77) 20 (38) 43 (52) 0.001 
↑GZB(%) 13 (43) 11 (19) 24 (27) 0.023 
↑CD68((%) 12 (38) 15 (25) 27 (29) 0.24 
 
Table 8.1 - Distribution of clinical and pathology variables between cases with 
strong HLA-DR+ and cases with decreased HLA-DR expression. IPI = 
International Prognostic Index score, CR = complete remission, PR = partial 
remission, NR = no response. 
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Table 8.2 - Distribution of different T cell subsets between cases with strong 
HLA-DR+ and cases with decreased HLA-DR expression. Statistical analysis 
was performed using Pearson Chi-test and survival analysis was performed 
using the log rank test.  
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Table 8.3 - Distribution of clinical and pathology variables between cases with 
cases with increased TIA1+ cells (>10%) and cases with decreased TIA1+ cells 
(<10%). Statistical analysis was performed using Pearson Chi-test and survival 
analysis was performed using the log rank test. IPI indicates International 
Prognostic Index. 
. 
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8.8 FIGURES 
 
 
Figure 8.1- Primary Mediastinal B-Cell Lymphoma (PMBCL) infiltrating the 
thymus (left image). It is composed of medium to large-sized cells with 
abundant cytoplasm, ovoid nuclei and is characteristically associated with 
background fibrosis (right image). Olympus BX40 / Nikon Elipse®; Digital 
Camera Dxm1200; 10x (left) & 400x (right). 
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Figure 8.2 - Primary Mediastinal B-Cell Lymphoma (PMBCL) Tissue Microarray 
duplicate 0.6mm cores of paraffin embedded diagnostic biopsies. Olympus 
BX40 / Nikon Elipse®; Digital Camera Dxm1200; 40x. 
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Figure 8.3. - Overall Survival (left) and Progression Free Survival (right) based 
on IPI groups. IPI: International Prognostic Index. 
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Figure 8.4 - Representative immunohistochemical images from two patients for 
HLA-DR expression. The top images show a sample with strong cytoplasmic 
membrane HLA-DR expression and the bottom ones show loss of HLA-DR 
expression by the malignant cells. Olympus BX40 / Nikon Elipse®; Digital 
Camera Dxm1200; 40x & 400x.. 
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Figure 8.5 - Overall Survival (left) and Progression Free Survival (right) based 
on strong cytoplasmic membrane HLA-DR expression (HLA-DR POS) vs. 
decreased of HLA-DR expression by the malignant cells (HLA-DR NEG). 
Olympus BX40 / Nikon Elipse®; Digital Camera Dxm1200; 40x. 
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Figure 8.6 - Representative immunohistochemical images from two patients (left 
and right images) for TIA1+ cell content and HLA-DR expression. On the left is 
shown increased TIA1+ cell infiltration (top and middle images) associated with 
strong cytoplasmic membrane HLA-DR expression (bottom). On the right, there 
is low TIA1+cells infiltration (top and middle images) and loss of HLA-DR 
expression by the malignant cells (bottom). Olympus BX40 / Nikon Elipse®; 
Digital Camera Dxm1200; (top images 40x; middle & bottom images 400x). 
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Figure 8.7 - Overall Survival (left) and Progression Free Survival (right) based 
on increased infiltration of TIA1+ cells vs. decreased infiltration of TIA+ cells 
(cut off value 10%). Olympus BX40 / Nikon Elipse®; Digital Camera Dxm1200; 
400x. 
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Figure 8.8 - Immuno-surveillance in PMBCL. This study suggests loss of 
immunogenicity and immune-surveillance are key mechanisms in the response 
to treatment of PMBCL patients. Decreased HLA-DR expression correlated with 
decreased numbers of infiltrating benign T cell populations, especially cytotoxic  
TIA1+ cells, and both features correlated independently of clinical parameters 
with inferior survival. 
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Section 9: Conclusions 
    
9.1 SUMMARY 
Human B cell lymphomas comprise over 85% of lymphoid neoplasms and 
contrary to most other cancers, the incidence of lymphoma is increasing 
worldwide. Non-Hodgkin lymphomas (NHL) are made up of many different 
subtypes having heterogeneous clinical behaviour, but in most cases clinical 
outcome is insufficiently predicted using the currently available clinical 
prognostic indices used to risk-stratify patients (1). Prognostic and in particular 
predictive biomarkers are needed for risk stratification and planning more 
targeted therapies. The identification of novel biomarkers will be required to 
personalize treatments in NHL and identify critical targets for innovative novel 
therapies. Prior to the routine use of new therapies, companion diagnostics will 
be required at diagnosis to identify at-risk patients who will require alternative, 
more targeted therapy. 
FL is the second most common lymphoma worldwide and the most frequent 
indolent small B cell lymphoma. The clinical course if highly variable and there 
are no agreed upon standard treatment approaches. Histologic transformation 
represents a dominant clinical event in the course of disease, heralding 
aggressive behaviour and shortened survival. Thus, the identification of 
clinically useful biomarkers that predict both overall survival and risk of 
transformation are needed in order to identify at-risk patients who might benefit 
from alternative treatment approaches. At the initiation of this thesis work, there 
were no consistent clinical markers that could predict with accuracy the 
likelihood of survival and the probability of transformation. New genome-wide 
analysis platforms were just introduced including gene expression profiling and 
aCGH (2).  We hypothesized that these unbiased genome-wide platforms might 
be of value to identify novel biomarkers, including candidate oncogenes and 
tumour suppressor genes that might be contained within genomic gains and 
losses, respectively. Moreover, the use of these analysis tools might identify 
candidate loci wherein important driver mutations might be found. The planned 
analyses in this thesis held the promise of improving our understanding of 
lymphomagenesis and at the same time allowing the identification of clinically 
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useful biomarkers that might inform on survival and transformation risk in FL. 
Ultimately we hoped that novel insights into FL pathogenesis would facilitate the 
development and implementation of new targeted therapies.  
As I started my PhD thesis, tissue microarrays (TMA) were just beginning to be 
used and offered an inexpensive and ideal platform for both discovery and 
validation of large cohorts of clinical cases, while reducing experimental noise 
and reagent consumption. TMAs allowed for the analysis of biomarkers using 
diagnostic FFPET samples based on IHC, FISH and ISH techniques. TMA 
technology opened up the possibility of surveying large numbers of samples 
from pathology archives of diagnostic FFPET and is the platform that was 
ideally suited to test and validate new biomarkers related to lymphoma 
prognosis. This innovation happened about the same time as insights into the 
role of the tumoral microenvironment were being recognized (3). A gene 
expression profiling study was just published in FL, requiring that these gene 
expression changes be validated using other orthogonal technologies such as 
TMA and IHC. Furthermore, these translational research techniques offered the 
possibility to determine the cells responsible for specific gene expression and 
the real possibility of extending these studies to several other common 
lymphoma subtypes. 
 
 
9.2 DISCUSSION & CONCLUSIONS 
9.2.1. Genomic Mechanisms of FL Transformation into DLBCL 
Chapter 2 details the search for biological mechanisms underlying the 
transformation of FL. The comparison of biopsy material from the same 
individual pre and post-transformation was defined as the prerequisite for clear 
understanding the molecular mechanisms driving the event. Until recently, most 
studies have revealed a number of recurring cytogenetic abnormalities (4-11) 
each one occurring in a small subset of cases, highlighting the molecular 
diversity of transformation. The combination of global gene expression analysis 
supplemented with genomic copy-numbered analysis may provide new and 
unbiased insights into the mechanisms of FL transformation. 
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In the current study we used a combination of genome-wide microarray 
techniques including different commercially available expression microarrays 
platforms as well as the Vancouver BCCRC arrayCGH based platform (SMRT 
arrays, aCGH). We studied histologic transformation using two different 
strategies: (1) a series of paired fresh snap frozen lymph node biopsies 
retrieved pre and post the transformation and, (2) a cohort of FFPET composite 
lymphomas with FL and DLBCL diagnosed in the some lymph node 
representing clonally related early transformation events.  
In the first study we found using GEP a short list of 18 new genes not previously 
reported in association with transformation. Importantly, the correlation between 
these GEP results with aCGH was complex and favoured that mechanisms 
other than copy number alterations were responsible for deregulated gene 
expression in FL transformation. Interestingly, genomic copy number complexity 
was not always associated with the more aggressive disease favoring sub-clone 
selection and evolution from a common malignant ancestral clone in contrast to 
clonal evolution resulting from stochastic genetic hits accumulated over time 
(12, 13). Furthermore, given this heterogeneity and the complex relationship 
between genomic aberrations and GEP, this small study indicated a much 
larger number of cases will need to be studied to fully appreciate the specific 
genetic events responsible for transformation, especially if using whole-genome 
analysis. 
The second study validated the recently described methodology of extracting 
RNA of sufficient quantity and quality from FFPET diagnostic samples 
producing successful and meaningful GEP results (14).  Using composite 
lymphomas, we showed three potential different mechanisms were present as 
early events of FL transformation. One distinct pattern was associated with a 
proliferation signature as previously reported (15). Despite the low number of 
genes, distinctive gene sets characterizes the other two clusters with several 
good candidate genes for diagnostic and eventual therapeutic use. Further 
cases are needed and mandatory to validate these results. 
 
9.2.2. Biological Prognostic Markers in Lymphoma 
The importance of microenvironment and non-malignant cells within human 
tumours is not a recent finding. Rudolf Virchow first suggested it more than one 
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hundred years ago (16, 17) and Paul Erlich proposed the concept of tumoral 
immunosurveilance (18). Since then, tumoral immunity has been shown to have 
different contexts. Along with the better studied anti-tumoral response there are 
several different mechanisms by which tumoral immunity promotes tumoral 
growth, so called cancer immunoediting, as the tumour sculpts its own immunity 
promoting its growth and progression (19). 
In lymphoma, the microenvironment has well been recognized since the early 
descriptions of these diseases, such as Hodgkin lymphoma, where it is a crucial 
& required feature for its diagnosis. Similarly, FL lymphoma retains many of the 
morphological features of the normal follicle suggesting intense cross talk 
between malignant B cells and non-malignant immune cells, including T cells, 
Follicular Dendritic Cells (FDCs), macrophages, mast cells and endothelial 
cells. Important survival and trophic signals from FDCs/macrophages and T 
cells reach the neoplastic B cells, which are highly dependent on these signals. 
These data in-part help explain the difficulty of establishing FL cell lines without 
cytokine stimulation or feeder layers (20). 
In chapter 3 we used diagnostic lymph nodes of FL patients treated uniformly at 
BCCA and tested the impact of morphological features of microenvironment, 
such as architectural distribution and cell content of non-malignant cells. We 
used routine FL diagnostic lymph node biopsies arrayed in TMA and stained 
with different antibodies. We provided compelling new data that supported a 
role for benign macrophages, microvessels and Tregs in predicting outcome in 
aggressively treated FL patients and further validated the recent gene 
expression profiling data highlighting the importance of non-neoplastic cells in 
determining prognosis in FL. Notably and for the first time we showed two 
biomarkers, the architectural pattern of Tregs and the microvessel density as 
measured by TVD90 to significantly predict risk of transformation. This cohort 
comprised two very important and rare advantages; the patients were all treated 
uniformly and had very long follow-up. In a disease with many different 
treatment options used in clinical practice, most reports in the literature of FL 
show heterogeneous treatment modalities within and between different series. 
This has been considered responsible for the controversy in the published 
literature as to the prognostic significance of a number of biomarkers (21-31). 
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Following these encouraging results in FL we decided to expand the study of 
the microenvironmental impact on prognosis to a number of other lymphoma 
types. 
Classical Hodgkin lymphoma (CHL) was one ideal candidate as its most 
characteristic and defining features is the predominance of reactive cells in the 
tumour microenvironment, which largely outnumber the malignant ones (32). 
CHL is one of the success stories of oncology as roughly 80% of all patients are 
currently cured; yet about 20% of patients with advanced-stage disease are still 
dying of relapse or progressive disease while a similar proportion of patients are 
likely over-treated (33, 34), many of whom suffer from treatment-related 
sequelae such as solid tumours and end-stage organ dysfunction (35-37). None 
of the clinical variables used to help guide treatment decisions can predict the 
majority of patients in whom standard treatment will fail to eradicate disease.  
In chapter 6, we aimed to determine cellular signatures that correlate with 
treatment outcome in classical HL, using gene expressing profiling and 
immunohistochemical analysis of diagnostic lymph node biopsies.  We further 
validated these significant findings using a cohort of CHLs patients uniformly 
treated in a single institution. We demonstrated that CD68+ macrophage 
content measured as an IHC score in diagnostic lymph node samples was a 
strong and independent predictor of outcome after primary treatment and even 
secondary treatment. If absent in patients with limited stage disease, this finding 
defined a subgroup of patients with 100% (and 97% in the validation set) long-
term disease-specific survival. Moreover, the IHC score was applied and 
validated to routine whole section diagnostic biopsies, which not only validates 
the aforementioned results obtained in tissue microarrays but also facilitates its 
use in daily practice. Given these results, enumeration of CD68+ LAM in lymph 
node specimens is a strong candidate marker to become a routine pathology 
test in CHL. It may be used to develop personalized treatment strategies in 
CHL, identifying at diagnosis those patients with increased resistance to current 
therapeutic options.  
 
MCL is another important NHL subtype with few candidate biomarkers. MCL is 
a clinically aggressive lymphoma characterized by frequent relapses and very 
short overall survival. The clinical behavior and response to therapy in MCL 
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vary considerably and are often unpredictable based on clinical factors. 
Proliferative rate and TP53 mutations are biological factors that strongly 
influence survival (38-40), but the significance of the non-malignant cellular 
components impacting the prognosis of patients with MCL is unknown and has 
never been studied using diagnostic samples from clinical material. In chapter 
7, we assessed the prognostic impact of microenvironment in MCL patients 
using FCM, GEP and IHC using TMAs of diagnostic lymph node biopsies. 
Although the non-neoplastic cellular infiltrate constitutes only a minor fraction of 
the tumor mass in MCL, we demonstrated and validated that 
microenvironmental factors are important in MCL biology, prognosis and 
response to therapy. We showed that the number of lymphoma-associated 
macrophages and MVD are important prognostic factors in MCL, independent 
of clinical parameters, proliferation and TP53 expression. Interestingly, 
expression of CD163, described as a marker of M2 polarized macrophages, 
also predicts survival and correlates with increased angiogenesis. Importantly, a 
distinct inflammatory and cytotoxic microenvironment characterized by the 
production of IFN, a Th1 (CD8-rich) cellular response and M1 macrophages 
were associated with diminished response to rituximab. 
 
Primary mediastinal large B cell lymphoma (PMBCL) was studied in chapter 8. 
It shares histological and gene expression features with both DLBCL and CHL 
(41, 42). These findings suggest that the microenvironment might represent a 
relevant feature in PMBCL. This disease frequently shows decreased 
expression of Major Histocompatibility Class II (MHC II) antigens (43). When we 
started this study, the mechanisms underlying loss of MHCII expression were 
largely unknown. We hypothesized that the lack of expression of MHCII may 
constitute a mechanism by which tumor cells escape immunosurveillance after 
chemotherapy. In this study, we aimed to validate HLA-DR protein expression 
as a prognostic biomarker in a larger cohort of PMBCLs and correlate it with the 
immune response using Immunohistochemistry (IHC). We demonstrated a 
negative prognostic impact of loss of HLA-DR expression by neoplastic B cells 
in patients treated with multi-agent chemotherapy in a single institution 
experience. Loss of HLA-DR expression correlated with decreased numbers of 
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infiltrating benign T cell populations, especially cytotoxic CD8+ and TIA1+ cells. 
Significantly, decreased cytotoxic T cell content correlated independently with 
inferior survival. This study shows loss of immunogenicity and immune 
surveillance are key mechanisms affecting the response to treatment of PMBCL 
patients. These results proved to be important in promoting further evaluation 
by our group of the mechanisms responsible for HLA-DR loss in the malignant 
cells. Genomic breaks in the master controller of MHC Class II expression, the 
transactivator CIITA that maps to chromosome 16p, were found to be highly 
recurrent in PMBCL. The gene fusion partners were promiscuous, with 50% of 
the fusion partners accounted for by translocations involving the PD1 ligands 
PDL1 and PDL2, mapping to chromosome 9p24 (44). These genes encode 
ligands to PD1 receptor on T cells and have been reported to have regulatory 
effects on T cell responses, including inhibition of tumour immunity (45). 
Importantly, cases harbouring CIITA breaks had a negative impact on survival 
(44).  
 
Finally, in chapter 5 we focused on DLBCL, the most common lymphoma type, 
accounting for 30-40% of newly-diagnosed cases of NHL (46). Although curable 
in a sizable proportion of patients with CHOP chemotherapy, approximately 
60% of patients with DLBCL will relapse after standard first-line therapy (47, 
48). This variability in clinical outcome likely relates to genetic heterogeneity 
within DLBCL, reflected in a wide array of cytogenetic and molecular 
abnormalities. Several other biologic factors have been proposed as 
prognostically significant, including TP53 mutations, TP53 and/or BCL2 protein 
expression and BCL6 and FOXP1 expression (49-55). Moreover, landmark 
DLBCL studies using microarray gene expression techniques defined two major 
biological categories of DLBCL with clinical and prognostic differences based on 
cell of origin distinctions; including germinal centre B cell (GCB) and activated B 
cell (ABC) subtypes (56). Currently, the addition of rituximab (R) to CHOP 
chemotherapy (R-CHOP) represents the standard of care and has improved 
significantly the survival of DLBCL patients. However, the addition of R-CHOP 
has diminished the significance of established prognostic biomarkers including 
BCL2 and BCL6 protein expression (57, 58). The underlying mechanism(s) 
responsible for this effect is/are largely unknown. Thus, in chapter 5 we 
 414 
assessed the prognostic impact of several candidate biomarkers in the current 
era of immunochemotherapy. 
Using TMAs, IHC, microarray mutational analysis and FISH we were able to 
establish the following biomarkers as significant prognostic factors in DLBCL 
treated with R-CHOP: 
TP53 Mutations and Protein Expression: TP53 is the most extensively 
studied tumor suppressor gene and a key regulator of cell homeostasis. In 
cancer, TP53 function is lost due to mutation of the gene in about half of all 
human tumors and there are many reports including lymphoma, correlating the 
presence of mutant TP53 and more advanced cancer and worse prognosis (59, 
60). In this study we showed strong TP53 protein expression to be an easy 
biomarker to assess in routine FFPET diagnostic biopsies of DLBCL patients 
and it correlated almost universally with TP53 missense mutations also studied 
in FFPET using a AmpliChip p53 microarray. Importantly, strong TP53 protein 
expression was an independent prognostic factor for patients with DLBCL even 
when treated with R-CHOP. Interestingly, its prognostic impact is superior within 
the GCB subgroup. This was one of the first significant biomarkers of R-CHOP, 
identifying a subgroup of patients with inferior survival deserving alternate 
therapies. 
Rituximab Impact on COO Subgroup Survival: COO distinctions in DLBCL 
are well established, since the initial studies using gene expression profiling, 
having identified two distinct subgroups of DLBCL, namely GCB and ABC with 
different clinical outcomes (56). Using TMA and immunohistochemical staining 
we have shown in a collaborative study that COO subtyping correlates closely 
with the results of gene expression profiling in predicting outcome (51). We also 
showed that non-GCB cases do not harbor the t(14;18), more commonly have 
isolated BCL2 gene copy number gain and have a higher percentage of 
cytogenetically “normal” BCL2+ cases. The latter finding suggests a prominent 
role for transcriptional up-regulation resulting from constitutive activation of 
NFB. DLBCL cases with a t(14;18) are virtually always GCB and never show 
isolated BCL2 gene copy number gains, suggesting that these two events are 
mutually exclusive (61). In the current era of R-CHOP, rituximab was show to 
preferentially prevent chemotherapy failures in DLBCLs that express BCL2 (57). 
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As BCL2 is differentially expressed in COO subgroups it is expected that the 
effect of the introduction of rituximab is greater in the non-GCB subtype. In this 
study we confirmed that R-CHOP is associated with better OS in DLBCL due 
largely to its effect on the non-GCB subgroup. Moreover, the OS of BCL2+ 
DLBCL patients is significantly improved by the addition of rituximab. These 
results provided insight into the possible mechanisms by which rituximab exerts 
its beneficial therapeutic effect. 
Prognostic Significance of BCL6 Rearrangements in DLBCL: 
Rearrangement of the BCL6 proto-oncogene located at chromosome band 
3q27 is the most frequent cytogenetic abnormality in DLBCL, occurring in up to 
35% of cases (54, 62, 63). In this study we compared for the first time the 
impact of BCL6 gene rearrangement on survival in DLBCL patients treated with 
CHOP and R-CHOP and secondly determined the relationship between BCL6 
rearrangement and other clinical and biological prognostic variables in DLBCL, 
including COO phenotype. Our data suggested an association between BCL6 
rearrangement and inferior outcome in patients treated with R-CHOP, but not in 
patients treated with CHOP chemotherapy alone. However, BCL6 
rearrangement also correlated with the presence of high-risk clinical features 
and did not demonstrate prognostic significance independent of the 
International Prognostic Index (IPI) score.  BCL6 rearrangement was also 
correlated strongly with a non-GCB immunophenotype. 
MYC Genomic Breaks in DLBCL: Approximately 5-10% of DLBCLs harbor a 
MYC rearrangement (64). Although approximately 20% of these cases may also 
harbor a concurrent IGH-BCL2 translocation t(14;18), the so-called ‘double-hit’ 
or dual translocation lymphomas (65), which is known to be associated with a 
poor outcome, there is very little information of the prognostic importance of 
isolated MYC aberrations in DLBCL. In the current study we studied using FISH 
an unselected series of patients with DLBCL for MYC aberrations to determine 
the frequency of this occurrence and any associated pathologic or clinical 
defining features as well as to assess the prognostic impact of MYC aberrations 
in DLBCL patients treated with R-CHOP chemotherapy.   
MYC gene rearrangements defined a small group of patients with DLBCL, 
independent of COO, who had an adverse outcome with R-CHOP and may 
have an increased risk of CNS relapse (66). There are no identifiable clinical, 
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histological, or immunophenotypic features that signal that a case of DLBCL 
may harbour a MYC aberration. Thus, it is recommended that all patients with 
DLBCL should undergo FISH analysis for assessment of the MYC 
rearrangement in addition to analysis of the t(14;18) if BCL2 expression is 
found. MYC+ DLBCL likely represent a distinct DLBCL subtype and regimens 
more in line with those used in Burkitt lymphoma may be more appropriate in 
this patient population.    
 
Finally, in chapter 3 we describe a new biomarker in FL, NOXA, which is 
expressed by malignant B cells. NOXA is a BCL2 homology 3-only member of 
the BCL2 family, also called apoptosis “sensitizer / derepressor” as it promotes 
apoptosis.  This gene has been previously reported in FL transformation GEP 
studies (67). In this study we showed NOXA protein expression (NPE) 
significantly correlated with a favorable OS in FL. In this uniformly treated cohort 
from the BCCA, NOXA was an independent predictor of outcome. This is the 
first pro-apoptotic member of the BCL2 family to impact FL prognosis. It is a 
TP53 target gene that is physiologically up-regulated in cell stress and damage 
responses (68, 69). In accordance, in our study NOXA expression correlated 
with increasing histological grade and proliferation index (Ki67). This significant 
result in FL may open new therapeutic options for this lymphoma, as 
intracellular levels of NOXA can be increased in malignant cells by therapeutic 
agents such as proteasome inhibitors (Bortezomib) leading to NOXA-mediated 
apoptosis (70, 71).  
 
9.2.3. Phenotype & Genotype Assessment of LAMs 
In this thesis we demonstrated that LAM content is an independent adverse 
prognostic factor in advanced-stage FL patients treated uniformly with 
chemotherapy and radiation (21). This finding suggests LAMs may be recruited 
and “educated” by tumours using a range of growth factors and chemokines, so 
that they adopt a “trophic” role that facilitates matrix breakdown, tumour-cell 
motility and angiogenesis (72). Recent data suggests there is more plasticity 
between the B cell and myeloid lineages than previously thought (73). This 
plasticity is associated with changes in transcription factor expression and/or 
 417 
activity  that  induce the transdifferentiation of committed B lymphocytes into 
functional macrophages that still retain immunoglobulin gene rearrangements 
as evidence of their B cell origin (74).  
The favoured hypothesis regarding the pathogenesis of FL suggests that B cells 
harbouring a t(14;18) arise at the pre-B stage in the marrow and occurs as a 
result of an error during VDJ rearrangement. The translocation is insufficient but 
necessary for the malignant transformation (75). These cells eventually enter 
the circulation, home to the lymph node and seed the follicles. The t(14;18) has 
been found frequently in the blood of healthy blood donors as well as in 
germinal centers of patients who are asymptomatic or only develop FL several 
years later (76, 77). Interestingly, it has been shown that in FL, a subpopulation 
of endothelial cells show the characteristic t(14;18) translocation of FL.(78).  
In chapter 4 we aimed to verify if intratumoural monocytes & macrophages in FL 
patients were clonally related with the malignant B cell clone. Using FICTION 
we found a significant proportion of macrophages with BCL2 abnormalities in 
patients harbouring the translocation, but not in reactive lymph nodes or 
lymphomas with no evidence of BCL2 breaks. Despite many open questions, 
our findings are provocative as may indicate neoplastic precursor cell plasticity 
and the ability of neoplastic B cells to transdifferentiate into mature-like 
monocytes & macrophages, providing the neoplastic B cells with a trophic / pro-
survival microenvironment. Further validation is mandatory to convincingly 
demonstrate these findings. 
 
 
9.3 FUTURE DIRECTIONS 
Currently, all these significant biomarkers related with malignant or non-
malignant cells remain interesting clinic-pathological findings established using 
retrospective patient cohorts. Many of them, especially those related to the 
microenvironment still represent functionally untested hypotheses. The difficulty 
in establishing in vivo models of FL hampers their study. Cell sorting strategies 
to study specific cell types in isolation are underway, and may in time further 
improve the understanding of the interactions between non-neoplastic 
macrophages, T cells, microvessels with neoplastic B cells. Similarly, cell 
purification techniques would also help validate the findings that suggest a 
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clonal relation between neoplastic B cells and a minor subset of macrophages 
in FL. 
Hopefully, the range and complexity of genomic and phenotypic studies done 
using routine FFPET biopsies will expand and accelerate the use of these and 
newly identified biomarkers into routine clinical practice. 
Moving forward, it will be important to test all potentially useful biomarkers in 
prospective clinical trials that might expedite their validation and their eventual 
use in clinical practice. Ultimately, it may be possible to manipulate the 
lymphoma microenvironment in favour of the host and turn off tumoral immune-
suppression and trophic survival signals and fuel the immunosurveillance and 
modulatory signals derived from non-neoplastic B cells.  
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Resumo Alargado 
Os linfomas de células B correspondem a 85% das neoplasias linfóides e 
contrariamente à maioria dos outros cancros, a sua incidência está a aumentar 
globalmente. Os linfomas dividem-se em vários subtipos com comportamentos 
clínicos heterogéneos, e na maioria dos casos, os índices de prognósticos 
clínicos utilizados actualmente são insuficientes (1). São necessários novos 
biomarcadores que permitam: uma melhor estratificação de prognóstico e de 
resposta à terapêutica; o planeamento de terapias mais personalizadas e a 
identificação de novos alvos terapêuticos. O LF é o segundo linfoma mais 
comum globalmente e o linfoma indolente mais frequente. Tem um 
comportamento clínico variável e uma abordagem terapêutica heterogénea. A 
transformação histológica num linfoma de alto grau representa um evento 
clínico determinante, correspondendo a comportamentos clínicos mais 
agressivos e a sobrevidas mais curtas. Assim, a identificação de 
biomarcadores preditivos de sobrevida global e risco de transformação são 
mandatórios a fim de identificar doentes de risco que poderão beneficiar de 
abordagens alternativas de tratamento. Nesta tese, utilizamos plataformas de 
análise global do genoma, através de perfis de expressão genómica e de 
alterações quantitativas do genoma, recentemente disponíveis no início dos 
trabalhos (2). A hipótese principal é que através destas novas tecnologias 
poderemos identificar novos biomarcadores, nomeadamente oncogenes e 
genes supressores que possam estar contidos dentro de segmentos do 
genoma ganhos ou perdidos nas células tumorais. Além disso, a utilização 
dessas ferramentas de análise pode identificar loci que contenham mutações 
determinantes à transformação do LF. Finalmente, estes novos marcadores 
poderão facilitar o desenvolvimento e implementação de novas terapias 
direccionadas.  
Também no início desta tese, o uso de “tissue microarray” (TMA) era recente e 
ofereceu uma plataforma de baixo custo e ideal para a descoberta e validação 
de hipóteses utilizando grandes coortes de casos, todos submetidos às 
mesmas condições técnicas e reduzindo drasticamente o consumo de 
reagentes. Os TMAs permitem a análise de biomarcadores utilizando amostras 
de diagnóstico fixadas em formol e parafina (FFPET). Permitem igualmente 
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aplicar várias técnicas como, imunohistoquímica (IHC) e fluorescência e 
hibridização in situ (FISH & ISH). Nesta tese, utilizamos os TMAs para 
examinar um grande número de amostras de diagnóstico de linfoma presente 
no arquivo do departamento de Patologia do BCCA e validar novos 
biomarcadores relacionados com o prognóstico do LF, sobretudo relacionados 
com o papel do microambiente tumoral (3). Em 2004 apenas um estudo usando 
“gene expression profilling” (GEP) tinha sido publicado realçando o impacto do 
microambiente no LF. O uso de TMAs & IHC permitiram validar estes 
resultados, e expandir a pesquisa translacional a outras áreas relacionadas 
com o LF e outros subtipos de linfomas. O principal objectivo foi validar 
resultados dos estudos das técnicas recentes do “genomics” utilizando técnicas 
que permitam o seu uso imediato na prática clínica destas doenças. 
 
Mecanismos biológicos envolvidos na transformação do LF em LDGCB.  
O capítulo 2 centra-se no estudo dos mecanismos biológicos envolvidos na 
transformação do LF em LDGCB. Neste estudo, a comparação de material do 
mesmo doente, pré e pós-transformação, é um pré-requisito para a 
compreensão clara dos mecanismos moleculares da transformação. A maioria 
dos estudos publicados revelou uma série de alterações citogenéticas 
recorrentes (4-11) cada uma ocorrendo apenas em reduzidos números de 
casos, realçando a diversidade molecular da transformação. A combinação da 
análise global da GEP complementados com a análise das alterações 
quantitativas do genoma (“copy-number”) poderão fornecer novos “insights” 
sobre os mecanismos de transformação. No presente estudo foi utilizada uma 
combinação de técnicas de microarrays do genoma, incluindo diferentes 
plataformas de microarrays de GEP disponíveis comercialmente, bem como a 
plataforma de arrayCGH construída em Vancouver, no centro associado ao 
BCCA, o BCCRC (SMRT aCGH). Estudámos a transformação histológica do 
LF utilizando duas estratégias diferentes: (1) uma série de pares de biopsias de 
gânglios linfáticos congelados a fresco pré e pós a transformação e, (2) um 
grupo de linfomas compostos com LF e LDGCB diagnosticados 
simultaneamente em biopsias FFPET. No primeiro estudo encontramos por 
GEP uma lista de 18 novos genes não associados previamente com a 
transformação. É importante sublinhar que a correlação entre esses resultados 
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GEP com aCGH foi complexa, tecnicamente e na análise bioinformática, tendo 
os resultados sugerido que outros mecanismos para além das alterações no 
número de cópias são responsáveis pela expressão destes genes na 
transformação do FL. Curiosamente, a complexidade genómica nem sempre 
está associada com a transformação em doença mais agressiva, favorecendo a 
selecção e evolução de sub-clones a partir de um clone maligno ancestral 
comum, em contraste com a evolução clonal resultante da acumulação 
estocástica de mutações genómicas acumulados ao longo do tempo (12, 13). 
Além disso, dada a heterogeneidade e a complexa relação entre as aberrações 
cromossómicas e GEP, este estudo está limitado pelo reduzido número de 
amostras, obrigando a análise de um número muito maior de casos para 
determinar as alterações genéticas específicos responsáveis pela 
transformação, especialmente quando utilizamos técnicas de estudo global do 
genoma. O segundo estudo validou a metodologia recentemente descrita de 
extracção de RNA a partir de amostras de diagnóstico em FFPET, que 
permitem obter resultados significativos de GEP (14). Usando uma série de 14 
linfomas compostos, evidenciamos três potenciais mecanismos distintos de 
transformação, já presentes nas fases iniciais de transformação de FL em 
LDGCB. Um destes caracteriza-se por uma assinatura genómica de 
proliferação como anteriormente descrito (15). Dos conjuntos de genes 
característicos dos outros dois grupos, e apesar do seu reduzido número, 
distinguem-se alguns como eventuais candidatos para diagnóstico e eventual 
utilização terapêutica. Novamente, dado o reduzido número de amostras, casos 
adicionais são necessários e obrigatórios para validar estes resultados. 
 
Marcadores biológicos de prognósticos em linfoma. 
Os capítulos 3 e 5 a 8 centram-se na identificação e validação de 
biomarcadores relacionados com microambiente tumoral. A importância do 
microambiente e das células não-malignas presentes nos tumores humanos 
não é uma descoberta recente. Rudolf Virchow foi o primeiro a sugeri-la, há 
mais de cem anos (16, 17) e Paul Erlich propôs em 1909 o conceito de 
“immunosurveilance” tumoral (18).  
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Desde então, demonstrou-se que a imunidade tumoral tem diferentes 
contextos. Juntamente com a mais bem estudada resposta anti-tumoral, 
existem vários mecanismos diferentes, através dos quais a imunidade tumoral 
promove o crescimento tumoral, esculpindo a sua própria imunidade como 
factor indutor do seu crescimento e progressão (19). No linfoma, o 
microambiente também tem sido reconhecido, desde as primeiras descrições 
destas doenças, tais como no linfoma de Hodgkin, onde é uma característica 
fundamental e necessária para o seu diagnóstico. Da mesma forma, o LF 
mantém muitas das características morfológicas do folículo normal, sugerindo 
uma intensa interacção entre as células B malignas e as células imunes não-
malignas, que incluem as células T, células dendríticas foliculares (FDC), 
macrófagos, mastócitos e células endoteliais. A sobrevivência das células B 
neoplásicas está totalmente dependente dos sinais tróficos destas células 
como é evidenciado na dificuldade de estabelecer culturas celulares de LF sem 
estimulação por citocinas (20). 
Linfoma Folicular 
No capítulo 3 foram utilizadas biopsias ganglionares de diagnóstico de doentes 
com LF tratados uniformemente no BCCA e foi testado o impacto das 
características morfológicas do microambiente, nomeadamente a arquitectura e 
conteúdo das células não-malignas. Utilizaram-se TMA corados por IHC com 
diferentes anticorpos e demonstraram-se, nesta análise, o impacto significativo 
dos macrófagos, microvasos e células T reguladoras (Tregs) no prognóstico 
destes doentes. Notavelmente e pela primeira vez, foi possível demonstrar que 
dois biomarcadores, o padrão arquitectural de Tregs e a densidade de 
microvasos, correlacionam-se significativamente com o risco de transformação. 
Este coorte, quando comparado com outros estudos de LF, caracteriza-se por 
duas grandes vantagens, o tratamento uniforme dos doentes e a duração 
alargada de seguimento deste grupo de doentes. 
Numa doença caracterizada por modalidades terapêuticas muito heterogéneas, 
a maioria dos estudos publicados incluem séries de doentes tratados com 
esquemas diferentes entre diferentes estudos e mesmo dentro de cada série. 
Esta heterogeneidade tem sido considerada como o principal factor para a 
obtenção de resultados controversos dos biomarcadores associados ao 
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microambiente em LF (21-31). Após os resultados obtidos no LF, decidimos 
expandir o nosso estudo destes biomarcadores a outros tipos de linfomas.  
Linfoma de Hodgkin Clássico 
O linfoma de Hodgkin clássico (CHL) é um dos candidatos ideais, pois tem 
como principal característica o predomínio das células reactivas no 
microambiente tumoral, correspondendo as células neoplásicas a menos de 
1% das células tumorais (32). O CHL é uma das histórias de sucesso de 
oncologia com taxas de cura muito próximas dos 80%. Contudo, cerca de 20% 
dos doentes com estadio avançado ainda morrem de recidiva ou progressão da 
doença, enquanto uma proporção similar de doentes sofre de morbilidade 
associada a sobre-tratamento (33, 34), tais como tumores sólidos ou 
hematológicos ou insuficiências crónicas de vários órgãos (35-37). Nenhuma 
das variáveis clínicas usadas actualmente no processo de planeamento de 
tratamento consegue prever a erradicação da doença na maioria dos doentes 
que sofrem progressão/ recidiva. No capítulo 6, foram estudados em doentes 
com CHL, perfis de expressão genómica global (GEP) obtidos de biopsias 
diagnósticas congeladas a fresco, complementados com a análise de 
biomarcadores por IHC em FFPET, e correlacionados com prognóstico e 
resposta terapêutica. Os resultados significativos foram posteriormente 
validados num coorte de doentes uniformemente tratados numa única 
instituição. Neste estudo, demonstra-se que o conteúdo de macrófagos CD68+ 
(LAM) no microambiente do CHL é um biomarcador independente e preditivo 
da resposta à terapêutica primária e até mesmo do tratamento secundário. Em 
doentes com doença limitada, a presença de apenas escassas destas células 
caracteriza um grupo de doentes com 100% (e 97% na série de validação) de 
sobrevivência a longo prazo. Além disso, no estudo de validação, adaptamos a 
avaliação dos LAMs na totalidade das secções das biopsias de diagnóstico 
usadas na rotina, o que não só valida os resultados acima obtidos em TMA, 
mas também facilita a sua utilização na prática diária. Assim, a enumeração de 
células CD68 + em amostras de diagnóstico torna este marcador um forte 
candidato a tornar-se um teste de rotina em CHLs. Pode ser utilizado para 
desenvolver estratégias de tratamento personalizado no CHL, identificando no 
diagnóstico os doentes com resistência aumentada às actuais opções 
terapêuticas. 
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Linfoma do Manto 
MCL é um linfoma de células B, indolente mas agressivo, clinicamente 
caracterizado por surtos frequentes e uma curta sobrevida global. O 
comportamento clínico e resposta à terapêutica em MCL variam 
consideravelmente e são muitas vezes imprevisíveis com base em factores 
clínicos. O índice proliferativo e as mutações de TP53 são factores biológicos 
que influenciam fortemente a sobrevida (38-40), mas o significado das 
características do microambiente tumoral, nomeadamente das células imunes 
não-neoplásicas, no prognóstico dos doentes com MCL é desconhecido e 
nunca foi estudado. Utilizando amostras de diagnóstico FFPET usadas na 
rotina, avaliou-se no capítulo 7, o impacto no prognóstico do microambiente em 
pacientes MCL utilizando FCM, GEP e IHQ em TMAs de biópsias ganglionares 
de diagnóstico. Apesar de estas células corresponderem habitualmente a uma 
pequena fracção da massa tumoral em MCL, demonstramos e validamos que 
factores microambientais são importantes na biologia MCL, no prognóstico e na 
resposta à terapêutica. O número de macrófagos LAM e a densidade de 
microvasos (MVD) são importantes factores de prognóstico em MCL, 
independentes de parâmetros clínicos, da proliferação e da expressão do gene 
TP53. Curiosamente, a expressão de CD163, descrito como um marcador de 
macrófagos polarizados M2, correlaciona-se com o aumento da angiogénese e 
tem impacto no prognóstico. De realçar que o microambiente com 
características inflamatórias e citotóxicas caracterizado pela produção de IFN, 
com uma resposta celular com predomínio Th1 (rico em CD8+) e de 
macrófagos M1 associou-se significativamente à diminuição da resposta ao 
rituximab. 
Linfoma de Grandes Células B Primário do Mediastino 
O PMBCL partilha aspectos histológicos, fenotípicos e genómicos com os 
linfomas LDGCB e CHL (41, 42). Estes achados sugerem que o microambiente 
possa representar um aspecto relevante nos PMBCL. Esta doença apresenta 
frequentemente uma expressão diminuída de antigénios do complexo Major de 
Histocompatibilidade Classe II (MHC II) (43). Quando começamos este estudo, 
os mecanismos subjacentes à perda de expressão MHCII eram em grande 
parte desconhecidos. Neste estudo, colocamos a hipótese de que a reduzida 
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expressão de MHCII pudesse constituir um mecanismo pelo qual as células 
tumorais escapam à imunovigilância após a quimioterapia. Neste estudo, 
validamos a expressão da proteína HLA-DR como um biomarcador de 
prognóstico num coorte de mais de 100 doentes com PMBCL. Demonstramos 
um impacto negativo no prognóstico relacionado com a perda de expressão de 
HLA-DR pelas células B neoplásicas em doentes tratados com quimioterapia, 
numa única instituição. Além disso, a perda de HLA-DR correlacionou-se com a 
diminuição do número de células T reactivas, em especial as células citotóxicas 
CD8+ e TIA1+. A diminuição de células T citotóxicas correlaciou-se de forma 
independente com uma sobrevida inferior. A perda da imunogenicidade e da 
vigilância imunológica são mecanismos importantes que afectam a resposta ao 
tratamento de pacientes PMBCL. Estes resultados levaram o nosso grupo a  
estudar possíveis mecanismos responsáveis pela perda de HLA-DR nas 
células malignas. Foram identificadas quebras genómicas recorrentes no gene 
CIITA, no cromossoma 16, o controlador principal da expressão de proteínas 
MHC Classe II. Os parceiros de fusão deste gene foram vários, com 50% dos 
parceiros de fusão explicada por translocações que envolvem os ligandos de 
PD1, PDL1 e PDL2, ambos localizados em 9p24 (44). Estes genes codificam 
ligandos do receptor PD1 nas células T e têm sido descritos como reguladores 
das respostas de células T, incluindo a inibição da imunidade tumoral (45). É 
importante realçar que a presença destas quebras em CIITA tem um impacto 
negativo na sobrevida dos doentes com PMBCL (44). 
Linfoma Difuso de Grandes Células B 
Finalmente, no capítulo 5 estudamos LDGCBs, o linfoma mais comum e 
responsável por 30-40% dos casos recém-diagnosticados de NHL (46). 
Embora curável numa proporção considerável de doentes sujeitos a 
quimioterapia CHOP ou CHOP-like, aproximadamente 60% dos doentes com 
LDGCB sofrem recaídas após a terapêutica de primeira linha (47, 48). Essa 
variabilidade da evolução clínica provavelmente correlaciona-se com a 
heterogeneidade genética existente nos LDGCB, reflectida numa grande 
variedade de alterações moleculares e citogenéticas. Múltiplos factores 
biológicos de prognóstico têm sido propostos como significativos, incluindo 
mutações do TP53 e/ou expressão da proteína TP53, expressões de BCL2, 
BCL6 e FOXP1 (49-55). Além disso, estudos utilizando técnicas GEP em 
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microarray definiram duas grandes categorias biológicas de LDGCB com 
diferenças biológicas, clínicas e de prognóstico baseado na distinção da célula 
de origem, em linfomas relacionáveis com células B do centro germinativo 
(GCB) ou células B activadas (ABC) (56). Actualmente, a introdução da 
imunoterapia, rituximab (R) à quimioterapia CHOP (R-CHOP) representa a 
terapêutica padrão, esta veio melhorar significativamente a sobrevida destes 
doentes. No entanto, a adição de R-CHOP diminuiu o impacto de 
biomarcadores definidos na época pré-R, incluindo a expressão de BCL2 e 
BCL6 (57, 58). Os mecanismos subjacentes, responsáveis por este efeito, são 
em grande parte desconhecidos. Assim, no capítulo 5 avaliou-se o impacto de 
prognóstico de vários biomarcadores na era actual de imunoquimioterapia. 
Usando TMAs, IHC, análise mutacional em microarray e FISH, pudemos 
estabelecer os seguintes biomarcadores como importantes factores de 
prognóstico em doentes com LDGCB tratados com R-CHOP: 
Mutações e expressão da proteína TP53; impacto de R nos grupos definidos 
por COO e rearranjos de BCL6 e MYC.  
1. O TP53 é o gene supressor de tumor mais extensivamente estudado e 
um gene regulador chave da homeostase celular. Em cerca de metade 
de todos os tumores humanos, a função do TP53 é perdida devido à 
mutação do gene, mais frequentemente associada a neoplasias, 
incluindo os linfomas, em estádios avançados e com pior prognóstico 
(59, 60). Neste estudo, demostramos que a expressão intensa da 
proteína TP53 é um biomarcador facilmente avaliado por IHC em 
biópsias FFPET de diagnóstico de doentes com LDGCB e correlaciona-
se com a presença de mutações "missense" do TP53, também 
estudados em FFPET usando um microarray p53 AmpliChip. É 
importante realçar que a expressão intensa da proteína TP53 é um 
factor independente de prognóstico mesmo para doentes tratados com 
R-CHOP. Curiosamente, o seu impacto no prognóstico é superior dentro 
do subgrupo GCB dos LBDGC. Este foi um dos primeiros biomarcadores 
a identificar um subgrupo de doentes com sobrevida inferior após a 
introdução de R, que possam eventualmente beneficiar de outras 
terapias alternativas. 
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2. Impacto do rituximab na sobrevida dos subgrupos de LDGCB definidos 
por COO. Os dois subgrupos, GCB e ABC, caracterizam-se não só por 
diferentes alterações moleculares e fenotípicas, mas também por 
prognósticos clínicos distintos (56). Previamente, num estudo 
cooperativo usando TMA e IHC, validamos o impacto de COO no 
prognóstico inicialmente publicado em estudos usando GEP (51). Nesta 
tese, demonstramos que os casos não-GCB não têm t(14;18) com 
rearranjo do BCL2, sendo contudo mais frequente o ganho de número 
de cópias de BCL2, e tem uma maior percentagem de casos sem 
alterações do gene BCL2 mas com sobre-expressão da proteína BCL2. 
O último achado sugere um papel proeminente da activação constitutiva 
da via NFkB. Os casos com t(14;18) são quase sempre GCB e nunca 
mostram ganhos isolados de cópias de BCL2, sugerindo que esses dois 
eventos são mutuamente exclusivos (61). Na era actual de R-CHOP, o 
benefício de sobrevida ganho com rituximab relaciona-se com a 
diminuição de resistência à quimioterapia em LGCBD que expressam 
BCL2 (57). Como BCL2 é expresso diferentemente nos subgrupos COO 
espera-se que o efeito da introdução do rituximab será maior no subtipo 
não-GCB. Neste estudo, confirmou que R-CHOP está associado com 
melhor OS em LDGCB em grande parte devido ao seu efeito sobre o 
subgrupo não-GCB. Além disso, o prognóstico dos doentes com 
linfomas BCL2+ é significativamente melhorado pela adição de 
rituximab. Estes resultados sugerem possíveis mecanismos pelos quais 
rituximab exerce o seu efeito terapêutico. 
3. O rearranjo do proto-oncogene BCL6 localizado em 3q27 é a alteração 
citogenética mais frequente em LDGCB, ocorrendo em cerca 35% dos 
casos (54, 62, 63). Neste estudo, comparamos, pela primeira vez, o 
impacto do rearranjo de BCL6 na sobrevivência de doentes tratados com 
CHOP e R-CHOP e em segundo determinamos a relação entre o 
rearranjo de BCL6 e outras variáveis clínicas e biológicas prognósticas 
em LDGCB, incluindo o fenótipo COO. Os nossos resultados sugerem 
uma associação entre o rearranjo BCL6 e a sobrevida inferior em 
doentes tratados com R-CHOP, mas não em doentes tratados apenas 
com quimioterapia CHOP. No entanto, o rearranjo BCL6 também se 
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correlacionou com a presença de características de alto risco clínico e 
não demonstrou significado prognóstico independente do IPI. 
Finalmente, o rearranjo BCL6 também se associou significativamente 
com o fenótipo não-GCB. 
4. Aproximadamente 5-10% dos LGCBD tem rearranjo MYC (64). Cerca de 
20% destes casos tem concomitantemente a translocação t(14;18), 
envolvendo IGH e BCL2, também chamados linfomas com translocação 
dupla ou “double-hit” (65), característica associada com um mau 
prognóstico. Contudo, a informação sobre a importância prognóstica de 
aberrações isoladas MYC em LDGCB é desconhecida. No presente 
estudo foram estudadas por FISH alterações do MYC, numa série não 
seleccionada de pacientes com LDGCB. Determinou-se a frequência 
desta ocorrência, quais as alterações patológicas ou clínicas 
associadas, bem como o impacto prognóstico das aberrações MYC em 
doentes tratados com R-CHOP. O rearranjo do MYC está presente num 
pequeno grupo de doentes com LDGCB, é independente de COO.Estes 
doentes apresentam uma resposta inferior à terapêutica a R-CHOP e um 
risco aumentado de recaída no CNS (66). Não se documentaram 
características clínicas, histológicas, ou imunofenotípicas associadas à 
presença uma aberração MYC. Assim, recomenda-se que todos os 
pacientes com LDGCB deverão ser submetidos a análise FISH para a 
avaliação do rearranjo MYC, além de análise da t(14;18), se BCL2+. Os 
LDGCB MYC+, provavelmente representam um subtipo distinto de 
LDGCB, cujos doentes poderão beneficiar de esquemas terapêuticos 
semelhantes aos utilizados no linfoma de Burkitt. 
Finalmente, no capítulo 3, descrevemos um novo biomarcador em LF, a 
expressão de NOXA pelas células B malignas. NOXA é um membro da 
família BCL2, “BCL2 homology 3-only”, com funções de "sensibilizador / 
derepressor" da apoptose. Este gene foi previamente descrito associado a 
transformação de LF, em estudos de GEP (67). Neste estudo 
demonstramos que a expressão proteica de NOXA (NPE) está 
significativamente correlacionada com o prognóstico do LF. No coorte de 
doentes uniformemente tratados no BCCA, NOXA foi um marcador 
independente de prognóstico. Trata-se do primeiro membro pró-apoptótico 
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da família BCL2 descrito com impacto de prognóstico do LF. É um gene 
alvo do TP53 que é fisiologicamente sobre-expresso em situações de stress 
celular (68, 69). Em conformidade, no nosso estudo, NOXA correlacionou-
se com o aumento do grau histológico e do índice de proliferação (Ki67). 
Este resultado significativo no LF pode abrir novas opções terapêuticas para 
este linfoma, através do aumento dos níveis intracelulares de NOXA nas 
células malignas por agentes terapêuticos, tais como inibidores de 
proteosoma (bortezomib) que induzam apoptose mediada por NOXA (70, 
71). 
 
Fenótipo & Genótipo dos Macrófagos-Associados-Linfoma (LAMs) 
Nesta tese, demonstrou-se que o conteúdo LAM é um factor independente de 
prognóstico em doentes com LF em estadios avançados e tratados 
uniformemente com quimioterapia e radiação (21). Este achado sugere que 
estas células podem ser recrutadas e "educadas" pelos tumores, utilizando 
factores de crescimento e quimocinas, tornando-se "tróficas" e favorecendo a 
degradação da matriz, a motilidade das células tumorais e a angiogénese (72). 
Dados recentes sugerem que há maior plasticidade entre as células B e células 
das linhagens mielóides do que se pensava anteriormente (73). Esta 
plasticidade está associada a alterações na expressão de factores de 
transcrição que induzem a transdiferenciação de linfócitos B em macrófagos 
funcionais que ainda mantêm rearranjos do gene da imunoglobulina como 
evidência da sua origem nos linfócitos B (74). A hipótese mais provável da 
patogenia inicial do LF, sugere que as células B portadoras de t(14;18) surgem 
na fase de célula pré-B na medula óssea e ocorrem como um resultado de um 
erro durante o rearranjo VDJ. A translocação é insuficiente por si só, mas 
necessária para a transformação maligna (75). Estas células entram na 
circulação geral e são recrutadas para os folículos linfóides, onde poderão 
acumular mais alterações genómicas que facilitem a linfomagénese. A t(14;18) 
é detectada frequentemente no sangue de dadores de sangue saudáveis bem 
como em centros germinativos com morfologia conservada de indivíduos sem 
doença ou que apenas desenvolvem LF vários anos mais tarde (76, 77). 
Curiosamente, foi descrito no LF uma subpopulação de células endoteliais com 
a mesma translocação t(14;18) das células neoplásicas (78). O capítulo 4 teve 
 440 
como objetivo verificar se os monócitos e macrófagos intra-tumorais de doentes 
com LF estão clonalmente relacionados com o clone maligno de células B. 
Usando a técnica de FICTION, descobrimos que uma proporção significativa de 
macrófagos contém rearranjos do BCL2, em doentes com LF portadores da 
translocação, mas não em gânglios linfáticos reactivos ou linfomas, sem 
evidência de rearranjo do BCL2. Estes resultados sugerem plasticidade das 
células neoplásicas precursoras e a capacidade das células B neoplásicas 
poderem se transdiferenciar em monócitos e macrófagos, fornecendo às 
células B neoplásicas um microambiente pró-linfoma. A validação adicional é 
mandatória para demonstrar de forma convincente estes achados. 
 
Direcções Futuras 
Presentemente, todos os biomarcadores significativos relacionados com 
células malignas ou não-malignas, descritos nesta tese, permanecem como 
interessantes associações clínico-patológicas estabelecidas usando coortes 
retrospectivas. Muitos deles, especialmente aqueles relacionados ao 
microambiente, representam ainda hipóteses funcionalmente não testadas. A 
dificuldade em estabelecer modelos in vivo de LF dificulta o seu estudo. Várias 
estratégias de “cell sorting” estão em curso para estudar os diferentes tipos de 
células específicas e assim obter uma melhor compreensão das interacções 
entre os macrófagos, células T, microvasos e as células B neoplásicas. Da 
mesma forma, técnicas de purificação de células poderão também ajudar a 
validar os resultados que sugerem uma relação clonal entre as células B 
neoplásicas e uma população de macrófagos intra-LF. Felizmente, a variedade 
e complexidade de estudos genómicos e fenotípicos, que já se podem realizar 
em biópsias FFPET de rotina, irão acelerar o uso destes biomarcadores na 
prática clínica. Será muito importante testar todos os biomarcadores em 
ensaios clínicos prospectivos que possam acelerar a sua validação e a sua 
eventual utilização na prática clínica. Em última análise, pode ser possível 
manipular o microambiente do linfoma em favor do hospedeiro e abolir os 
sinais de sobrevida tumoral e de imunosupressão induzidos pelo linfoma. 
 441 
REFERENCIAS 
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Stein H, Thiele J, et al. 
WHO classification of tumours of haematopoietic and lymphoid tissue. IARC. 
2008;4th Edition. 
2. Golub TR. Mining the genome for combination therapies. Nat Med. 2003 
May;9(5):510-1. 
3. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et 
al. Prediction of survival in follicular lymphoma based on molecular features of 
tumor-infiltrating immune cells. N Engl J Med. 2004 Nov 18;351(21):2159-69. 
4. De Jong D, Voetdijk BM, Beverstock GC, van Ommen GJ, Willemze R, 
Kluin PM. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of 
follicular lymphoma, presenting as composite lymphoma. N Engl J Med. 1988 
May 26;318(21):1373-8. 
5. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in 
histologically progressed follicular lymphomas. Blood. 1992 Aug 1;80(3):758-67. 
6. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. 
p53 mutations are associated with histologic transformation of follicular 
lymphoma. Blood. 1993 Oct 15;82(8):2289-95. 
7. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 
mutation is associated with progression in follicular lymphomas. Blood. 1993 
Oct 1;82(7):1994-2004. 
8. Joos S, Otano-Joos MI, Ziegler S, Bruderlein S, du Manoir S, Bentz M, et 
al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of 
chromosomal material including 9p and amplification of the REL gene. Blood. 
1996 Feb 15;87(4):1571-8. 
9. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic 
transformation of follicular lymphoma is associated with somatic mutation of the 
translocated Bcl-2 gene. Blood. 1996 Nov 15;88(10):3937-44. 
 442 
10. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, 
Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 
are associated with histologic progression in follicle center lymphoma. Blood. 
1998 Jun 15;91(12):4677-85. 
11. Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA, et al. The 
use of real-time quantitative polymerase chain reaction and comparative 
genomic hybridization to identify amplification of the REL gene in follicular 
lymphoma. Br J Haematol. 2000 Nov;111(2):618-25. 
12. Martinez-Climent JA, Fontan L, Gascoyne RD, Siebert R, Prosper F. 
Lymphoma stem cells: enough evidence to support their existence? 
Haematologica.  Feb;95(2):293-302. 
13. Hoglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Sall T, et al. 
Identification of cytogenetic subgroups and karyotypic pathways of clonal 
evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004 
Mar;39(3):195-204. 
14. Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger 
JM, et al. Quantitative nuclease protection assay in paraffin-embedded tissue 
replicates prognostic microarray gene expression in diffuse large-B-cell 
lymphoma. Lab Invest. 2007 Oct;87(10):979-97. 
15. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, 
et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma 
proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007 
Jan;136(2):286-93. 
16. Virchow R. Reizung und Reizbarkeit. Arch Pathol Anat Klin Med. 
1858;14:1-63. 
17. Virchow R. Aetiologie der neoplastischen Geschwulste/Pathogenie der 
neoplastischen Geschwulste. In: Hirschwald VvA, editor. Die Krankhaften 
Geschwustle. Berlin; 1863. p. 57-101. 
 443 
18. Ehrlich P. Über den jetzigen stand der karzinomforschung. Ned Tijdschr 
Geneeskd. 1909;5:273-90. 
19. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer 
immunosurveillance and immunoediting. Immunity. 2004 Sep;21(2):137-48. 
20. Eray M, Postila V, Eeva J, Ripatti A, Karjalainen-Lindsberg ML, Knuutila 
S, et al. Follicular lymphoma cell lines, an in vitro model for antigenic selection 
and cytokine-mediated growth regulation of germinal centre B cells. Scand J 
Immunol. 2003 Jun;57(6):545-55. 
21. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et 
al. Analysis of multiple biomarkers shows that lymphoma-associated 
macrophage (LAM) content is an independent predictor of survival in follicular 
lymphoma (FL). Blood. 2005 Sep 15;106(6):2169-74. 
22. Alvaro T, Lejeune M, Salvado MT, Lopez C, Jaen J, Bosch R, et al. 
Immunohistochemical patterns of reactive microenvironment are associated 
with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006 
Dec 1;24(34):5350-7. 
23. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, 
Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory 
T cells are associated with improved overall survival in follicular lymphoma. 
Blood. 2006 Nov 1;108(9):2957-64. 
24. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in 
follicular lymphoma: importance of markers of immune response. Leuk 
Lymphoma. 2007 Dec;48(12):2403-11. 
25. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. 
A high tumor-associated macrophage content predicts favorable outcome in 
follicular lymphoma patients treated with rituximab and cyclophosphamide-
doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007 Oct 1;13(19):5784-9. 
26. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser 
F, et al. High numbers of tumor-associated macrophages have an adverse 
 444 
prognostic value that can be circumvented by rituximab in patients with follicular 
lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008 
Jan 20;26(3):440-6. 
27. de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, 
Heisterkamp S, et al. Impact of the tumor microenvironment on prognosis in 
follicular lymphoma is dependent on specific treatment protocols. 
Haematologica. 2009 Jan;94(1):70-7. 
28. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The 
architectural pattern of FOXP3-positive T cells in follicular lymphoma is an 
independent predictor of survival and histologic transformation. Blood. 2010 Jan 
14;115(2):289-95. 
29. Koster A, van Krieken JH, Mackenzie MA, Schraders M, Borm GF, van 
der Laak JA, et al. Increased vascularization predicts favorable outcome in 
follicular lymphoma. Clin Cancer Res. 2005 Jan 1;11(1):154-61. 
30. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Olsen ML, Funder 
AM, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological 
correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 
2007 Mar;48(3):584-95. 
31. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne 
RD. Vascularization predicts overall survival and risk of transformation in 
follicular lymphoma. Haematologica. 2010 Dec;95(12):2157-60. 
32. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009 
Jan;9(1):15-27. 
33. Bjorkholm M, Axdorph U, Grimfors G, Merk K, Johansson B, Landgren 
O, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in 
Hodgkin's disease. A prospective randomized trial. Ann Oncol. 1995 
Nov;6(9):895-9. 
 445 
34. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, 
Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin's 
lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. 
35. Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, et 
al. Second solid tumors in patients with Hodgkin's disease cured after radiation 
or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996 
Sep;14(9):2435-43. 
36. Salloum E, Tallini G, Levy A, Cooper DL. Burkitt's lymphoma-leukemia in 
patients treated for Hodgkin's disease. Cancer Invest. 1996;14(6):527-33. 
37. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter 
UA, et al. Long-term risk of second malignancy in survivors of Hodgkin's 
disease treated during adolescence or young adulthood. J Clin Oncol. 2000 
Feb;18(3):487-97. 
38. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VV, Schluger A, et al. p53 
overexpression as a marker of poor prognosis in mantle cell lymphomas with 
t(11;14)(q13;q32). Blood. 1995 Oct 15;86(8):2892-9. 
39. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, 
et al. The proliferation gene expression signature is a quantitative integrator of 
oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 
2003 Feb;3(2):185-97. 
40. Katzenberger T, Petzoldt C, Holler S, Mader U, Kalla J, Adam P, et al. 
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle 
cell lymphoma. Blood. 2006 Apr 15;107(8):3407. 
41. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. 
The molecular signature of mediastinal large B-cell lymphoma differs from that 
of other diffuse large B-cell lymphomas and shares features with classical 
Hodgkin lymphoma. Blood. 2003 Dec 1;102(12):3871-9. 
42. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. 
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a 
 446 
clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin 
lymphoma. J Exp Med. 2003 Sep 15;198(6):851-62. 
43. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, et 
al. Loss of MHC class II gene and protein expression in diffuse large B-cell 
lymphoma is related to decreased tumor immunosurveillance and poor patient 
survival regardless of other prognostic factors: a follow-up study from the 
Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004 Jun 
1;103(11):4251-8. 
44. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. 
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid 
cancers. Nature.  Mar 17;471(7338):377-81. 
45. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor 
immunity. J Mol Med. 2003 May;81(5):281-7. 
46. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. 
World Health Organization Classification of Tumours of Haematopoietic and 
lymphoid Tissues. Lyon: IARC press; 2008. 
47. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, 
Ferme C, et al. Long-term results of the R-CHOP study in the treatment of 
elderly patients with diffuse large B-cell lymphoma: a study by the Groupe 
d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. 
48. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. 
The revised International Prognostic Index (R-IPI) is a better predictor of 
outcome than the standard IPI for patients with diffuse large B-cell lymphoma 
treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857-61. 
49. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, 
et al. Expression of the FOXP1 Transcription Factor Is Strongly Associated with 
Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma. Clin Cancer 
Res. 2005 Feb 1;11(3):1065-72. 
 447 
50. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, 
Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 
gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 
1997 Jul 1;90(1):244-51. 
51. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott 
G, et al. Confirmation of the molecular classification of diffuse large B-cell 
lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 
Feb 1;103(1):275-82. 
52. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic 
significance of microvessel density and vascular endothelial growth factor 
(VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003 
Dec;44(12):2089-93. 
53. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak 
HL, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large 
B-cell lymphoma: a population-based study. J Clin Oncol. 1996 Jul;14(7):2131-
8. 
54. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken 
JH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse 
large B-cell lymphoma. Blood. 1998 Nov 1;92(9):3152-62. 
55. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. 
BCL2 overexpression associated with chromosomal amplification in diffuse 
large B-cell lymphoma. Blood. 1997 Aug 1;90(3):1168-74. 
56. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. 
Distinct types of diffuse large B-cell lymphoma identified by gene expression 
profiling. Nature. 2000 Feb 3;403(6769):503-11. 
57. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et 
al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to 
chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). 
Blood. 2003 Jun 1;101(11):4279-84. 
 448 
58. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, 
Habermann TM, et al. Prognostic significance of Bcl-6 protein expression in 
DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 
2006 Jun 1;107(11):4207-13. 
59. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000 
Nov 16;408(6810):307-10. 
60. Soussi T, Beroud C. Assessing TP53 status in human tumours to 
evaluate clinical outcome. Nat Rev Cancer. 2001 Dec;1(3):233-40. 
61. Farinha P, Bebb G, Siebert R, Horsman D, Connors JM, Gascoyne R. 
Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma 
(DLBCL). Blood. 2004 November 16, 2004;104(11):Abstract#26. 
62. Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C, et al. 
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell 
lymphoma. N Engl J Med. 1994 Jul 14;331(2):74-80. 
63. Bastard C, Deweindt C, Kerckaert JP, Lenormand B, Rossi A, Pezzella 
F, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with 
histology, immunophenotype, karyotype, and clinical outcome in 217 patients. 
Blood. 1994 May 1;83(9):2423-7. 
64. Stein H, Warnke RA, Chan WC, Jaffe ES, Chan JKC, Gatter KC, et al. 
WHO classification of tumours of heamatopoietic and lymphoid tissues.  Diffuse 
large B-cell lymphoma, not otherwise specified. IARC. 2008 4th Edition. 
65. Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, 
Gascoyne RD, et al. Sequential transcription factor targeting for diffuse large B-
cell lymphomas. Cancer Res. 2008 May 1;68(9):3361-9. 
66. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha 
P, et al. MYC gene rearrangements are associated with a poor prognosis in 
diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. 
Blood. 2009 Oct 22;114(17):3533-7. 
 449 
67. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-
Moscardo F, Albertson DG, et al. Transformation of follicular lymphoma to 
diffuse large cell lymphoma is associated with a heterogeneous set of DNA 
copy number and gene expression alterations. Blood. 2003 Apr 15;101(8):3109-
17. 
68. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner 
MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only 
proteins puma and noxa. Science. 2003 Nov 7;302(5647):1036-8. 
69. Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK 
and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem. 
2004 Jul 2;279(27):28367-74. 
70. Letai A. Pharmacological manipulation of Bcl-2 family members to control 
cell death. J Clin Invest. 2005 Oct;115(10):2648-55. 
71. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. 
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell 
lymphoma through generation of ROS and Noxa activation independent of p53 
status. Blood. 2006 Jan 1;107(1):257-64. 
72. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized 
inflammation in the initiation and promotion of malignant disease. Cancer Cell. 
2005 Mar;7(3):211-7. 
73. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian 
of B cell identity and function. Nat Immunol. 2007 May;8(5):463-70. 
74. Cobaleda C, Busslinger M. Developmental plasticity of lymphocytes. Curr 
Opin Immunol. 2008 Apr;20(2):139-48. 
75. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev 
Cancer. 2005 Apr;5(4):251-62. 
 450 
76. Roulland S, Lebailly P, Lecluse Y, Heutte N, Nadel B, Gauduchon P. 
Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy 
individuals. Leukemia. 2006 Jan;20(1):158-62. 
77. Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES. 
In situ localization of follicular lymphoma: description and analysis by laser 
capture microdissection. Blood. 2002 May 1;99(9):3376-82. 
78. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, et al. 
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-
cell lymphomas. N Engl J Med. 2004 Jul 15;351(3):250-9. 
 
 451 
Appendices 
Major contributions already published in different Sections are appended: 
Section 1 
Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD.   
Prognostic Factors in Follicular Lymphoma. J Clin Oncol. 2010 Jun 
10;28(17):2902-13. Epub 2010 Apr 12. Review.  PMID: 20385990 
Section 3 
Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. 
Analysis of multiple biomarkers shows that lymphoma-associated macrophage 
(LAM) content is an independent predictor of survival in follicular lymphoma 
(FL). Blood 2005; 106:2169-2174. PMID: 15933054 
Farinha P , Al-Tourah, Jill K, Connors JM, Shumansky K, Spinelli JJ, Gascoyne 
RD. The Architectural Pattern of FOXP3+ T Cells Is an Independent Predictor of 
Survival in Patients with Follicular Lymphoma (FL). Blood. 2010 Jan 14; 
115(2):289-95. Epub 2009 Nov 9. PMID: 19901260 
Farinha P, Kyle A, Minchinton A, Connors JM, Karsan A, Gascoyne RD. 
Vascularization predicts overall survival and risk of transformation in follicular 
lymphoma. Haematologica. 2010 Dec;95(12):2157-60. Epub 2010 Aug 16. 
PMID: 20713461 
 Section 5 
Savage K, Johnson N, Ben-Nerian S, Connors J, Sehn L, Farinha P, Horsman 
D, Gascoyne R. MYC gene re-arrangements are associated with a poor 
prognosis in diffuse large B cell lymphoma patients treated with R-CHOP 
chemotherapy. Blood. 2009;114(17): 3533-7. PMID: 19704118 
Shustik J, Han G, Farinha P, Johnson N,  Connors JM, Sehn L, Gascoyne RD 
and Steidl C.  Prognostic significance of BCL6 rearrangements detected by 
 452 
fluorescence in situ hybridization in diffuse large B cell lymphoma. 
Haematologica. 2010 Jan; 95(1):96-101. Epub 2009 Oct 1. PMID: 19797725 
 Section 6 
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, 
Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, 
Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, 
Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated 
macrophages and survival in classic Hodgkin's lymphoma.N Engl J Med. 2010 
Mar 11;362(10):875-85. PMID: 21368758 
 
Prognostic Factors in Follicular Lymphoma
Thomas Relander, Nathalie A. Johnson, Pedro Farinha, Joseph M. Connors, Laurie H. Sehn,
and Randy D. Gascoyne
From the Departments of Pathology &
Laboratory Medicine and the Division of
Medical Oncology, British Columbia
Cancer Agency and the University of
British Columbia, Vancouver, British
Columbia, Canada.
Submitted September 14, 2009;
accepted December 17, 2009;
published online ahead of print at
www.jco.org on April 12, 2010.
Supported by grants from the Crafoord
Foundation (T.R.), The Gunnar Nilsson
Cancer Foundation (T.R.), The Michael
Smith Foundation (01793; N.A.J.), the
Canadian Institute of Health Research
(53912; N.A.J., P.F.), Fundac¸a˜o para la
Cieˆncia e Tecnologia (BD13230/2003;
P.F.), Genome Canada (J.M.C., R.D.G.),
The Terry Fox Foundation (019001;
J.M.C., R.D.G.), and the National Cancer
Institute of Canada (019005; N.A.J.).
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: Randy D.
Gascoyne, MD, FRCPC, Department of
Pathology, British Columbia Cancer
Agency, 600 W 10th Ave, Vancouver,
British Columbia V5Z 4E6, Canada;
e-mail: rgascoyn@bccancer.bc.ca.
© 2010 by American Society of Clinical
Oncology
0732-183X/10/2817-2902/$20.00
DOI: 10.1200/JCO.2009.26.1693
A B S T R A C T
Follicular lymphoma (FL) is one of the most common types of non-Hodgkin’s lymphoma. It is
usually diagnosed at an advanced stage, for which many treatment options exist, however, no
curative standard therapy has been identified. The outcome is highly variable with a median
survival of approximately 10 years. The life expectancy of patients with FL has been extended with
the use of rituximab, a monoclonal antibody targeting the CD20 antigen on FL cells, but there
remains a group of patients who fail to respond to chemoimmunotherapy and die early of their
disease. Transformation of FL to an aggressive histology is an important event with high morbidity
and mortality. The Follicular Lymphoma International Prognostic Index has become the clinically
useful prognostic tool, but gives only a rough estimate of expected outcome. There is a need for
useful biomarkers for prediction of the disease course of single patients to individualize therapy,
especially in the new era of chemoimmunotherapy.
J Clin Oncol 28:2902-2913. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Follicular lymphoma (FL) constitutes approximately
20% of all newly diagnosed lymphoma cases,1 mak-
ing it the second most common subtype of non-
Hodgkin’s lymphoma worldwide and the most
common subtype seen in North America.2 It is char-
acterized by an indolent clinical course, typical
morphology, and the presence of a chromosomal
translocation, t(14;18)(q32;q21) or variant in 85%
of patients. This chromosomal aberration results in
the juxtaposition of the immunoglobulin heavy
chain gene (IGH) on chromosome 14 with the BCL2
oncogene on chromosome 18 leading to constitu-
tive, and therefore inappropriate, expression of the
BCL2 protein. Overexpression of BCL2 confers rel-
ative resistance to apoptosis, thus giving the cells a
survival advantage that may facilitate the acquisition
and retention of secondary genetic abnormalities.
FL is a heterogeneous entity with some patients
developing progressive or transformed disease early
and 15% dying within 2 years from diagnosis, while
others remain alive for decades without need for
treatment. This variability in outcome underscores
the necessity to gain further insight into the biology
and clinical behavior of the disease to enable individ-
ualized therapy.
TREATMENT AND CLINICAL COURSE
The median age at diagnosis of FL is 59 years with a
male to female ratio of 1:1.7.3 FL is typically diag-
nosed in the advanced stages, with only 26% to 33%
of patients presenting with stage I to II disease.3,4
With conventional chemotherapy, even if combined
with radiotherapy, advanced-stage FL is incurable. It
is characterized by an indolent course with patients
developing slowly progressive lymphadenopathy
over many years, with or without constitutional B
symptoms (eg, fever, weight loss 10%, drenching
night sweats). Temporary, spontaneous regressions
occur in 20% of patients managed without initial
therapy.5 Historically, median survival has ranged
from 6 to 10 years.4-7
Transformation to an aggressive lymphoma
occurs at a rate of 3% per year and is associated with
substantial morbidity and mortality.8,9 Transforma-
tion is defined as the development of a more aggres-
sive histology lymphoma, most commonly diffuse
large B-cell lymphoma (DLBCL), that is thought to
be clonally related to the original FL.
Limited-stage FL treated with external-beam
radiotherapy results in prolonged remission in 30%
to 50% of patients and an apparent plateau on the
disease-free survival curve after 15 to 20 years.10,11
Two randomized studies showed that deferred ini-
tial treatment in asymptomatic advanced-stage pa-
tients does not compromise long-term outcome or
risk of transformation.7,12 FL is highly sensitive to
antineoplastic agents early, but grows increasingly
resistant with successive lines of therapy.4
The chimeric anti-CD20 monoclonal antibody
rituximab has significant activity alone13 and in
combination with chemotherapy.14 The addition of
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rituximab to chemotherapy has resulted in a higher rate of complete
remission (CR) and prolonged remission duration without increasing
clinically relevant toxicity.15 Several studies have confirmed an im-
provement in overall survival (OS) with immunochemotherapy as the
initial treatment for FL.15-17 Furthermore, rituximab as maintenance
therapy after induction therapy for relapse improves progression-free
survival (PFS) and OS.18 However, an improved survival for patients
diagnosed with FL has been noted over the past 25 years,19 an effect at
least in part predating the introduction of rituximab, likely explained
by improved diagnosis and supportive care.
CLINICAL PARAMETERS
Multiparameter Indices
The International Prognostic Index (IPI), originally developed
for aggressive lymphoma, identifies four risk groups based on age,
tumor stage, serum lactate dehydrogenase (LDH) level, performance
status, and number of extranodal sites of disease.20 The IPI also reliably
identifies risk groups among FL21-23; however, it only classifies a small
proportion of patients into the highest-risk category.
Three prognostic indices have been developed specifically for FL.
The Italian Lymphoma Intergroup (ILI) index identifies three risk
groups with 10-year survival rates of 65%, 54%, and 11% based on six
clinical parameters (advanced age, male sex, number of extranodal
sites of disease, B symptoms, serum LDH level, and erythrocyte sedi-
mentation rate).24
In 2004, the Follicular Lymphoma International Prognostic In-
dex (FLIPI) was published resulting from a multicenter effort.25 It
includes five parameters: age ( 60 v 60 years), stage (III-IV v I-II),
anemia (hemoglobin 120 v 120 g/L), number of involved nodal
areas ( 4 v 4), and serum LDH (elevated v normal), and classifies
patients into three groups with 10-year OS rates of 71%, 51%, and
36%, respectively. The FLIPI is predictive in patients treated with
immunochemotherapy,26 can be applied in first relapse,27 and pre-
dicts transformation.28 The IPI, FLIPI, and ILI indices have been
directly compared, all identifying somewhat different risk groups.29
Recently, the FLIPI-2 index was published, incorporating beta-2 mi-
croglobulin, lymph node size larger than 6 cm, bone marrow involve-
ment, anemia, and age older than 60 years (Table 1).25,30,36 All of these
clinical indices are robust, easy to use in clinical practice, and of value
for stratification in clinical trials; however, marked variations in out-
come remain within each risk group.
Biomarkers in Blood and Bone Marrow
There are conflicting reports regarding the prognostic impact of
bone marrow (BM) involvement by FL. BM involvement was associ-
ated with decreased survival in several investigations including those
of the ILI and the FLIPI.24,25,32,33 In contrast, others have not found
BM involvement in itself to affect survival,34 but rather the histologic
pattern35 or degree of marrow involvement.36 Importantly, BM status
at the time of diagnosis has been included in the FLIPI-2.30
The characteristic t(14;18)(q32;q21) generates a BCL2-IGH fu-
sion gene, which can be used as a marker of disease detectable by
polymerase chain reaction (PCR).37 This technique is highly sensitive
and can routinely detect one translocation-positive cell in 106 cells in
peripheral blood (PB) or BM. PCR has been used for detecting mini-
mal residual disease (MRD) after therapy.38 Three different break
points within the BCL2 gene have been identified in FL.39-41 However,
the value of molecular monitoring in FL has not yet been established.
Despite attaining a CR after chemotherapy, the BM remained positive
by PCR in all or most patients without clear prognostic impact in
some reports,42-44 whereas others have found molecular CRs to be
common.45 Rambaldi et al46 reported that the degree of BM in-
volvement by lymphoma by quantitative real-time PCR before
rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) therapy was predictive of outcome and that
patients attaining molecular CR experienced a prolonged freedom
from relapse.
Currently, the implication of the presence of t(14;18)-positive
cells detected by PCR remains unknown. Not all PCR-positive pa-
tients relapse, and some convert to PCR negativity without therapy.47
Furthermore, t(14;18)-positive cells have been found in patients in
long-term remission after therapy for FL48,49 and BCL2 translocations
have been detected by PCR in PB from healthy individuals and from
autopsies from patients without lymphoma.50,51
Other Biomarkers in Blood
Biomarkers readily measurable from the PB that have been cor-
related with outcome in FL are summarized in Table 2.52-67 Beta-2
microglobulin has reached wide acceptance as a prognostic marker
and is included in FLIPI-2,31 but is not universally available in retro-
spective cohorts.24,25 LDH is a robust prognostic factor in several
types of lymphoma; however, in FL it is elevated in only 20% of
patients.24,25 Serum angiogenic factors have been analyzed in het-
erogeneous groups of patients with lymphoma with partly conflict-
ing results.59,60,61,63,68 Interestingly, polymorphisms leading to
high expression of tumor necrosis factor may influence outcome
in non-Hodgkin’s lymphoma, pointing to the importance of
host factors.62,64-66
PATHOLOGIC PARAMETERS
FL is a neoplasm of germinal center B cells that mimic the architecture
of normal secondary lymphoid follicles. Benign and malignant
follicles contain a heterogeneous mixture of non-neoplastic cells
including T cells, benign B cells, follicular dendritic cells (FDC), and
macrophages. The majority of patients with FL manifest two major
types of neoplastic B cells: small centrocytes and larger centroblasts.
Histologic grading of FL is based on the relative proportions of these
two cell types.
Histologic Grade
The current WHO classification recognizes three histologic
grades (grades 1 to 3) of FL.69 Grading of FL is poorly reproducible
Table 1. Adverse Factors in the FLIPI and the FLIPI2 Indices
FLIPI25 FLIPI230
Age  60 years Age  60 years
Stage III-IV Bone marrow involvement
Anemia (Hb  120g/L) Anemia (Hb  120 g/L)
Number of involved nodal areas  4 Nodes  6 cm
LDH  ULN 2-microglobulin  ULN
Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; Hb,
hemoglobin; LDH, lactate dehydrogenase; ULN, upper level of normal.
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among pathologists, calling into question studies that report prognos-
tic impact based solely on this variable. Similarly, subtle architectural
variations, such as the presence of diffuse areas, have not been well
annotated in most FL studies. Immunostaining for FDCs has been
infrequently performed, making it difficult to accurately determine
true follicle formation in most reported studies.70,71 Several studies
have suggested a correlation between grade and survival in FL.23,69,72,73
Although there is no OS difference between patients with grade 1 or 2
FL, there remains controversy about an inferior OS correlating with
FL grade 3. This may reflect that grade 3 FL itself is heterogeneous.
Anthracycline-based therapy has been claimed to be beneficial when
treating patients with grade 3 FL69 and to have a potential for cure;
however, this remains controversial.23,55,56,74,75 Miller et al76 found no
plateau in the survival curve or difference in OS between patients
receiving aggressive therapy for FL of different grades. In a retrospec-
tive analysis, Chau et al73 found no difference in survival among FL
grades 1 to 3. Patients with FL grade 3 were similarly at risk for late
relapses as for grades 1 and 2.
The WHO classification subdivides FL grade 3 into FL grade 3A,
made up of a mixture of centroblasts and centrocytes, and FL grade 3B,
in which the centroblasts are distributed in confluent sheets.69 Poten-
tially, FL grade 3A may lie within the spectrum of disease with FL
grades 1 to 2, while FL grade 3B may behave similarly to de novo
DLBCL. Similar to FL grades 1 to 2, FL grade 3A is more likely to be
CD10 positive and t(14;18) positive compared with FL grade 3B.71
Furthermore, chromosomal aberrations involving 3q27 (BCL6) occur
in a similar frequency in FL grade 3B and DLBCL.71,77 However, in
one report comprising 190 patients with FL grade 3, no difference in
event-free survival or OS was found between patients classified as
grade 3A and grade 3B,70 which is supported by Chau et al.73 Thus, the
relevance of distinguishing between FL grade 3A and 3B remains
unclear. Identifying areas of diffuse disease,70 likely a harbinger of
transformation, may be more clinically relevant.
Immunophenotype: Neoplastic Cells
Proliferation index. The proliferation index has prognostic value
in FL.23,78 It correlates with the number of large cells and thus with
histologic grade and with OS in univariate analysis but not in multi-
variate analysis.79
BCL2 and BCL2 family proteins. The family of BCL2-related
proteins plays a central role in the surveillance of mitochondrial integ-
rity by balancing between pro- and antiapoptotic members. Only a
few of these proteins have been studied in relationship to prognosis in
FL and no consistent correlation has been found.80 As a possible
exception, a high number of MCL1-positive centroblasts has been
correlated with poor OS.81 Similarly, expression of the long RNA
isoform of BCLXL has been correlated with prognosis in FL,
82 how-
ever, expression of the protein did not.83
Using reverse-phase protein microarrays, when microdissected
follicles from reactive lymph nodes were compared with follicles with
FL, most proapoptotic and antiapoptotic proteins except for BCL2
were present at comparable levels in BCL2-positive and BCL2-
negative tumors with activation of the AKT/BAD signaling pathway.84
Gulmann et al85 also used a proteomic approach to analyze apoptotic
pathways in FL. They found phosphorylation of AKT to be frequent in
FL suggesting that it may act as an antiapoptotic agent along with
BCL2. High ratios of BCL2/BAK and BCL2/BAX were associated with
early death from disease. The expression patterns of other proapop-
totic members of the BCL2 family have largely unknown clinical
impact.86 Future studies on the role of BCL2 family proteins in FL are
Table 2. Peripheral Blood Biomarkers and Prognosis in FL
Biomarker Effect on OS Other Effects Comment
Absolute lymphocyte count Longer if 152
Beta-2 microglobulin Poor response and short TTF if 115,53
Shorter if 154
Shorter if 155 FL grade 3
Shorter if 156 Shorter FFP if 1 FL grade 3
Shorter FFP in first relapse if 157
LDH Shorter if 124,25,33
No effect58 Stage I-II
Albumin
Serum Shorter if 224,25
Urine Poor response and short PFS if158
VEGF Shorter if 159 Associated with other poor prognosis
factors
Only 13% FL
FGF Shorter if 160 Strong prognostic factor Only 14% FL
VEGF  FGF Shorter if 161 Combination independent of IPI Only 14% FL
No effect62 30% FL
Endostatin Shorter if 163 Associated with VEGF 1 Only 16% FL
TNF Shorter if 164,65 Shorter PFS if 1 Combined with receptor levels;
40% indolent lymphoma
TNF  sCD23 Poor response if 166 Indolent lymphoma
sICAM-1 Shorter if 167 Correlated to advanced disease and
B-symptoms
Minority FL
Abbreviations: FL, follicular lymphoma; OS, overall survival; TTF, time-to-treatment failure; FFP, freedom from progression; LDH, lactate dehydrogenase; PFS,
progression-free survival; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; IPI, International Prognostic Index; TNF, tumor necrosis factor;
sICAM-1, soluble inter-cellular adhesion molecule-1.
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needed as they may identify patients who will benefit from novel BH3
mimetics, small molecules that specifically target BCL2 proteins.87,88
Germinal center–related markers. BCL6 encodes a zinc finger
transcription factor involved in germinal center formation. CD10 is a
membrane metalloendopeptidase expressed in the germinal center. In
FL, these two markers of germinal center origin are expressed in more
than 95% and 75% of cases, respectively.89 Although their prognostic
significance is established in DLBCL,90 their relevance in FL is less
clear. Using immunohistochemical scoring systems to combine the
percentage of positive malignant cells and their intensity of expression,
the expression level of BCL6 has been correlated with favorable prog-
nosis in FL.91 PU.1 is an ETS-domain transcription factor essential for
the development of myeloid and B lymphoid cells. Constitutive PU.1
expression inhibits the earliest B-cell development, and low levels of
PU.1 expression in hematopoietic progenitor cells are instrumental in
promoting B-cell fate determination.92 Torlakovic et al93 studied the
clinical impact of proteins associated with the germinal center in FL
and found PU.1 protein expression, but not CD10 or BCL6, to be a
favorable marker of OS independent of the FLIPI.
Cell cycle regulators. TP53 mutations have been reported in FL at
diagnosis and are associated with an inferior survival.94 The presence
of mutations leading to overexpression of the TP53 protein has been
associated with transformation.95,96 Expression of TP53 protein is
only moderately correlated with the presence of mutations (64%) and
similarly with the expression of key regulators of TP53, such as
CDKN1A or MDM2.97 The latter have also been shown to correlate
with transformation.97,98 A gene expression profiling study of 57 pa-
tients with FL established a set of 14 genes that were highly expressed in
patients with a favorable response to CHOP; however, only expression
of CYCLIN B1 mRNA and protein level had prognostic impact inde-
pendent of the FLIPI.99
Others. SOCS3 is a cytokine suppressor that inhibits cytokine
signaling by Janus kinase (ie, the JAK-STAT pathway). Overexpres-
sion of SOCS3 has been reported to be an independent unfavorable
prognostic factor in FL.100 Overexpression of Ying-Yang 1, a zinc-
finger protein regulating IL4 gene expression, has also been linked
with shorter survival in FL.101
Cytogenetics and Molecular Genetics
Classical karyotyping. Cytogenetic analysis of FL reveals a wide
range of recurrent, nonrandom chromosomal alterations. FL is char-
acterized by the overexpression of the antiapoptotic protein BCL2 as a
result of the t(14;18)(q32;q21) or its rare variants t(2;18) and t(18;22).
t(14;18) is present in approximately 85% of grade 1 and 2 FL and
although it is considered insufficient on its own to cause FL, it provides
these B cells with a survival advantage leaving them prone to accumu-
late additional genomic abnormalities.102 However, in a study of FL
cases lacking the t(14;18), Horsman et al103 found distinct patterns of
recurrent chromosomal alterations. In another report, FLs lacking the
t(14;18) were less likely to express CD10 or BCL2, were more likely to
arise at extranodal sites and had a better OS. Recently, Katzenberger et
al104 described t(14;18)-negative FL characterized by a predominantly
diffuse growth pattern, presenting clinically with large but localized
inguinal tumors. The majority of FL patients without a t(14;18) have a
deletion in 1p36.
The malignant cells in FL have an average of four to six different
cytogenetic changes in addition to the BCL2 translocation.105,106 Only
5% of FL have t(14;18) as the sole detectable abnormality. The most
common abnormalities are break points in chromosome 1, deletions
in the long arm of chromosome 6 (6q), trisomy 7 (7), trisomy 12
(12), presence of a derivative of chromosome 18 (der(18), and
duplication of X (X).106
Early studies suggested that the number of abnormalities and
presence of certain alterations (6q,7,X,21) were associated
with an inferior survival.107 However, as karyotypic complexity in-
creases after therapy,108 there is an inherent selection bias if biopsies
-
Poor prognosis
or early transformation
Good prognosis
or diminished
risk of transformation
PU.1, CCNB1, BCL6, CD10
Non-t(14:18), +8, +der(18)
Host Immunity
SNPs: FcR3a, IL8, IL2, IL12B, IL1RN
Treatment Regimen
IR2, “Activated” T cells and FDC
CD3 content, CD4 F and content, CD8 
content, CD57 content, FOXP3 Tregs F and 
content, PD1 F and content
Macrophage content, “Immature” FDC
Mast cell content, increased MVD,
VEGF, FGF, Endostatin, TNF
MCL1, BCLXL, BCL2/BAK or BAX,
SOCS3, YY1, TP53, TP15 and TP16
p38MAPK, MUM1
-6q, +7, +X, +21, +12, +12q13-14, del6q25-q27, 
del1p36, del6q21-q24.3, del9p21, -17p
aUPD 1p36 and 16p
MYC translocations
IR1, “Resting” T cells and FDC
CD3 IF and content, CD4 IF and 
content, CD8 content,FOXP3 Tregs 
IF and content, PD1 content
Macrophages IF and content
“Activated” FDC
Reduced MVD
Fig 1. Biomarkers impacting survival or
transformation in follicular lymphoma (FL).
Some biomarkers are controversial, result-
ing from treatment heterogeneity. Larger
circle: features of nonmalignant cells. In-
ner circle: tumor cells. IR, immune re-
sponse; FDC, follicular dendritic cells; IF,
interfollicular; F, follicular; MVD, microves-
sel density; VEGF, vascular endothelial
growth factor; EGF, endothelial growth
factor; TNF, tumor necrosis factor; aUPD,
acquired uniparental disomy; SNPs, single
nucleotide polymorphisms.
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taken at the time of progression or relapse are used for analysis. Tilly et
al109 reviewed 66 FL biopsies taken at the time of diagnosis and found
deletion 6q to be associated with an inferior survival. Ho¨glund et al110
reviewed the karyotypes of 336 cases of FL and, using principle com-
ponents analysis, postulated distinct pathways of clonal evolution of
chromosomal changes arising in a temporal order with early changes
being 1q,7,8,12, andder(18) and later 2p, 10p,15,
17p, and 17q. Based on the clinical data on 165 patients,12 and
17p were correlated with an adverse outcome. In contrast, we re-
cently reviewed 210 karyotypes from FL biopsies taken at diagnosis
and found no association between the number or type of cytogenetic
abnormalities with clinical outcome.111
Comparative genomic hybridization. Comparative genomic hy-
bridization (CGH) can be performed by hybridizing tumor DNA
against normal chromosomes (chromosomal CGH) or by using mi-
croarray platforms with spotted DNA probes (array CGH).112 Viardot
and colleagues113 analyzed 124 samples of FL using chromosomal
CGH and reported a number of recurrent alterations. In a subset
analysis of 82 patients, loss of chromosomal material at 6q25-27 was a
strong independent predictor of inferior survival. Cheung et al114
identified two genomic regions, deletions in 1p36.22-p36.33 and
6q21-q24.3, to be highly associated with transformation and inferior
OS in patients with FL using array CGH. Recently, Schwaenen et al115
reported a large number of recurring genomic aberrations in FL as
analyzed by array CGH, of which deletions in 9p21 (CDKN2A/B),
6q25, and 6q26 were associated with inferior survival.
Single nucleotide polymorphism arrays. Copy-neutral loss of het-
erozygosity, undetectable by previously available methods, can be
identified using single nucleotide polymorphism (SNP) arrays. This
phenomenon, termed acquired uniparental disomy (aUPD), results
from mitotic recombination or nondisjunction and has been de-
scribed in FL.112,116 In a recent report, a number of recurring aUPDs
were described in FL, of which aUPD on 1p36 correlated with
shortened OS and aUPD on chromosome 16 was predictive
of transformation.117
Host Constitutional Genetics
SNPs are changes in the DNA sequence by one base pair. Recent
studies have suggested that SNPs in the FcR genes may signifi-
cantly alter the binding affinity between the Fc portion of ritux-
imab and the Fc receptors on macrophages.118,119 Cartron et al120
found a correlation between the FcRIIIA genotype and response to
single-agent rituximab in untreated FL. Patients homozygous for
158VV FcRIIIA polymorphism did significantly better than the
heterozygotes 158VF. In a study of recurrent FL, Weng and
Table 3. Morphologic, Immunophenotypic, and Gene Expression Biomarkers in FL
Biomarker Impact on Survival Risk of Transformation
Morphology
Tumor cells
Histologic grade70,74 Therapy-dependent, increasing grade associated
with worse OS; effect possibly mitigated by
doxorubicin-containing regimens
No effect
Grade 3A v 3B22,55,70,71,76,77 No effect Typically already present
in grade 3B
Architecture (diffuse)26,71 Controversial Increased
Proliferative rate22,78,79,133,174,175 Controversial No effect
Microenvironment
Microvessel density129-131 Controversial Not studied
Macrophages83,127,135-137 Unfavorable No effect
FDC102,135,176 Unfavorable if immature phenotype of FDCs Increased; associated
with FDC disruption
CD4 T cells83,102,136,140,142,149,177-179 Controversial No effect
CD8 T cells136,142,146,147 Controversial Controversial
Regulatory T cells136,140-142,177 Controversial Not studied
Single gene (RNA and/or protein)
BCL6 and CD10 91 Favorable Not studied
BCL2 and BCL2/BAX or BAK 80,86 High ratio favoring BCL-2 associated with early
death
Not studied
MCL181 High MCL-1 associated with worse outcome Not studied
BCLXL
82 High BCL-XL associated with inferior survival Not studied
MUM1180,181 Expression of MUM1 may be associated with
inferior survival
Not studied
PU.193 Favorable Not studied
SOCS3100 Unfavorable Not studied
YY.1101 Unfavorable Not studied
Multigene
IR-1 and IR-2127 Variable; IR-1 associated with favorable OS,
while IR-2 predicts for inferior OS
Not studied
81-gene predictor128 No effect; strongly predictive of immediate
clinical behavior
No effect
Abbreviations: FL, follicular lymphoma; OS, overall survival; FDC, follicular dendritic cells; IR, immune response signature.
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colleagues121 confirmed these findings and identified a second poly-
morphic site related to the duration of response (FcRIIA 131 histidine/
arginine). Similarly, Ghielmini et al122 reported that FcRIIIA V/V was
a predictive factor for event-free survival in rituximab monotherapy in
FL. In contrast, Maloney et al and others123,124 did not find that
FcRIIIA or RIIA polymorphisms correlated with outcome in a study of
R-CHOP.
Recently, Cerhan et al125 analyzed the impact of immune re-
sponse SNPs in FL. Germline DNA was analyzed from patients with
FL and a final set of four prognostically relevant immune response
SNPs was identified (interleukin [IL] -8, IL2, IL12B, and IL1RN). An
outcome predictor was built using clinical and demographic factors
combined with the four deleterious SNPs, which identified three risk
groups with 5-year OS estimates of 96%, 72%, and 58%, respectively.
These patients were treated in an era before the use of rituximab.
Although these four genes strongly predict outcome in patients with
FL, none of them has been shown to be associated with the risk of
developing FL.125,126 Together with the gene expression profiling
(GEP) data below,127 these results suggest that the composition and
functional status of the immune cells in the tumor microenvironment
of FL may largely be driven by the genetics of the host.
Non-Neoplastic Cells of the Microenvironment
Lymph nodes involved with FL contain an admixture of non-
neoplastic T cells, FDCs, macrophages, and other cells. A renewed
interest in the microenvironment in FL followed the Leukemia Lym-
phoma Molecular Profiling Project (LLMPP) study in 2004127 in
which GEP of whole-section frozen lymph nodes from 191 cases of FL
demonstrated that the tumor microenvironment was the most impor-
tant predictor of patient outcome. Two signatures of gene expression
were identified that best correlated with survival prediction. The
immune-response 1 (IR-1) signature included genes encoding for
T-cell markers and some genes that are highly expressed in mono-
cytes/macrophages, and predicted a favorable outcome. The IR-2 sig-
nature included genes preferentially expressed in macrophages or
dendritic cells, and predicted an unfavorable outcome. When patients
were grouped into quartiles based on their survival-predictor scores,
median survival rates ranged from 3.9 years to 13.6 years. These data
highlighted the dominant prognostic role of the microenvironment in
FL and suggested that the critical determinants of outcome might
already be present at diagnosis.
After the LLMPP study, Glas et al128 performed GEP in a series of
patients with FL who were grouped according to outcome and trans-
formation. They defined an 81-gene predictor that correlated with
immediate clinical behavior but not with long-term survival or risk of
transformation. Interestingly, the genetic profile of patients with early
transformation exhibited an activated status of T cells, FDCs, and
macrophages characterized by genes that were present in the favorable
IR-1 signature of the LLMPP study. Differences in experimental de-
sign, patient selection, gene expression platforms, and data analysis
may explain the different conclusions between these two studies.
Microvessel density. Despite evidence for a vital role of angiogen-
esis in supporting tumorigenesis,129 some reports have suggested that
increased vessel density correlates with better prognosis in FL.130 In-
triguing results by Streubel et al131 demonstrated that endothelial cells
of the microvasculature share the BCL2 rearrangement characteristic
of FL, implying an intimate relationship between the two.
FDC meshwork “immaturity.” In addition to presenting anti-
gens, FDCs comprise the scaffolding of both benign and malignant
follicles, their dendritic processes providing structural support for B
cells and non-neoplastic cells. An immature FDC phenotype is typi-
fied by expression of low-affinity nerve growth factor and CNA.42,
accompanied by absence of mature FDC markers such as CD21,
CD35, CD23, and CXCL13. This phenotype typifies undifferentiated
fibroblastic cells and has been reported to correlate with progression
Table 4. Molecular Genetic Biomarkers in FL
Gene Impact on Survival Risk of Transformation
BCL2165,182-186 No clear survival difference between t(14;18)-positive
FL and t(14;18) negative; suggestion that BCL2
breakpoint may affect survival, but unconfirmed by
later studies
Somatic mutations of BCL2 gene on the translocated
allele may rarely underlie transformation
MYC161-163,170 Translocations of MYC rarely encountered at
diagnosis; tend to confer an inferior survival
Infrequently associated with transformation, but when
found they are associated with markedly inferior post-
transformation survival
CDKN2A/B160,187 Tumor suppressor genes on chromosome 9p21; only
rarely found at diagnosis and not definitively
associated with survival
Paired sample studies clearly show loss of CDKN2A/B
through deletion, mutation, or hypermethylation is
associated with histologic transformation
TP53 95-97 Loss of TP53 tumor suppressor only rarely seen at
diagnosis; mutation is closely correlated with
protein expression in FL
Loss of TP53 was the first gene implicated in
transformation of FL; LOH not typically associated
with 17p13 deletion
MDM2 97,99 None Expression correlated with transformation, but not
obviously correlated with TP53 gene status; found
within the amplified region of chromosome 12q13-14
frequently associated with transformation
BCL6164,184,188 No clear affect on survival in FL Postulated to increase risk of transformation, but studies
documenting the presence of translocations were
based exclusively on inverse LD-PCR
CCNB199 Increased expression of cyclin B1 associated with
improved survival after CHOP chemotherapy
Abbreviations: FL, follicular lymphoma; LOH, loss of heterozygosity; LD, long-distance; PCR, polymerase chain reaction; CHOP, cyclophosphamide, doxorubicin,
vincristine, and prednisone.
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and/or transformation,132 but not in all studies.83 These changes cor-
relate with loss of normal T-cell infiltration within follicles and might
reflect a reduced cross-talk between these two cell types. Disruption of
the tight FDC meshwork that characterizes FL has been associated
with early transformation.133
Macrophages. Tumor-associated macrophages have been de-
scribed in a number of cancers, with increased numbers of benign
macrophages typically associated with inferior survival. Farinha and
colleagues83 demonstrated that the small subset of FL cases with high
macrophage content experienced markedly decreased OS and PFS
independent of the IPI. These data appear consistent with the LLMPP
GEP study, with high macrophage content being a surrogate for the
IR-2 signature.127 Alvaro et al134 reported opposite results finding that
increased macrophages were associated with indolent clinical behav-
ior. In a related study, these same authors found that 30% of macro-
phages express STAT1 protein and that presence of this subset of cells
was associated with inferior survival.135 In two recent trials, a high
macrophage content was associated with poor survival after chemo-
therapy, but not if combined with rituximab.136,137
Macrophage plasticity has been well described, as these cells can
be broadly separated into helper (M1) and healer (M2 or activated)
cell types.138 In most tumors, tumor-associated macrophages are
polarized to a M2 phenotype and appear to create a trophic envi-
ronment that favors the tumor cells.139 A pan-macrophage marker
(CD68) cannot capture these distinctions and may explain the discor-
dant results.
T-cell subsets. T cells comprise a majority of the non-neoplastic
cells in FL biopsies and play an important role in FL. Subsets include
helper CD4-positive T cells, cytotoxic CD8-positive T cells, CD57-
positive follicular helper T cells, and immunosuppressive regulatory T
cells (Treg), but the exact role played by these subsets is not completely
understood. Studies investigating the roles of CD4-positive and CD8-
positive T cells in FL utilize different methodologies and have conflict-
ing results.133,134,140-144 Tregs are a subset mostly with a CD4-positive
CD25-positive forkhead box protein P3-positive145 immunopheno-
type that serve a critical role in regulating CD4 and CD8 effector
functions by suppressing proliferation and cytokine production of
these cells.146 In epithelial malignancies, Tregs have been implicated in
creating an immunosuppressed microenvironment that allows the
tumor cells to escape the host immune response.147 Some investiga-
tors have reported that an increased number of Tregs was associated
with favorable clinical behavior in FL,134,141 while others claim that the
T-cell distribution may be more relevant.143,148 Recently, a low num-
ber of tumor-infiltrating programmed cell death 1–positive was asso-
ciated with transformation and with inferior survival.149 Still, the
precise role of T-cell subsets in FL biology remains unclear. The clin-
ical impact of these cells in the microenvironment may be largely
influenced by the characteristics of the patient and the treatments
received.145 Specific therapies may have different effects on neoplastic
cells versus cells within the microenvironment. Moreover, the role of
host genetics influencing the immune microenvironment has only
recently been explored.125
Transformation
Histologic transformation is often heralded by a sudden change
in clinical behavior, such as a rise in serum LDH or development of
unusual extranodal sites of disease. It is a dominant clinical event,
associated with shortened survival and relative resistance to therapy.
The reported frequency varies dramatically ranging from 5% to 60%
Pro-FL Immunity
Pre-FL B cell
Anti-FL Immunity
Host immunity and tumor cell genetics
treatment regimen
Cure ?
Transformation Progression
Fig 2. Model of how non-neoplastic cells
in the microenvironment might impact
survival and transformation in follicular
lymphoma (FL). Left: follicular polarization
of CD4 cells, especially forkhead box
protein P3–positive regulatory T cells (blue
circles), increased numbers of vessels
(red tubes), mast cells (blue stars), or
macrophages (gold stars): local immunity
supports tumor growth. Right: an antilym-
phoma immune response.
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of patients with FL.5,8,150-156 Since risk of transformation is time de-
pendent, approximately 3% per year, this variation probably reflects
differing durations of follow-up. The length of time that patients are
followed and the rigor with which biopsies are obtained at progression
heavily affect the reported frequency. Biomarkers that predict for
survival do not necessarily correlate with those that predict risk
of transformation.
An association between increased FLIPI score and frequency of
transformation has been noted.9,28 Morphologic features associated
with transformation risk include the presence of diffuse areas and
disruption of the FDC meshwork.132,157 The presence of grade 3B FL
and increased intrafollicular CD4-positive T cells have also been
linked to early transformation.133
Studies using paired samples (FL and subsequent DLBCL) have
demonstrated that transformation is a molecularly heterogeneous
event, including loss of TP53, loss of the CDKN2A tumor suppressor,
or acquisition of MYC translocations, leading to upregulation of MYC
or its target genes.95,96,98,158-163 Other molecular alterations include
mutations of the coding region of BCL2 and translocations involving
BCL6.164,165 Cytogenetic studies of paired samples have revealed can-
didate chromosomal alterations, including 7, 12q13-14, and
6q16-21.166-170 Lastly, a number of small studies using gene expres-
sion profiling of paired samples have been published.160,170-173
These demonstrate the molecular heterogeneity underlying trans-
formation, implicating upregulation of p38 MAP KINASE, up-
regulation of MYC and its target genes, and a generic increase in the
mitotic machinery.
Recent data suggest that FL may comprise two major patient
subgroups; those destined to develop transformation and those who
will not.9 Distinguishing between these two clinical risk groups might
have major implications for therapy.
Translation Into the Clinic
A summary of factors associated with outcome in FL is shown
in Figure 1. As presented in Tables 2, 3, and 4,174-188 consensus on
which biomarkers to use in clinical practice and how these might
impact treatment decisions is still lacking. Most prognostic mark-
ers were studied before the introduction of rituximab and require
validation in the current era of chemoimmunotherapy. At this
time, disease behavior and robust indices, such as the FLIPI and
FLIPI-2, remain the basis for clinical decision making. The key
elements in the interaction of host immunogenetics, tumor micro-
environment, and therapy in FL are still not well understood (Fig
2). The inclusion of correlative science into clinical trials should
help to determine the precise role of biomarkers in predicting
survival and transformation risk in FL. Prospective randomized
clinical trials will be instrumental in defining future prognostic
factors in FL, as uniform treatment groups can be compared (Fig
3). If patients who respond poorly to standard therapy can be
identified and the mechanism(s) underlying their inferior out-
come determined, these patients could reasonably be considered
candidates for novel therapies with the potential for improved
outcome avoiding toxicity from ineffective therapy.
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The impact of therapy on FL
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Biopsies obtained
prior to therapy
reflect differences in
basic biology in FL
Treatment
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differentially visited upon the neoplastic
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Results are
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Fig 3. Treatment influences prognostic
markers. Biopsies stained for CD4. Left, T
cells within neoplastic follicles; right, in
the interfollicular region. Importantly, treat-
ments differentially visit toxicity on tumor
cells versus cells in the microenviron-
ment. The prognostic role of any factor
must be interpreted with caution if treat-
ment varies. FL, follicular lymphoma; Rx,
therapeutic regimens.
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CORRECTIONS
Author Corrections
The January 10, 2010, article by Oktay et al, entitled, “As-
sociation of BRCA1 Mutations With Occult Primary Ovarian
Insufficiency: A Possible Explanation for the Link Between
Infertility and Breast/Ovarian Cancer Risks” (J Clin Oncol 28:
240-244, 2010), contained an error.
The primary institutional affiliation for David Barad was
inadvertently omitted and should have been listed as The Cen-
ter for Human Reproduction, New York, NY.
The authors apologize to the readers for the mistake.
DOI: 10.1200/JCO.2010.32.8278
■ ■ ■
The July 10, 2010, article by Sargent et al, entitled, “Defec-
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NEOPLASIA
Analysis of multiple biomarkers shows that lymphoma-associated macrophage
(LAM) content is an independent predictor of survival
in follicular lymphoma (FL)
Pedro Farinha, Hamid Masoudi, Brian F. Skinnider, Karey Shumansky, John J. Spinelli, Karamjit Gill, Richard Klasa, Nicolas Voss,
Joseph M. Connors, and Randy D. Gascoyne
We studied the role of multiple biomark-
ers in determining outcome in follicular
lymphoma (FL), concentrating in particu-
lar on the role of benign macrophages.
The study group consisted of uniformly
staged and treated patients with FL en-
rolled in a phase 2 trial between 1987 and
1993. All patients were younger than 61
years of age, had advanced-stage FL, and
were treated with a multiagent chemo-
therapy regimen, BP-VACOP (bleomycin,
cisplatin, etoposide, doxorubicin, cyclo-
phosphamide, vincristine, and pred-
nisone), followed by involved region radia-
tion. The median follow-up of living
patients was 12.5 years, and the median
survival was 16.3 years. The International
Prognostic Index (IPI) was predictive of
overall survival (OS) (P  .003). Biopsy
specimens from all cases were stained
with an anti-CD68 antibody. Of the 99
evaluable patients with FL, 87 had less
than 15 CD68 macrophages/high-power
field (hpf) (median, 7; range, 1-14) and 12
had more than 15 CD68 macrophages/
hpf (median, 20; range, 16-25) with a
median OS of 16.3 vs 5.0 years, respec-
tively (P < .001). A multivariate Cox model
that included the IPI score, the histologic
grade, and the lymphoma-associated
macrophage (LAM) score, showed IPI and
LAM to be independent predictors of OS
(P  .009 and P  .004, respectively). The
LAM content of FL predicts survival, and
these data support a prominent role for
nonneoplastic immune cells in the biol-
ogy of FL. (Blood. 2005;106:2169-2174)
© 2005 by The American Society of Hematology
Introduction
Follicular lymphoma (FL) is the second most common non-
Hodgkin lymphoma (NHL) subtype, surpassed only by diffuse
large B-cell lymphoma (DLBCL).1 The typical survival curve in
most studies attests to the marked clinical heterogeneity that
characterizes FL. With median survivals of 8 to 10 years, approxi-
mately 15% of newly diagnosed patients will die of their disease in
the first 2 years, while others are still alive more than 20 years
later.2 In addition, interpretation of clinical trials of FL is made
difficult by the fact that events unfold over many years.
A number of clinical prognostic variables have been described
in FL but a recent international effort has culminated in a scoring
system with a high likelihood of universal acceptance. The
Follicular Lymphoma International Prognostic Index, or FLIPI,3
measures 5 variables including age, Ann Arbor stage, hemoglobin
level, number of nodal sites, and serum lactate dehydrogenase
(LDH) level. Although clinical variables, which are surrogate
markers for underlying biology, can provide useful prognostic
information, there is a clear need to develop biomarkers in FL that
are predictive of outcome that could then be used to supplement
indices such as the FLIPI index.4 However, few biologic markers
have been developed that can be shown to have independent
prognostic impact in patients with FL. A possible impact on
survival has been described for several pathologic variables,
although the results are inconsistent at best. The list of candidate
biomarkers includes morphologic features (histologic grade, prolif-
eration rate, presence of marginal zone differentiation, diffuse
areas, small vessel content), molecular alterations (loss of p53, loss
of p16, acquisition of CMYC alterations), cytogenetic abnormali-
ties (del6q,17p13,18,12q13-14) and altered protein expres-
sion (Bcl-2 and Bcl-6 proteins).5-28 Problems with patient selection
and inclusion bias, lack of large patient cohorts treated with
uniform therapy, inconsistent interobserver reproducibility of histo-
logic/immunohistochemical features, and low frequency of several
of these molecular events hamper the clinical translation of these
biomarkers.
The presence of leukocytes in human tumors was first noted in
neoplastic tissues by Rudolf Virchow in 1863.29,30 He suggested
that the “lymphoreticular infiltrate” reflected an important interac-
tion between cancer cells and cells involved in chronic inflamma-
tion. Over the past 10 years our understanding of the inflammatory
microenvironment of tumors has provided support for Virchow’s
original hypothesis. Tumor-associated macrophages (TAMs) have
been the subject of investigation in a number of different tumors,
including breast, prostate, ovarian, and cervical cancers, where a
clear correlation with inferior survival has been seen with increased
TAM content.31 Curiously, in other tumors such as gastric and lung
cancer, the results have been contradictory.32 These disparate
findings may be due to specific functional characteristics of
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macrophages in some tumors and may be context dependent.
Nonetheless, in the majority of studies increased TAM density has
been associated with both metastatic spread and diminished
survival. We are unaware of any previous literature implicating
macrophages in the prognosis of FL.
Recent work by the Leukemia/Lymphoma Molecular Profiling
Project (LLMPP) has shown that gene expression profiling can be
used to establish a molecular subclassification of FL, and, impor-
tantly, was used to develop a powerful outcome predictor.33 In a
study of 191 patients using pretreatment biopsies, it was revealed
that nonneoplastic immune cells were predominantly responsible
for the gene expression signatures contributing most to the
outcome predictor. One signature, referred to as immune re-
sponse-1 (IR-1), appeared to be derived from reactive T cells in the
lymph node biopsies and conferred a favorable outcome. The other
signature, referred to as immune response-2 (IR-2), revealed a gene
expression pattern most reminiscent of macrophages and/or follicu-
lar dendritic cells. This IR-2 signature conferred an inferior
survival on patients with FL. Treatment in this study was not
uniform; nonetheless, these data allowed the development of a
molecular predictor score with widely divergent survivals. More-
over, these results clearly demonstrated that molecular characteris-
tics of the tumors that impact upon survival were present in original
diagnostic biopsies, suggesting that ongoing stochastic events may
not be as important for determining survival in FL. The character of
the IR-2 gene list (eg, complement genes, toll-like receptors, Fc
receptors, etc) suggested that macrophages might be playing an
important role in the biology and survival of patients with FL. On
the strength of these observations, we studied the clinical impact of
the content and morphologic patterns of follicular dendritic cells
(FDCs), T-cell subsets, and lymphoma-associated macrophage
(LAM) content in patients with FL who had been uniformly staged
and treated at our own institution.
Patients, materials, and methods
Patient characteristics
The British Columbia Cancer Agency (BCCA) is the primary referral center
for patients diagnosed with lymphoid malignancies in the province of
British Columbia, Canada. It serves a catchment area of approximately 4
million people. Consecutive patients seen at the BCCA between July 1987
and May 1993 were offered enrolment in the BP-VACOP program
consisting of chemotherapy (bleomycin, cisplatin, etoposide, doxorubicin,
cyclophosphamide, vincristine, and prednisone) followed by involved field
irradiation to sites of original nodal involvement. Patients were deemed
eligible for enrollment if they were aged 16 to 61 years with newly
diagnosed, treatment-naive, advanced-stage indolent non-Hodgkin lym-
phoma. Advanced stage disease was defined as Ann Arbor stage III or IV, or
stage II with B symptoms, nonradioencompassable disease, or bulk of 10
cm or greater in maximum diameter at any individual tumor site. Patients
were otherwise unselected other than to exclude those with independent
organ dysfunction that would have made administration of the chemo-
therapy unacceptably toxic. Approval to review, analyze, and publish the
data in this study was given by the University of British Columbia–British
Columbia Cancer Agency Research Ethics Board. Informed consent was
provided according to the Declaration of Helsinki. The source of pathology
specimens for diagnosis included only lymph node biopsies. All patients
had indolent lymphoma confirmed by standard histologic, immunohisto-
chemical, and immunophenotypic and cytogenetic methods. Pathology was
reviewed after enrollment but was not an inclusion criterion. A single
pathologist (R.D.G.) classified all cases as indolent according to the
Working Formulation for Clinical Usage and later updated them according
to the World Health Organization (WHO) classification.34 For this study of
tumor-associated macrophages, 2 pathologists (R.D.G. and B.F.S.)
re-reviewed all of the FL cases, graded them according to the WHO
criteria, and recorded those with evidence of marginal zone differentia-
tion.34 The histologic diagnoses of the other cases, not included in this
study, were small lymphocytic lymphoma, lymphoplasmacytic lym-
phoma, diffuse follicle-center lymphoma, mantle-cell lymphoma, and
marginal-zone lymphoma.
Tissue microarray construction
A tissue microarray (TMA) was constructed using a tissue arrayer device
(Beecher Instruments, Silver Spring, MD). Only those FL cases with
adequate biopsy material and available blocks could be included. Of the 126
cases of FL, paraffin blocks were available for 110 patients. Of these, 105
had adequate material remaining in the block to be used for the TMA.
Duplicate 1.0-mm cores were used to construct the TMA. Slides from the
TMA block were cut at 4 microns.
Histology and immunohistochemistry
A hematoxylin and eosin (H&E) stain of the TMA was prepared using
routine methods. All of the cores contained neoplastic follicles, and no
discrepant results were seen between duplicate cores. A battery of immuno-
histochemical stains were performed, including CD20 (L26), CD3, CD4,
CD7, CD8, CD10, CD21, CD57, MIB-1, T-cell intracellular antigen-1
(TIA-1), Bcl-2, Bcl-6, Bcl-XL, and CD68 (Table 1). Immunostaining was
performed using a Dako autostainer and the EnVision polymer detection
system, except for CD10 detection in formalin fixation, which employs the
PowerVision system (all from DakoCytomation, Glostrup, Denmark).
Antigen retrieval was used for all antibodies and included enzyme
predigestion for CD21 and pressure-cooking (5 minutes) for the remainder.
A variety of buffers were used depending on the specific antibody to allow
optimal detection of the antigens. The chromogen in all cases was
diaminobenzidine.
The immunostained TMA slides were scored both for architectural
pattern and the number of positively stained cells. In total, 14 biomarkers
were analyzed in this study. For CD10, CD20, Bcl-2, Bcl-6 and Bcl-XL, the
cases were scored qualitatively, as duplicate cores were either completely
positive or negative. In addition to the qualitative CD10 scoring, the
presence or absence of interfollicular CD10 neoplastic cells was noted.
The proliferation rate of the neoplastic cells was scored based on the
percentage of the MIB-1 cells within neoplastic follicles (MIB-
1  10%  1; MIB-1  10 and  50%  2; MIB-1  50%  3). T-cell
markers (CD3, CD4, CD7, CD8, and CD57) were evaluated both for their
distribution in relation to the neoplastic follicles (interfollicular or perifol-
licular compartments), the predominance of CD4 versus CD8 cells, and
counting the mean number of the CD57 cells. Cytotoxic granule TIA-1
cells were scored qualitatively, with cases called positive in the presence of
Table 1. Antibodies used in the study
Antibody Clone Source Dilution
Bcl-2 124 DAKO 1:20
Bcl-XL 2H12 ZYMED 1:50
Bcl-6 PG-B6p DAKO 1:10
CD3 — Cell Marque/Novocastra 1:100
CD4 4B12 Novocastra 1:50
CD7 CD7-272 Novocastra 1:30
CD8 C8/144B DAKO 1:50
CD10 56C6 Novocastra 1:50
CD20 L26 DAKO 1:500
Ki67 MIB1 DAKO 1:100
CD21 1F8 DAKO 1:30
CD57 NK-1 Novocastra 1:30
CD68 KP1 DAKO 1:2000
TIA-1 2G9A10F5 Beckman 1:250
ZYMED (Invitrogen, Carlsbad, CA); Cell Marque (Hot Springs, AR); Novocastra
(Newcastle upon Tyne, United Kingdom).
— indicates CD3 clone PS1 (Ultra Marque CD3).
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more than 10% of positive T cells. Follicular dendritic-cell (FDC)
meshworks (CD21) were morphologically classified either as follicular
pattern (tight concentric FDC cytoplasmic processes) or expanded when
there was dissolution of the normal pattern and coalescence of FDC
processes in a loose arrangement between follicles.
CD68 macrophages were first evaluated for their consistency between
duplicate cores and then qualitatively. The initial analysis of CD68 staining
revealed that macrophage content could be divided into 2 groups, cases with
either none or few cells positive versus many positive cells. To make the
determination of macrophage numbers more objective, we counted cells
using high-power magnification ( 1000 oil lens). This high magnification
was used to avoid counting neutrophils and intercellular debris occasionally
stained with this antibody. Five representative fields per case were counted.
We chose to count in areas where the staining was the strongest and most
uniform. In virtually all of the cases scoring was made easier by the fact that
cases were either clearly positive or negative (Figure 1). Neither FDCs nor
neoplastic B cells stained with anti-CD68 in any case.
Statistics and survival analysis
Progression-free survival (PFS) was defined as the interval between
diagnosis and death or lymphoma progression, whichever came first;
disease-specific survival (DSS) was defined as the interval from diagnosis
until death when the underlying cause of death was lymphoma or treatment
toxicity, with all other causes of death censored; and overall survival (OS)
was defined as the interval from date of diagnosis until death from any
cause. International Prognostic Index (IPI) score originally developed for
large-cell lymphomas, histologic grade, the presence of marginal zone
differentiation, age, sex, and each of the 14 biomarkers (Table 2) including
LAM were evaluated for prognostic significance. The relationships between
LAM and other potential prognostic factors were assessed by the Pearson 2
test. Survival estimates were calculated using the Kaplan-Meier method.35
Significance levels, estimates of hazard ratios (HR), and their 95%
confidence intervals (CIs) were calculated using the proportional-hazards
regression model.36
Results
Clinical characteristics and outcome
A total of 99 patients were included in this study, representing the
patients with FL from the original clinical cohort (n 126) with
available blocks, sufficient tissue remaining in the blocks, and
successful TMA construction and interpretation. The median age of
the evaluable patients was 44 years (range, 19-61 years). There
were 49 women and 50 men. The distribution of IPI score included
58 patients with IPI scores of 0/1 (group 1), 40 with IPI scores of
2/3 (group 2), and only a single patient with an IPI score of 4/5
(group 3). For analysis purposes, the single patient in IPI group 3
was included with IPI group 2 in order to eliminate a clinical group
with only 1 patient. The median follow-up of living patients
(n  55) was 12.5 years. The median OS was 16.5 years. The IPI
was highly significant as a predictor of OS, disease-specific
survival (DSS) and progression-free survival (PFS) (P  .001,
.003, and .007, respectively).
Pathology variables
Histologic grading of FL subtypes according to the WHO
classification included 77 with grade 1, 15 with grade 2, and 7
with grade 3a. A total of 15 patients were determined to have
Figure 1. Representative tissue microarray cores of patients with
follicular lymphoma. The image on the left shows the uncommon
finding of large numbers of macrophages both within and surrounding
neoplastic follicles (n  12). The image on the right shows the more
common finding of very few macrophages (n  87). The insert shows
the typical strong cytoplasmic staining of reactive macrophages with
anti-CD68 antibody. Images were acquired using a Nikon Eclipse
E600 clinical microscope and Dxm1200 digital camera and software
(Nikon, Tokyo, Japan). Original magnification  100 (objective, 10 /
0.3 NA) for the larger panels and 1000 (objective, 100 /1.3 NA) for
the insert.
Table 2. Biomarkers in follicular lymphoma
Biomarker
No.
failed No. positive (%)
Morphologic
pattern OS P Comments
Bcl-2 2 92 (89) — NS
Bcl-XL 1 15 (14) — NS  10% lymphoma cells
Bcl-6 1 81 (78) — NS
CD10 2 94 (91) — NS
Interfollicular CD10 2 78 (76) — NS Presence of interfollicular CD10
neoplastic cells
Ki-67 (MIB-1) 5 62 (62) — NS  50% neoplastic nuclei
CD4 2 78 (76) — NS Majority of T cells
CD7 pattern 1 73 (70) Interfollicular NS Interfollicular CD7 predominance
CD4/CD8 pattern 5 71 (71) Follicular NS Intrafollicular CD4 and
perifollicular CD8
FDC (CD21) pattern 19 27 (31) Expanded
follicles
NS Coalescence of FDC meshwork
CD57 1 67 (64) — NS  10% of T cells
CD57 pattern 13 68 (63) Follicular NS Intrafollicular CD57 predominance
TIA-1 1 47 (45) — NS  10% T cells
CD68 macrophages 6 12 (12) —  .001  15 macrophages/hpf ( 1 000)
— indicates not evaluated; NS, not significant.
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marginal zone differentiation, as defined by a zone of pale cells
at least 3 cells in thickness, expressing CD20 and surrounding
neoplastic follicles. Neither histologic grade nor the presence of
marginal zone differentiation had an effect on OS, DSS, or PFS
(data not shown).
Some cores were lost during the preparation of the sections
or were uninterruptible due to poor fixation and/or inadequate
staining (varies with biomarker). The percentage of informative
individual cores was 96%, which varied with the different
biomarkers (1%-18%; Table 2). Results of the biomarkers are
summarized in Table 2. The percentage of the positive cases for
Bcl-2, Bcl-6, and CD10 were in line with previous reports. In
total, 16% of the CD10 FL had no or minimal interfollicular
involvement by CD10 neoplastic cells. Only a small number of
cases (14%) had more than 10% Bcl-XL cells. There was a
correlation between the proliferative rate (MIB-1) and the
histologic grade, at least for the small number of grade 3a cases.
The majority (83%) of grade 3a FL cases had a proliferative rate
greater than 50%. Grade 2 FL cases showed more heterogeneity,
with 62% having a proliferative rate between 10% and 50%,
while the bulk of the remaining cases had more than 50%
MIB-1 cells. Only 50% of the grade 1 FL cases revealed less
than 10% MIB-1 cells, with the majority of the remaining cases
demonstrating proliferative rates between 10% and 50%. These
data indicate the imperfect relationship between histologic
grade and proliferative rate. Importantly, neither grade nor
MIB-1 score were predictive of outcome (data not shown).
The FDC pattern (CD21) was disrupted with expansion of the
meshwork and fusion of the follicles in 27% of the cases. The
reactive T cells showed a predominantly perifollicular distribution
in most cases (70%), as well as a CD4 phenotype (76%). In 71% of
the cases there was a unique follicular pattern, with CD4 cells
inside the follicles surrounded by CD8 positive cells outside the
follicles, whereas in other cases the distribution was diffuse for
both subsets. CD57 cells represented more than 10% of the T cells
in most cases (64%) and they had a clear follicular pattern in 68%,
with most of the positive cells localized inside the follicles. In 82%
of these cases the CD57 follicular pattern correlated with the
CD4/CD8 follicular pattern and both CD57 and CD4 cells had an
equal distribution within the follicles. Cases with more than 10%
cytotoxic TIA-1 granule cells were found in 45% of the cases. The
numbers of CD68 macrophages (LAMs) were initially deter-
mined using low-power magnification. None of the cases showed
staining of neoplastic B cells with anti-CD68 antibody. It was clear
that most cases had few or no macrophages, while a small number
had many (Figure 1). The distribution of these CD68 cells was
uneven throughout cores with both intrafollicular and perifollicular
macrophages observed. We then used high-power magnification
( 1000 oil lens) to count the CD68 macrophages, which ranged
between 1 and 25 cells per high-power field (hpf). Because many of
the cases had no or few macrophages, we established a cut-off of 15
cells/hpf for analysis purposes. Importantly, most of the negative
cases had less than 10 cells (82%), and the positive cases had more
than 20 cells (58%) per hpf, respectively. Table 3 shows the
distribution of clinical and pathologic variables for the FL cases
with high LAM (n 12) versus those with low LAM content
(n  87). Only histologic grade was unevenly distributed between
these 2 groups and thus was included in a multivariate model along
with the IPI. All biomarker determinations were measured without
knowledge of the clinical outcome. Except for the LAM score,
none of the other markers showed a significant impact on outcome.
Cases with less and more than 15 CD68 macrophages/hpf had
median OSs of 16.3 and 5.0 years, respectively (P  .001; Figure
2). Figure 3 shows the progression-free survival curve. Cases with
less and more than 15 CD68 macrophages/hpf had a median PFS
of 7.05 and 1.69 years, respectively (P  .001). A multivariate
proportional hazards model that included the LAM content, the IPI
score, and histologic grade showed that LAM is an independent
predictor of OS (HR 2.4, 95%CI 1.3-4.5, P  .004). The
inferior PFS and OS of the patients with a high LAM score cannot
be explained by a lower response rate to treatment (Table 3), nor an
increased risk of histologic transformation (0 of 12 developed
transformed disease) nor lack of appropriate treatment for relapse
(all patients with relapse were treated with systemic chemotherapy,
3 with high-dose chemotherapy and hematopoietic stem cell
transplantation). All but 1 of the 10 deaths among the patients with
high LAM scores resulted from progressive lymphoma.
Figure 2. Overall survival curve based on lymphoma associated macrophage
(LAM) content. The top curve represents cases with less than 15 CD68 macro-
phages/hpf; the bottom curve, those cases with more than 15 CD68 macrophages/
hpf. The median OSs were 16.3 and 5.0 years, respectively (P  .001).
Table 3. Distribution of clinical and pathologic variables between
high LAM and low LAM cases
Feature
No. patients
with
high LAM (%)
No. patients
with
low LAM (%) Total (%) P
No. 12 (12) 87 (88) 99 (100) —
Clinical features .058*
IPI Group 1 (0/1) 4 (33) 54 (62) 58 (59)
Group 2 (2/3) 8 (66) 32 (37) 40 (40)
Group 3 (4/5) 0 (0) 1 (1) 1 (1)
BM involvement 6 (50) 44 (51) 50 (51)
Treatment response NS†
CR 6 (50) 48 (55) 54 (55)
PR 6 (50) 36 (41) 42 (42)
NR 0 (0) 3 (3) 3 (3)
Pathology features .046‡
FL grade
Grade 1 6 (50) 67 (77) 73 (74)
Grade 2 4 (33) 16 (18) 20 (20)
Grade 3 2 (17) 4 (5) 6 (61)
MZ differentiation 3 (25) 22 (25) 25 (25) NS
Transformation 0 (0) 8 (9) 8 (8) NS
IPI indicates International Prognostic Index score; BM, bone marrow; CR,
complete remission; PR, partial remission; NR, no response; NS, not significant; —,
; and MZ, presence of marginal zone differentiation.
*IPI group 1 versus 2/3.
†CR versus PR/NR.
‡Grade 1 versus 2/3.
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Discussion
FL represents a lymphoma subtype characterized by a significant
degree of clinical heterogeneity.2 The recent development of a
clinical prognostic model (FLIPI) may help to define those patients
at risk of failing current therapies, but the degree to which this
index will be helpful in planning initial therapy for newly
diagnosed patients remains undefined.3 Importantly, this model
includes clinical surrogates for the underlying molecular genetic
alterations and thus will not help to identify novel targets for
therapy. An improved understanding of the molecular abnormali-
ties that underlie the survival differences among patients with FL
may lead to improvements in risk stratification, but more impor-
tantly would offer the possibility of identifying new targets for
rationale design of future treatments. To a large extent, the future of
tailored or personalized therapies in cancer will depend on this very
hypothesis.
Most published data for FL suggest that the molecular
alterations that characterize this lymphoma result from a
combination of abnormalities present at the time of diagnosis
and ongoing stochastic events that occur in association with
clonal evolution.5,8,11,13,33 Because FL is a germinal center
derived neoplasm and frequently reveals intraclonal heterogene-
ity at the level of the immunoglobulin heavy chain, there is a
belief that additional molecular alterations are occurring over
time and contribute to disease progression. However, a number
of other possibilities exist to explain disease progression in FL,
including the outgrowth of subclones that may have been
present as minor populations at diagnosis.24,37 Whatever the
relative contribution of these 2 processes, there is little doubt
that the molecular signature present in initial diagnostic biopsies
plays a prominent role in predicting outcome in FL. The recent
gene expression profiling studies of the LLMPP have clearly
shown that the signatures from coordinately expressed genes
play a dominant role in affecting survival, as evidenced by
widely divergent survivals.33 The most important gene expres-
sion signatures in the recently developed molecular predictor
were not derived from neoplastic B cells but instead were
expressed by nonneoplastic immune response cells. One of these
signatures, called IR-2, included a number of genes that
appeared to correspond to the repertoire expressed by macro-
phages and was associated with inferior survival. These results
suggest that benign macrophages play a role in the biology of
FL. Data supporting such a role for reactive macrophages as
biomarkers in cancer have been described in a number of different
tumors including breast, prostate, ovarian, and cervical cancer.31 A
suspected role in lymphoma was untested until recently conducted
studies by the LLMPP consortium.
The current study clearly shows that LAM content is an
independent predictor of survival in uniformly treated FL. Not
unexpectedly, the IPI strongly predicted survival in this study
(P  .003). The content of LAM was, however, also predictive
of survival, including OS (P  .003), disease-specific (P  .001),
and progression-free (P  .001) survivals, and remained an
independent variable distinct from the IPI in a Cox multivariate
model (P  .004). These data agree with similar observations
made in epithelial cancers that increased numbers of macro-
phages portend a worse outcome.31,32 Moreover, these results
also agree with the recent gene expression studies and provide
indirect validation at the protein level for the role of IR-2.
Ongoing investigations of the biologic functions of macro-
phages in FL continue, as do studies to validate gene expression
in FL by studying the expression of other proteins using
paraffin-embedded material.
The precise biologic function of tissue-based macrophages in
this setting remains undefined, but they may be providing impor-
tant growth signals to the FL cells in the form of cytokine
stimulation or specific chemokine production. Macrophage hetero-
geneity is well studied in the mouse, but less is known about human
macrophages.31,38,39 The plasticity of macrophage function is
evident in the diverse range of functions of these cells, including
inflammatory responses, immune reactions, tissue remodeling, and
morphogenesis. Depending on the microenvironment, macro-
phages appear to be either “classic” M1 (inflammatory responses
induced by interleukin-12 [IL-12] and tumor necrosis factor-
[TNF-]) or “alternative” M2 (tissue remodeling and morphogen-
esis induced by IL-4, IL-13, and IL-10) subtypes, referred to as
polarized macrophages. These 2 types differ in their receptor
expression and cytokine/chemokine profiles.39
In advance of this study we studied macrophage content and
distribution in a series of reactive lymph nodes (n  10; data not
shown). Virtually all cases showed large numbers of tissue-
based macrophages both within and between reactive lymphoid
follicles. Thus, we were surprised to find that most cases of FL
in this study had no or very few macrophages. We hypothesize
that in the minority of cases of FL with large numbers of
macrophages the neoplastic B cells display signals that attract
and/or retain predominantly M2-type macrophages. Alterna-
tively, an inflammatory microenvironment might be created by
the antitumor-responsive T cells that attract or retain the
macrophages. Once in the lymph node, these cells might provide
the neoplastic B cells with trophic/survival signals, facilitate
tumoral invasion by disrupting basement membranes, promote
angiogenesis by secreting angiogenic factors, alter the pheno-
type and/or function of antigen-presenting dendritic cells, or
amplify regulatory T cells, leading to an immunosuppressive
intratumoral environment.40 At present, these remain untested
hypotheses. Nonetheless, an improved understanding of the
interactions between nonneoplastic macrophages and neoplastic
B cells in FL should provide important insights into the biology
of this common tumor. Ultimately it may be possible to
Figure 3. Progression-free survival curve based on lymphoma-associated
macrophage (LAM) content. The top curve represents cases with less than 15
CD68 macrophages/hpf; the bottom curve, those cases with more than 15 CD68
macrophages/hpf. The median PFSs were 7.05 and 1.69 years, respectively
(P  .001).
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manipulate the microenvironment of the lymph node in favor of
the host and turn off any trophic survival signals derived from
nonneoplastic tissue-based macrophages. Finally, this study
provides compelling data that support a role for benign macro-
phages in predicting outcome in aggressively treated patients
with FL and further substantiate the recent gene expression
profiling data highlighting the importance of nonneoplastic cells
in determining prognosis in FL.
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LYMPHOID NEOPLASIA
The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an
independent predictor of survival and histologic transformation
Pedro Farinha,1,2 Abdulwahab Al-Tourah,3 Karamjit Gill,3 Richard Klasa,3 Joseph M. Connors,3 and Randy D. Gascoyne1
1Pathology and Laboratory Medicine, BC Cancer Agency Center for Lymphoid Cancers, Vancouver, BC; 2Centro Hospitalar de Lisboa Central, Lisboa, Portugal;
and 3Medical Oncology, BC Cancer Agency Center for Lymphoid Cancers, Vancouver, BC
Previous studies of follicular lymphoma
(FL) patients treated heterogeneously
have suggested that decreased numbers
of regulatory T cells correlates with im-
proved survival. We studied advanced-
stage FL patients from a single institution
phase 2 trial. All patients were treated
uniformly with multiagent chemotherapy
and radiation. Tissue microarrays were
constructed using diagnostic biopsies
available in 105 patients and stained with
CD4, CD8, CD25, and forkhead/winged
helix transcription factor 3 (FOXP3) anti-
bodies. Both cell content and cell distribu-
tion were evaluated. For all antibodies,
there were cases with a predominant in-
trafollicular or perifollicular localization
of cells (follicular pattern) while others
displayed a diffuse pattern. The median
follow-up of living patients was 17.1 years.
The International Prognostic Index score
predicted overall survival (OS; P  .004)
but not risk of transformation (RT). Cell
content did not impact survival, while
immunoarchitectural patterns of CD4/
CD8 were significant for progression-free
survival (PFS; P  .056), CD25 for both
PFS and OS (P  .002 and P  .024, re-
spectively), and FOXP3 predicted PFS,
OS, and RT (P  .001, P < .001 and
p  .002, respectively). A Cox multivari-
ate model showed both International Prog-
nostic Index score and FOXP3 pattern
were independent predictors of OS
(P  .008 and P < .001, respectively),
while only FOXP3 pattern predicted RT
(P  .004). We conclude that FOXP3 cell
distribution significantly predicts sur-
vival and RT in FL. (Blood. 2010;115:
289-295)
Introduction
Follicular lymphoma (FL) is the most common indolent non-
Hodgkin lymphoma worldwide.1 It is characterized by a signifi-
cant degree of clinical heterogeneity.2 Transformation into
aggressive lymphoma, usually diffuse large B cell lymphoma is
a dominant clinical event frequently associated with inferior
survival.3 Clinical prognostic variable scoring systems such as
the International Prognostic Index (IPI) can be used to assess
patient risk and guide therapeutic decisions.4 However, such
clinical variables represent only surrogate markers for the
underlying biology. Although desirable, no consistent biologic
markers have been identified that predict survival or, equally
importantly, risk of transformation. The majority of candidate
biomarkers studied in the past have focused on the malignant
cells, including morphologic features, cytogenetic abnormali-
ties, molecular aberrations, and altered protein expression.
However, the lack of large, uniformly treated patient cohorts and
the low frequency of several of these molecular events have
hampered their translation into clinical practice.
Recent gene expression studies have revealed that both
survival and progression of disease were significantly associated
with non-neoplastic immune cell gene signatures.5,6 On the
strength of these observations we have shown in FL treated
uniformly with multiagent chemotherapy (bleomycin, cisplatin,
etoposide, doxorubicin, cyclophosphamide, vincristine, and
prednisone [BP-VACOP]) and involved region radiotherapy,
lymphoma-associated macrophage (LAM) content significantly
predicted survival. Using tissue microarrays and immunohisto-
chemistry, we found that in a minority of tumors (12%) a high
density of macrophages infiltrating the tumor correlated with
inferior survival.7 Several other subsequent studies have found
similar results.8-11
Regulatory T cells (Tregs) have the important role of suppress-
ing effector T cells and preventing reactivity to self-antigens.12
These cells recognize specific tumor antigens and differentiate into
cells capable of suppressing naive and CD4 Th1 antitumor
effector cells.13 It has been shown that tumor immunosurveillance
is more efficient when Tregs are depleted.14,15 In human cancer,
effective antitumor responses are also affected by the presence of
Tregs. These cells have been identified in increased frequency in
the peripheral blood of patients with several different tumor
types.16-20 Furthermore, increased density of Tregs within carci-
noma biopsies is predictive of poor survival.20
Tregs differ from other lymphocytes in origin, phenotype,
and mode of action. In humans, they constitute 5% to 10% of
CD4 T cells and arise as a distinct lineage within the thymus,
so-called “natural” Tregs, but regulatory function can also be
acquired peripherally when uncommitted CD4 cells receive antigenic
stimulation.12 These cells also express other surface molecules associ-
ated with activated/memory cells such as CD25, glucocorticoid-
inducible tumor necrosis factor receptor (GITR), CD62L, and cytotoxic
T lymphocyte–associated antigen 4, and these cells can secrete transform-
ing growth factor-beta (TGF) and interleuking-10 (IL-10). However,
none of these proteins is unique to these cells. The forkhead/winged
helix transcription factor 3 (FOXP3) is a transcriptional factor
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shown to be the key control gene in the development and function
of Tregs both in mice and humans.21-23 Although multiple T-cell
subsets (eg, Tr1, Th3, Th1, Th17, Tfh) have been shown to exert
negative immunoregulatory effects by producing immunomodula-
tory cytokines, such as TGF and IL-10, FOXP3 T cells represent
the major Treg population critical for immune homeostasis.
In lymphoma, FOXP3 is expressed by a subset of adult T-cell
leukemia/lymphoma cases that tend to have a worse prognosis.24
In FL, FOXP3 expression is only detected in the background
reactive T cells present at variable frequency. Importantly,
intratumoral FOXP3 T cells have been shown to migrate or be
induced in response to chemokines produced by malignant
B cells and they display the ability to suppress the function of
other infiltrating T cells.25-29 The mechanisms by which Tregs
exert their suppressive function are likely multiple30 but not
fully elucidated in FL.
In retrospective studies of FL, increased numbers of Tregs
expressing FOXP3 have been associated with improved overall
survival, a finding that is contradictory to nonhematopoietic
cancers.8,31 However, these series are limited by the marked
heterogeneity of treatments used, thereby confounding straight-
forward interpretation of these data. Treatment heterogeneity
has been shown to correlate with different, sometimes contradic-
tory results regarding the clinical impact associated with
different cells of the microenvironment in FL.9,11,32 We hypoth-
esize that these markedly different treatments are differentially
visited on the malignant B cells versus the nonneoplastic
immune cells in the tumor microenvironment. These observa-
tions and hypotheses prompted us to analyze the role of Tregs as
a prognostic marker in FL, both in terms of their numbers and
their distribution in the tumoral microenvironment, in a series of
uniformly treated patients with long follow-up.
Methods
Patient characteristics
The British Columbia Cancer Agency is the primary referral center for patients
diagnosed with lymphoid malignancies in the province of British Columbia.
Consecutive patients seen at the British Columbia Cancer Agency between July
1987 and May 1993 were offered enrolment in a phase 2 trial consisting of
multiagent chemotherapy (BP-VACOP) followed by involved field irradiation to
sites of original nodal involvement. Patients were eligible for enrollment if they
were aged 16 to 61 years, were newly diagnosed, treatment-naive, HIV-negative,
and had advanced-stage indolent non-Hodgkin lymphoma. Advanced-stage
disease was defined as Ann Arbor stage III or IV, or stage II with B symptoms,
nonradioencompassable disease, or bulk 10 cm or larger in maximum diameter at
any individual tumor site. Approval to review, analyze, and publish the data in
this study was given by the University of British Columbia–British Columbia
Cancer Agency Research Ethics Board. The source of pathology specimens for
diagnosis included only lymph node biopsies. One pathologist (R.D.G.) classi-
fied all cases as indolent according to the Working Formulation for Clinical
Usage and later updated them according to the World Health Organization
(WHO) classification.33 For this study, 2 pathologists (R.D.G. and P.F.) re-
reviewed all of the FL cases, grading them according to the 2008 WHO criteria.
Transformation was defined as biopsy proven or clinically diagnosed diffuse
large B cell lymphoma or other aggressive lymphoma as described previously.3
TMA
A tissue microarray (TMA) was constructed using a tissue arrayer device
(Beecher Instruments). Of the 126 cases of FL treated with BP-VACOP and
radiation, 105 had paraffin blocks with adequate material remaining in the
block to be used for the TMA. Duplicate 1.0-mm cores were used to
construct 2 TMAs, including both B5 and formalin-fixed cases. The
2 TMAs shared 40% overlapping cases, which provided a valuable internal
control. Slides from the TMA block were cut at 4 m.
Histology and immunohistochemistry
A hematoxylin and eosin stain of the TMA was prepared using routine
methods. All cases contained neoplastic follicles (average of 3 follicles per
core). A battery of immunohistochemical stains were performed including
CD20, CD21, CD4, CD8, CD25, and FOXP3 (see Table 1). Immunostain-
ing was performed using a Dako autostainer and the EnVision polymer
detection system. Pressure cooking antigen retrieval was used for all
antibodies. A variety of buffers were used depending on the specific
antibody to allow optimal detection of the antigens. The chromogen in all
cases was diaminobenzidine.
The immunostained TMA slides were screened with CD20 to ensure
tumor cell content. For the different T-cell markers (CD4, CD8, CD25, and
FOXP3), the numbers of positively stained cells and their patterns of
distribution were evaluated. Before counting, the morphologic patterns and
cell content were first evaluated for their consistency between duplicate
cores and between TMAs (B5 vs formalin).
The total number of positive cells (FOXP3 and CD25) was counted per
core ( 1000 magnification). Immunoarchitectural patterns of distribution
of the different T-cell markers were determined in relation to the neoplastic
follicles. The “follicular” pattern was characterized by an intrafollicular and
perifollicular predominance of positive cells, whereas in the “diffuse”
pattern the cells were diffusely distributed with no clear relationship to the
follicles. To better classify these patterns a follicular dendritic cell
meshwork stain (CD21) was used. Whenever the majority of positive cells
were within the follicles in each core, cases were labeled as having a
follicular pattern. From the remaining cases with predominance of positive
cells outside the follicles, those with a predominant perifollicular rim of
positive cells were labeled perifollicular. For purposes of analysis, both
groups, those with a follicular distribution of positive cells and those with a
perifollicular distribution, were grouped together as having a follicular
pattern. Assignment of the CD4 pattern and the combined CD4 versus CD8
pattern was done similarly to our previous study.7 Both were scored
semiquantitatively and in the CD4 versus CD8 pattern determination, both
stains were evaluated using sequential sections by overlaying both slides on
the microscope. Cases with a follicular predominance of CD4 versus CD8
cells were identified as having a follicular pattern, whereas cases with a
similar distribution of CD4 versus CD8 cells were defined as “diffuse.”
Statistics and survival analysis
Progression-free survival (PFS) was defined as the interval between
diagnosis and progression of lymphoma or death due to lymphoma or
toxicity of treatment. Overall survival (OS) was defined as the interval from
date of diagnosis until death from any cause, and risk of transformation was
defined as the interval from diagnosis until clinical or biopsy-confirmed
transformation into aggressive disease. The variables IPI score, histologic
grade, age, gender, and each of the 4 new biomarkers (see Table 2) were
evaluated for prognostic significance. Survival estimates were calculated
using the Kaplan-Meier method.34 Significance levels, estimates of hazard
ratios (HR), and their 95% confidence intervals (CI) were calculated using
the proportional hazards regression model.35
Table 1. Antibodies used in the study
Antibody Clone Source Dilution
CD4 4B12 Novocastra 1:50
CD8 C8/144B Dako 1:50
CD20 L26 Dako 1:500
CD21 1F8 Dako 1:30
CD25 4C9 Novocastra 1:100
FOXP3 236A/E7 Abcam 1:2
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Results
Clinical characteristics and outcome
A total of 102 patients were included in this study, representing the
FL patients from the original clinical cohort (n 126) with
available blocks, sufficient tissue remaining in the blocks, and
successful TMA construction and interpretation (FOXP3). The
median age of the evaluable patients was 45 years (range, 19-
61 years). There were 50 women and 52 men. The distribution of
IPI scores included 62 patients with IPI scores of 0/1 (group 1),
39 with IPI score of 2/3 (group 2), and only 1 patient with an IPI
score of 4/5 (group 3). For analysis purposes, the single patient in
IPI group 3 was included with IPI group 2 to eliminate a clinical
group with only 1 patient. The median follow-up of living patients
(n  51) was 17.1 years. The median OS was 15.5 years. The IPI
was highly significant as a predictor of OS (HR 2.4, 95%
CI  1.4-4.2, P  .001) and PFS (HR 2.0, 95% CI 1.2-3.3,
P  .006), but not risk of transformation.
Pathology variables
Some cores ( 6%, variable by biomarker) were lost during the
preparation of the sections or were not interpretable due to poor
fixation and/or inadequate staining. Histologic grading of FL
subtypes according to the WHO classification included 80 grade 1,
16 grade 2, and 6 grade 3A FL. Histologic grade, the presence of
marginal zone differentiation, the proliferation rate (Ki-67), and the
patterns of T cells (total CD3, total CD7, CD4 vs CD8 predomi-
nance, CD57 content, and architectural distribution) and follicular
dendritic cell patterns had no effect on survival (data previously
published).7 Results of the new biomarkers (CD4 vs CD8 distribu-
tion, CD25, and FOXP3) are summarized in Table 2.
The total number of any individual T-cell population analyzed as
well as the CD4 pattern showed no impact on survival. Follicular versus
diffuse pattern of distribution of CD4 versus CD8 cells was associated
with PFS only (HR 0.54, 95% CI 0.29-1.0, P .05), and CD25
pattern was significant for both PFS (HR 2.4, 95% CI 1.4-3.9,
P .001) and OS (HR 1.8, 95% CI 1.1-3.1, P .024) but not risk
of transformation. Only the FOXP3 score had a significant impact on
PFS, OS, and risk of transformation (Table 2). As described in
“Methods,” cases with either a follicular pattern (n 20) or a perifollicu-
lar pattern (n 18) were grouped together as Follicular FOXP3, and the
remaining cases were classified as Diffuse (n 64; see Figure 1). Cases
with a follicular versus diffuse FOXP3 pattern of distribution had a
median OS of 7.13 years and not reached, respectively (HR 3.1, 95%
CI 1.8-5.4, P .001; Figure 2), and a median PFS of 2.2 and
8.8 years, respectively (HR 2.7, 95% CI 1.6-4.6, P .001). Fi-
nally, cases with follicular versus diffuse patterns had median risks of
transformation of 13.3 years and not reached, respectively (HR 3.7,
95% CI 1.5-8.9, P .004; Figure 3). Histologic grade, IPI, and bone
marrow involvement were evenly distributed between these 2 groups
(Table 3). Interestingly, all but 1 case with a high content of LAM had a
FOXP3 follicular pattern and a follicular pattern of CD25 cells. The
pattern of CD25 and FOXP3 cells was significantly correlated (Table
3).A multivariate proportional hazards model that included the FOXP3
immunoarchitectural pattern, the IPI, and the LAM content showed that
Table 2. Biomarkers in follicular lymphoma
Biomarker No. failed No. positive (%) Morphological pattern OS P PFS P Comments
CD4 cells 2 78 (76) NS NS Quantity of T cells (//)
CD4/CD8 pattern 5 71 (71) Follicular NS .056 Preferential intrafollicular CD4 and
perifollicular CD8 localization
CD25 cells 6 51 (52) NS NS  200 cells/core (100X)
CD25 pattern 6 40 (40) Follicular .024 .002 Preferential intrafollicular or/and perifollicular
localization
FOXP3 cells 3 34 (33) NS NS  300 cells/core (100x)
FOXP3 pattern 3 38 (36) Follicular  .001 .001 Preferential intrafollicular or/and perifollicular
localization
OS indicates overall survival; PFS, progression-free survival; and NS, not significant.
Figure 1. Representative tissue microarray cores of follicular
lymphoma stained for FOXP3. The images on the left and center
show the follicle-based patterns with FOXP3 cells present mostly
within the follicle or around the follicle and in the mantle zone,
respectively (n  38). On the right, the image shows a diffuse
case with no follicle-centered pattern defined (n  64). Micro-
scope: Nikon Eclipse E600; digital camera: Dxm1200.
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FOXP3 pattern and IPI are independent predictors of OS (HR 2.9,
95% CI 1.7-5.1, P .001 and HR 2.1, 95% CI 1.1-3.7, P .008,
respectively). Interestingly, in the multivariate Cox model for risk of
transformation only FOXP3 positivity showed significance (HR 3.9,
95% CI 1.5-9.9, P .004).
Discussion
It has been almost a century since immunosurveillance was
proposed as a mechanism responsible for the repression of cancer
growth.36 Since then, our understanding of tumor immunobiology
has increased indicating that immunosurveillance represents 1 di-
mension of the complex relationship between the immune system
and cancer.37 It is now a widely held idea that the growth of tumors
is influenced by nonneoplastic cells of the immune system. These
cells are thought to exert selective pressure on the malignant cells.
Ultimately, the malignant cells escape immune recognition and
destruction and much like tolerance to self-antigens, tolerance to
tumor-associated antigens may arise and permit or even promote
disease progression.37
Tregs were initially defined as a subset of suppressor T cells that
mediate immune tolerance by inhibiting autoreactive T cells.38
Naturally occurring Tregs play a vital role in maintenance of
tolerance to self-antigens and immunologic homeostasis through
the antigen-specific suppression of effector CD4 and CD8
T cells.12 However, mechanisms whereby Tregs, including periph-
erally induced cells, bring about the inhibition of other T-cell
subtypes are still not well understood.30 They include direct
suppression by cell contact and/or cytokine production, as well as
inhibition of antigen-presenting cell function. The T-cell receptor
repertoire of Treg cells is as broad and diverse as that of other
CD4 T cells, but it is skewed toward recognizing complexes of
self-peptides and major histocompatibility complex.
Many of the tumor-associated antigens recognized by autolo-
gous T cells in cancer are antigenically normal self constituents.
This suggests that Tregs normally engaged in the maintenance
of self-tolerance may also suppress immunosurveillance against
autologous tumor cells. Depletion of these Treg cells before a
tumor challenge encourages effective immune responses to
tumors in mouse models.39 In mice with advanced tumors,
including lymphoma, the administration of anti-CD25 or intratu-
moral agonistic anti-GITR antibodies reduces tumor-infiltrating
Foxp3CD25CD4 Tregs and results in enhanced antitumor
immunity with a significant decrease of the tumor burden
without causing autoimmune disease.40,41 In humans, T cells
reactive to tumor-associated antigens can expand and become
detectable in the peripheral blood when Tregs are first de-
pleted.13,42 Tregs accumulate within different types of tumor-
draining lymph nodes and the peripheral blood.16-20 FOXP3
T cells present in the tumor microenvironment contribute to the
growth of the tumor, and their presence is associated with
unfavorable prognosis in patients with ovarian carcinoma.20
This study by Curiel et al highlights the importance of the
chemokine network in the recruitment and function of these
cells. Decreased CCL22 produced by the tumor cells and/or
tumor-associated macrophages reduced the recruitment of the
Tregs that characteristically express the CCL22 cognate recep-
tor CCR4.
In reactive lymphoid tissues, FOXP3 Tregs are found mostly
at the borders between T and B cells and within germinal centers
where they suppress T cells as well as B-cell responses through
both inhibition of immunoglobulin class switch recombination43 or
generation of “Treg epitopes” identified in the Fc region of the
immunoglobulin molecule itself.44
Intratumoral CD4 T cells (CD25 or CD25) expressing
FOXP3 are increased in FL compared with reactive lymph nodes.25
These FOXP3 cells are either attracted (CCL22) or induced
locally by lymphoma cells through cell contact without stimulation
of TCR but by expressing CD70.25,28,45 These FOXP3 cells
suppress intratumoral CD4 or CD8 T cells either through TCR
activation, cell contact, or by producing TGF.25,27,28 In a small
series of FL cases purified using fluorescence-activated cell sorting,
we found that CCL22 was one of the chemokine genes most highly
expressed by the malignant B cells (R.D.G., unpublished observa-
tion, 2008). Moreover, Tregs have also been shown to induce
alternatively activated macrophages, the so-called M2 type,46
which are also associated with protumoral immunity. Finally, in
combination with CpG vaccination, antibody-mediated T cell modu-
lation, mostly by depletion of Tregs through antifolate receptor 4
antibodies or functionally blocking them using anti-GITR, anti–
cytotoxic T lymphocyte–associated antigen 4, or antiprogrammed
death-ligand 1 antibodies, correlates with a significant reduction of
Figure 3. Risk of transformation curve based on FOXP3 immunoarchitectural
patterns. The top curve represents cases with a follicular pattern and the bottom
curve those cases with a diffuse pattern.
Figure 2. Overall survival curve based on FOXP3 immunoarchitectural pat-
terns. The top curve represents cases with a diffuse pattern and the bottom curve
those cases with a follicular pattern.
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tumor burden both in mouse models and a phase 2 clinical trial in
patients with recurrent FL.47,48
In concordance with most published data, including mouse
models and several different primary human tumors as well as in
vitro and functional data in FL, where Tregs are associated with a
protumoral immunity, we found a follicular pattern of FOXP3
Tregs to be associated with inferior survival in FL. Importantly, this
follicular pattern also predicted an increased risk of transformation.
Superficially, this finding appears to contradict previous retrospec-
tive studies of the survival impact of Tregs in FL using TMAs and
immunohistochemistry.8,31 However, in contrast to those studies,
our analysis found the distribution of Tregs to be more important
than their numbers. In addition, our patients received uniform
therapy, thus holding this important variable constant. Recent data
convincingly demonstrate the dramatically variable impacts that
different therapies have on the nonneoplastic immune cells in the
microenvironment.7,9,11,32 Indeed, studies of the microenvironment
in FL become nearly impossible to interpret when patients receive
very heterogeneous treatments, because the specific chemotherapeu-
tic agents, radiation, and biologic agents differentially impact
immune cells. As was shown in several recent series studying the
impact of LAM in FL, the specific therapeutic regimens used
decisively influenced the prognostic impact of nonneoplastic cells
in the microenvironment.7,9-11,32
In FL, where the content and distribution of various immune-
related cells is markedly heterogeneous, we reasoned that the
topographic distribution of Tregs relative to the neoplastic follicle
might reflect their function and thus their clinical impact. Qualita-
tive (architectural patterns) or semiquantitative biomarkers (cell
counts) such as those measured in this study are difficult to define
precisely and may be difficult to reproduce.49 However, the use of
TMAs and immunohistochemistry at least partially overcomes this
difficulty and has been shown to provide a reliable strategy to
assess large numbers of clinical samples and validate novel
biomarkers discovered by gene expression profiling.7,50
In this study we analyzed Tregs within FL biopsies using
3 markers known to be characteristically expressed by Tregs: CD4,
CD25, and FOXP3. As previously described, Tregs belong to the
CD4CD25 T-cell subset. However, Tregs can be CD25, and
CD8CD25 T cells can exhibit regulatory activity.51 FOXP3 is
the single best marker of activation of Tregs.21 Simple enumeration
of cells identified using these markers showed no impact on
survival or risk of transformation. However, we found that a
follicular distribution of these CD25 or/and FOXP3 cells
strongly correlates with outcome (Table 3). Interestingly, the
survival associations in our cohort followed a pattern linked to
specificity for the regulatory phenotype: CD4/8 pattern had an
impact just on PFS, CD25 showed significance for PFS and OS,
and FOXP3 had an impact on PFS, OS, and, importantly, risk of
transformation.
This impact of either follicular or perifollicular FOXP3 cells
suggests a functional suppression of immunosurveillance within
the tumor microenvironment that is present at the time of diagnosis.
The malignant cells may have the capacity to “recruit” or “skew”
Treg activity toward the suppression of antitumoral T cells, thus
allowing the malignant cells to “escape” from the regulatory
activity.37 Interestingly, 11 of 12 cases with a high content of
LAMs in this series had a follicular FOXP3 pattern. Both Tregs and
macrophages may cooperate, in a subset of cases, providing the
neoplastic B cells with trophic and survival signals that promote
tumor progression, the accumulation of further genetic damage,
and transformation.
In summary, the immunoarchitectural pattern of Tregs within
lymph nodes involved with follicular lymphoma predicts both
Table 3. Distribution of clinical and pathology variables between follicular and diffuse pattern of FOXP3 cells
Feature No. patients with follicular FOXP3 cells, (%) No. patients with diffuse FOXP3 cells (%) Total (%) P
No. 38 (37) 64 (63) 102 (100)
Clinical features
Median age (y) 45 45 .9
Female (%) 15 (40) 37 (58) .6
Median follow-up (y) 17 16 .011
IPI
Group 1 (0/1) 19 50) 43 (67) 62 (61)
.14
Group 2 (2/3) 19 (50) 20 (32) 39 (38)
Group 3 (4/5) 0 (0) 1 (1) 1 (1)
BM involvement 22 (60) 29 (45) 52 (51) .3
Treatment response
CR 18 (47) 40 (63) 58 (57)
.3
PR 19 50) 22 (34) 41 (40)
NR 1 (3) 2 (3) 3 (3)
Pathology features
FL Grade
Grade 1 29 (76) 51 (80) 80 (78)
.8
Grade 2 6 16) 10 (16) 16 (16)
Grade 3 3 (8) 3 (4) 6 (6)
FOXP3 cells, MD (SD) 312 (145) 200 (125)  .001
LAM 15 cells HPF 11 1 12 (12)  .001
CD4/8 pattern (F) 29 40 69 (68) .2
CD25 pattern (F) 31 7 38 (37)  .001
Transformation 12 (32) 9 (14) 20 (20) .04
BM indicates bone marrow; CR, complete remission; PR, partial remission; NR, no response; MD, median; IPI, International Prognostic Index; LAM, lymphoma-associated
macrophages; HPF, high-power field; and F, follicular pattern.
*IPI group 1 versus 2/3.
†CR versus PR/NR.
‡Grade 1 versus 2/3.
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survival and risk of transformation in patients treated uniformly
with an aggressive combination regimen including multiagent
chemotherapy (BP-VACOP) and involved region radiation. These
findings require validation in other patient cohorts, but they will
likely only be meaningful if treatment is held constant. Previous
publications analyzing patients treated with heterogeneous regi-
mens may have shown discrepant results because of the differential
effect of these therapies on neoplastic B cells versus nonneoplastic
immune cells in the microenvironment. Moreover, these findings
will need to be validated in the current era of immunochemo-
therapy, again requiring uniform treatment and lengthy follow-up
best performed in the context of phase 3 clinical trials.
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Follicular lymphoma patients display heterogeneous overall
survival and variable risk of transformation.  Recent studies
have highlighted the role of the microenvironment. The
contribution of microvessel density to follicular lymphoma
survival remains controversial. We used a quantitative
tumor mapping approach to determine whether the degree
of vascularization correlated with outcome in a uniformly
treated cohort. Whole-tissue sections of diagnostic biopsies
from 84 cases were stained for CD34 and tumor-to-vessel-
distance that encompassed 90% of the tumor (TVD90) was
determined using image analysis. Twenty-one cases with
lower TVD90 showed inferior overall survival (P=0.0001) and
high risk of transformation (P=0.01). These cases significant-
ly correlated with increased Lymphoma-Associated
Macrophages (χ2=0.025). In multivariate analysis
macrophages content, IPI and TVD90 were independent pre-
dictors of overall survival (P=0.05, P=0.001 and P=0.01,
respectively) and IPI and TVD90 predicted risk of transforma-
tion (P=0.008 and P=0.08, respectively). Increased angiogen-
esis is an independent marker of inferior survival and may
promote transformation. 
Key words: follicular lymphoma, vascularization, prognosti-
cation.
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Vascularization predicts overall survival and risk of transformation 
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ABSTRACT
Introduction
The clinical course of follicular lymphoma (FL) is unpre-
dictable, with median survivals in the range of ten years.
Histological transformation, usually into diffuse large B-cell
lymphoma (DLBCL), heralds aggressive clinical behavior and
is typically associated with inferior survival. A recent popula-
tion based analysis from the British Columbia Cancer Agency
(BCCA) including 600 newly diagnosed FL patients showed
an annual risk of transformation (RT) of 3% continuing
beyond 15 years of follow up.1 The treatment of FL patients
is markedly heterogeneous, as no optimal treatment approach
has yet been established. The number of prior treatments,
tumor burden, advanced-stage and high-risk FLIPI or IPI are
the only established clinical features associated with RT.2
Importantly, none of the clinical variables consistently predict
RT. Thus, biological predictors of transformation are needed
to individualize therapy and better assess risk. Angiogenesis
plays a crucial role in oncogenesis, promoting growth and
progression of both solid and hematologic tumors.3,4 The
acquisition of an angiogenic phenotype, referred to as the
“angiogenic switch”, allows the formation of neovessels that
are vital for tumor growth.5 This "angiogenic switch" results
not only from interactions between vessels and cancer cells,
but also involves non-neoplastic cells in the microenviron-
ment, including macrophages. Microvessel density (MVD)
has, in some tumor types, shown a correlation with survival.
Yet, in FL the impact of MVD on prognosis is controversial.6,7
In most series the number of cases studied is small and/or the
therapies markedly heterogeneous, both of which preclude
definitive conclusions. In this study, we report the clinical sig-
nificance of MVD in uniformly treated FL patients using a
quantitative tumor mapping approach.
Design and Methods
Patients
Between July 1987 and May 1993, patients with FL were enrolled in
a single institution phase II trial using BP-VACOP chemotherapy
(bleomycin, cisplatin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine and prednisone) followed by involved field irradiation to sites
of original nodal involvement. Patients aged 16 to 61 years, with
newly diagnosed, treatment-naïve and advanced-stage disease,
defined as Ann Arbor stage III or IV, or stage II with B symptoms, non-
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radioencompassable disease, or bulk of 10 cm or more in maxi-
mum diameter at any individual tumor site were included.
Approval to this study was given by the University of British
Columbia BCCA Research Ethics Board. All biopsies were
reviewed and classified according to the 2008 WHO classifica-
tion.8 Transformation was defined as biopsy proven or clinically
diagnosed aggressive lymphoma as described previously.1
Histology and immunohistochemistry
Of the 126 cases of FL, 84 had formalin-fixed paraffin blocks
with adequate material remaining in the block to be used for
whole sections. Immunohistochemistry was performed routinely
for CD20 (L26, dilution 1:800, Dako®, Carpentaria, California,
USA) and CD34 (QBEend10, dilution 1:30, Dako®, Carpentaria,
California, USA) using a Dako® autostainer and the EnVision
polymer detection system. CD68+ cell content biomarker,
Lymphoma-Associated Macrophages (LAM) data were based on a
previous study.9
Microvessel density and follicle size 
Images of whole sections were stained for CD34 and captured
using a cooled CCD camera, a motorized stage and customized
NIH software.10 Thresholding was applied to identify CD34 posi-
tive objects. The motorized stage allowed for tiling of adjacent
microscopic fields, thereby allowing reassembly of the entire
tumour section at high resolution (Figure 1). High-resolution
images of tumor vasculature over the entire whole-sections of
each case defined “distance maps”. The distance from each tumor
cell in the tissue to the nearest CD34+ pixel was measured auto-
matically and the mean of distances of all cells to the nearest vessel
in the whole section was used to calculate the tumour-to-vessel
distance that encompassed 90% of the tumor (TVD90). Average
follicle size per case was visually ranked according to the follow-
ing groups: 0 - loss of follicular pattern; 1 - small follicles (dense
staining), and 2 - large follicles (sparse staining).
Statistics and survival analysis
Overall survival (OS) was defined as the interval from date of
diagnosis until death from any cause. Survival estimates were cal-
culated using the Kaplan-Meier method11 and multivariate analysis
using the proportional-hazards regression model.12
Results and Discussion
There were 84 suitable cases for analysis. The median
follow up of the living patients was 14.3 years and 20
patients underwent transformation. The IPI was signifi-
cant for both OS and risk of transformation (RT) in uni-
variate analysis (P=0.0001 and P=0.01, respectively).
Estimated 10-year OS and RT for all patients were 65%
and 20%, respectively. TVD90 ranged from 50.3 to 144
microns (median 78.4) and these data were divided into
quartiles. In univariate analysis the quartile (21 cases) with
low TVD90 (i.e. high MVD) showed inferior OS (P=0.0001)
and an increased RT (P=0.01) (Figure 2). These 21 cases are
defined as Low TVD90 while the three other quartiles (63
cases) are defined as High TVD90. Clinical characteristics
are summarized in Table 1. As most cases showed a dis-
tinct perifollicular pattern, we correlated TVD90 with folli-
cle size in each case. There was a significant association
between low TVD90 and small follicle size (χ2, P=0.01).
Low TVD90 also correlated with younger age (χ2, P=0.034),
increased IPI (χ2, P=0.01) and increased CD68+
macrophages (χ2, P=0.025). In univariate analysis, TVD90
and IPI are significant for both OS and RT, but not age or
follicle size. In this cohort, CD68+ macrophages predicted
OS (P=0.0004), but not RT (P=0.38). In a Cox’s model
including TVD90, CD68+ and IPI, all three markers were
independent variables for OS, TVD90 (RR=2.5, 95%
CI=1.1-5.0, P=0.01), CD68+ (RR=2.2, 95% CI=1.0-5.0,
P=0.05) and IPI (RR=2.9, 95% CI=1.5-5.5, P=0.001).
Finally, in a Cox’s model for RT, only IPI significantly pre-
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Figure 1. High-resolution image of a CD34 immunostained section
allowing the identification of tumor vasculature across the entire
section.
Figure 2. Tumor-to-vessel distance including 90% of malignant cells
showing Overall Survival (OS) and Risk of Transformation (RT).
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dicted RT (P=0.008), while TVD90 was of borderline signif-
icance (P=0.08). Angiogenesis plays a crucial role in the
growth and progression of human solid tumors.13 In most
tumor types, increased MVD correlates with increased
disease progression and decreased survival. Similar results
have been reported in hematopoietic tumors, including
multiple myeloma and lymphoma.3,4,14,15 In murine lym-
phoma models and in lymphoma patients, circulating
endothelial cells and serum vascular endothelial growth
factor (VEGF) levels appear to correlate with lymphoma
volume and increased angiogenesis.16,17 In contrast, previ-
ous studies of MVD in FL have resulted in conflicting
results. Koster et al. showed increased MVD to be associ-
ated with a more favorable OS in a series of 36 uniformly
treated patients given CVP and interferon (IFN) α2b fol-
lowed by IFN maintenance.6 In a later report, Jorgensen et
al. analyzed 107 FL cases with heterogeneous treatments
and found increased interfollicular MVD predicted inferior
OS and increased transformation to DLBCL.7 In both stud-
ies, MVD was calculated using quantification of focal
“vessel hot spots” within the tumor. In FL, however, the
vessels show a heterogeneous distribution. Therefore, in
order to avoid a scoring bias, we studied whole sections of
FL biopsies and quantified automatically the average dis-
tance from CD34 stained vessel that included 90% of
tumor cells: TVD90. We believe this is a more accurate
measurement of vessel density. Because of vessel predom-
inance within the interfollicular and perifollicular areas,
TVD90 was correlated with the average size of the follicles
in each case. Interestingly, cases with low TVD90 correlat-
ed with small sized follicles although follicle size itself did
not affect survival or risk of transformation. 
In the current study, all 84 patients were treated uni-
formly with multi-agent chemotherapy and radiation,
while in the series by Koster et al. all 36 patients were
treated with CVP chemotherapy and IFN followed by IFN
maintenance. In addition to the difference in cohort size,
different therapeutic regimens may explain the contradic-
tory results. IFN has both immunomodulatory and anti-
angiogenic effects and thus may have been more effective
in tumors with increased MVD.18 Radiation has been
shown to induce tumor cells to secrete cytokines capable
of inhibiting apoptosis in endothelial cells, thereby dimin-
ishing treatment response.19,20 It remains possible that this
treatment modality influenced survival and transforma-
tion risk in our study. 
It is well known that angiogenesis in cancer is critically
influenced by the local tumor microenvironment.21 Using
the same uniformly treated cohort, we previously showed
that increased numbers of Lymphoma-Associated
Macrophages (LAM) is associated with adverse outcome.9
Similar to solid tumor-associated macrophages, these LAM,
possibly originating from bone marrow derived myeloid
cells, may be attracted by hypoxia and tumor-derived
chemotactic factors and show a distinct phenotype that pro-
motes angiogenesis.22-24 Consistent with this hypothesis, we
show a significant association between TVD90 and LAM. 
In summary, this study confirms the clinical relevance of
increased angiogenesis affecting both FL survival and
transformation risk in a series of advanced-stage FL
patients uniformly treated with chemotherapy and radio-
therapy. These findings suggest MVD as a useful biomark-
er in initial therapeutic decisions of patients with FL, and
thus may provide a rationale for trials of anti-angiogenic
therapy in FL patients with increased MVD.
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Table 1. Distribution of clinical and pathology variables between high
TVD90 and low TVD90 cases.
Feature                # Patients with  # Patients with   Total (%)     P value
                               Low TVD 90       High TVD 90                          (χ2)
                                      (%)                      (%)                    
Number                          21 (25)                   63 (75)             84 (100)            -
Clinical Features                                                                                                 
Median age (y)                  39                            46                        -               0.034
Female (%)                        52                            48                        -                 0.63
Median follow up (y)      13.9                         14.3                       -                 0.83
IPI Group 1 (0/1)           8 (38)                    45 (71)              62 (61)         0.01*
Group 2 (2/3)              13 (62)                   17 (27)              39 (38)              
Group 3 (4/5)                0 ( 0)                      1 (2)                  1 (1)                
BM Involvement (%)   14 (66)                   28 (44)              42 (50)          0.13
Treatment Response                                                                                          
CR                                   8 (38)                    39 (62)              47 (56)        0.08**
PR                                  13 (62)                   23 (36)              36 (43)              
NR                                    0 (0)                       1 (2)                  1 (1)                
Pathology Features                                                                                             
FL Grade                                                                                                               
Grade 1                         17 (80)                   49 (78)              66 (78)       0.76***
Grade 2                          4 (20)                    10 (16)              14 (17)              
Grade 3                           0 (0)                       4 (6)                  4 (5)                
Large follicles (%)         1 (5)                     20 (32)              21 (25)          0.01
Increased CD68+          5 (24)                      4 (7)                     9               0.025
cells (%)                               
Transformation (%)       8 (38)                    12 (19)              20(24)          0.076
IPI: International Prognostic Index score, BM: bone marrow, CR: complete remission,
PR: partial remission, NR: no response; *IPI group 1 vs. 2/3 **CR vs. PR/NR ***Grade
1 vs. 2/3A.
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Background
BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large
B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variabil-
ity in clinical outcome. The prognostic significance of BCL6 rearrangement has not been
evaluated in the context of rituximab therapy for diffuse large B-cell lymphoma. We ana-
lyzed the effect of the BCL6 rearrangement on survival in patients with diffuse large B-cell
lymphoma treated with CHOP and CHOP plus rituximab (R-CHOP).
Design and Methods
BCL6 rearrangement status was analyzed by fluorescence in situ hybridization with break-
apart probes in 164 patients with diffuse large B-cell lymphoma treated with CHOP (n=65)
or R-CHOP (n=99). Cell-of-origin immunophenotype including BCL6 protein expression
were determined by immunohistochemistry on a tissue microarray.
Results
BCL6 rearrangement was detected in 19.5% of cases. The presence of the gene rearrange-
ment was associated with a non-germinal center B-cell immunophenotype (P=0.006), and
showed no correlation with BCL6 protein expression. A trend toward inferior overall sur-
vival was observed in association with the BCL6 rearrangement among patients treated
with R-CHOP (P=0.08), but not among patients treated with CHOP (P=0.64). However,
BCL6 rearrangement also correlated with a high International Prognostic Index score
(P=0.02), and did not demonstrate independent prognostic value by multivariate analysis. 
Conclusions
The introduction of rituximab may have altered the prognostic impact of BCL6 gene
rearrangement in patients with diffuse large B-cell lymphoma. However, prospective
analysis within large randomized clinical trials will be needed to clarify the prognostic sig-
nificance of this biomarker in the rituximab era.
Key words: diffuse large B-cell lymphoma, biomarkers, BCL6, FISH, rituximab.
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Correlations between BCL6 rearrangement and outcome in patients with diffuse
large B-cell lymphoma treated with CHOP or R-CHOP
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common subtype of non-Hodgkin’s lymphoma, account-
ing for 30-40% of newly-diagnosed cases.1 Although cur-
able in the majority of cases with anthracycline-based
combination chemotherapy and the monoclonal antibody
rituximab, approximately 30-40% of patients with
DLBCL will relapse after standard first-line therapy.2,3 This
variability in clinical outcome likely relates to genetic het-
erogeneity within DLBCL, reflected in a wide array of
cytogenetic and molecular abnormalities. Recently,
microarray gene expression studies have identified multi-
ple genes of potential prognostic significance in DLBCL,
and have led to the subdivision of DLBCL into two major
biological categories based on their presumed cell of ori-
gin: germinal center B-cell (GCB), and activated B-cell
(ABC).4 However, the prognostic value of genetic markers
in DLBCL remains controversial, and these have not yet
been incorporated into routine clinical practice.5
Rearrangement of the BCL6 proto-oncogene at chromo-
some band 3q27 is the most frequent cytogenetic abnor-
mality in DLBCL, occurring in up to 35% of cases.6-8 The
BCL6 gene, a zinc-finger transcription factor, may be
translocated with diverse partners in DLBCL, including
both immunoglobulin (IGH, IGK, IGL) and non-IG loci.9,10
Clinical studies investigating the prognostic impact of
BCL6 rearrangement in DLBCL have yielded contradicto-
ry results, variably demonstrating favorable,6 intermedi-
ate,7,8,11 and adverse outcomes12,13 in association with this
abnormality. 
An association has recently been reported between
BCL6 rearrangement and ABC phenotype.14 This cell-of-
origin profile was initially demonstrated as an adverse bio-
logical marker in DLBCL patients treated with CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone),
and has been shown to retain its predictive impact in
patients treated with CHOP plus rituximab (R-CHOP).15
The introduction of rituximab to standard first-line ther-
apy has significantly improved clinical outcome in
DLBCL, and may alter the prognostic impact of both clin-
ical and biological markers in this disease.2,3 The prognos-
tic significance of BCL6 rearrangement has not been re-
evaluated since the introduction of rituximab into DLBCL
therapy. In this study we used tissue microarray-based flu-
orescence in situ hybridization (FISH) to analyze BCL6
rearrangement status in a retrospective cohort of patients
with DLBCL. The objectives of this study were to: (i) com-
pare the effect of BCL6 rearrangement on survival in
DLBCL patients treated with CHOP and R-CHOP, and (ii)
evaluate the relationship between BCL6 rearrangement
and other clinical and biological prognostic variables in
this disease, including cell-of-origin phenotype. 
Design and Methods
Patients’ samples
We included all patients identified through the Centre for
Lymphoid Cancer database of the British Columbia Cancer
Agency (BCCA) who met the following criteria: (i) confirmed
diagnosis of DLBCL (excluding primary mediastinal B-cell lym-
phoma) following a pathology review; (ii) treated with either
CHOP alone or in combination with rituximab immunotherapy
(R-CHOP); (iii) available diagnostic paraffin material on a tissue
microarray; (iv) negative for human immunodeficiency virus; (v)
treated at the BCCA between 1999 and 2007. Ethical approval for
this study was obtained from the University of British Columbia
– BCCA Research Ethics Board.
Fluorescence in situ hybridization and 
immunohistochemistry on tissue microarrays
Archived, formalin-fixed, paraffin-embedded, diagnostic biop-
sy specimens were selected for construction of the tissue
microarrays and 0.6 mm duplicate cores were obtained from rep-
resentative areas containing large B cells with typical morpholo-
gy. FISH was performed according to a standard protocol for
paraffin-embedded material, described elsewhere,14,16 using com-
mercially available Vysis LSI BCL6 Dual Color, Break-Apart
Rearrangement Probes (Abbott Molecular, IL, USA). Cases were
recorded as having BCL6 rearrangement (BCL6+) if break aparts
occurred in at least one signal of more than 5% of nuclei. All
other signal constellations were regarded as negative (BCL6–).
Immunohistochemical analysis was performed using monoclon-
al antibodies for BCL2 (Dako, clone 124, Denmark), BCL6
(Ventana Medical Systems, Tucson, Arizona), CD10 (Ventana
Medical Systems, Tucson, Arizona), and MUM1 (Dako,
Denmark), following routine protocols for automated immuno-
histochemistry on the Ventana Benchmark XT (Ventana Medical
Systems, Tucson, Arizona). Cases were then categorized as GCB-
like or non-GCB using a standard algorithm.17 Accordingly, for
each case, the core with the highest percentage of tumor cells
stained was used for analysis. Cases were considered positive if
30% or more of the tumor cells were stained with an antibody.
Statistical analysis
Group comparisons were performed by means of χ2 and
Student’s t tests. For time to event analyses we used SPSS soft-
ware version 11.0.0, applying Kaplan-Meier survival estimates
and univariate and multivariate Cox proportional hazard models
with the end-point of overall survival, defined as the time from
initial diagnosis to death from any cause. P values less than 0.05
were considered statistically significant.
Results
Patients’ characteristics
A total of 174 patients with DLBCL who met all inclu-
sion criteria were identified. FISH was successfully per-
formed in 164 out of these 174 cases (94.3%). BCL6
rearrangement was detected in 32 out of the 164 cases
(19.5%). Representative BCL6+ FISH images of the tissue
microarray sections are shown in Figure 1A. 
The baseline clinical characteristics of the patients,
divided according to BCL6 rearrangement status, are listed
in Table 1. There were no significant differences in initial
treatment regimen between the two subgroups, with sim-
ilar proportions of BCL6+ (15/32) and BCL6– (84/132)
patients receiving rituximab as part of their initial therapy.
A higher proportion of patients in the BCL6+ subgroup had
a high-intermediate or high-risk International Prognostic
Index (IPI) score (IPI 3-5) (62.5% versus 40.2%, P=0.02).
Stage IE/IIE cases were designated as ‘primary extranodal
BCL6 rearrangement in DLBCL
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disease’, while all other cases were considered as ‘primary
nodal disease’. The frequency of primary extranodal dis-
ease was not significantly different between the BCL6+
and BCL6– subgroups (13% versus 25%, P=NS). 
Table 2 shows the patients’ immunohistochemical char-
acteristics according to BCL6 rearrangement status. BCL6
staining and cell-of-origin classification17 was successfully
performed in 162 of the 164 patients. Representative BCL6
staining results are shown in Figure 1B. Results  of BCL2
staining were available for 115 of the 164 (70%) patients.
The presence of BCL6 rearrangement was significantly
correlated with cell-of-origin; 68% of BCL6+ patients had
a non-GCB subtype, as compared with 48% of BCL6–
patients (P=0.006). No association was found between
BCL6 rearrangement and either BCL6 (P=0.78) or BCL2
(P=0.95) protein expression.
Survival
The median duration of follow-up was 2.9 years (range,
0.3-8.7). Rituximab use was associated with a significant
survival improvement among BCL6– patients (5-year over-
all survival, 70.1% versus 45.0%, P=0.009), but not among
BCL6+ patients (5-year overall survival, 45.3% versus
41.2%, P=0.70). Kaplan-Meier analysis of the entire
cohort revealed a trend toward decreased overall survival
in patients with a BCL6 rearrangement, though this did
not reach statistical significance (5-year overall survival,
59.4% versus 43.4%, P=0.07). Within treatment groups,
BCL6 rearrangement was associated with a trend toward
inferior overall survival among patients treated with R-
CHOP (5-year overall survival, 45.3% versus 70.1%;
P=0.08), but not among patients treated with CHOP (5-
year overall survival, 41.2% versus 45.0%; P=0.64) (Figure
2). No significant association was found between BCL6
protein expression and overall survival in the whole
cohort (5-year overall survival, BCL6+ versus BCL6–, 52.2%
versus 31.8%, P=0.11).18
Subgroup analysis of overall survival was performed
according to the site of presentation of disease and the
patients’ age. Survival analysis limited to patients with pri-
mary nodal disease showed that the 5-year overall sur-
vival among BCL6+ patients was 39.7% compared with
54.7% in BCL6– patients (P=0.09). Among patients who
presented with primary extranodal disease, no difference
in overall survival was found between BCL6+ and BCL6–
patients (P=0.95). Subgroup analysis by patients’ age did
not reveal statistically significant associations between
gene rearrangement status and overall survival in patients
under 65 (P=0.38) or those over 65 years of age (P=0.24).  
In R-CHOP-treated patients, high IPI score (IPI 3-5) pre-
dicted a significantly worse overall survival (5-year overall
survival, 46.1% versus 77.8%, P=0.002), while non-GCB
immunohistochemical profile was associated with a trend
toward inferior outcome (5-year overall survival, 50.8%
versus 76.8%, P=0.07). A Cox regression analysis was per-
formed for the R-CHOP-treated cohort using the follow-
ing four variables: IPI score, cell-of-origin immunopheno-
type, BCL2 protein expression, and BCL6 gene rearrange-
ment status. In multivariate analysis, only high IPI score
was found to be an independent adverse prognostic factor
for overall survival (P=0.002).
Discussion
This study analyzed the clinical impact of BCL6 gene
rearrangement in a retrospective cohort of DLBCL patients,
treated in both the pre- and post-rituximab eras. Our data
suggest an association between BCL6 rearrangement and
inferior outcome in patients treated with R-CHOP, but not
in patients treated with CHOP. However, BCL6 rearrange-
ment also correlated with the presence of high-risk clinical
features and was not demonstrated to have a prognostic
significance independent of the IPI score.  
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Figure 1. (A) Fluorescence in situ
hybridization on formalin-fixed, paraf-
fin-embedded tissue sections on a tis-
sue microarray. Left panel: interphase
nuclei with BCL6 break apart (BCL6+).
The most common signal pattern is
one fusion signal (yellow) and two
split signals (1 red, 1 green) visual-
ized at 200x magnification. Right
panel: BCL6+ interphase nuclei with
break apart (split signals) and poly-
ploidy (multiple fused signals) of the
BCL6 locus (high power field). (B)
Immunohistochemistry for BCL-6 on
tissue microarray cores. Left panel:
positive staining in virtually all large B
cells. Right panel: negative staining.
The effect of the BCL6 rearrangement on outcome in
DLBCL has remained uncertain despite previous clinical
analyses. In a seminal study by Offit et al., BCL6
rearrangement was found to be a favorable prognostic
marker in DLBCL, possibly due to an association with lim-
ited extranodal disease.6 Most subsequent investigators
failed to demonstrate any influence of BCL6 rearrange-
ment on prognosis in DLBCL, and similarly our analysis
did not find that this marker had predictive value in
patients treated with CHOP alone.7,8,11,14 A more recent
analysis, restricted to DLBCL patients with primary nodal
disease, reported inferior survival in patients with BCL6
rearrangement, as well as a correlation between this mark-
er and non-GCB immunophenotype.12 In agreement with
our results, Vitolo et al. reported a correlation between
BCL6 rearrangement and adverse clinical features,11
although this has not been a uniform finding in previous
studies. These discrepancies may be explained in part by
heterogeneity between study populations, due to con-
comitant genetic alterations, selection biases, and differ-
ences in molecular diagnostic techniques. Specifically,
rearrangement of the MYC oncogene has been found by
several authors to impart an inferior prognosis in CHOP-
treated DLBCL patients, although this abnormality occurs
in only 5-10% of patients19,20 and MYC and BCL6
rearrangement rarely coexist.6,8,11
The addition of rituximab to first-line combination ther-
apy has led to a significant improvement in survival in
patients with DLBCL, requiring a re-evaluation of estab-
lished prognostic markers.3 Biological prognostic markers
in particular may be influenced by changes in standard
therapy, because of the differential effects of new agents
within biological subgroups. It has recently been reported
that BCL2 protein expression, an adverse prognostic
marker in CHOP-treated patients, loses its prognostic
effect in the rituximab era, due to a disproportionate ben-
efit from rituximab in BCL2+ cases.21 In our analysis, the
addition of rituximab appeared primarily to benefit
patients without BCL6 rearrangement, and was associated
with significantly prolonged overall survival in this sub-
group. In contrast, little improvement in outcome was
observed with the addition of rituximab among BCL6+
patients, in whom long-term survival remained less than
50% even with R-CHOP. These data suggest a potential
value for BCL6 rearrangement as an adverse predictive
biomarker in DLBCL in the rituximab era.
The IPI remains the most successful clinical prognostic
instrument in DLBCL.22 However, the IPI score appears to
lose discriminatory power in R-CHOP-treated patients,
and in a recent analysis was unable to identify a subgroup
with a less than 50% chance of long-term survival.3
Biological markers may help to refine risk-stratification in
DLBCL, and to identify high-risk subgroups of patients
who might benefit from intensified or novel therapies.
However, to be clinically useful these markers must pro-
vide prognostic information complementary to that pro-
vided by the IPI. In our study, the presence of a BCL6 gene
rearrangement correlated with high IPI score, and in mul-
tivariate analysis this biomarker did not show independ-
ent prognostic significance. BCL6 rearrangement has also
shown an association with non-GCB immunophenotype,
previously demonstrated to be an unfavorable prognostic
marker in CHOP-treated patients with DLBCL.17
However, in our cohort of R-CHOP-treated patients, cell-
of-origin phenotype did not emerge as an independent
prognostic variable in multivariate analysis.
The clinical impact of oncogene rearrangements may
also depend on the site of disease presentation. DLBCL
arising from extranodal sites differs from nodal DLBCL in
terms of pathogenesis and cell of origin, and several dis-
tinct subtypes of extranodal DLBCL are recognized in the
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Table 1. Clinical characteristics of 164 DLBCL patients, by BCL6
rearrangement status.
BCL6+ ‡ BCL6– P
(n=32) (n=132) value 
Age (years), median 65.5 63 P=NS
(range, sd) (35-85, 14.1) (16-92, 14.8)
Gender (%)
Male 63 61 P=NS
Female 37 39
Mass size (cm), median 10 6 P=NS
(range, sd) (3-20, 5.4) (1-25, 5.0)
Lactate dehydrogenase (%)
Normal 25 51 P=0.007
Elevated 75 49
Extranodal sites (%)
0-1 68 75 P=NS
>1 32 25
Site of presentation(%)
Primary nodal 87 75 P=NS
Primary extranodal 13 25
Stage, Ann Arbor (%)
I-II 31 43 P=NS
III-IV 69 57
IPI score (%)
0-2 38 60 P=0.022
3-5 62 40
‡BCL6+: BCL6 gene rearrangement present; BCL6-: BCL6 gene rearrangement absent;
sd: standard deviation.
Table 2. Immunophenotypic characteristics of 164 DLBCL patients, by
BCL6 rearrangement status.
BCL6+ BCL6– P
(n=32) (n=132) value 
BCL2 protein expression (%)
Positive 78 71 P=NS
Negative 22 29
BCL6 protein expression (%)
Positive 69 71 P=NS
Negative 31 29
Cell-of-origin* (%)
GCB 32 59 P=0.006
Non-GCB 68 41
*According to Hans et al.
17
2008 revision of the WHO classification of lymphoid
malignancies.1 Unlike previous groups, we found no corre-
lation between BCL6 rearrangement and extranodal pres-
entation,6,8 and no statistically significant difference in
overall survival between BCL6+ and BCL6– patients was
demonstrated in either the primary nodal or extranodal
subgroup, although this analysis was limited by the small
numbers in the two groups.
The BCL6 proto-oncogene encodes a transcriptional
repressor essential for normal germinal center formation.
Its deregulated expression has been implicated as an
important pathway in lymphomagenesis.23 BCL6 protein
expression has been identified as a hallmark of GCB deri-
vation in DLBCL, and has been associated with a favorable
clinical outcome.17,24 However, in keeping with prior stud-
ies, we did not find a correlation between BCL6 rearrange-
ment and BCL6 protein expression, but demonstrated a
relationship between BCL6 rearrangement and non-GCB
phenotype.12,14 This seemingly paradoxical finding may be
related to several factors. First, mechanisms other than
gene rearrangement have been shown to deregulate BCL6
expression in DLBCL, including targeted mutations which
may interrupt negative gene autoregulation.23 Second, the
functional effect of BCL6 rearrangement may vary depend-
ing on other biological factors, including the chromosomal
translocation partner and cellular context. One group of
investigators demonstrated significantly lower BCL6
expression with non-IGH/BCL6 than with IGH/BCL6
rearrangements, and also reported inferior survival in
DLBCL patients with non-IGH/BCL6 translocations.13,25 A
more recent study by the Leukemia/Lymphoma Molecular
Profiling Project examined the effect of BCL6 rearrange-
ment on gene expression in patients with both GCB- and
ABC-subtype DLBCL.14 In this analysis, BCL6 rearrange-
ment was associated with increased BCL6 mRNA levels in
patients with ABC-subtype DLBCL, but not in patients
with GCB-subtype DLBCL. The clinical significance of
these biological subdivisions remains to be clarified.
In summary, the introduction of rituximab may have
altered the prognostic impact of BCL6 gene rearrangement
in patients with DLBCL. However, to be incorporated into
clinical practice as a useful prognostic biomarker, BCL6
rearrangement must be shown to provide prognostic
information additional to that afforded by the IPI. BCL6
rearrangement also correlates strongly with non-GCB
immunophenotype, and the interdependence of these two
prognostic variables requires further study. Correlative
biomarker analysis within prospective randomized clini-
cal trials will be needed to determine the prognostic value
of BCL6 rearrangement in the rituximab era.
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Figure 2. Overall survival according to BCL6 rearrangement status. (A) CHOP-treated patients (n=65). (B) R-CHOP-treated patients (n=99).
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CLINICAL TRIALS AND OBSERVATIONS
MYC gene rearrangements are associated with a poor prognosis in diffuse large
B-cell lymphoma patients treated with R-CHOP chemotherapy
Kerry J. Savage,1 Nathalie A. Johnson,2 Susana Ben-Neriah,2 Joseph M. Connors,1 Laurie H. Sehn,1 Pedro Farinha,3
Douglas E. Horsman,2 and Randy D. Gascoyne2
Departments of 1Medical Oncology and 2Pathology, British Columbia Cancer Agency, Vancouver, BC; and 3Department of Pathology, Centro Hospitalar de
Lisboa Central (CHLC), Lisbon, Portugal
Approximately 5% to 10% of diffuse large
B-cell lymphomas (DLBCLs) harbor an
MYC oncogene rearrangement (MYC).
The prognostic significance of MYC
DLBCL was determined in an unselected
population of patients with newly diag-
nosed DLBCL treated with rituximab in
combination with cyclophosphamide,
doxorubicin, vincristine, and prednisone
chemotherapy (R-CHOP). Using a Vysis
break-apart fluorescence in situ hybridiza-
tion probe, 12 of 135 (8.8%) cases of
MYC DLBCL were identified that had no
defining high-risk features. MYC DLBCL
was associated with an inferior 5-year
progression-free survival (66% vs 31%,
P  .006) and overall survival (72% vs
33%, P  .016). Multivariate analysis con-
firmed the prognostic importance of MYC
for both progression-free survival (haz-
ard ratio  3.28; 95% confidence interval,
1.49-7.21, P  .003) and overall survival
(hazard ratio  2.98; 95% confidence in-
terval, 1.28-6.95, P  .011). Cases of MYC
DLBCL also had a higher risk of central
nervous system relapse (P  .023), inde-
pendent of other risk factors. The diagno-
sis of MYCDLBCL is likely underappreci-
ated; and given the lack of defining risk
factors, fluorescence in situ hybridization
for MYC rearrangements should be per-
formed in all patients with DLBCL. In the
R-CHOP treatment era, MYC DLBCLs
have an inferior prognosis. Treatment
regimens similar to those used in Burkitt
lymphoma may be more appropriate in
this patient population and need to be
prospectively tested. (Blood. 2009;114:
3533-3537)
Introduction
Diffuse large B-cell lymphomas (DLBCLs) are recognized to be
a heterogeneous group of diseases with clinical, morphologic,
immunohistochemical, and molecular subtypes defined in the
updated World Health Organization (WHO) classification.1
Further, a new category has been created defined as “borderline
cases,” which are considered B-cell lymphomas, unclassifiable,
with features intermediate between DLBCL and Burkitt lym-
phoma.2 Morphologically, these tumors typically have a mixture
of medium- to large-sized cells, a high proliferation rate, and
35% to 50% of cases have an 8q24/MYC translocation.2
However, approximately 5% to 10% of DLBCLs with typical
morphology also harbor an MYC rearrangement (herein after
referred to as MYC), and these cases are considered in the
category of DLBCL, not otherwise specified, in the updated
WHO classification.3
There is very little information regarding the prognostic impor-
tance of an isolated MYC rearrangement in DLBCL using modern
diagnostic criteria. A recent study suggested that MYC gene
rearrangements identified by fluorescence in situ hybridization
(FISH) in pathologically defined DLBCL patients treated with
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)–
like chemotherapy are associated with an inferior prognosis.4
However, it is unclear whether there are identifiable clinical or
pathologic characteristics that suggest that a case may harbor an
MYC rearrangement to prompt evaluation. Further, prior studies
evaluating the prognostic implications of MYC in DLBCL have
been performed before the use of rituximab. With studies showing
improved outcome using rituximab in combination with CHOP
(R-CHOP) or CHOP-like therapies in the treatment of DLBCL,5-8
the importance of MYC rearrangement status in this population
must be reestablished.
The purpose of this study was 2-fold: (1) to screen an unselected
series of patients with DLBCL for MYC rearrangements to
determine the frequency of this occurrence and whether there were
any pathologic or clinical defining features in the MYC group and
(2) to assess the prognostic impact of MYC gene rearrangements in
DLBCL patients treated with R-CHOP chemotherapy.
Methods
Patient identification
The British Columbia Cancer Agency (BCCA) Lymphoid Cancer Database
was screened to identify adult patients ( 15 years of age) with newly
diagnosed DLBCL treated with curative intent with CHOP in combination
with rituximab (R-CHOP). Patients who were HIV were excluded. Those
cases with available paraffin-embedded tissue blocks from the diagnostic
biopsy were used to construct a tissue microarray (TMA). For this analysis,
only those cases considered to be DLBCL, not otherwise specified, by the
recently updated WHO classification of lymphomas recently published
were included.3 Clinical information, including baseline characteristics for
the calculation of the International Prognostic Index (IPI), was determined.9
This study was approved by the BCCA Research Ethics Board.
Submitted May 26, 2009; accepted August 5, 2009. Prepublished online as
Blood First Edition paper, August 28, 2009; DOI 10.1182/blood-2009-
05-220095.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2009 by The American Society of Hematology
3533BLOOD, 22 OCTOBER 2009  VOLUME 114, NUMBER 17
 For personal use only. by guest on December 29, 2011. bloodjournal.hematologylibrary.orgFrom 
TMA
Three independent TMAs were constructed using duplicate 0.6-mm cores
from formalin-fixed, paraffin-embedded tissue derived from a total of
137 samples of newly diagnosed cases of DLBCL according to the WHO
classification.3
Immunohistochemistry
Immunohistochemistry (IHC) was performed on archived paraffin-
embedded tissue using CD20 (L26; Dako North America), CD3 (Dako
North America), CD10 (clone 56C6; Vector Laboratories), Ki-67 (Dako
North America), BCL6 (clone PG-B6p; Dako North America), MUM1
(clone MUM1p),10 and BCL2 (clone 124; Dako North America). The
TMAs were stained using automated IHC on a Ventana Benchmark using
standard protocols. The Ki-67 antibody MIB1 was used to determine the
proliferation rate, and more than 80% was defined as “high proliferation” as
previously described.11 For all other immunostains, a cutoff of more than
30% was used in accordance with other studies.12
Determination of DLBCL cell of origin subtypes
For 76 patients, frozen tissue was available for gene expression profiling
(GEP) analysis. RNA was extracted using the ALL PREP kit (QIAGEN),
and after reverse transcription it was hybridized to the U133-2 Plus arrays
(Affymetrix) according to the manufacturer’s protocol. CEL files were
normalized using robust multichip analysis.13 The cell of origin (COO)
phenotype (germinal center B-cell type [GCB], activated B-cell type
[ABC], or unclassified) was determined using the 185 gene list and model
scores determined by the Bayesian formula as previously described.14 For
the remaining patients, the COO was determined to be GCB or non-GCB
using IHC according to the Hans algorithm.12 Cases that were unclassified
by the Bayesian formula were assigned using the Hans criteria.
Cytogenetic analysis
All cases were screened for an MYC rearrangement using a commercial
Vysis dual-color FISH break-apart probe (Abbott Molecular) applied to the
TMA. Cases harboring an MYC rearrangement were also screened for the
presence of a t(14;18) rearrangement using the LSI IGH/BCL2 dual-color,
dual-fusion translocation probe (Abbott Molecular) on isolated cells from
the original paraffin-embedded tissue block and/or frozen or methanol/
acetic acid-fixed cell pellets if available.
Statistical analysis
Progression-free survival (PFS) was determined from the date of the
pathologic lymphoma diagnosis to the date of relapse, progression or death
resulting from lymphoma, or treatment toxicity. Overall survival (OS) was
determined from the date of diagnosis to the date of death of any cause. The
time to central nervous system (CNS) relapse was defined from the date of
diagnosis to the date of documented relapse in the CNS. The 2 test was
used to compare baseline characteristics between MYC and MYC cases.
Survival curves were plotted using the Kaplan-Meier method and compared
using the log-rank test.15 The Cox proportional hazards model was used,
including factors with a P less than .1 in univariate analysis, to determine
the impact of multiple factors on PFS, OS, and time to CNS relapse.16 All
statistical analyses were performed using SPSS software, Version 11.5.
Results
A total of 137 R-CHOP–treated cases of DLBCLs had tissue
available for the TMA (61% nodal and 39% extranodal biopsy
specimens), and FISH analysis was successful in 135 cases at
defining the presence or absence of an MYC rearrangement, with
2 technical failures. In total, 12 of 135 (8.8%) cases of DLBCL
were positive for an MYC rearrangement in this series. Three of the
MYC cases had a concurrent t(14;18) chromosome, so-called dual
translocations or “double-hit.”
Patients who had MYC DLBCL were predominantly male
(75%) with a median age of 69 years (range, 22-85 years) with no
particular high risk defining clinical features other than a higher
incidence of testicular involvement at disease presentation, com-
pared with MYC cases (Table 1). Half were early stage and were in
a favorable risk group by the IPI (Table 1). There was no difference
in the frequency of extranodal versus nodal primary biopsy sites in
the MYC and MYC groups (P  .301).
IHC and cell of origin
MYC  cases were more likely to have a high proliferation rate
(Table 1). Eight cases (67%) of the MYC DLBCL were BCL2
using the commercially available Dako antibody with no difference
in frequency observed compared with the MYC cases (Table 1).
Of interest, 2 out of 3 of the MYC cases that were also t(14;18)
were BCL2 protein by IHC using the Dako antibody. Given this
finding, these 2 cases were subsequently analyzed using an
alternate antibody, clone E17 (Epitomics), which targets amino
acids 60 to 80 compared with the Dako BCL2 clone 124, which
targets amino acids 41 to 54. Using the E17 antibody, there was
nearly 100% staining for BCL2. In one of these cases, subsequent
sequencing of the BCL2 gene detected mutations in the flexible
loop domain but not the BH3 domain,17 thus interfering with
binding of the Dako antibody. However, the clinical significance of
this finding is unknown.
The updated WHO classification of lymphomas recognizes
2 molecular subtypes of DLBCL based on the COO phenotype as
GCB and ABC3,14 or by IHC as GCB and non-GCB. The COO
Table 1. Characteristics of MYC and MYC DLBCL patients
Feature
MYC, n (%)
(n  12)
MYC, n (%)
(n  123) P
Median age, y 68 61 —
Age 60 y 8 (67) 68 (55) .448
Male sex 9 (75) 73 (59) .289
Stage 3 or 4 6 (50) 75 (61) .459
B symptoms
Extranodal any site 8 (67) 72 (58) .584
Extranodal  1 4 (33) 25 (20) .295
Bone marrow 0 11 (9) .280
Testicular 2 (17) 3 (2) .013
Sinus 0 2 (1.6) .280
Gastrointestinal 2 (17) 19 (15) .911
Kidney 0 2 (1.6) .656
Liver 0 7 (6) .396
Bulky disease* 4 (33) 31 (26) .575
PS  2* 5 (42) 42 (36) .677
LDH abnormal* 9 (75) 54 (50) .100
LDH  2 ULN 3 (25) 28 (26) .930
IPI 0-2 vs 3-5 6 (50) 48 (39) .459
Ki-67†
More than 80% 7 (58) 27 (22.5) .007
More than 90% 6 (50) 9 (7.5)  .001
More than 95% 4 (12) 8 (6.7) .002
BCL2 protein‡ 8 (67) 86 (70) .782
GCB phenotype§ 7 (58) 61 (51) .640
PS indicates Performance Status; LDH, lactic dehydrogenase; and ULN, upper
limit of normal.
*Missing data: LDH, n  15; bulky disease, n  3; PS, n  5.
†Failed in 3 MYC cases.
‡Results using the Dako antibody; not available in 1 MYC case.
§Not available in 4 MYC cases.
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phenotype was available for 131 cases (97%; 4 missing in the
MYC group); 62 were assigned by GEP14 and 69, including
14 unclassified cases by GEP, using IHC by the Hans algorithm.12
Of note, there were 58 cases in which we had both GEP and IHC
results that were obtained in a blinded fashion, to evaluate the
concordance of the 2 approaches at assigning the COO status. Of
the 46 cases with a definitive COO assignment by GEP (12 were
unclassified), 35 were concordant with the Hans COO designation
for an overall agreement rate of 85%, consistent with prior
studies.12
For the purpose of the COO assignment in our study, 2 groups
were considered: GCB and non-GCB (the latter including those
assigned as ABC by GEP). Cases that were unclassifiable by GEP
were assigned by the Hans criteria. A GCB phenotype was
observed in 68 (51%) cases. There was no difference in the
frequency of GCB versus non-GCB between the MYC and MYC
cases (Table 1). Not surprisingly, the 3 cases with dual transloca-
tions had a GCB phenotype.
Impact on survival of MYC rearrangements in R-CHOP–treated
patients
The 5-year PFS (66% vs 31%, P  .006) and OS (72% vs 33%,
P  .016) were inferior in cases of DLBCL treated with R-CHOP
that harbored an MYC rearrangement (Figure 1). Within the
favorable GCB subgroup (n 68), cases that harbored an MYC
translocation had an inferior PFS (P  .049) and OS (P  .014).
However, within the non-GCB subgroup (n 63), there was an
inferior PFS (P  .033) but not OS (P  .303). In univariate
analysis, in addition to the presence of an MYC rearrangement, the
IPI, a non-GCB phenotype, extranodal involvement and bone
marrow involvement with DLBCL were all associated with an
inferior PFS (Table 2). Similar results were observed for OS,
although only a trend for an inferior outcome was observed with a
non-GCB phenotype. BCL2 protein expression and a high prolif-
eration rate, including variable cutoffs for Ki-67 ( 80%,  90%,
or  95%) were not prognostic for PFS or OS (Table 2).
Multivariate analysis using a Cox proportional hazard model
confirmed that the presence of an MYC rearrangement remained a
significant factor for both PFS (hazard ratio [HR] 3.28; 95%
confidence interval [CI], 1.49-7.21, P  .003) and OS (HR 2.98;
95% confidence interval, 1.28-6.95, P  .011; Table 3). Of note, if
the MYC cases with a dual translocation are removed and the
analysis is repeated, MYC status retains prognostic significance
for both PFS (P  .009) and OS (P  .036; results not shown).
Risk of CNS relapse in R-CHOP–treated patients with an MYC
rearrangement
Given that CNS relapse is a known consequence in Burkitt
lymphoma, we evaluated whether there was an increased risk of
CNS relapse in cases of DLBCL that harbor an MYC rearrange-
ment. Only one patient with testicular involvement received
intrathecal prophylaxis at the time of primary therapy; otherwise,
CNS prophylaxis was not used in the primary therapy. In total,
there were 6 CNS relapses (2 of 12, 17% MYC vs 4 of 123, 3%
MYC). Neither of the cases of CNS relapse in the MYC group
had testicular involvement. Using the time to CNS relapse as the
endpoint, the presence of an MYC rearrangement (P  .018) was
predictive of a CNS relapse in R-CHOP–treated patients (Figure 2).
In multivariate analysis, the presence of an MYC rearrangement
(HR 8.0; 95% CI, 1.33-48.03, P  .023) and kidney involve-
ment (HR 25.28; 95% CI, 2.60-245.86, P  .005) remained
significant in the Cox proportional hazards model after adjusting
for the IPI, extranodal sites more than 1, or other high-risk
extranodal sites (bone marrow, testicular involvement, and sinus
involvement). Of interest, a high proliferation rate was not
predictive of an increased risk of CNS relapse (results not shown).
Figure 1. Outcomes of patients with MYC DLBCL treated with R-CHOP.
(A) Progression-free survival of MYC and MYC DLBCL. (B) Overall survival of
MYC and MYC DLBCL.
Table 2. Univariate analysis of risk factors for PFS and OS for
DLBCL patients treated with R-CHOP
Risk factor PFS P OS P
MYC .006 .016
IPI  3  .001  .001
Non-GCB phenotype .041 .058
BCL2 protein* .313 .492
Ki-67
More than 80% .582 .418
More than 90% .759 .751
More than 95% .351 .642
Extranodal sites, any .014 .034
Extranodal sites  1 .013 .040
Bone marrow DLBCL  .001  .001
Testicular .124 .263
Bulky disease .334 .841
*Results using the Dako antibody; not available in 1 MYC case.
Table 3. Multivariate analysis of risk factors of PFS and OS of
DLBCL patients treated with R-CHOP
Risk factor
PFS OS
Hazard ratio (CI) P Hazard ratio (CI) P
MYC 3.28 (1.49-7.21) .003 2.98 (1.28-6.95) .011
IPI  3 2.69 (1.48-4.86) .001 3.29 (1.68-6.46) .001
Non-GCB phenotype* 1.86 (1.04-3.34) .038 — NS
Bone marrow DLBCL 3.74 (1.67-8.36) .001 4.06 (1.72-9.58) .001
NS indicates not significant; and —, not applicable.
*Not available in 4 MYC cases.
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Discussion
A limited number of studies have evaluated the prognostic impor-
tance of MYC status in DLBCL patients treated with CHOP-like
regimens.4,18-20 In the large GEP effort by the Molecular Mecha-
nisms in Malignant Lymphomas Network project, MYC aggres-
sive lymphomas with a “nonmolecular Burkitt lymphoma” or
“intermediate” gene expression signature profile had an inferior
prognosis compared with those that were MYC. However, not all
of these cases were morphologically DLBCL, and most were
treated with CHOP-like chemotherapy without rituximab.19 Inter-
estingly, 11 cases of DLBCL in this study were determined to have
a molecular signature of Burkitt lymphoma, but only 8 of these
cases harbored an MYC translocation, suggesting that other genetic
alterations can lead to MYC deregulation, such as copy number
changes. The outcome of these patients is not reported; thus, it is
unknown whether they may have benefitted with a more dose-
intensive approach. The German High-Grade Non-Hodgkin Lym-
phoma Study Group recently evaluated 177 patients who were
treated in the BH121 and BH222 clinical trials, which compared
CHOP-like regimens in patients with aggressive B-cell lympho-
mas.4 Confining the analysis to DLBCL, cases were selected if they
had tissue available for the construction of a TMA to assess for the
presence of an MYC gene rearrangement. In this comprehensive
analysis, the presence of an MYC rearrangement was associated
with an inferior OS (P  .047), and there was a trend to a reduction
in EFS (P  .062).4 It is unclear from this analysis what proportion
of cases had a concurrent t(14;18) translocation. In a study by
Niitsu et al, 11% of cases of DLBCL were found to harbor an MYC
translocation; however, the cases evaluated were those that had
abnormal karyotypes, which may have been selected based on
high-risk features, which is also reflected by the high proportion of
cases with a concurrent BCL2 translocation.20 The presence of an
MYC translocation was associated with an inferior prognosis;
however, this was largely driven by the presence of a concurrent
t(14;18). In contrast, one study found that the presence of an MYC
rearrangement did not predict for a worse outcome in DLBCL;
however, the treatment received was not detailed, and it is possible
that patients may have received more dose-intensive regimens.23
Importantly, all of the prior studies were performed before the
routine use of rituximab-containing anthracycline-based regimens,
which is the accepted standard of care in DLBCL based on
established superiority in several randomized controlled tri-
als.5,7,8,24 The present study is the first published to evaluate
whether the presence of an MYC gene rearrangement is still of
clinical relevance in patients treated in the R-CHOP era. In this
“unselected” population of DLBCL, the frequency of MYC rear-
rangements was 8.8%, which is comparable with the German study
(7.9%). Similar to the German study, we did not identify any
high-risk clinical features at presentation in the MYC group; and
contrary to prior studies, there was no difference in the frequency
of extranodal disease in MYC patients.23 Although there was a
tendency for the tumors in our study to have a high Ki-67 score, a
range was seen, and this feature cannot be relied on to identify
patients at a higher risk of harboring an MYC rearrangement.
Furthermore, our results are in contrast to the German High-Grade
Non-Hodgkin Lymphoma Study Group study in which no correla-
tion between a high proliferation rate and the presence of an MYC
rearrangement was found, which may reflect the high variability
and poor reproducibility of this IHC marker.25 Nevertheless, a high
proliferation rate was also not associated with outcome in this
analysis. In contrast, the presence of an MYC rearrangement
retained prognostic significance in R-CHOP–treated patients in
multivariate analysis for both PFS and OS; thus, it is independent
of clinical risk factors and COO phenotype.
CNS relapse is a known risk in patients with Burkitt
lymphoma; and as a result, chemoprophylaxis is incorporated
into treatment regimens for this disease. Although there was a
small number of CNS relapse cases overall, we did find that
there was an increased risk of CNS relapse in cases of DLBCL
treated with R-CHOP that harbored an MYC rearrangement
adjusting for other high-risk factors. Given the overall poor
outcome of patients with secondary CNS disease, these results
raise the question as to whether this population should be treated
with Burkitt lymphoma–type regimens, which integrates inten-
sive CNS prophylaxis. This approach has been explored in
patients with aggressive B-cell lymphomas with a high Ki-67
fraction ( 95%) who received dose-modified CODOX (cyclo-
phosphamide, doxorubicin, vincristine, methotrexate)–M/IVAC
(ifosfamide, Ara-C, carboplatin). The authors concluded that the
regimen did not improve outcome in patients with DLBCL26;
however, the overall 2-year PFS for the DLBCL patients in this
study was 55%, which appears to be more favorable than
estimates with CHOP-like chemotherapy. Furthermore, this
study did not provide information on the outcome of patients
with MYCDLBCL in isolation and was performed in the
prerituximab treatment era. Thus, the efficacy of this regimen
and other dose-intensive therapies, in combination with ritux-
imab, in MYC DLBCL requires further study.
In conclusion, MYC gene rearrangements define a small group
of patients with DLBCL who are less probable to be cured with
R-CHOP and may have an increased risk of CNS relapse. There are
no identifiable clinical, histologic, or immunophenotypic features
signaling that a case of DLBCL may harbor an MYC rearrange-
ment. Thus, all patients with DLBCL should undergo FISH or
karyotype analysis for assessment of MYC rearrangement status in
addition to analysis for the t(14;18) and BCL2 protein expression.
MYC DLBCL may represent a distinct DLBCL subtype, and
regimens more in line with those used in Burkitt lymphoma may be
more appropriate and require further study in this patient population.
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Background
Despite advances in treatments for Hodgkin’s lymphoma, about 20% of patients 
still die from progressive disease. Current prognostic models predict the outcome 
of treatment with imperfect accuracy, and clinically relevant biomarkers have not 
been established to improve on the International Prognostic Score.
Methods
Using gene-expression profiling, we analyzed 130 frozen samples obtained from 
patients with classic Hodgkin’s lymphoma during diagnostic lymph-node biopsy to 
determine which cellular signatures were correlated with treatment outcome. We 
confirmed our findings in an independent cohort of 166 patients, using immuno-
histochemical analysis.
Results
Gene-expression profiling identified a gene signature of tumor-associated macro-
phages that was significantly associated with primary treatment failure (P = 0.02). 
In an independent cohort of patients, we found that an increased number of CD68+ 
macrophages was correlated with a shortened progression-free survival (P = 0.03) 
and with an increased likelihood of relapse after autologous hematopoietic stem-cell 
transplantation (P = 0.008), resulting in shortened disease-specific survival (P = 0.003). 
In multivariate analysis, this adverse prognostic factor outperformed the Interna-
tional Prognostic Score for disease-specific survival (P = 0.003 vs. P = 0.03). The ab-
sence of an elevated number of CD68+ cells in patients with limited-stage disease 
defined a subgroup of patients with a long-term disease-specific survival of 100% 
with the use of current treatment strategies.
Conclusions
An increased number of tumor-associated macrophages was strongly associated 
with shortened survival in patients with classic Hodgkin’s lymphoma and provides 
a new biomarker for risk stratification.
The New England Journal of Medicine 
Downloaded from nejm.org on December 29, 2011. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 362;10 nejm.org march 11, 2010876
Current therapies do not cure at least 20% of patients with classic Hodg-kin’s lymphoma, and a similar proportion 
of patients are overtreated.1 It remains a chal-
lenge to identify patients whose disease will not 
be eradicated by standard therapies. Currently, 
most patients receive at least four cycles of poly-
chemotherapy and, if indicated, radiotherapy.2 
Autologous hematopoietic stem-cell transplanta-
tion can rescue about 50% of patients in whom 
primary therapy has failed.
Initial clinical decisions and risk stratification 
for patients with Hodgkin’s lymphoma are largely 
based on clinical variables that distinguish those 
who are at high risk from those at standard risk. 
Classic Hodgkin’s lymphoma, which constitutes 
about 95% of all cases of Hodgkin’s lymphoma 
and is distinguished by the presence of Reed–
Sternberg cells with characteristic features, is 
usually managed on the basis of Ann Arbor stag-
ing as follows: limited disease (stages I and IIA 
without constitutional symptoms) or advanced 
disease (stages IB and IIB with bulky disease 
[largest deposit, ≥10 cm in diameter] and stages 
III and IV either A or B [with or without consti-
tutional symptoms]).3 The International Prog-
nostic Score (on a scale of 0 to 7, with higher 
scores indicating increased risk) is the standard 
that is used for risk stratification of advanced-
stage Hodgkin’s lymphoma,4 but it does not 
apply to limited stages, and none of the pub-
lished prognostic-factor systems can reliably iden-
tify patients in whom treatment is likely to fail. 
Moreover, neither the International Prognostic 
Score nor its individual clinical components are 
suitable for accurately predicting the outcome 
of autologous hematopoietic stem-cell transplan-
tation in patients with Hodgkin’s lymphoma. 
For these reasons, reliable biomarkers for pre-
dicting long-term survival at diagnosis are need-
ed for such patients.
In Hodgkin’s lymphoma, unlike most other 
cancers, the malignant Reed–Sternberg cells 
are outnumbered by non-neoplastic cells in the 
microenvironment of the tumor. The frequency 
and distribution of these cellular components and 
Reed–Sternberg cells vary considerably among in-
dividual patients and among subtypes of Hodg-
kin’s lymphoma.5 Several studies have focused 
on the prediction of outcomes by means of mark-
ers expressed predominantly by Reed–Sternberg 
cells6-9 or the microenvironment.10-13 However, 
most of these markers require validation in inde-
pendent cohorts.
Me thods
Samples from Patients
For gene-expression profiling, we selected fresh-
frozen lymph-node specimens, which had been 
obtained at the time of diagnosis from 130 pa-
tients with Hodgkin’s lymphoma, from the tissue 
archives at the British Columbia Cancer Agency 
(BCCA) and the University of Nebraska Medical 
Center. The criteria that we used included a pri-
mary diagnosis of classic Hodgkin’s lymphoma 
after central review, representative lymph-node 
tissue (at least 1 cm2 in tissue sections), negative 
status for human immunodeficiency virus infec-
tion, and first-line treatment with ABVD chemo-
therapy (doxorubicin, bleomycin, vinblastine, 
and dacarbazine) or an ABVD-like regimen and, 
if indicated, radiation therapy (including wide-
field radiation for patients with limited-stage 
disease).
Primary treatment was defined as a failure if 
the lymphoma had progressed at any time after 
the initiation of therapy; treatment success was 
defined as the absence of progression or relapse. 
The median follow-up time for living patients in 
the treatment-success group was 3.9 years (range, 
0.5 to 21.0). The gene-expression cohort was 
stratified according to treatment outcome (failure 
or success) in order to analyze differences be-
tween the two outcomes (see Fig. S1 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org). Advanced-stage dis-
ease was defined with the use of Ann Arbor 
staging criteria.3
On the basis of the availability of formalin-
fixed, paraffin-embedded diagnostic lymph-node 
specimens, we also selected samples from 166 
independent cases of classic Hodgkin’s lympho-
ma for immunohistochemical testing on a tissue 
microarray. To increase the statistical power for 
observations linked to progression-free and dis-
ease-specific survival, this cohort was enriched 
for all available cases of treatment failure that 
were identified through the Centre for Lymphoid 
Cancer database at the BCCA. The number of 
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cases of treatment failure was roughly matched 
to the number of cases of treatment success. For 
the independent cohort, we also recorded the 
outcome of secondary therapy delivered with cu-
rative intent in 61 patients; these secondary thera-
pies included autologous stem-cell transplantation 
in 55 patients, CVPP chemotherapy (cyclophos-
phamide, vinblastine, procarbazine, and predni-
sone) plus involved-field radiation in 5 patients, 
and GDP chemotherapy (gemcitabine, dexametha-
sone, and cisplatin) plus extended-field radiation 
in 1 patient. In this cohort, the median follow-up 
time was 4.0 years (range, 0.5 to 20.8).
The study was approved by institutional review 
boards at the University of British Columbia–
BCCA and the University of Nebraska Medical 
Center. Written informed consent was obtained 
from all patients in accordance with the princi-
ples of the Declaration of Helsinki.
Gene-Expression Analysis
Total RNA was extracted from multiple (10 to 20) 
20-μm freshly cut tissue sections after mechani-
cal homogenization. Expression profiles were ob-
tained with the use of GeneChip Human Genome 
U133 Plus 2.0 arrays (Affymetrix). (Data are avail-
able at www.ncbi.nlm.nih.gov/geo/query/acc.cgi 
[accession number, GSE17920].) RNA preparation, 
array hybridization, and washing were performed 
according to routine protocol with modifications. 
All 130 microarrays met homogeneous criteria 
for quality control (for details on data processing 
and statistical analysis of array data, see the Sup-
plementary Appendix).
Immunohistochemical Analysis
To confirm the findings of the gene-expression 
analysis, we performed immunohistochemical 
analysis on a tissue microarray that was con-
structed from duplicate 1.5-mm cores of 166 in-
dependent samples enriched for cases of treat-
ment failure. Markers that were used included 
CD3, CD20, CD30, CD68, and MMP11. Immu-
nohistochemical scoring ranged from 1 to 3 for 
CD68, from 1 to 4 for CD20, and from 0 to 3 for 
MMP11, with higher scores indicating a greater 
proportion of positive cells (for details, see the 
Supplementary Appendix). Scores were strati-
fied as high (3 or 4) or low (1 or 2) for CD20 
staining.
Predictive Models
In brief, we used the gene-expression data from 
the 130 patients for whom all prognostic factors 
of the International Prognostic Score were record-
ed and constructed a multidimensional classifier 
on the basis of feature selection, using sparse 
multinomial logistic regression (SMLR) and leave-
one-out cross-validation.14 Our aim was to build 
a robust discriminative model that was predictive 
of treatment failure in addition to identifying a 
small set of features (genes) that could be used 
as the basis for separating these data into the 
respective outcome groups. We determined the 
relative importance of variables by means of a 
decision-tree–based algorithm (random forest),15 
using the SMLR selected features. The relative im-
portance of variables was defined with the use of 
a standard method, which is based on random-
ization of the variable values and measurement 
of the resultant decline in the accuracy of the 
model. We measured classification accuracy us-
ing a receiver-operating-characteristic (ROC) curve 
and the area under the curve (AUC).
Treatment failure was assigned as the positive 
class, and treatment success as the negative class. 
Thus, an accurate prediction of failure was a true 
positive result, and an inaccurate prediction of 
failure was a false positive result; an accurate 
prediction of success was a true negative result, 
and an inaccurate prediction of success was a false 
negative result. (For additional details on the pre-
dictive models, see the Supplementary Appendix.)
Statistical Analysis
Group comparisons were performed by means of 
the chi-square test and Student’s t-test. For time-
to-event analyses, we used two primary end points: 
progression-free survival (based on the time from 
initial diagnosis to progression at any time, re-
lapse from complete response, or initiation of 
new, previously unplanned treatment) and disease-
specific survival (based on the time from initial 
diagnosis to death from lymphoma or its treat-
ment, with data for patients who died of unre-
lated causes censored at the time of death). Cox 
proportional-hazards models and time-to-event 
analyses with the use of the Kaplan–Meier method 
were performed with SPSS software, version 11.0. 
Two-sided P values of less than 0.05 were consid-
ered to indicate statistical significance.
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R esult s
Gene-Expression Analysis
Unsupervised hierarchical clustering of the gene-
expression results did not identify clusters that 
were significantly associated with the outcome 
of treatment or any other reported clinical vari-
able (data not shown). However, using Globaltest, 
with which we tested all prefiltered genes, we 
found a significant correlation between the gene-
expression profile and the outcome of first-line 
treatment (P = 0.02) (Table S1 in the Supplemen-
tary Appendix).
Table 1 shows the clinical characteristics of 
the gene-expression cohort. On the basis of su-
pervised analyses with the data set stratified 
according to the failure or success of primary 
treatment (Fig. S1 in the Supplementary Appen-
dix), we identified 271 differentially expressed 
genes in the two outcome groups (Tables S2 and 
S3 in the Supplementary Appendix). Unsupervised 
hierarchical clustering of all 130 expression pro-
files with the use of these differentially expressed 
genes identified two clusters, one of which was 
associated with treatment success (cluster A) and 
the other with both success and failure (cluster B) 
(Fig. 1A). In the treatment-failure group, pathway 
analyses identified the functions of cell-mediated 
immune response, cell-to-cell signaling and inter-
action, and up-regulation of pathway genes in-
volved in interleukin-12 signaling and production 
in macro phages and apoptosis (Table S4 in the 
Supplementary Appendix). Down-regulated path-
ways in the treatment-failure group included genes 
involved in CTLA4 signaling in cytotoxic T lym-
phocytes and G-protein–coupled signaling.
These results prompted an investigation of the 
association between microenvironment gene sig-
natures and outcome. Using Globaltest, we per-
formed associative testing to identify previously 
described cellular and pathway gene signatures 
that were differentially expressed in the two out-
come groups.16 In the treatment-failure group, 
there was overexpression of gene signatures of 
tumor-associated macrophages (P = 0.02)17 and 
monocytes (P = 0.01),18 findings that are in agree-
ment with the reported overexpression of macro-
phage-signaling–associated genes according to 
pathway analysis (Table S1 and Fig. S2 in the 
Supplementary Appendix). There was also over-
expression of gene signatures for angiogenic cells 
(P = 0.04),19 adipocytes (P = 0.01),20 and Reed–
Sternberg cells (P = 0.047)21 and underexpres-
sion of a signature for germinal center B cells 
(P = 0.01)22 in the treatment-failure group (Table 
S1 in the Supplementary Appendix). Furthermore, 
previously described genes that are associated 
with an unfavorable outcome in Hodgkin’s lym-
phoma,23 such as lysozyme (LYZ) and cathepsin 
L1 (CTSL1), were overexpressed in the treatment-
failure group (P = 0.04).
To test the overall power of expression profiles 
for outcome prediction, we constructed a classi-
fier by means of sparse multinomial logistic 
regression.14 This algorithm identified 86 non-
redundant annotated genes (Table S5 in the Sup-
plementary Appendix), age, and Ann Arbor stage 
by a cross-validation approach. Figure 1C shows 
the 30 features with the highest discriminative 
power, as determined by a random-forest algo-
rithm.15 Among the 27 individual genes with 
discriminative power exceeding that of the best 
clinical variable (age) was MMP11 (probe set 
235908_at), which was overexpressed in the 
treatment-failure group (P = 0.03 after adjustment 
for the false discovery rate). We selected this 
gene for further immunohistochemical testing, 
since previous studies have shown that the gene 
family of matrix metallopeptidases are overex-
pressed in patients in whom treatment has 
failed24 and that MMP11 in particular is ex-
pressed by tumor-associated macrophages.25
We compared the three data sources for fea-
ture selection and settled on a gene-expression 
profiling model for gene-expression probe sets 
only, a clinical model based on the International 
Prognostic Score only, and a combination model 
including both features. This comparison showed 
that the AUC value was highest for the gene-
expression model, as compared with the clinical 
and combination models (0.837 vs. 0.625 and 
0.821, respectively) (Fig. 1B). The differences in 
accuracy among the models were most prominent 
at low false negative rates, with the gene-expres-
sion model and the combination model yielding 
higher true negative rates than the clinical model.
Immunohistochemical Analysis
Our gene-expression study and previous studies 
by other investigators suggested that a predomi-
nance of tumor-infiltrating macrophages, a lack 
of small B cells, and overexpression of matrix 
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metallopeptidases were correlated with the fail-
ure of primary treatment. For these reasons, we 
selected the markers CD68 (macrophages), CD20 
(B cells), and MMP11 for immunohistochemical 
analysis of a tissue array containing samples 
from lymph-node biopsies in 166 patients with 
classic Hodgkin’s lymphoma (who were unrelat-
ed to the patients in the gene-expression analy-
sis), including 79 patients in whom treatment had 
failed (Table 1). Of these markers, CD68 and 
CD20 antibodies are routinely used in the diag-
nosis of lymphoma. The tissue microarray was 
also stained for CD30 (a marker for Reed–Stern-
berg cells) and CD3 (a marker for T cells), but 
neither the number of CD30+ cells nor the num-
ber of CD3+ cells was correlated with outcome 
(data not shown).
Of these immunohistochemical markers, CD68 
Table 1. Demographic and Clinical Characteristics of the Two Cohorts of Patients.
Variable
Gene-Expression Profiling
(N = 130)
Immunohistochemical Analysis
(N = 166)
Treatment 
Success
(N = 92)
Treatment 
Failure
(N = 38) P Value
Treatment 
Success
(N = 87)
Treatment 
Failure
(N = 79) P Value
Median age (range) — yr 37 (8–80) 46 (12–84) 0.03 33 (16–80) 36 (15–82) 0.21
Male sex — % 51 68 0.08 51 53 0.74
Histologic subtype — % 0.15 0.19
Nodular sclerosis 82 63 89 80
Mixed cellularity 12 26 6 8
Lymphocyte-rich 2 3 0 4
Lymphocyte- depleted 1 5 0 3
Not classifiable 3 3 6 6
Stage — % 0.003 0.01
I 14 8 11 3
II 60 32 53 39
III 16 37 20 34
IV 10 24 16 24
Presence of constitutional symptoms — % 36 50 0.14 40 53 0.10
Tumor size 0.39 0.27
Median (range) — cm† 6 (2–17) 7 (2–26) 6 (0–28) 7 (0–19)
≥10 cm — % 18 26 33 30
IPS ≥4 (high risk) — %‡ 14 18 0.05 14 20 0.27
Primary treatment — % 1.00 0.32
ABVD chemotherapy with or without radiation 96 95 99 100
Extended-field radiation alone 4 5 1 0
Secondary treatment — %
Autologous stem-cell transplantation ND ND NA 70
Other therapy with curative intent (CVPP or  
GDP plus radiation)
ND ND NA 8
Palliative treatment (including single-agent  
chemotherapy or radiation)
ND ND NA 22
* ABVD denotes doxorubicin, bleomycin, vinblastine, and dacarbazine, CVPP cyclophosphamide, vinblastine, procarbazine, and prednisone, 
GDP gemcitabine, dexamethasone, and cisplatin, IPS International Prognostic Score, NA not applicable, and ND not done.
† The tumor size was calculated as the longest diameter of the largest involved area.
‡ The IPS ranges from 0 to 7, with higher scores indicating increased risk.
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stood out because of its significant correlation 
with primary and secondary treatment outcomes 
(Fig. 2). Using univariate analysis, we found a 
significant correlation between the number of 
CD68+ tumor-infiltrating macrophages and short-
ened progression-free survival (P = 0.03) (Table 2). 
Patients with a high number of CD68+ cells (an 
immunohistochemical score of 3) had a median 
progression-free survival of 2.7 years, whereas 
during an observation period of 16.4 years, the 
median survival was not reached in patients with 
a score of 1 (Fig. 3A). In a multivariate Cox re-
gression model that included factors with respect 
to the International Prognostic Score and immu-
nohistochemical scores for CD68, CD20, and 
MMP11, CD68 was not an independent factor for 
an association with progression-free survival. In 
contrast, an increased number of CD68+ macro-
phages correlated with disease-specific survival 
in both univariate and multivariate analysis 
(P = 0.003 for both comparisons) and outper-
formed the International Prognostic Score (P = 0.03) 
(Table 2).
The 10-year disease-specific survival rate was 
significantly lower among patients with a CD68 
immunohistochemical score of 3 (59.6%) than 
among those with a score of 2 (67.4%) or 1 (88.6%) 
(P = 0.003 for all comparisons) (Fig. 3B). The num-
ber of tumor-infiltrating macrophages was also 
correlated with the outcome after secondary 
treatment. Secondary treatment that was admin-
istered with curative intent failed in only 12.5% 
of patients with a CD68 immunohistochemical 
score of 1, as compared with failure in 51.7% of 
those with a score of 2 and in 62.5% of those 
with a score of 3 (P = 0.009 for all comparisons). 
In particular, there was a significant correlation 
between the failure of autologous hematopoietic 
stem-cell transplantation and a CD68 score of 
more than 1 (P = 0.008). A high-risk International 
Prognostic Score (>3)4 was not significantly asso-
ciated with the number of CD68+ macrophages 
in diagnostic biopsy samples (8.7% for a score 
of 1, as compared with 18.1% for a score of 2 and 
22.9% for a score of 3; P = 0.17 for all compari-
sons). When the analysis was restricted to limited-
stage disease, a CD68 score of 1 was associated 
with a long-term disease-specific survival rate of 
100% (P = 0.04) (Fig. 3C).
In agreement with the findings of the gene-
expression study, MMP11 immunohistochemical 
staining showed a significant correlation with 
progression-free survival in both univariate analy-
sis (P = 0.008) and multivariate analysis (P = 0.009), 
although not with disease-specific survival (Ta-
ble 2). Among the cells with positive staining 
were Reed–Sternberg cells, macrophages, and 
endothelial cells (data not shown).
Using univariate analysis, we also found that 
an increased number of CD20+ small B cells (im-
munohistochemical score, >2) was significantly 
associated with prolonged progression-free survi-
val (P = 0.02) and disease-specific survival (P = 0.02) 
(Table 2). However, the number of CD20+ small 
B cells was not an independent predictor of sur-
vival and was strongly correlated with advanced-
stage disease (P = 0.002). Neither the number of 
CD20+ Reed–Sternberg cells nor the presence or 
Figure 1 (facing page). Hierarchical Clustering of Gene-
Expression Profiles in Hodgkin’s Lymphoma, True  
and False Positive and Negative Rates for Three Models 
of Outcome Prediction, and the Importance of Individ-
ual Genes for Outcome Prediction.
Panel A shows hierarchical clustering of 130 gene- 
expression profiles for patients with classic Hodgkin’s 
lymphoma. Cluster A has been enriched with primary 
treatment successes, and Cluster B with both primary 
treatment successes and failures. Immediately below 
the cluster bars, the first multicolored bar indicates sex 
(red for male and black for female), the second bar in-
dicates stage (yellow for limited disease and gray for 
advanced disease), the third bar indicates the type of 
treatment failure (green for no treatment failure, purple 
for refractory, dark blue for early relapse, and light blue 
for late relapse), and the fourth bar indicates the pri-
mary treatment outcome (black for failure and red for 
success). (For details, see Tables S2 and S3 in the Sup-
plementary Appendix, available with the full text of this 
article at NEJM.org.) Panel B shows plots of true positive 
and false positive rates and true negative and false nega-
tive rates (receiver-operating-characteristic curves) for 
three models that were used for feature selection: 
gene-expression profiling (GEP), a model based on the 
International Prognostic Score (IPS) for clinical vari-
ables, and a model combining these two features. This 
comparison showed that the value for the area under 
the curve was highest for the GEP model, as compared 
with the clinical and combined models (0.837 vs. 0.625 
and 0.821, respectively). For comparison with the es-
tablished IPS, red asterisks indicate an IPS of more 
than 3, as calculated with the use of IPS thresholds.4 
Panel C shows the relative importance of individual 
genes for outcome prediction. Relative importance is 
shown for 30 annotated probe sets (selected with the 
use of sparse multinomial logistic regression) that were 
more influential than Ann Arbor staging. Among the 
27 individual genes exceeding the importance of the 
best clinical variable, age (shown in red), was MMP11.
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absence of primary or secondary lymphoid folli-
cles was associated with the outcome.
Discussion
We found that the overexpression of a macro-
phage signature in expression-profile studies of 
diagnostic lymph-node specimens obtained from 
patients with classic Hodgkin’s lymphoma was 
associated with the failure of primary treatment. 
Using immunohistochemical analysis, we also 
found that an increased number of CD68+ cells 
(a marker of benign macrophages) in the diag-
nostic sample was associated with a poorer out-
come in an independent set of samples from 166 
patients. Multivariate analysis revealed that the 
number of CD68+ cells was also associated with 
the outcome of secondary treatment, indepen-
dently of the International Prognostic Score.
Three previous studies that have used expres-
sion profiles of the microenvironment in Hodg-
kin’s lymphoma have been reported.23,24,26 Of 
these, one identified a gene signature of macro-
phages but did not show the clinical value of 
tumor-associated macrophages assessed by means 
of a common immunohistochemical marker.23 
The association between the number of macro-
phages and treatment outcome has also been 
studied in other B-cell cancers.19,27,28 Differences 
in survival among patients with various lympho-
ma subtypes, which are linked to macrophage 
content, might be explained by the variable pres-
ence of macrophages with M1 or M2 differentia-
tion in biopsy samples, indicating distinct bio-
logic features of the tumors.29 However, in these 
lymphoma subtypes, including Hodgkin’s lym-
phoma, the functional link between macrophage 
numbers and the contribution of these cells to 
the treatment outcome remains unclear.23,30 Our 
gene-expression classifier for the outcome of pri-
mary treatment outcome revealed MMP11, a gene 
that has been found by other investigators to be 
expressed in tumor-associated macrophages in-
volved in remodeling of apoptotic lymphatic tis-
sue.25 Using immunohistochemical analysis, we 
were able to confirm the correlation between 
the number of MMP11+ cells and progression-
free survival in an independent cohort of pa-
tients. However, MMP11 stained many different 
cell types, including macrophages, and thus 
did not allow us to identify the particular cells 
that were responsible for the production of the 
protein.
Our findings also validate the recent report of 
a correlation between an increased number of 
small B cells and a favorable outcome.26 The re-
cently described correlation between the number 
of CD20-positive B cells and survival in patients 
with classic Hodgkin’s lymphoma31 needs to be 
reassessed in the context of clinical studies show-
ing successful treatment with the addition of 
rituximab to standard chemotherapy.32,33
We report the clinical value of a single marker, 
CD68, in the identification of tumor-associated 
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Figure 2. Representative Immunohistochemical Analy-
ses for CD68 in Lymph-Node Biopsy Samples from Two 
Patients.
Panel A shows a sample obtained from a patient in the 
treatment-success group, with few CD68+ macrophag-
es, and Panel B shows a sample from a patient in the 
treatment-failure group, with many CD68+ macrophag-
es. Both patients had the nodular sclerosis subtype of 
Hodgkin’s lymphoma.
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macrophages by immunohistochemical analysis, 
an analytic method that can be easily incorpo-
rated into a routine diagnostic approach. The use 
of such markers in combination with well-estab-
lished clinical risk factors could improve on the 
predictive value of a single biomarker used alone.
We focused on tumor-associated macrophages 
because of the strong signal from the gene-expres-
sion data and the recently renewed interest in 
these non-neoplastic cells as major contributors 
to the biologic features of lymphoma and out-
come prediction.19 The value of assessing the 
number of tumor-associated macrophages as a 
biomarker is highlighted by the association be-
tween these cells and the outcome after second-
ary therapy with autologous stem-cell transplan-
tation, a widely used treatment option. Accurate 
prediction of the outcome after secondary treat-
ments with curative intent would provide better 
risk stratification for these therapeutic options. 
Clinical predictors of the outcome after autolo-
gous stem-cell transplantation have been of lim-
ited value.34 In addition, our finding that in the 
tissue-microarray cohort, none of the patients 
Table 2. Progression-free and Disease-Specific Survival in a Validation Cohort of 166 Patients.*
Variable
Patients with  
Characteristic
P Value for Progression-free 
Survival
P Value for Disease-Specific 
Survival
Univariate 
Analysis
Multivariate 
Analysis
Univariate 
Analysis
Multivariate 
Analysis
no. (%)
Demographic data
Male sex 86 (51.8) 0.90 0.63
Age >44 yr 54 (32.5) 0.32 0.05
Immunohistochemical data†
≥5% CD68+ cells (IHC score, >1) 120 (72.3) 0.03 0.003 0.003
CD20+ cells
≤10% Background B cells (IHC score, <3) 85 (51.2) 0.02 0.02
Reed–Sternberg cells 20 (12.0) 0.95 0.59
Lymphoid follicles 44 (26.5) 0.24 0.34
≥1% MMP11+ (IHC score, >1)‡ 65 (40.6) 0.008 0.009 0.09
Laboratory data
Albumin <40 g/liter 68 (41.0) 0.047 0.03
Hemoglobin <10.5 g/dl 29 (17.5) 0.004 0.11
White-cell count >15,000/mm3 23 (13.9) 0.52 0.23
Lymphocyte count <600/mm3 or <8% 25 (15.1) 0.13 0.15
Clinical data
IPS >3 (high risk)§ 28 (16.9) 0.38 0.004 0.03
Advanced-stage disease 125 (75.3) 0.002 0.001 0.05
Constitutional symptoms 76 (45.8) 0.08 0.48
Bulky tumor (≥10 cm in diameter) 53 (31.9) 0.82 0.57
* P values are for the correlation between each factor and survival. Univariate analyses were calculated with the use of a Cox proportional- 
hazards regression model, and multivariate analyses were performed with a Cox proportional-hazards regression model (forward stepwise 
likelihood ratio).
† Immunohistochemical (IHC) scores range from 1 to 3 for CD68, from 1 to 4 for CD20, and from 0 to 3 for MMP11, with higher scores indi-
cating a greater proportion of positive cells.
‡ Data regarding immunohistochemical staining were missing for six patients.
§ The International Prognostic Score (IPS) ranges from 0 to 7, with higher scores indicating increased risk.
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with limited-stage disease and a low number of 
macrophages died is encouraging, since the ap-
plicability of the International Prognostic Score 
is restricted to advanced-stage disease. Thus, the 
CD68+ macrophage content represents a bio-
marker with clinical applicability in all stages of 
classic Hodgkin’s lymphoma, both at the time of 
diagnosis and at the time of relapse.
In summary, our study showed the value of 
enumerating CD68+ macrophages in diagnostic 
lymph-node samples for prediction of the out-
come after primary treatment and secondary 
treatment (in particular, autologous stem-cell 
transplantation). The absence of an increased 
number of CD68+ cells in patients with limited-
stage disease defines a subgroup of patients for 
whom the rate of long-term disease-specific sur-
vival is 100% with the use of available treatments.
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Figure 3. Survival in a Validation Cohort of 166 Patients, 
According to the Number of Infiltrating CD68+ Macro-
phages in Pretreatment Lymph-Node Biopsy Specimens.
The graphs show progression-free survival in all patients 
(Panel A) and disease-specific survival in all patients 
(Panel B) and in 41 patients with limited-stage dis-
ease (Panel C). According to the immunohistochemical 
scoring system that was used, a score of 1 indicates 
less than 5% CD68+ cells, a score of 2 indicates 5 to 
25%, and a score of 3 indicates more than 25%. Clini-
cally relevant biomarkers for predicting the outcome of 
treatment in patients with Hodgkin’s disease have not 
been established. In this study, gene profiling and im-
munohistochemical analysis were used to find such a 
marker. A strong association was found between a poor 
outcome of treatment and an increased number of CD68+ 
cells in the microenvironment of Reed–Sternberg cells. 
CD68, a marker of macrophages, outperformed the 
conventional International Prognostic Score and can 
be immunohistochemically stained in diagnostic sam-
ples of Hodgkin’s lymphoma.
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